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Abstract

2',3'-Dideoxynucleoside analogs are commonly used as anti-HIV, anti-HBV,
and anti-cancer drugs. Despite of their potent activities, there are some major limitations
in using 2',3'-dideoxynucleosides as therapeutic agents. The nucleosides have usually
poor cellular uptake because of their hydrophilic nature. Some of the nucleoside
\

analogs, such as anti-HIV agents, become ineffective after multiple administrations
because of the development of the drug resistance, and therefore they must be
administered in combination therapy. It is hard to deliver the nucleoside analogs to a
particular tissue for site specific targeting. Furthermore, nucleoside analogs undergo
three intracellular phosphorylation steps to become active. The first phosphorylation
step is slow and a rate-limiting process for several compounds.

Herein, we report the synthesis and evaluation of 2',3'-dideoxynucleoside
conjugates with fatty acids, peptides, other nucleosides, fatty acyl phosphotriesters, or
polymer derivatives. The primary hypothesis of this project was that conjugation of
nucleosides with other compounds offers a novel strategy in designing compounds with
enhanced anti-HIV activity. This combination may result in development of anti-HIV
agents having enhanced lipophilicity, longer duration of action by sustained
intracellular release of active substrates at adequate concentrations, higher uptake into
infected cells, and/or site specificity. The development of viral resistance to the
nucleosides would occur at a slower rate than to either compound alone. Furthermore,
some of the compounds may be used to bypass first rate-limiting phosphorylation step.

In the first two chapters, synthesis and anti-HIV activities of fatty acyl
derivatives of Zidovudine (AZT), Allovudine (FLT), Emtricitabine (FTC), Lamivudine
(3TC), and Stavudine (d4T) are discussed. Among all the compounds, 5'-0-myristoyl
derivative of FTC (2.31, ECso

=

70 nM against cell-free virus) exhibited the best anti-

HIV profile when compared with other fatty acyl derivatives of other nucleosides and
the physical mixture of FTC and myristic acid. 5'-0-Fatty acyl derivatives of FLT, 5'~

0-(12-azidododecanoyl)

derivative

of

FLT

(KP-1),

and

5'-0-(12-

thioethyldodecanoyl)thymidine (KP-17), also displayed good activity against cell-free
(EC 50 values of <0.2 to 0.4 µM, respectively) and cell-associated (EC 50 values of 0.9 to
1.0 µM , respectively) virus and minimal cellular toxicity. Cellular uptake studies for 5'0-fatty acyl derivatives of FLT and 3TC were conducted on CCRF-CEM cell line using
a 5(6)-carboxyfluorescein derivative attached through 12-aminododecanoic acid as a
linker to the nucleosides. The fluorescence-based studies indicated that the fatty acyl
derivatives of FLT and 3TC have a higher cellular uptake versus that of the
corresponding parent nucleoside substituted with a short alkyl group, such as

~-alanine.

The cellular uptake was concentration- and time-dependent.

In the third chapter, the synthesis and anti-HIV activities of succinate, suberate,
and peptide derivatives of AZT, FLT, and 3TC are discussed. The compounds were
designed in such a way to have 1 to 3 nucleosides. The hypothesis underlying this
project is that the conjugates are able to deliver 1 to 3 nucleoside analogs to the HIVinfected cells. Some of the nucleoside-peptide conjugates were also substituted with the
fatty acids. Peptides conjugated with fatty acids and nucleosides exhibited higher anti-

HIV activities when compared with those substituted only with nucleosides. Increasing
the number of anti-HIV nucleosides to 2 or 3 on the peptide chain enhanced the antiHIV potency. A glutamic acid ester derivative, FLT-Succinate-AZT(glutamyl)-3TC,
containing three different nucleosides was the most active compound among all the
derivatives with an ECso value of 0.9 µM.

Chapter 4 describes the synthesis of FLT from thymidine using a solid-phase
method to circumvent some of the problems associated with the solution-phase
methods, such as multiple protecting and deprotecting steps.

Fifth chapter discusses the synthesis and anti-HIV activities of phosphotriesters
of AZT and FLT. The conjugates were expected to get hydrolyzed inside the cell, to
release nucleoside monophosphates, and to bypass first rate limiting phosphorylation
step. The synthesized phosphotriester derivatives showed only modest anti-HIV
activity, significantly lower than that of their parent nucleosides

In chapter 6, synthesis and characterization of dextran prodrug (3TCSD) of the
antiviral drug 3TC is discussed. Dextran-3TC conjugate was synthesized to localize
3TC selectively in the liver and provide sustained release of the drug by the action of
liver lysosomes. Liver accumulation of conjugated 3TC was enhanced by 50 fold when
compared to that of parent drug.

In chapter 7 the synthesis and biological evaluation of double-barreled
conjugates of sodium cellulose sulfate (CS) with 2',3'-dideoxynucleosides analogs
(AZT, FLT and 3TC) using different linkers are described. Cellulose sulfate is a
polyanionic polymer which blocks HIV entry into the cells by interacting with the
positive charge of viral gp 120 protein. Nucleosides analogs act as reverse transcriptase
inhibitors (RTis). Conjugates were expected to undergo enzymatic hydrolysis and
\

thereby releasing nucleosides and cellulose sulfate targeting two different strains of
virus. Cellulose sulfate conjugates of nucleosides containing an acetate linker showed
good activity against both R5 and X4 strains of HIV. For example a CS-AZT conjugate
(acetate linker; 1.73% loading) was more effective than CS, especially against the RS
HIV-I lab-adapted strain BaL. Similarly, sodium cellulose sulfate-acetate-FLT and
showed better anti-HIV profile than sodium cellulose sulfate and the mixture of sodium
cellulose sulfate and FLT.

Overall, the research described in this dissertation demonstrated that conjugation
of anti-HIV nucleoside analogs with appropriate compounds (e.g., fatty acids, polymers,
peptides groups, or other nucleosides) is an alternative strategy for designing more
effective anti-HIV agents that can be further developed as therapeutic or preventative
agents.
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Preface
This thesis is written in the manuscript format. This work is dedicated to my
beloved parents whose constant support and unmatched love guided me throughout the
period of this study.

Chapter 1 and Chapter 2 discuss the synthesis and biological evaluations of fatty

'
acyl derivatives of various ddNs including FLT, AZT, 3TC, FTC, and d4T. Nucleosides
and myristic acid analogs act as RT inhibitors (RTis) and viral NMT inhibitors,
respectively. It was expected that the conjugation of compounds to enhance the
lipophilicity and thus the cellular uptake and to reduce the toxicity associated with
nucleosides. Furthermore, development of viral resistance to two active drugs would
occur at a slower rate than to either compound alone.

In Chapter 3, various peptide, succinate and suberate derivatives of nucleosides
were synthesized and evaluated for anti-HIV activities. Derivatives were synthesized in
such a way to allow the incorporation of several anti-HIV nucleosides in one compound
for combinational therapy. Peptide derivatives were myristoylated at N-terminal to
improve the cellular uptake. The derivatives were expected to release different
nucleosides intracellularly, to provide synergic effect, and to reduce the viral drug
resistance.

Chapter 4 deals with reported solution-phase methods for the synthesis of 3'fluoro-3 '-deoxythymidine (FLT) are cumbersome, require purification of intermediates,

Vlll

and include several protecting/deprotecting steps. To circumvent these problems, a solidphase strategy was designed for the synthesis of FLT.

In Chapter 5 nucleosides are converted into their monophosphate, diphosphate

and finally to triphosphate by enzymatic phosphorylation. Conversion to nucleoside
monophosphate is the rate-limiting step. Several phosphate triester derivatives of FLT
\

and AZT with myristic acid analogues were synthesized using glycol as a linker in order
to improve their cellular uptake and bypass rate-limiting monophosphorylation.

In Chapter 6, 3TC is used to treat hepatitis B viral infection. Treatment of HBV
infection is significantly dependent on its distribution and accumulation in the liver.
Therefore, 3TC was conjugated with dextran (25 kD) by using succinate linker to
synthesize 3TC-succinate-dextran conjugates. Since dextran (25 kD) has the capacity to
accumulate in the liver, the conjugate was expected to get hydrolyzed inside the liver
releasing free 3TC. Using this approach allowed a higher amount of 3TC to target the
liver.

Capter 7 deals with cellulose sulfate that belongs to the category of sulfonate and
sulfate polyanionic microbicides which inhibitors HIV entry

and sperm-function.

Bifunctional conjugates containing AZT or FLT as RTis and cellulose sulfate as HIV
entry blockers were synthesized. The conjugates were expected to provide additional
bisubstrate compounds having synergistic and broad-spectrum activity against susceptible
and AZT-resistant strains and sperm and STD-pathogen inhibiting properties.
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Introduction

1. Human Immunodeficiency Virus (HIV)

Human immunodeficiency virus (HIV) is a reterovirus, which mainly targets
the immune cells, such as T-lymphocytes, monocytes, B lymphocytes, and
macrophages that have CD4, a member of the immunoglobulin superfamily (Costin,
2007). The infection induces progressive loss of immune system, which ultimately
results in the opportunistic infections and malignancies associated with acquired
immunodeficiency syndrome (AIDS). According to the UNAIDS reports almost 33.2
million people were living with HIV at the end of 2007, a year in which 2.5 million
people were newly infected with HIV infection and 2.1 million died of AIDS. Current
antiretroviral drugs do not eliminate HIV and restore the immune system completely.
However, all combination therapy can reduce the viral replication to the minimum
level to prevent the advance of the infection. Another problem is the continued
development of drug-resistant virus to current antiretroviral drugs. Thus, there is an
urgent need to discover new, safe, and potent anti-HIV agents and preventive
strategies as existing therapies succumb to newly developed resistant virus.

HIV shares features common to all retroviruses and is able to route genetic
information from RNA to DNA. This is accomplished by a unique enzyme, Reverse
transcriptase (RT), which is encoded by a gene within the retroviral genome. HIV
contains three different types of structural proteins named the external glycoprotein
(Env), the capsid protein (Gag), and the viral enzymes necessary for replication (Pol)
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proteins. Env proteins (gp 120 and gp41) are responsible for viral binding with the
host cell membrane and for the infectivity of the viral particle by means of attachment
to specific cellular receptors. Gag proteins are responsible for forming the reteroviral
core (capsid). Pol proteins include pr integrases, RT, and protease which are
responsible for viral replication (Cohen et al., 2008).
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Fig l:(A) HIV and host cell; (B) Binding of gpl20 at CD4 inducing changes in
gpl20; (C) Attachment of gp120 with coreceptor; (D) Dissociation of gp41 from
gp 120; (E) Confirmation changes in gp4 l leading to hairpin formation bringing the
two membranes closer; (F) fusion of viral envelope and release of viral content in
cell

HIV life cycle starts with the attachment of HIV gp120 Env proteins to the
host cell membrane receptors. First, HIV Env gpl20 glycoprotein binds to CD4
receptor of the host cell (Dimitrov et al., 2005 and Weissenhom et al., 1997). This
binding induces conformational changes in gp 120 molecule and exposes its other
binding sites becoming suitable for attachment with coreceptors. Coreceptor binding
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leads to another conformational change in the viral envelope leading to gp 120
dissociation from gp41. Exposure of hydrophobic gp41 domains results in gp41-cell
membrane interaction. Finally, HRl and HR2 regions of gp41 form a six-helix hairpin
like structure bringing the two membranes closer to each other initiating fusion
process and release of viral contents in the host cell (Fig. 1).
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Fig. 2. HIV Life cycle

Once inside the host cell, the single stranded RNA gets converted into the
double stranded DNA by the action of RT (Fig. 2). Proviral DNA is then incorporated
into the host cell DNA by the action of integrase enzyme. Proviral DNA produces
viral RNA, which after translation forms polyproteins. Polyproteins undergo posttranslation by the action of protease enzyme to form functional proteins. These
proteins are further myristoylated at N-terminal glycine residue in the presence of Nmyristoyl transferase (NMT) enzyme to make them lipophilic. Lipophilic proteins
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along with the genetic material move towards the cell membrane resulting in the
formations of virus particles (Farazi et al., 2001; Wu et al., 2004).

2. RS and X4 Strains of HIV-1
Positively charged V3 loop of the viral protein gp 120 interacts with the
negatively charged CD4 receptor, CCR5, and CXCR4 coreceptors (Kajumo et al.,
2000, Cheng-Mayer et al., 1997). Transmembrane chemokine receptors belong to two
different classes of receptors C-X-C (a-receptor) and C-C W-receptor) (Deng et al.,
1996). The classification is on the basis of separation of first two cysteines by single
amino acid in C-X-C class and adjacent in C-C class.

Depending on the type of coreceptors used for viral binding to the cell
membrane, HIV can be classified in two categories; R5 and X4 strains of virus. These
two strains show completely different interactions with the host cells and produce
different pathogenic effects (Pollaskis et al., 2004, Fais et al., 1999). R5 strain of virus
interacts with CCR5 chemokine coreceptors for cell-binding (monocytotropic strain,
M-tropic) (Cheng-Mayer et al., 1997, Knox et al., 2004, Alkhatib et al., 1996). X4
strains of virus uses CXCR4 coreceptors to enter in the cells (lymphocytotropic strain,
T-tropic) (Yi et al., 1999, Kajumo et al., 2000). X4-strains of HIV contain higher
strength of positive charges at V3 loop than R5 virus (Shattock et al., 2002, Meylan et
al., 1994). Therefore, X4 virus interacts much better with the cell-membrane than R5,
but at the same time are more vulnerable to polyanionic entry blockers.
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3. 2',3'-Dideoxynucleoside Analogs as Reverse Transcriptase Inhibitors

2',3'-Dideoxynucleoside (ddN) analogs are used as the commercial drugs for
the treatment of HIV infection, AIDS, hepatitis B virus (HBV), and cancer. Several
ddNs, such as 2',3'-dideoxy-3'-thiacytidine (lamivudine, 3TC), 2',3'-didehydro-2',3'dideoxythymidine
(emtricitabine,
deoxythymidine

(stavudine,

FTC),

d4T),

2',3'-dideoxycytidine

(zidovudine,

AZT),

2',3'-dideoxy-5-fluoro-3'-thiacytidine
(zalcitabine,

ddC),

3'-azido-3'

(R)-9-(2-phosphonomethoxypropyl)adenine

(tenofovir, TFV), and 5-fluoro-2'-deoxyuridine (Floxuridine, 5FU) are commercially
used as in combination therapy with other drugs.

In order to produce their pharmacological effects, on entering the cells the
majority of ddNs are phosphorylated intracellularly to monophosphates, diphosphates,
and triphosphates in the presence of host cellular kinases. RT is a key enzyme in the
replicative cycle of HIV and HBV. In case of anti-retroviral therapy, ddNs are called
RT inhibitors. For example, anti-HIV ddNs are prodrugs that must enter the infected
cell and then be phosphorylated to the active triphosphates by host cell kinases. As
triphosphates, the ddNs act through inhibition of RT by means of substrate
competition with natural deoxynucleosides and through chain termination of the
nascent DNA being transcribed by the viral RT by means of incorporation of the ddN
triphosphates that lacks the 3'-hydroxyl group (Lee et al., 2001, Nikolenko et al.,
2005). Fig. 3 shows the activation of AZT as a representative example.
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The major problems with ddNs are their high level of clinical toxicities such as
bone marrow suppression and neuropathy For example, AZT triphosphate also inhibits
mitochondrial DNA polymerase (Lewis et al., 2006, Lund et al., 2007). Thus,
treatment with ddNs faces several challenges, such as a low therapeutic index caused
in part by inhibition of cellular polymerases, absolute dependence on host cell kinasemediated activation (Fig. 1), limited brain uptake, short half-life in blood, low
potential for metabolic activation, and the rapid development of resistance to drugs by
HIV-I. Some important limitations are discussed briefly.

The hydrophilic nature of ddNs leads to limited cellular uptake and
bioavailability. Extensive efforts have been carried out to synthesize lipophilic
prodrugs of anti-HIV nucleosides (Parang et al., 1998, 1997). The lipophilic prodrugs

6

0

must have acceptable stability prior to cellular uptake and selective biotransformation
to the active species.

The individuals being treated with the ddNs stops responding to the treatment
due to drug resistance. The continual use of ddNs often results in emergence of drugresistant virus. For example, single point mutation at Met 184 with Val and Ile results
in 3TC and FTC resistant HIV strains (Mulder et al., 2008, Sarafianos et al., 1999,
Diallo et al., 2003). HIV also produces resistance against d4T by K65R mutation
(Garcia-Lerma et al., 2007). Similarly, mutation at Met 552 with Val and Ile results in
3TC and FTC resistant HBV strains (Das et al., 2001). Viruses with resistance
mutations accumulate, sometimes with complete replacement of wild-type virus by
drug resistant mutants.
Combination therapy for controlling HIV-1 infections involving different
classes of anti-HIV drugs provides several potential advantages to reduce the drug
resistance (Zdanowicz, 2006). Two or more drugs may have additive or synergistic
interactions that produce better efficacy than either drug alone. In highly active antireteroviral therapy (HAART) HIV is targeted by different classes of reverse
transcriptase inhibitors along with protease inhibitors.
Furthermore, the first phosphorylation step of conversion of several ddNs to
their monophosphates is a slow and rate-limiting process (Van et al., 1990). In
attempts to bypass the first rate-limiting phosphorylation step in the metabolic
conversion of nucleoside analogs, numerous prodrugs of 5'-monophosphate types,
such as neutral species of phosphotriester derivatives of nucleosides have been
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proposed (Parang et al., 2000) which are readily taken by the infected cells. After the
action of hydrolytic enzymes, phosphotriesters results are converted to active
nucleoside monophosphate intracellularly.

4. Objectives of research
Various ddN conjugates with fatty acids, peptides, other nucleosides, and
polymer derivatives were synthesized with an intention to develop multifunctional
anti-HIV-1 agents. The hypothesis underlying this project was that safe, potent, and
broad-spectrum multifunctional anti-HIV agents can be designed to deliver and release
different active species intracellularly at the same time. Furthermore, development of
viral resistance to several active drugs would occur at a much slower rate than to either
compound alone. Subtype and mutant coverage will also be enhanced. Specific
objectives for each class of compounds are discussed here briefly.

Chapter 1 and Chapter 2
First two chapters discuss the synthesis and biological evaluations of fatty acyl
derivatives of various ddNs including 3'-fluoro-3'-deoxythymidine (FLT), AZT, 3TC,
FTC, and d4T. Nucleosides and myristic acid analogs act as RT inhibitors (RTis) and
viral NMT inhibitors, respectively. It was expected that the conjugation of compounds
to enhance the lipophilicity and thus the cellular uptake and to reduce the toxicity
associated with nucleosides. Furthermore, development of viral resistance to two
active drugs would occur at a slower rate than to either compound alone.
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Chapter 3

Various peptide, succinate and suberate derivatives of nucleosides were
synthesized and evaluated for anti-HIV activities. Derivatives were synthesized in
such a way to allow the incorporation of several anti-HIV nucleosides in one
compound for combinational therapy. Peptide derivatives were myristoylated at Nterminal to improve the cellular uptake. The derivatives were expected to release
different nucleosides intracellularly, to provide synergic effect, and to reduce the viral
drug resistance.

Chapter 4

Reported solution-phase methods for the synthesis of FLT are cumbersome,
require purification of intermediates, and include several protecting/deprotecting steps.
To circumvent these problems, a solid-phase strategy was designed for the synthesis of
FLT (Agarwal et al., 2007)

Chapter 5

Nucleosides are converted into their monophosphate, diphosphate and finally
to

triphosphate

by

enzymatic

phosphorylation.

Conversion

to

nucleoside

monophosphate is the rate-limiting step. Several phosphate triester derivatives of FLT
and AZT with myristic acid analogues were synthesized using glycol as a linker in
order to improve their cellular uptake and bypass rate-limiting monophosphorylation
(Agarwal et al., 2008).
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Chapter 6

3TC is used to treat hepatitis B viral infection. Treatment of HBV infection is
significantly dependent on its distribution and accumulation in the liver. Therefore,
3TC was conjugated with dextran (25 kD) by using succinate linker to synthesize
3TC-succinate-dextran conjugates (Chimalakonda et al., 2007). Since dextran (25 kD)
has the capacity to accumulate in the liver, the conjugate was expected to get
hydrolyzed inside the liver releasing free 3TC. Using this approach allowed a higher
amount of 3TC to target the liver.

Chapter 7

Cellulose sulfate belongs to the category of sulfonate and sulfate polyanionic
microbicides which inhibitors HIV entry (Ketas et al., 2003; Chan and Kim, 1998) and
sperm-function (Anderson et al., 2000). Bifunctional conjugates containing AZT or
FLT as RTis and cellulose sulfate as HIV entry blockers were synthesized. The
conjugates were expected to provide additional bisubstrate compounds having
synergistic and broad-spectrum activity against susceptible and AZT-resistant strains
and sperm and STD-pathogen inhibiting properties.
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1.1. Abstract
A number of 5'-0-fatty acyl derivatives of 3'-fluoro-2',3'-dideoxythymidine
(FLT) were synthesized and their anti-HIV activities were evaluated and compared
with the corresponding 5'-0-fatty acyl derivatives of 3'-azido-2',3'-dideoxythymidine
(AZT). Various assays such as anti-HIV activity against cell-free and cell-associated
virus, multidrug resistant virus, vaginal cell viability studies, and sperm viability
studies were performed for the selected compounds. Among the compounds, 5'-0-(12azidododecanoyl) (KP-1), 5'-0-myristoyl (KP-16), and 5'-0-(12-thioethyldodecanoyl)
(K.P-17) derivatives of FLT with EC 50 values of 0.4 µM, 1.1 µM , and < 0.2 µM,
respectively, against cell-free virus were found the most potent compounds with
minimal cellular toxicity, and were selected for further studies. The tetradecanol ether
analogs of FLT (1.7, EC 5o = 176 µM) and AZT (1.8, EC 5o = 27.6 µM) were found to
be inactive under similar conditions because of the lack of hydrolysis to the parent
compounds, nucleosides and myristic acid. The data suggest that the ester hydrolysis
to FLT or AZT and fatty acids was critical for producing the anti-HIV activity. A
number of FLT derivatives were further studied to determine their physicochemical
properties (e.g., solubility, Log P, pKa) and cellular uptake. Cellular uptake studies
were conducted on CCRF-CEM cell line using 5(6)-carboxyfluorescein derivatives of
FLT attached through ~-alanine (1.5) or 12-aminododecanoic acid (1.6) as linkers.
Fluorescein-substituted analog of FLT with long chain length (1.6) showed > 12 times
better cellular uptake profile than analog with short chain length (1.5). Cellular uptake
studies revealed that the attachment of fatty acid improves the cellular uptake of the

16

nucleoside conjugate. KP-1 and KP-17 are currently under evaluation m the
preclinical studies.

1.2. Introduction
Alovudine (FLT, 3'-fluoro-2',3'-dideoxythymidine) is a thymidine nucleoside
analogue and a potent human immunodeficiency virus (HIV) reverse transcriptase
(RT) inhibitor. FLT showed 10 times more potency against HIV 1 when compared
with Zidovudine (AZT) and was even active against AZT resistant virus (Kong et al.,
1992). FLT displayed similar pharrnacokinetic parameters as AZT and Stavudine
(d4T) in monkey and rats (Schinazi et al., 1990 and Boudinot et al., 1991).

Once enters the cell, FLT gets converted into FLT triphosphate by the action of
host cellular kinases (Kong et al., 1992). FLT triphosphate is then incorporated into
the DNA of HIV leading to chain termination at 3'-position. FLT is also a potent
inhibitor of RT enzyme, which coverts viral RNA into proviral DNA (Mansuri et al. ,
1990) (Figure 1.1 ).

FLT was under clinical evaluation from 1990- 1992. The studies were stopped
after FLT failed phase II clinical trials because of the observed hematological
toxicities including neutropenia, leucopenia, and anemia (Rusconi, 2003). The toxicity
of FLT was suggested to be the result of DNA damage and apoptosis (Sundseth et al.,
1996). In 2001, Medivir (Sweden) again started the phase II clinical trials of FLT
(Rusconi, 2003). The trials were conducted on fifteen HIV infected patients with 7.5
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mg/day alovudine and all the patients showed significant reduction in HIV load with
no serious side effects. In the latest study, alovudine was used in doses of 0.5, 1.0 and
2.0 mg/day for four weeks to test the viral inhibition (Ghosn et al., 2007). The results
indicated that FLT produced modest viral load reduction but could not produce the
desired clinical anti-viral activity.

N-Myristoyl transferase (NMT) enzyme is involved in catalyzing the
myristoylation of several proteins in HIV life cycle (e.g., capsid protein pl 7, Pr160gagP01,

Pr55gag, p27nef). At N-terminal glycine, viral proteins (gag and nef) are covalently

attached to myristic acid in the presence of NMT. Myristic acid attachment makes the
proteins more hydrophobic, which improves protein-protein and protein-membrane
interactions (Farazi et al., 2001). For example, after the N-myristoylation, p17 protein
localizes itself towards the cell membrane, where new virus is produced (Wu et al.,
2004) (Figure 1.1).

The replication of HIV-1 can be inhibited by heteroatom-containing analogs of
myristic acid without accompanying cellular toxicity (Bryant et al., 1993, Takamune
et al. , 2002). It has been previously reported that several fatty acids, such as 2methoxydodecanoic acid, 4-oxatetradecanoic acid, and 12-thioethyldodecanoic acid,
reduce HIV-1 replication in acutely infected T-lymphocytes. For example, 12thioethyldodecanoic acid was moderately active (EC 50 = 9 .4 µM) against HIV-infected
T4 lymphocytes (Parang et al., 1997).
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It is hypothesized that the attachment of nucleoside analogs to the long chain

myristic acid analogs enhances their lipophilicity and thus their cellular uptake. Once
the ester conjugate enters the cells, it gets hydrolyzed by esterases and generates two
active molecules, nucleoside analog and fatty acid, targeting reverse transcriptase (RT)
and N-myristoyl transferase (NMT) enzymes, respectively (Figure 1.1 ).

A number of 5'-0-fatty acyl derivatives of FLT were previously reported to
have better and wider activity profile than FLT (Parang et al., 1996, 1997). These
compounds were designed to act as bifunctional anti-HIV agents targeting two
important enzymes for viral reproduction. Herein, we report the synthesis of additional
compounds, a more extensive evaluation of biological activities of 5'-0-fatty acyl
derivatives of FLT in comparison with 5'-0-fatty acyl derivatives of AZT and parent
nucleosides, cellular uptake, mechanistic studies, and their applications as anti-HIV
agents and microbicides.
Microbicides are the compounds that can be applied inside the vagma or
rectum topically to protect against sexually transmitted diseases including HIV. There
is an urgent need to develop a safe over-the-counter intravaginal/intrarectal anti-HIV
microbicide for prevention of HIV transmission.

1.3. Materials and Methods
1.3.1. Materials

FLT was synthesized in 5 g scale according to the previously reported method
(Herdewijn et al., 1987). FLT and AZT were purchased from Euro Asia Tran
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Continental (Bombay, India) for large-scale synthesis of ester conjugates. 12Bromododecanoic acid was purchased from Sigma Aldrich Chemical Co. 5(6)Carboxyfluorescein (FAM) was purchased from Novabiochem. All the other reagents
including solvents were purchased from Fisher scientific.
The products were purified on a Phenomenex®Gemini 10 µm ODS reversedphase column (2.1

x

25 cm) with Hitachi HPLC system using a gradient system at

constant flow rate of 17 ml/min (Table 1.1).

Table 1.1. HPLC method used for purification of the compounds.
Acetonitrile
Concentration
B (%)
0.0

Flow rate
(mL/min)

0.00

Water
Concentration
A(%)
100.0

1.0

100.0

0.0

17.0

45.0

0.0

100.0

17.0

55.0

0.0

100.0

17.0

59.0

100.0

0.0

17.0

60.0

100.0

0.0

1.0

Time
(min)

1.0

The purity of the compounds was confirmed by usmg analytical Hitachi
analytical HPLC system on a C18 column (Grace Allsphere ODS 2-3 µ, 150 X 4.6

mm) using a gradient system (water:acetonitrile 30:70 v/v) at constant flow rate of 1
ml/min with a UV detection at 265 run. The chemical structures of final products were
characterized by nuclear magnetic resonance spectrometry (1H NMR and
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C NMR)

determined on a Bruker NMR spectrometer (400 MHz) and confirmed by a highresolution PE Biosystems Mariner API time-of-flight electrospray mass spectrometer..
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Chemical shifts are reported in parts per millions (ppm) and confirmed by a highresolution PE Biosystems Mariner API time-of-flight electrospray mass spectrometer.
For cellular uptake studies, cells were analyzed by flow cytometry (F ACSCalibur:
Becton Dickinson) using FITC channel and CellQuest software. Cell-viability studies
were conducted using Cellometer Auto T.4 (Nexcelom Biosciences). The real time
microscopy in live CCRF-CEM cell line with or with compounds were imaged using
ZEISS Axioplan 2 light microscope equipped with transmitted light microscopy with a
differential-interference contrast method and an Achroplan 40X objective.

1.3.2. Chemistry
1.3.2.1. 5'-0-(Fatty Acyl) Ester Derivatives of FLT and AZT
First, Several 5'-0-(fatty acyl) ester derivatives of FLT and AZT were
synthesized at scale of 100 mg according to the previously reported procedure (Parang
et al., 1998) by the reaction of FLT and fatty acyl chloride derivatives in the presence
of 4-dimethylaminopyridine (DMAP). In the next step, three FLT esters [5'-0(myristoyl)-3'-fluoro-2',3'-dideoxythymidine

(KP-16),

(12-azidododecanoyl)thymidine

and

(KP-1 ),

3'-fluoro-2',3'-dideoxy-5'-0-

3'-fluoro-2 ',3 '-dideoxy-5 '-0-(12-

thioethyldodecanoyl)thymidine (KP-17)] were synthesized at larger scale of 5 g, and
25 g. Fatty acyl chloride derivatives were synthesized by the reaction of fatty acids
with oxalyl chloride.
In general, a reaction mixture consisting of the appropriate fatty acid (1.3
mmol), oxalyl chloride (0.25 g, 1.95 mmol), and anhydrous benzene (18 mL) was
stirred at room temperature (25 °C) for 1 h. the yellow solution thus obtained was
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evaporated to dryness under reduced pressure. The residual oil was dissolved in
benzene (18 mL) and the solution was added dropwise to an ice-cold, stirred solution
consisting of the AZT (0.34 g, 1.3 mrnol) or the FLT (0.32 g, 1.3 mrnol), DMAP (0.23
g, 1.9 mmol) and anhydrous benzene (18 mL) under anhydrous conditions. The

solution was stirred in an ice bath for 1 h and then refluxed in an oil bath for about 3 h.
the mixture was cooled and diluted with benzene (72 mL). The organic solution was
washed with saturated aqueous sodium carbonate (2

x

11 mL) and then with water (2

x 11 mL). The organic layer was dried over anhydrous sodium sulfate and was

evaporated to dryness. The residue consisting of one major product was purified by
silica gel chromatography using chloroform as eluent to yield the product. The
procedure was used for the synthesis of most of ester analogs, unless noted otherwise.

(±)-3'-Azido-2 ',3 '-dideoxy-5 '-0-(pentadecanoyl)thymidine (KP-6). Oil; yield (100
mg, 90%); 1H NMR (400 MHz, CDCh, 8 ppm): 8.00-8.10 (br s, lH, N-H), 7.24 (s,

lH, H-6), 6.10-6.18 (m, lH, H-1'), 4.39 (dd, J= 12.2 and 4.3 Hz, lH, H-5\ 4.31 (dd,
J= 12.2 and 4.3 Hz, lH, H-5\ 4.15-4.23 (m, lH, H-3\ 4.09 (dd,

=

4.3 and 8.7 Hz,

IH, H-4\ 2.28-2.52 (m, 3H, CH2 COO, H-2", H-2\ 1.95 (s, 3H, 5-CH3), 1.60-1.72
(m, 2H, CH2 CH2 COO), 1.22-1.31 (br s, 22H, methylene protons), 0.89 (t, J= 6.4 Hz,

3H, CH3).

(±)-3 '-Azido-2 ',3 '-dideoxy-5 '-0-(2-methoxyteradecanoyl)thymidine (KP-8). Oil;
yield (100 mg, 90%); 1H NMR (400 MHz, CDCh, 8 ppm): 9.00 (s, lH, N-H), 7.28 (s,
lH, H-6), 6.17 (t, J= 6.2 Hz, lH, H-1'), 4.50 (dd, J= 12.2 and 3.7 Hz, lH, H-5), 4.35
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(dd, J= 12.2 and 3.7 Hz, lH, H-5\ 4.20 (ddd, J = 7.6, 6.2, and 5.0 Hz, lH, H-3\
4.10 (ddd,

=

5.0, 3.7, and 3.0 Hz, lH, H-4\ 3.38 (t, J= 7.6 Hz, lH, CHCO), 3.39 (s,

3H, OCH3 ), 2.50 (ddd, J = 13.9, 6.2, and 6.2 Hz, lH, H-2"), 2.37 (ddd, J = 13.9, 7.6
and 6.2 Hz, H-2\ 1.95 (s, 3H, 5-CH3), 1.70-1.80 (m, 2H, CH2CH(OCH3)), 1.32-1.42
(m, 2H, CH2CH2CH(OCH3)), 1.22-1.31 (br m, 18H, methylene protons), 0.89 (t, J =

7.6 Hz, 3H, CH3); HR-MS (ESI-TOF) (m/z):

C2s~1Ns06,

calcd, 507.3057; found,

530.6788 [M +Nat.

{±)-3'-Fluoro-2',3'-dideoxy-5'-0-(2-methoxyteradecanoyl)thymidine (KP-15). Oil;
yield (100 mg, 90%); 1H NMR (400 MHz, CDCh, 8 ppm): 8.50 (s, lH, NH), 7.31 (s,
lH, H-6), 6.40 (dd, J= 9.0 and 5.6 Hz, lH, H-1'), 5.08-5.26 (dd, J= 52.5 and 5.5 Hz,
lH, H-3'), 4.46 (dt, J= 25.6 and 4.0 Hz, lH, H-4'), 4.55 (dd, J= 12.5 and 4.1 Hz, lH,
H-5'), 4.25 (dd, J = 12.5 and 4.1 Hz, lH, H-5"), 3.38 (t, J = 7.6 Hz, lH, CHCO), 1.95
(s, 3H, 5-CH3), 2.55-2.72 (m, lH, H-2"), 2.15-2.25 (m, lH, H-2'), 1.70-1.80 (m, 2H,
CH2CH(OCH3)), 1.32-1.42 (m, 2H, CH2CH2CH(OCH3)), 1.20-1.30 (br m, 18H,
methylene protons), 0.87 (t, J = 7.6 Hz

3H, CH3). HR-MS (ESI-TOF) (m/z):

C2sH41fN206, calcd, 484.2949; found, [M +Nat,

1.3.2.2. 5(6)-Carboxyfluorescein Derivatives of FLT
General

Procedure

for

aminopropanoyl)thymidine

the

Synthesis
(1.3)

and

of 3'-Fluoro-2',3'-dideoxy-5'-0-(33 '-Fluoro-2 ',3 '-dideoxy-5'-0-(12-

aminododecanoyl)thymidine (1.4). FLT (0.60 mmol, 150 mg), the appropriate
Fmoc-amino

acid

(1.2

mmol),

and
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2-(lH-benzotriazole-l-yl)-1,1,3,3-

tetramethyluronium hexafluorophosphate (HBTU, 500 mg, 1.3 mmol) were dissolved
in dry DMF (10 mL) and dry N-methylmorpholine (2 mL). The solution was stirred
overnight at room temperature. Reaction mixture was concentrated and dried under
reduced pressure to afford crude 5'-0-Fmoc-amino acid derivatives of FLT, 1.1 and
1.2. The crude products compounds were dissolved in THF (10 mL). To the reaction

mixture was added piperidine (6 µL, 0.06 mmol), 1-octanethiol (10 mM solution in
THF, 6 mmol, 0.6 mL). The reaction mixture was allowed to stir for 1 h at room
temperature. The reaction solution was concentrated at reduced pressure. The residue
was purified with reversed phase HPLC using C 18 column and using a gradient system
water/acetonitile as solvents as described above.

3 '-Fluoro-2 ',3 '-dideoxy-5 '-0-(3-aminopropanoyl)thymidine (1.3). White Powder;

yield (100 mg, 55%). HR-MS (ESI-TOF) (m/z): C 13 H 1sFN30 5: calcd. 315.1230; found
316.3369 [M +Ht, 631.4397 [2M +Ht.

3 '-Fluoro-2 ',3 '-dideoxy-5 '-0-(12-aminododecanoyl)thymidine

(1.4).

White

Powder; yield (150 mg, 57%). 1H NMR (400 MHz, CD 30D, 8 ppm): 11.38 (s, lH,
NH), 7.81-7.98 (br s, 2H, NH2 ), 7.45 (s, lH, H-6), 6.18 (t, J= 7.9 Hz, H-1'), 5.30 (dd,

J = 53.2 and 4.2 Hz, lH, H-3'), 4.15-4.36 (m, 3H, H-5', H-5", H-4'), 3.15 (t, J = 8.2

Hz, 2H, CH2NH), 2.68-2.82 (m, 2H, CH2CO), 2.21-2.52 (m, 4H, CH2CH2NH, H-2',
H-2"), 1.76 (s, 3H, 5-CH3), 1.05-1.24 (br m, 16H, methylene envelope);

13

C NMR

(DMSO-d6, 100 MHz, 8 ppm): 173.08 (COO), 164.07 (C-4 C=O), 150.87 (C-2 C=O),
136.08 (C-6), 110.03 (C-5), 94.38 (d, J= 175.5 Hz, C-3'), 84.66 (C-1'), 82.03 (d, J=
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25.8 Hz, C-4'), 63.49 (d, J= 10.6 Hz, C-5'), 55.32, 51.54 (CH2NH), 36.33 (d, J= 20.6
Hz, C-2'), 33.73 (CH2COO), 29.30, 29.25, 29.12, 28.96, 28 .91, 28.84, 27.41, 26.23,
24.79, 23 .51 (methylene carbons), 13.86 (5-CH3). HR-MS (ESI-TOF) (m/z):

c22H36FN30s : calcd. 441.5367; found 442.1974 [M +Ht, 883.5248 [2M +Ht.

General

Procedure

for

the

Synthesis

of

5'-0-(5(6)-Carboxyfluorescein)

Derivatives of FLT (1.5 and 1.6)
FLT was attached to 5(6)-carboxyfluorescein through

~-alanine

and 12-

aminododecanoic acid as linkers. A mixture of 5(6)-carboxyfluroscein (430 mg, 1.15
mmol), the corresponding FLT-amino acid (1.3 and 1.4, 0.29 mmoL), and HBTU (440
mg, 1.15 mmol) were dissolved in dry DMF (10 mL) and diisopropylethylamine
(DIPEA, 2 mL, 15 mmol) and stirred overnight at room temperature. Reaction mixture
was concentrated and dried under vacuum. Final compounds were purified with
reversed phase HPLC using C 18 column and water/acetonitile as solvents as described
above.

3'-Fluoro-2 ',3 '-dideoxy-5 '-0-(3-(N(5(6)carboxyfluorescein)aminopropanoyl)thymidine (1.5). Yield (25 mg, 15 %). 1H

NMR (400 MHz, CD 30D, 8 ppm): 8.48 (s, 0.5H, FAM-Ar-H, 5 or 6 isomer), 8.19 (d,
J

= 8.2 Hz, 0.5H, F AM-Ar-H, 5 or 6 isomer), 8.04, 8.13 (two dd, J = 1.6 and 8.0 Hz,

lH, FAM-Ar-H), 7.58 (s, 0.5H, FAM-Ar-H, 5 or 6 isomer), 7.20-7.42 (m, lH, H-6,
and 0.5 H FAM-Ar-H, 5 or 6 isomer), 6.96-7.05 (m, 4H, FAM-Ar-H), 6.84 (d, J = 8.9
Hz, 2H, FAM-Ar-H), 6.11and6.17 (two dd, J= 5.6 and 8.9, lH, H-1'), 5.16 and 5.23
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(two dd, J= 53.3 and 5.0 Hz, lH, H-3'), 4.20-4.40 (m, 3H, H-5' and H-5", H-4'), 3.53
and 3.64 (two t, J = 6.5 Hz, 2H, CH2NH), 2.10-2.74 (m, 4H, H-2', H-2", CH2CO),

1.72 and 1.78 (two s, 3H, 5-CH3);

13

C NMR (CD3CN, 100 MHz,

o ppm):

172.63

(COO), 172.47 (NHCO), 168.06, 165.63, 156.25 (FAM-Ar-C), 160.49 (C-4 C=O),
151.20, 151.14 (C-2 C=O), 139.64, 133.27, 131.43, 129.24, 129.60, 127.37, 127.82,
126.07 (FAM-Ar-C), 136.46, 136.52 (C-6), 116.84 (FAM-Ar-C), 113.47, 113.58 (C5), 102.83 (FAM-Ar-C), 94.31, 94.19 (two d,J= 176.5 Hz, C-3'), 85.53, 85.57 (C-1'),
82.57, 82.48 (two d, J = 26.8 Hz, C-4'), 64.13, 64.00 (two d, J = 11.2 Hz, C-5'),
55.11 , 49.09 (Cl-hNH), 36.07, 35.97 (C-2'), 33.76, 33.89 (CH2COO), 11.95, 12.01 (5CH3). HR-MS (ESI-TOF) (m/z): C34H2sFN3011: calcd. 673.1708; found 674.5083 [M

+Ht, 1348.6951 [2M + H(

3'-Fluoro-2 ',3 '-dideoxy-S'-0-(12-(N(S(6)carboxyfluorescein)aminododecanoyl)thymidine (1.6). Yield (30 mg, 13%); 1H

NMR (400 MHz, CD 30D,

oppm): 8.45 (s, 0.5H, FAM-Ar-H, 5 or 6 isomer), 8.17 (dd,

J= 1.5 and 8.0 Hz, 0.5H, FAM-Ar-H, 5 or 6 isomer), 8.10 (s, lH, FAM-Ar-H), 7.64
(s, 0.5H, FAM-Ar-H, 5 or 6 isomer), 7.43 (s, lH, H-6), 7.30 (d, J = 5.1 Hz, 0.5H,
FAM-Ar-H, 5 or 6 isomer), 6.76 (s, lH, FAM-Ar-H), 6.70 (dd, J = 3.2 and 8.7 Hz,
3H, FAM-Ar-H), 6.61 (dd, J= 2.0 and 8.7 Hz, 2H, FAM-Ar-H), 6.16-6.26 (m, lH, H1'), 5.20 (dd, J= 53.4 and 4.9 Hz, lH, H-3'), 4.30-4.45 (m, 2H, H-5' and H-5"), 4.19
(d, J= 5.5 and 13.6 Hz, lH, H-4'), 3.38 (t, J= 7.0 Hz, 2H, CH2NH), 2.44-2.63 (m, lH,
H-2'), 2.15-2.38 (m, 3H, CH2CO, H-2"), 1.83 (s, 3H, 5-CH3), 1.47-1.66 (m, 4H,
CH2CH2COO, CH2CH 2 -NH), 1.05-1.24 (br m, 16H, methylene envelope);
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13

C NMR

(CD 30D, 100 MHz, 8 ppm): 174.85 (COO), 170.11 (NHCO), 168.34, 166.35, 155.35
(FAM-Ar-C), 163.45 (C-4 C=O), 152.29 (C-2 C=O), 142.15, 138.28, 137.40, 131.01,
129.46, 126.86, 126.08, (FAM-Ar-C), 135.12 (C-6), 115.14 (FAM-Ar-C), 112.02 (C5), 103.72 (FAM-Ar-C), 95.32(d,J=177.6 Hz, C-3'), 86.92 (C-1'), 84.15 (d,J=26.3
Hz, C-4'), 64.66 (d, J = 11.7 Hz, C-5'), 54.98, 41.40 (CH2NH), 38.83 (d, J = 21.0 Hz,
C-2'), 35.02 (CH2COO), 30.77, 30.74, 30.68, 30.59, 30.54, 30.45, 30.41, 30.34, 30.26,
30.21, 28.18, 26.10 (methylene carbons), 12.81 (5-CH3). HR-MS (ESI-TOF) (m/z):
C43 !ii 6FN3011: calcd. 799.3116; found 800.4325 [M +Ht.

1.3.2.3. General Procedure for the Synthesis of 3'-Fluoro-2',3'-dideoxy-5'-0(tetradecanyl)thymidine

and

(1.7)

3'-Azido-2',3'-dideoxy-5'-0-

(tetradecanyl)thymidine (1.8). Ether derivatives of AZT and FLT were synthesized

by using Mitsunobu reaction. AZT or FLT (100 mg, 0.4 mrnol), tetradecanol (0.8
mmol), and triphenylphosphine (TPP, 210 mg, 0.8 mrnol) were dissolved in DMF (10
mL). To the reaction mixture was added diisopropylazodicarboxylate (DIAD, 100 mg,

0.5 mrnol)). The mixture was stirred for 5 h at room temperature. The solvent was
removed in vacuo. The residue was purified by reversed phase HPLC using C1s
column and water/acetonitile as solvents as described above.

3 '-Fluoro-2 ',3 '-dideoxy-5 '-0-( tetradecanyl)thymidine (1. 7). White Powder; yield

(80 mg, 50%); 1H NMR (400 MHz, CDCh, 8 ppm): 7.52 (s, lH, H-6), 6.19 (dd, J=
9.0 and 5.6 Hz, lH, H-1'), 5.18 (dd, J= 54.0 and 4.6 Hz, lH, H-3'), 4.18 (d, J= 27.5
Hz, lH, H-4'), 3.65-3.86 (m, 4H, CH20, H-5' and H-5"), 2.34-2.52 (m, lH, H-2'),
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2.10-2.34 (m, lH, H-2"), 1.77 (s, 3H, 5-CH3), 1.37-1.55 (m, 2H, CH2CH20), 1.051.24 (br s, 20 H, methylene envelope), 0.74 (s, 3H, CH3);

13

C NMR (CDCh, 100 MHz,

8 ppm): 163.35 (C-4 C=O), 150.65 (C-2 C=O), 134.57 (C-6), 109.98 (C-5), 94.37 (d, J
== 176.8 Hz, C-3'), 86.75 (C-1'), 85.20 (d, J= 24.2 Hz, C-4'), 61.95 (d, J= 11.0 Hz, C-

5'), 41.28 (CH2-0), 38.15 (d, J = 20.9 Hz, C-2'), 32.45, 31.65, 29.38, 29.28, 29.22,
29.08, 27.31, 26.72, 25.54, 22.41 (methylene carbons), 13.81 (CH3), 12.94 (5-CH3).
HR-MS (ESI-TOF) (m/z): C24H41FN204: calcd. 440.305; found 441.1052 [M +Ht.

3 '-Azido-2 ',3 '-dideoxy-5'-0-(tetradecanyl)thymidine (1.8). White Powder; yield

(90 mg, 50%. 1H NMR (400 MHz, CDCh, & ppm): 7.35 (s, lH, H-6), 6.02 (t, J= 6.6

Hz, lH, H-1'), 4.35 (dd, J= 5.1, 11.5 Hz, lH, H-3'), 3.88-3.96 (m, 2H, H-5' and H-5"),
3.85 (t, J= 7.3 Hz, lH, CH2 0), 3.76 (d, J= 10.6 Hz, lH, H-4'), 2.40-2.54 (m, lH, H2'), 2.28-2.40 (m, lH, H-2"), 1.86 (s, 3H, 5-CH3), 1.53 (t, J = 6.3 Hz, 2H, CH2 CH20),
1.12-1.30 (br s, 20H,methylene envelope), 0.82 (t, J = 6.6 Hz, 3H, CH3 );

13

C NMR

(CDCh, 100 MHz, & ppm): 163.28 (C-4 C=O), 150.72 (C-2 C=O), 134.58 (C-6),
110.29 (C-5), 87.23 (C-1'), 84.47 (C-4'), 61.89 (C-5'), 59.90 (C-3'), 41.46 (CH2 0),
37.35 (C-2'), 31.85, 29.58, 29.53, 29.48, 29.28, 29.24, 27.51, 26.93, 22.62, (methylene
carbons), 14.05 (CH3), 13.22 (5-CH3). HR-MS (ESI-TOF) (m/z): C24 H41 N 504: calcd.
463.3159; found 464.1528 [M +Ht.

1.3.3. Physicochemical Properties (pKa, Log P, Log D., Solubility).

Physicochemical properties including pKa, LogD, and solubility were
determined for KP-1 as a model compound.
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1.3.3.1. pKa

The pKa of KP-1 was determined using the D-PAS (spectroscopic) technique.
The sample was initially titrated in a fast titration between pH 1.8 and pH 12.1 at
concentrations of 33-49 µM under aqueous conditions. Precipitation of the sample
from solution was observed below approximately pH 11 . The sample was
subsequently titrated under methanol-water cosolvent conditions in two triple titrations
from pH 12.2 to pH 3. 7 at concentrations of 31-49 µM. The methanol ratio varied
from to 25.5-50.8%. No precipitation of the sample from solution was observed under
this condition. The pKa was determined from the spectroscopic data by YasudaShedlovsky extrapolation of the individual obtained results. KP-1 was found to have
an aqueous pKa value of 9.67 ± 0.02 determined by spectroscopic method under
methanol-water cosolvent conditions.

1.3.3.2. Log P and Log D
It was not possible to measure the partition coefficient of the fatty acyl

derivatives of FLT and AZT in standard n-octanol/water mixture, because of the
insolubility of the compounds in water. The Log P of KP-1 was initially investigated
by the pH-metric (potentiometric) method. The sample was titrated in three triple

titrations from pH 2. 5 to pH 11 .9 at concentrations of 0. 7-1.1 mM in various ratios of
octanol/water. The results indicated high sample lipophilicity although the Log P
could not be determined potentiometrically due to the apparent pKa in octanol shifting
out of the measurable range.
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Log D Determination by LDA- Liquid Liquid Distribution Chromatography

The Log D at pH 7.4 was measured as 5.04 using liquid chromatography. The
ProfilerLDA is an isocratic chromatography system, which uses an octanol-coated
column

with

octanol

saturated

mobile

phases

adjusted

to

pH

7.4.

A set of standard compounds with well known Log D octanol values are run
through the column before the samples, the generated retention times are used as a
calibration curve to relate retention times generated for sample compounds to Log D
(Table 1.2., Figure 1.2).

Table 1.2. Log D values and retention time for standard compounds
LDA Calibration 3
Retention
LogD
Time
3.1800
109.00
197.70
3.5000
420.79
4.0000
1067.35
4.6000

Standard Name
Compounds

Benzophenone
Diphenylamine
Diphenylether
Dibutylphtalate

Change in energy counts (summed)

600000
500000
400000
300000
200000
100000

·2.0

-1.5

-1.0

-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4 .5

5.0

5.5
logo

Figure 1.2. Standard curve (LDA Calibration 3) for Standard compounds.

31

Detection was carried out by using an UV diode array. A multi-wavelength
peak location system is used to home on the largest peak present in the chromatogram.
This reduces interference from impurity peaks to a minimum (assuming that impurities
are much smaller in size than the sample peak). It is assumed that the largest peak in
the chromatogram is the compound of interest as there is no positive identification in
this system (e.g. MS detection). A value of 5.04 was obtained, which should
correspond to the neutral Log P, in consideration of the sample pKa (Figure 1.3, Table
1.3).
Table 1.3. LogD values and retention time for KP-1

KP-1

Test Name
Compounds

LogD

KP-1

5.04

Retention
Time
2205 .69

Change in energy counts (summed)

180000
160000
140000
120000
100000
80000
60000
40000
20000
0

J_~~~~-==:::=::::::".~==~~~~~~~~'!!!._~~
-0.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

5.0

5.5
logD

Figure 1.3. LDA calibration 3 curve for KP-1

1.3.3.3. Solubility

Difficulties were also encountered in our solubility analysis of KP-1 due to the
low sample solubility in ionized form and suspected sample decomposition at high pH.
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We were able to determine an upper limit for the sample solubility of 510 nM by
shake-flask methodology, however.

The sample solubility was initially analyzed using the Sirius CheqSol method.
The sample was titrated under aqueous conditions from pH 12.1 to low pH at an initial
concentration of 3.1 mM. As full sample dissolution was not evident at the start of the
CheqSol study, the experiment was paused and the sample was sonicated in an
ultrasonic bath containing hot water, for several minutes. When the experiment was
resumed, sample precipitate was only observed below approximately pH 7, where a
second sample ionization stage was apparent. We consider the sample to have
decomposed to produce another species with a significantly lower acidic pKa during
the "hot"-sonification at high pH. To avoid further complication due to sample
decomposition, the sample solubility was subsequently investigated by shake-flask
methodology with UV -spectroscopic sample detection.

To produce a saturated solution of KP-1, approximately 1 mg of solid material
was added to 10 mL of aqueous solution, adjusted to pH 2.3 with 0.5 M HCI. The
sample was then sonicated in an ultrasonic bath for several hours (at room
temperature) before being left to equilibrate for a period of approximately three days.
The supernatant was then filtered under vacuum through a 0.2 µm PVDF filter plate,
and the UV absorption spectrum of the sample was measured (after adjusting the pH

of the solution to 11.8 with 0.5M KOH). Molar absorption coefficients of KP-1 were
obtained at pH 11.8 for 25 µM, 50 µM and 100 µM solutions of KP-1, in order to
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quantify the concentration of sample in the saturated supernatant. The UV-absorption
signal (0.0039) of the supernatant at the absorption maximum of KP-1 (264 nm,

CY=

7650 dm3cm-1Mor 1) (Figure 1.4) was close to the detection limit of the apparatus and
it is considered appropriate to quote the solubility value determined as an upper limit.
The intrinsic aqueous solubility of KP-1 is therefore determined to be <510 nM. KP-1
was completely soluble in ethanol (>30 mg/rnL) and the mixture of water/methanol
(60:40). KP-1 was less soluble in DMSO

250

260

270

280

(~4.1

290

mg/mL).

300

310

320

330

340

350

Wavelength I nm

Figure 1.4. Average KP-1 molar extinction coefficients between 250-350 nm at pH
11.8. The curve is the average of spectra collected at sample concentrations of 25 µM,
50µM and lOOµM.

1.3.4. Anti-HIV Assays

Anti-HIV activities of the compounds were evaluated according to the
previously reported procedure (Krebs et al., 1999). In summary, HeLa (Human
cervical carcinoma: ATCC CCL-2.1) cell line was used to measure inactivation of
both cell-free virus preparations and virus-infected cell preparations. Cells were plated
34

in culture plates 24 hrs prior to each experiment. Cell-free viral preparations of HIV-1

strains IIIB (lymphocytotropic strain) and BaL (monocytotropic strain) were used for
cell-free assay. For cell-associated assay, SulTl cells were infected with IIIB virus 5
days prior to the experiment. Cell-free virus and virus-infected cells were mixed with
different compounds and diluted to make different concentrations. The mixture was
further diluted with the buffer and added to the HeLa cells. The cells were incubated at
37 °C for 48 h, stained for P-galctosidease expression and compared with Pgalctosidease expression from the P-gal-positive cells in absence of any microbicidal
compound to get IC 5o values.

1.3.5. Cellular Uptake Study

All of the stock solutions for compounds FAM, 1.5, and 1.6 were prepared in
DMSO. The human T lymphoblastoid cells CCRF-CEM (ATCC No. CCL-119) were
grown on 25 cm2 cell culture flasks with RMPI-1640 medium containing 10% fetal
bovine serum. Upon reaching about 70% confluency, the cells were treated as
described below and incubated for 1 h or longer at 37 °C.

1.3.5.1. Cellular Uptake of FAM, 1.5 and 1.6 at Different Time Points

When the cells reached about 70% confluency, FAM, 1.5, or 1.6 (1 mL, 20
µM) in RMPI-1640 medium were added to 1 mL of cells to make the final

concentration as 10 µM. The cells were incubated for 0.5, 1, 2, 4 and 8 h at 37 °C.
Then the flow cytometry assays were performed as described below.
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1.3.5.2. Cellular Uptake of 1.6 at Different Concentrations
When the cells reached about 70% confluency, 1 mL of graded concentrations
(0, 10, 20, 40, 80, and 200 µMin RMPI-1640) of 1.6 was added to 1 mL of cells to
make the final concentration as 0, 5, 10, 20, 40 and 100 µM. The cells were incubated
for 1hat37 °C. Then the flow cytometry assays were performed as described below.

1.3.5.3. Cellular Uptake of FAM, 1.5 and 1.6 with Trypsin Treatment
The assays were performed as previously described in section 1.3.5.1 at 1 h
time point with the exception that the cells used were incubated with 0.25%
trypsin/0.53 mM EDTA for 5 min before washing with PBS (pH 7.4) for flow
cytometry studies.

1.3.5.4. Flow Cytometry
The cells were washed twice with PBS (pH 7.4) at 2000 rpm for 5 min. Then
the cells were analyzed by flow cytometry (F ACSCalibur: Becton Dickinson) using
FITC channel and CellQuest software. The data presented are based on the mean
fluorescence signal for 10000 cells collected. All the assays were carried out in
triplicate.

1.3.6. Cell Viability Assay
When the cells reached about 70% confluency, the cells were incubated with a
solution of CCRF-CEM cell alone or 10 µM FAM, 1.5, or 1.6 for 24 hat 37 °C. Then
20 µL of the cells from each flask were treated with 2 µL of trypan blue (0.1 %) for 1
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min. The cells were then transferred to a Cellometer® counting slide and analyzed
using Cellometer® Auto T.4 (Nexcelom Bioscience). All the assays were performed
in triplicate.

1.3.7. Real Time Fluorescence Microscopy in Live CCRF-CEM Cell Line
The cellular uptake studies and intracellular localization of CCRF-CEM cell
alone, or incubated with 1.5 and 1.6 were imaged using a ZEISS Axioplan 2 light
microscope equipped with transmitted light microscopy with a differentialinterference contrast method and an Achroplan 40X objective. The human T
lymphoblastoid cells CCRF-CEM (ATCC No. CCL-119) were grown on 60 mm Petri
Dishes with RPMI-1640 medium containing 10% fetal bovine serum. Upon reaching
about 70% confluency, the cells were incubated with a solution of 10 µM 1.5 or 1.6
for 1 hat 37 °C. The cells were then observed under the fluorescent microscope under
bright field and FITC channels (480/520 run).

1.4. Results and Discussion
1.4.1. Chemistry
1.4.1.1. 5'-0-(Fatty acyl) Ester Derivatives of FLT and AZT
FLT was synthesized using thymidine as the starting material according to
previously reported procedure (Herdewijn et al. , 1987). 5'-0-(Fatty acyl) ester
derivatives of FLT and AZT (Table 1.4) were synthesized from the reaction of FLT or

AZT with the corresponding fatty acyl chloride in the presence of oxalyl chloride and
DMAP as described previously (Parang et al; 1998) at the scale of 100 mg . KP-1, KP-
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l6, and KP-17 showed higher potency and minimal cellular toxicity when compared to
the other compounds (Table 1.2). KP-1 and KP-17 were then synthesized in larger
scale (25 g) for further biological evaluation, preclinical and formulation studies.
Compounds were purified first by using silica gel column chromatography and then
HPLC to achieve >99% purity.

Table 1.4. Chemical structures of 5'-0-fatty acyl derivatives of AZT and FLT.

0

H3C~NH
1

N~O

R 1 0~
R2
Compd.

R1

R1

Com pd.

R1

R1

AZT

H

NJ

KP-10

CH3(CH 2)40(CH 2)1CO

NJ

FLT

H

F

KP-12

Br(CH2)11CO

F

KP-1

NJ(CH2)11CO

F

KP-13

CH3(CH2)4S(CH2)1CO

F

KP-2

CH3(CH2)4S(CH2)1CO

NJ

KP-15

CHJ(CH2) 11CH(OMe)CO

F

KP-3

CH3CH2S(CH2)10CO

NJ

KP-16

CH3(CH2)12CO

F

KP-4

Br(CH2)11CO

NJ

KP-17

CH3CH2S(CH2)11CO

F

KP-5

CH3(CH2)12CO

NJ

1.4

NH2(CH2)11CO

F

KP-6

CH 3(CH2)13CO

NJ

1.7

CH3(CH 2)130

F

KP-8

CH3(CH2) 11 CH(OMe)CO

NJ

1.8

CH3(CH2)130

NJ

KP-9

CH3(CH2)90(CH2)2CO

NJ

1.4.1.2 5(6)-Carboxyfluorescein derivatives of FLT

FLT was attached to 5(6)-carboxyfluorescein usmg

~-alanine

and 12-

aminododecanoic acid as linkers. First, FLT was reacted with the corresponding
Fmoc-amino acid in presence of HBTU and DIPEA. Second, N-Fmoc deprotection to
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free amino group was achieved in the presence of piperidine. Finally, FAM was
attached to free amino group in the presence of HBTU and DIPEA to afford 5(6)carboxyfluorescein derivatives of FLT, 1.5 and 1.6 (Scheme 1.1). These compounds
were used for cellular uptake studies to determine cellular uptake profile of fatty acyl
ester derivatives of FLT. FLT attached to FAM through

~-alanine

(1.5) was used as a

control FLT analog. FLT attached to FAM through 12-aminododecanoyl (1.6) was
used as an analog of 5'-0-(12-azidododecanoyl)-3'-fluoro-2',3'-dideoxy-thymidine
(KP-1) and other fatty acid ester analogs of FLT.

~J:

Fmoc-Arnino Acid,
HBTU, DIPEA, DMF

Fmoc,

J--L'nl, . . 0 \ d
N
0
0

0

N"'
H

F
1.1 n=2
1.2 n = 11

~J:

P;p";d;"', OotMoth;ol

H,N~°'d

O FAM,

HBTU,

DIPEA, DMF

F
1.3 n = 2
1.4 n = 11

1.5 n = 2
1.6 n = 11

0

Scheme 1.1. Synthesis of 5'-carboxyfluorescein derivatives of FLT (1.5 and 1.6)
through different linkers.
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l.4.1.3. 5'-0-(Tetradecanol) ether derivatives of AZT and FLT

AZT and FLT were reacted with tetradecanol in the presence of TPP and DIAD
using Mitsunobu conditions to afford 5'-0-(tetradecanol) ether derivatives of AZT and
FLT (1. 7 and 1.8) (Scheme 1.2).

~J:

-°'0

N

Tetradecanol, TPP, DIAD, DMF

14

C H

29

R
1.7 R = F
1.8 R = N3

Scheme 1.2. Synthesis of 5'-0-(tetradecanol) ether derivatives of FLT and AZT.

1.4.2. Physicochemical Properties

Physicochemical properties including pKa, LogD, and solubility were
determined for KP-1 as a model compound

1.4.2.1. pKa

The pKa of KP-1 was determined using the D-PAS (spectroscopic) technique.
The sample was subsequently titrated under methanol-water cosolvent conditions in
two triple titrations from pH 12.2 to pH 3. 7 at concentrations of 31-49 µM. The pKa
was determined from the spectroscopic data with an aqueous value of 9.67± 0.02,
obtained by Yasuda-Shedlovsky extrapolation of the individual results obtained.
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0

1.4.2.2. Log P and Log D
The Log D was measured at pH 7.4 by liquid chromatography. The
ProfilerLDA is an isocratic chromatography system, which uses an octanol-coated
column with octanol saturated mobile phases adjusted to pH 7.4. A value of 5.04 was
obtained, which should correspond to the neutral Log P, in consideration of the sample
pKa.

1.4.2.3. Solubility
An upper limit for the sample solubility of 510 nM was determined by shake-

flask methodology with UV-spectroscopic sample detection. To produce a saturated
solution of KP-1, approximately 1 mg of solid material was added to 10 rnL of
aqueous solution, adjusted to pH 2.3 with 0.5 M HCI. The sample was then sonicated
in an ultrasonic bath for several hours at room temperature and then equilibrated for a
period of approximately three days. The supernatant was then filtered, and the UV
absorption spectrum of the sample was measured. The UV-absorption signal (0.0039)
of the supernatant at the absorption maximum of KP-1 (264 nm,

CJ=

7650 dm3cm-

1Mor1) was close to the detection limit of the apparatus and it is considered
appropriate to quote the solubility value determined as an upper limit. The intrinsic
aqueous solubility of KP-1 is therefore determined to be <510 nM. KP-1 was
completely soluble in ethanol (>30 mg/rnL) and the mixture of water/methanol
(60:40). KP-1 was less soluble in DMSO (~4.1 mg/mL).
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t.4.3. Biological Activities

Tables 1.5-1.8 illustrate anti-HIV-1 activities against cell-free and cellassociated virus, anti-sperm activity, vaginal cell cytotoxicity, and sperm inhibiting
properties of the compounds. In summary, structure-function analysis revealed that the
anti-HIV activity of 5'-substituted derivatives of FLT and AZT was clearly dependent
on the nature of the 3'-substituent. 5'-0-Fatty acyl derivatives of FLT exhibited higher
anti-HIV activities against HIV when compared to 5'-0-fatty acyl derivatives of AZT
derivatives. For example, FLT derivatives (KP-1, KP-16, and KP-17) were more
potent inhibitors of HIV replication than AZT derivatives (KP-2, KP-3, and KP-4) and
AZT under the similar assay conditions. The FLT ester conjugate KP-16 was
approximately 15-fold more potent than AZT in viral entry inhibition assay
(lymphocytotropic strain) (Table 1.5). These results suggest that the increased
inhibition by fatty acyl ester derivatives of FLT, KP-1, KP-15, KP-16, and KP-17,
may be due to the intracellular release of FLT that is more potent than AZT released
by fatty acyl ester derivatives of AZT. The inability of fatty acyl derivatives of AZT,
KP-2, K.P-4, and KP-6, to enhance antiviral activity compared to AZT may be due to
incomplete intracellular hydrolysis of the conjugates under the in vitro assay
conditions.

5'-0-Ether substituted FLT and AZT, 1.7 and 1.8, had tetradecanyl (myristyl)
group instead of tetradecanoyl (myristoyl) ester group. The ether bond is not
susceptible to the cleavage action of esterases, thus the hydrolysis of the tetradecanyl
group from the conjugate in 1.7 and 1.8 is not possible. Ether derivatives of FLT and
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AZT substituted with 5'-tetradecanol (1.7 and 1.8, Scheme 1.2) were significantly
were less potent than the corresponding 5'-0-(tetradecanoyl) ester derivatives (KP-16
and KP-5). The data demonstrate that the ester bonds are important in enabling anti-

HIV activity of fatty acyl ester derivatives of FLT and AZT. The ester moiety in the
conjugates needs to be hydrolyzed rendering parent nucleosides and fatty acids. The
data demonstrate the importance of ester group in 5'-fatty acyl derivatives of AZT and
FLT, such as KP-6 and KP-16 . The same conclusion can be extrapolated to KP-1 and
KP-17. The ester group in KP-1 and KP-17 needs to be hydrolyzed to produce active
moieties with anti-HIV activity. In other words, the anti-HIV activity is not due to the
incorporation of the compounds in the HIV membrane and/or detergent effect, since
lipophilic ether derivatives, 1.7 and 1.8, were not potent anti-HIV agents.

Furthermore, the anti-HIV activity of 5'-substituted derivatives of FLT and
AZT was dependent on the nature of the 5'-substituent. Among FLT derivatives, KP-1 ,
KP-15 , KP-16, and KP-17 derivatives had significant anti-HIV activity at
concentrations that were not cytotoxic. As shown in Table 1.5, compounds KP-1, KP16, and KP-17 displayed EC 50 values against cell-free X4 and RS viruses below 1 µM.
KP-1, KP-16, and KP-17 were at least 7-fold more potent against X4 HIV-1 when
compared with AZT. KP-1, KP-16, and KP-17 were also active against cell-associated
HIV with EC 50 values between 2.3 and 12.6 µM. On the other hand, FLT and AZT
were not active against cell-associated virus, at least under the conditions tested. The
difference in the activity of fatty acyl derivatives of FLT compared to each other and
FLT may be due to their difference in their rate of uptake and intracellular hydrolysis

43

yielding two antiviral agents, FLT and fatty acid analog, targeting different enzymes
in HIV life cycle.

Table 1.5. Anti-HIV activities of fatty acyl ester derivatives of AZT and FLT
compound Code

CTS"
EC(50)b (µM)

VBl(IIIB)c EC(50)

VBI(BaL)d

(µM)

EC(50) (µM)

CTC° EC(50)
(µM)

KP-1

1598

0.9

0.4

12.6

KP-2
KP-3
KP-4
KP-5
KP-6
KP-8
KP-9
KP-10
KP-12
KP-13
KP-15
KP-16
KP-17
1.4
1.6
1.7
1.8
AZT
FLT

>202
>101
>190
629
611
197
>209
>209
>198
64
>206
606
>2000
>226
>125
179
205
375
1598
64.0
>1000
>1000

9.3
7.7
14.8
3.1
17.9
9.7
6.7
4.8
1.8
11.4

12.9
5.2
4.6
5
4.5
6.7
2.1
6.1
<0.2
4.4
0.2

0.7

1.1

<0.2

>202
90.7
>190
629
611
197
>209
>209
>198
64
>206
6.4
2.3

176
27.6
14.2
0.4
46.7
85 .9
>1000

>227
>216
>375
>410
48.6
5.1
>1000

C-lr

C-2g
DMSO

1.5
5.4
180
125
10.9
0.8
71.7
1.6
>1000

a

Cytotoxicity assay; b50% Effective concentration; cviral entry inhibition assay (lymphocytotropic

strain); dViral entry inhibition assay (monocytotropic strain); °Cell- to- cell transmission assay (IIIB);
rVirucidal control; gViral-entry inhibition control.

Table 1.6 displays the anti-HIV activity (in µg/mL) of FLT and AZT, their
equimolar mixtures with fatty acids, and their corresponding ester conjugates. It was
observed that the 5'-0-myristoyl ester conjugate of FLT (KP-16) was more consistent
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in displaying antiviral activity against cell-associated virus compared to FLT, AZT,
and physical mixtures of FLT or AZT with fatty acids (50:50 in equimolar ratio; 1.91.11). All three physical mixtures, 1.9 (myristic acid and AZT (50:50)), 1.10 (myristic

acid and FLT (50:50)), and 1.11 (12-bromododecanoic acid and AZT (50:50)),
showed lower inhibitory potency against cell-associated HIV compared to KP-1 and
KP-17. Compound 1.10 exhibited higher potency than that of FLT in cell-associated
virus, but not as much as KP-1 and KP-17, suggesting the conjugation is required for
efficient inhibition of cell-associated virus. Compound 1.11 was about 2-fold weaker
inhibitor than the corresponding conjugate KP-4 (5'-0-(12-bromododeconyol)AZT)
against IIIB and Bal strains. The comparative studies of physical mixtures with the
corresponding ester conjugate indicated that the esterification is important for the
inhibitor activity, especially against cell-associated virus.

In general, these data indicate that the nature of a substituent(s) on the fatty
acid chain and the presence of fluorine or azide at 3'-position are determinants of antiHIV activity. The decreased activities observed for certain analogs may be due to

slower regeneration of the parent nucleoside or slower uptake of the fatty acyl
derivative. The ability of fatty acyl derivatives of FLT, such as KP-1 and KP-17, to
control cell to cell transmission of virus whereas FLT is not active at all, could be due
to their higher cellular uptake compared to FLT in infected cells and enhanced
delivery of FLT in infected cells. Additionally, KP-1 and KP-17 are also releasing
myristic acid analogs intracelularly that can inhibit the post-translation modification of
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viral proteins, such as protein myristoylation, and eventually blocking the release of
new virus for infecting other cells.

Table 1.6. Comparison of anti-HIV activities of fatty acyl derivatives of AZT and
FLT with physical mixtures of AZT or FLT + fatty acids
Chemical Name

CTS8
EC(SO)b
(µg/mL)

VBI(IIIB}°
EC(SO)
(µg/mL)

VBI(BaL)a
EC(SO)
(µg/mL)

CTC°
EC(SO)
(µg/mL)

AZT

AZT

> 100

2.9

3.8

> 100

FLT

FLT

> 100

0.2

0.1

> 100

KP-1

5'-0-(12azidododecanoyl)FL T

746 .7

0.4

0.2

5.9

KP-17

5'-0-(12thioethyldodecanoyl)FL T

> 1000

0.5

<0.1

1.1

KP-5

5 '-0-(Myristoyl)AZT

> 100

1.5

2.4

> 100

1.9

Myristic acid + AZT
(50:50)

> 100

0.7

22.9

> 100

KP-16

5'-0-(Myristoyl)FLT

> 100

0.3

0.5

2.9

1.10

Myristic acid+ FLT
(50:50)

> JOO

< 0.1

0.4

15.6

KP-4

5'-0-(12Bromododecanoyl_ AZT

> 100

7.8

2.4

> 100

1.11

12-bromododecanoic acid
+ AZT (50:50)

> 100

19

4.8

> 100

Compound
Code

a

Cytotoxicity assay; b50% Effective concentration; 0 Viral entry inhibition assay (lymphocytotropic

strain); dViral entry inhibition assay (monocytotropic strain); •cell- to- cell transmission assay (IIIB).

1.4.4. Anti-HIV Activities Against MDR Isolates
KP-1 , KP-2, KP-16, and KP-17 were further tested against RS and multidrug
resistant (MDR) clinical isolates. Results indicated that several FLT derivatives
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exhibited antiviral activity against HIV -1, lab-adapted, clinical isolates, and resistant
virus. For example, FLT derivatives (KP-1, KP-16, and KP-17) were more potent
inhibitors of HIV replication than AZT and AZT derivatives under the conditions
employed in the assays. While AZT and KP-2 showed a drop in activity against MDR
virus (>10 fold), FLT, KP-1, KP-16 and KP-17 showed similar potencies against RS
and MDR isolates (Table 1.7). KP-1 was at least 100-fold more potent against MDR
virus when compared to that of AZT. KP-1, KP-16 and KP-17 were found to be safe
compounds for cell viability studies as their toxic concentration limits were >40. AZT
and FLT on the other hand displayed toxicity even at half the concentration. KP-2 not
only showed less activity but also demonstrated high toxicity towards the cells at very
low concentration. The impact of the compounds was further studied by looking at
their antiviral index which is the ratio of TC 5o/IC 5o. KP-1, KP-16 and KP-17 had >4
times better Also values than FLT and >30 times effective values than AZT.

1.4.5. Cytotoxicity and Proinflammatory Effects

Compounds cytotoxicity was evaluated using human vaginal cells (VK-2).
Contrary to N-9 (used as positive control), at 1 mg/mL, highest concentration tested,
KP-1, KP-16, and KP-17 did not show significant cytotoxic effects during a 6 h
incubation at multiple concentrations (Figure 1.5). Furthermore, although FLT is
considerably more cytotoxic than AZT toward uninfected lymphocytes, 5'-fatty acyl
derivatives of FLT did not exhibit higher toxicity in epithelial cell and vaginal cell
cytotoxicity assays (Figure 1.5). All analogs of FLT demonstrated lower toxicity than
FLT probably due to a sustained release of FLT upon the hydrolysis of the conjugates.
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Table 1.7. Anti-HIV evaluation of FLT Derivatives, KP-1, KP-2, KP-16, and KP-17,

in PBMC assay
compound
Solvent

Type of Virus

Endpoint

RS

RT

MDR

RT

RS

RT

MDR

RT

RS

RT

MDR

RT

RS

RT

MDR

RT

RS

RT

MDR

RT

RS

RT

MDR

RT

IC 50 (µg/ml) 1

Alsoc

code
DMSO

KP-I

medium

KP-2

KP-16

KP-17

DMSO

DMSO

AZT

FLT

"IC50

DMSO

0.0064

>42.8

0.0064

>42.8

0.060S

> JO.I

l.8S76

> IO. I

0.0066

>44.0

0.0044

>44 .0

0.0041

>41.1

0.00411

>41 .1

0.0749

> 18.7

l.23S9

> 18.7

0.0040

>20.S

0.0123

>20.S

>6700
>74Sl
>163

>S.46
>7044
>8669
>8649
>8370
>207
>lS.2
>48S
>l,4S7

= The minimum drug concentration that inhibits HIV-induced cytopathic effect by SO%,

calculated by using a regression analysis program for semilog curve fitting; bTC 50 = The minimum drug
concentration that reduces cell viability by SO%;

0

AI

=

Abbreviation for Antiviral Index. A

measurement of the potential activity of drug, calculated by dividing the TC 50 by the IC 50 ; RS =
92TH014; MDR = Multidrug resistant virus 7324-1.

Furthermore, unlike N-9, KP-1, KP-16, and, KP-17 did not induce the release
ofIL-la, a powerful proinflammatory cytokine (Figures 1.6 and 1.7).
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Figure 1.5. Dose-response curves of vaginal cytotoxicity in VK-2 cells (MTS assay)
for KP-1, KP-16, KP-17, AZT, and N-9 after 6 h incubation
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Figure 1.6. Proinflammatory cytokine (IL-1 a) production in VK-2 Cells (ELISA) after
a 6 h incubation in the presence ofKP-1, KP-16, KP-17, AZT, and N-9.
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Figure 1.7. Summary of AUC Data for proinflammatory cytokine (IL-la) production

in VK-2 cells after a 6 h incubation in the presence of KP-1, KP-16, KP-17, AZT, and
N-9.

KP-2 showed significantly less cytotoxicity and proinflammatory potential
than N-9 (Figure 1.8), while displaying potent anti-HIV activity. The percentage of the
vaginal cell that could survive at the concentration of 50 and 100 µg/mL of KP-2 was
86 and 73% respectively, whereas for N-9, the values were below 4% suggesting that
KP-2 is much safer in comparison to N-9 even at higher concentrations. It was found
that N-9 was producing very high concentration of proinflammatory cytokines such as
IL-la and IL-6 in comparison to KP-2 (Figure 1.9). Observed cytotoxicity from N-9
(Figure 1.8) could be correlated with the generation of higher levels of cytokines by
N-9. On the other hand, KP-2 did not show cytotoxicity and were not generating high

amount of cytokines. Similar assays were performed with other compounds in two
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different sets and the cytokines generation for all the compounds except KP-12 was
nearly similar to that ofKP-2 (Figure 1.10).
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Figure 1.8. In vitro assay for vaginal cytotoxicity
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t.4.6. Spermicidal Activity.

The spermicidal activities of several fatty acids have been previously reported
(Brown-Woodman et al., 1985; Jianzhong et al., 1987). None of these derivatives
showed significant spermicidal activity (Figure 1.11). In a dose-response study to
evaluate spermicidal activity, compounds KP-1, KP-16, and KP-17 did not show
significant sperm immobilizing or spermicidal activity, even at their maximum
concentrations (1 mg/mL). KP-7, one of the FLT analogs, displayed spermimmobilizing activity, although it was comparatively weak (Table 1.8).

Table 1.8. Spermicidal activity of submitted analogs using modified Sander-

Cramer assay.
Compound

Highest Spermicidal

Code

Dilution (1/Xt

M.E.C. (mg/ml)b

KP-1

3.2 ± 0.4

3.5±0.5

KP-3

2.4 ± 0.4

4.5±0.4

KP-7

12.8 ± 4.3

1.1±0.2

KP-14

8.8 ± 1.8

1.4±0.3

N-9

227.2 ± 104.2

0.227±0.101

DMSO

3.6 ± 0.4

N.A.c

aSolvent = DMSO, initial concentration = 10 mg/rnL. Values are expressed as means±
SE; bMinimum Effective Concentration; cNot assayed.
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Figure 1.11. In vitro assays for spermicidal activity of fatty acyl derivatives of FLT and AZT.
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t.4. 7· Cellular Uptake Study
Cellular uptake profile of 5'-0-fatty acyl derivatives were investigated in
comPar

ison with FLT. FLT attached to FAM through P-alanine (1.5) was used as a

control FLT analog. FLT attached to FAM through 12-aminododecanoic acid (1.6) was
used as an analog of 3'-fluoro-2',3'-dideoxy-5'-0-(12-azidododecanoyl)thymidine (KP-1)
and other fatty

acid ester analogues of FLT.

3'-Fluoro-2',3'-dideoxy-5'-0-(12-

aminododecanoyl)thymidine (1.4) showed anti-HIV activities comparable to other fatty
acyl derivatives of FLT. Fluorescein-labeled fatty acyl ester derivative of FLT (1.6)
showed slightly lower anti-HIV activity when compared with unsubstituted 12aminododecanoyl derivative (1.4).

The human T lymphoblastoid cells (CCRF-CEM, ATCC No. CCL-119) were
used for the study and were grown to the 70% confluency in the culture media. The cells
were incubated with the fluorescein-substituted conjugates (1.5 and 1.6) in different time
periods, concentrations, and in the presence or absence of trypsin (Figures 1.12-1.14).

DMSO and FAM were used as control for the study. The cells were analyzed by flow
cytometry (F ACSCalibur: Becton Dickinson) using FITC channel and Cell Quest
software. The data presented are based on the mean fluorescence signal for 10000 cells
collected. All the assays were carried out in triplicate.

First, cells were incubated with 10 µM of the compounds in different time periods
(0.5 h, 1 h, 2 h, 4 h and 8 h, Figure 1.12). Compound 1.6 exhibited 10-15 fold higher
cellular uptake than that of 1.5 and FAM alone. The results clearly indicate that presence
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of Jong chain enhances the cellular uptake of FLT, by increasing lipophilicity. The
continuous incubation of cells with compounds up to 8 h did not show significant
difference in the cellular uptake, suggesting that most of the fatty acyl ester derivative is
absorbed into cells within first 30 minutes incubation and the cellular uptake was not time
dependent.
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Figure 1.12. Cellular uptake studies for 5(6)-carboxyfluorescein derivatives of FLT (1.5
and 1.6) along with FAM and DMSO as controls at different time intervals.

Cells were then incubated with different concentrations (5, 10, 20, 40 and 100
µM) of carboxyfluorescein derivative of FLT, 1.6 for 1 h (Figure 1.13). The data
suggested that the cellular uptake was concentration dependent.
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Figure 1.13. Cellular uptake studies for 5(6)-carboxyfluorescein derivative of FLT (1.6)
at different concentrations.

To confirm that the enhanced uptake of 5(6)-carboxyfluorescein derivative of

FLT, 1.6, is not due to the absorption on the cell membrane surface, cells were incubated
with 10 µM of DMSO, FAM, 1.5, and 1.6 for 1 h and then treated with trypsin for 5 min
to wash the adsorbed molecules (if any) from the cell membrane. The cellular uptake
studies after trypsin treatment showed that the cellular uptake of 1.6 was still much
higher than those of contro 1 compounds, FAM and 1.5 (Figure 1.14), suggesting that the
higher cellular uptake of 1.6 is not due to artificial absorption to the cell membrane.
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Figure 1.14. Cellular uptake studies for 5(6)-carboxyfluorescein derivatives of FLT (1.5
and 1.6) along with FAM and DMSO as controls after treatment with trypsin.

1.4.8. Cell Viability Study

Cell viability study was performed to analyze the effect of FAM, 1.5, and 1.6 on
the live cells. CCRF-CEM cells were incubated with 10 µM of the compounds and mixed
with trypan blue (0. 1% ) to color the dead cells. The percentage of viability was calculated

by using Cellometer Auto T.4 (Nexcelom Bioscience). It was observed that at least 80%
of the cells were viable in presence of the compounds in 24 h incubation period (Figure

1.15).
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Figure 1.15. Cell viability assay after 3h and 24 h incubation of 1.5 and 1.6 with CCRFCEM cells. DMSO and FAM were used as positive controls.

1.4.9. Real Time Fluorescence Microscopy in Live CCRF-CEM Cells

CCRF-CEM cells were incubated with 10 µM of DMSO, FAM, 1.5 and 1.6 for 1
hand were imaged using light microscope (ZEISS Axioplan 2) equipped with transmitted
light microscopy with a differential-interference contrast method and an Achroplan 40X
objective. Cells showed no significant fluorescence when incubated with DMSO, FAM,
and 1.5 (Figure 1. 16). On the other hand, cells incubated with 1.6 showed fluorescence.
The results further confirm the higher cellular uptake of 1.6, a fatty acyl derivative of
FLT, in comparison to 1.5 and FAM alone. In general, these data indicate that the fatty
acyl derivatives of nucleosides have better cellular uptake than their parent nucleosides.
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Figure 1.16. Real time fluorescence microscopy in live CCRF-CEM cell line. Control=
DMSO, FAM = 5(6)-carboxyfluorescein.

61

t,5. Conclusions.

Several bifunctional 5'-0-fatty acyl derivatives of FLT were designed and
synthesized as prodrugs of FLT, a nucleoside reverse transcriptase inhibitor, and their
biological activities were evaluated as anti-HIV agents and microbicides. It was expected
that after intracellular hydrolysis, the compounds would release two active parent
analogs, FLT and fatty acid, targeting RT and NMT, respectively, involved in HIV life
cycle.
Among all the compounds, KP-1, KP-16, and KP-17 were found to have better
anti-HIV activity profile when compared with FLT, AZT, and 5'-0-fatty acyl derivatives
of AZT. KP-1, KP-16, and KP-17 were active against cell-free virus (lymphocytotropic
and monocytotropic strains). Furthermore-, KP-1, KP-16, and KP-17 showed significantly
higher activity against cell-associated virus when compared with AZT and FLT. These
compounds were equally active against R5 and MDR, while AZT was not active against
multidrug resistant virus. KP-1, KP-16 and KP-17 exhibited >4 and >30 times better
antiviral index, respectively, than FLT and AZT. The compounds did not show any
significant cytotoxicity in vaginal cells when compared with N-9 (a commercial
microbicidal drug) suggesting that the compounds may be safer than N-9 for microbicidal
applications. The 5'-0-ether derivatives of FLT and AZT (1.7 and 1.8) showed
significantly less anti-HIV activity than the corresponding 5'-0-fatty acyl ester
derivatives (KP-16 and KP-5), confirming the hypothesis that the hydrolysis of the
prodrug to the parent analogs was critical for generation of anti-HIV activity.
The presence of long chain fatty acid at 5'-position enhanced the lipophilicity of
FLT and the cellular uptake as was shown by cellular uptake studies of 5'-
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carboxyfluroscein derivatives of FLT containing short chain (1.5) and long chain (1.6)
alkyl ester groups. FACS experiments showed that 1.6 had at least 8-fold higher cellular
uptake in CCRF-CEM cells than 1.5. Fluorescence microscopy of the cells incubated
with these compounds further confirmed the FACS results as cells incubated with 1.6
showed significantly higher fluorescence when compared with cells incubated with FAM
and 1.5. These results suggest that the increased inhibition by KP-1, KP-16, and KP-17
may be due to a higher intracellular level of active nucleoside achieved by the conjugate.
The high activity of these compounds was possibly due to their increased rate of uptake
and intracellular hydrolysis yielding two antiviral agents with different targets, FLT and
fatty acid analog.

KP-1 and KP-17 are currently undergoing further preclinical studies, such as
ADMET, animal toxicity, lactobacillus inhibition, and preformulation studies. These
compounds may be used as topical microbicidal applications (such as vaginal insert or
jellies) to prevent HIV infection during the sexual activity. These data provided insights
for more rational design of additional potent and safe anti-HIV microbicides using the

FLT as the parent nucleoside. When taken together, the results will have significant
implications for the design of more potent and innovative anti-HIV agents.
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z.t. Abstract
A number of fatty acyl derivatives of 2',3'-didehydro-2',3'-dideoxythymidine
(Stavudine, d4 T), (-)-5-fluoro-2' ,3 '-dideoxy-3 '-thiacytidine (Emtricitabine, FTC), and (-)2',3 '-dideoxy-3 '-thiacytidine (Lamivudine, 3TC) were synthesized. Anti-HIV activities of
the compounds were evaluated and compared against cell-free and cell-associated virus.
Fatty acyl derivatives of FTC (ECso = 0.04-0.2 µM) were the most potent compounds
when compared with the corresponding fatty acyl derivatives of AZT, FLT, d4T, and
3TC derivatives (ECso = 0.2-12.9 µM). Among the compounds, 5'-0-myristoyl
derivative of FTC (2.31) was found to be the most potent compound with minimal
cellular toxicity. Compound 2.31 exhibited 10-fold higher anti-HIV activity against cellfree virus (EC 50 = 0.07 µM) versus to FTC (ECso = 0.7 µM). The anti-HIV activity of
2.31 against cell-associated virus (EC 50 = 3.7 µM) was 24 times higher when compared

with FTC (EC 50

=

88.6 µM). Furthermore, 5'-0-12-azidododecanoyl derivative of FTC

(2.32, EC 50 = 0.2 µM) showed 4 and 10 times higher anti-HIV activities than FTC against

cell-free and cell-associated virus, respectively. Among 3TC derivative, 5'-0-myristoyl
(2.16, EC 50 >0.2 µM) and 5'-0-12-azidododecanoyl (2.17, EC 50

=

0.7 µM) derivatives of

3TC exhibited at least 57- and 16-fold higher anti-HIV activities than 3TC (2.1, ECso

=

11.3 µM) against cell-free virus, respectively. Cellular uptake studies were conducted on
CCRF-CEM cell line using 5(6)-carboxyfluorescein derivatives of 3TC attached through
P-alanine (2.38) or 12-aminododecanoic acid (2.39) as linkers. Fluorescein-substituted
analog of 3TC with long chain length (2.39) showed3-6 fold higher cellular uptake
profile than analog with short chain length (2.39) and 5(6)-carboxyfluorescein. The data
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revealed that the attachment of fatty acid enhances the cellular uptake of the nucleoside
conjugate.

2.2. Introduction
3TC, FTC, and d4T are the nucleoside reverse transcriptase (RT) inhibitors that
inhibit human immunodeficiency virus-1

(HIV-1) replication. These drugs are

commercially used in combination with two or more other anti-HIV drugs in Highly
Active Antiretroviral Therapy (HAART) program. For example, 3TC and FTC are used
in combination with Abacavir and Tenofovir, respectively, in the treatment of HIV

infection (Masho et al., 2007). These drugs are known to have higher therapeutic index
than AZT and FLT and show also anti-HIV activity against AZT resistant virus (Mansuri
et al., 1990).

Lamivudine is a (-)-2',3'-dideoxy-3'-thiacytidine analog that is used in the
treatment of both HIV-1 and hepatitis disease. Two isomers[(-) and(+)] of 2',3'-dideoxy3'-thiacytidine show different biological profiles against HIV. (-)-Isomer is six-fold
higher activity against HIV when compared with that of (+)-isomer and is nearly two
times less cytotoxic, therefore it is used in clinic (Skalski et al., 1993). Although
Larnivudine has good activity against wild type HIV, a single point mutation at 184
residue results in 3TC-resistant mutant virus (M184V/I) (Mulder et al., 2008, Sarafianos
et al., 1999, Diallo et al., 2003 ). Several studies have provided different reasons for
resistance development, such as cytidine deamination and the generation of steric
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hindrance at 184 amino acid residues. Similar to the HIV, mutation at Met5 52 with Val
and Ile (M552V/I) results in 3TC and FTC resistant HBV strains (Das et al., 2001).

Stavudine is a thymidine nucleoside analog and was approved in 1994 for
treatment against HIV-1. d4 T is well absorbed orally and is metabolized intracellularly to
d4T 5'-triphosphate. d4T shows synergic effect with the other anti-HIV drugs and is
generally used in triple therapy. Application of d4T as anti-HIV agent faces major
challenges in the form of drug resistance. Different point mutations in RT, such as V75T
and K65R, reduces d4T sensitivity against virus (Gracia-Lerma et al., 2003; Hurst and
Noble, 1999).

FTC, a 5-fluoro derivative of 3TC, is 10-17 times more potent than 3TC. FTC and
3TC share common mechanism of action and drug resistance patterns (Masho et al.,
2007). It is suggested that use of FTC with Tenofovir results in a higher barrier to drug
resistance (Gallant et al., 2006; Pozniak et al., 2006).

N-Myristoyl

transferase

(NMT)

enzyme

is

involved

in

catalyzing the

myristoylation of several proteins in HIV life cycle (e.g., capsid protein pl 7, Prl60gag-pol,
Pr55gag, p27ner) . At N-terminal glycine, viral proteins (gag and nef) are covalently
attached to myristic acid in the presence of NMT. Myristic acid attachment makes the
proteins more hydrophobic, which improves protein-protein and protein-membrane
interactions (Farazi et al., 2001). For example, after the N-myristoylation, pl 7 protein
localizes itself towards the cell membrane, where new virus is produced (Wu et al., 2004)
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The replication of HIV-I can be inhibited by heteroatom-containing analogs of
myristic acid without accompanying cellular toxicity (Bryant et al., I993, Takamune et
al., 2002). It has been previously reported that several fatty acids, such as 2methoxydodecanoic acid, 4-oxatetradecanoic acid, and I 2-thioethyldodecanoic acid,
reduce HIV-I replication in acutely infected T-lymphocytes. For example, 12thioethyldodecanoic acid was moderately active (ECso = 9.4 µM) against HIV-infected
T4 lymphocytes (Parang et al., 1997).

It is hypothesized that the attachment of nucleoside analogs to the long chain
myristic acid analogs enhances their lipophilicity and thus their cellular uptake. Once the
ester conjugate enters the cells; it gets hydrolyzed by esterases; and generates two active
molecules, nucleoside analog and fatty acid targeting RT and NMT enzymes,
respectively.

We previously reported the synthesis and evaluation of fatty acyl derivatives of
AZT and FLT (chapter I). Herein, we report the synthesis of fatty acyl derivatives of
3TC, FTC, and d4T, their anti-HIV activities, spermicidal activity, and cellular uptake
profiles.

Three

fatty

acids,

myristic

acid,

I2-azidododecanoic acid,

and

I2-

thioethyldodecanoic acid, were conjugated with the nucleosides. The selection of the
fatty acids was based on the anti-HIV activities of the corresponding fatty acyl
derivatives of FLT (chapter I). The conjugation of fatty acids to the selected nucleosides
may result in development of anti-HIV agents having enhanced lipophilicity, longer
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duration of action by sustained intracellular release of active substrates at adequate
concentrations, and higher uptake into infected cells.

2.3. Materials and Methods
2.3.1. Materials.

Lamivudine (3TC) and Emtricitabin (FTC) were purchased from Euro Asia Tran
Continental (Bombay, India). Stavudine (d4T) was purchased from Kemprotec
(Middlesbrough, U.K.). 12-Bromododecanoic acid was purchased from Sigma Aldrich
Chemical Co. 5(6)-Carboxyfluorescein (FAM) was purchased from Novabiochem. All
the other reagents including solvents were purchased from Fisher scientific.

The products were purified on a Phenomenex®Gemini 10 µm ODS reversedphase column (2.1

x

25 cm) with Hitachi HPLC system using a gradient system at

constant flow rate of 17 ml/min (Table 2.1 ).

Table 2.1. HPLC method used for purification of the final compounds.
Time
(min)

A€etonitrile
Concentration
B (%)
0.0

Flow rate
(mL/min)

0.00

Water
Concentration
A(%)
100.0

1.0

100.0

0.0

17.0

45.0

0.0

100.0

17.0

55.0

0.0

100.0

17.0

59.0

100.0

0.0

17.0

60.0

100.0

0.0

1.0
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1.0

The purity of the compounds was confirmed by using analytical Hitachi analytical
HPLC system on a C18 column (Grace Allsphere ODS 2-3 µ, 150 X 4.6 mm) using a
gradient system (water:acetonitrile 30:70 v/v) at constant flow rate of 1 ml/min with a
UV detection at 265 nm. The chemical structures of final products were characterized by
nuclear magnetic resonance spectrometry (1H NMR and

13

C NMR) determined on a

Bruker NMR spectrometer (400 MHz) and confirmed by a high-resolution PE
Biosystems Mariner API time-of-flight electrospray mass spectrometer. Chemical shifts
are reported in parts per millions (ppm). For cellular uptake studies, cells were analyzed
by flow cytometry (F ACSCalibur: Becton Dickinson) using FITC channel and Cell Quest
software.

Cell~viability

studies were conducted using Cellometer Auto T.4 (Nexcelom

Biosciences). The real time microscopy in live CCRF-CEM cell line with or with
compounds were imaged using ZEISS Axioplan 2 light microscope equipped with
transmitted light microscopy with a differential-interference contrast method and an
Achroplan 40X objective.

2.3.2. Chemistry
(-)-N4,5'-(Ditetradecanoyl)-2' ,3'-dideoxy-3'-thiacytidine (2.2)

and

(-)-N 4,S'-di(l2-

azidododecanoyl)-2' ,3' -dideoxy-3' -thiacytidine (2.3)

In general, a reaction mixture consisting of the appropriate fatty acid (1.0 mmol),
oxalyl chloride (100 µL, 1.2 mmol), and anhydrous benzene (18 mL) was stirred at room
temperature (25 °C) for 1 h. The yellow solution thus obtained was evaporated to dryness
under reduced pressure to prepare acid chloride. Lamivudine (2.1, 100 mg, 0.44 mmol)
and 4-dimethylaminopyridine (DMAP, 160 mg, 1.3 mmol) were dissolved in dry benzene
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(20 mL). The freshly prepared acid chloride (1.1 mmol) from the reaction of fatty acid
with oxalyl chloride was added to the mixture. The reaction mixture was refluxed at 100

oc for 4 h.

After the completion of reaction, the reaction mixture was cooled down to

room temperature and neutralized with 5% sodium bicarbonate solution. Benzene layer
was separated and aqueous layer was extracted with dichloromethane (3 x 100 mL). The
Organic layer was separated and mixed with the benzene layer and concentrated at
reduced pressure. The residue was purified with silica gel column chromatography using
dichloromethane and methanol (0-1 %) as eluents.

(-)-N 4,5'-(Ditetradecanoyl)-2' ,3'-dideoxy-3'-thiacytidine (2.2). Yield (155 mg, 53%);

1H NMR (400 MHz, CDCh,

oppm): 8.90-9.40 (br s,

lH, NH), 8.16 (d, J = 7.5 Hz, lH,

H-6), 7.48 (d, J = 7.5 Hz, lH, H-5), 6.34 (dd, J = 3.2 and 5.1 Hz lH, H-1'), 5.41 (t, J =
3.8 Hz, lH, H-4'), 4.65 (dd, J = 12.5 and 4.8 Hz, lH, H-5"), 4.45 (dd, J = 12.5, 3.0 Hz,
lH, H-5'), 3.64 (dd, J = 5.1, 12.6 Hz, lH, H-2"), 3.29 (dd, J = 3.2, 12.6 Hz, lH, H-2'),
2.47 (t, J = 7.6 Hz, 2H, CH2CO), 2.40 (t, J = 7.6 Hz, 2H, CH2 CO), 1.60-1.75 (m, 4H,
CH2CH2CO), 1.20-1.40 (br m, 40H, methylene protons), 0.89 (t, J = 6.7 Hz, 6H, CH3);
13

C NMR (DMSO-d6, 100 MHz,

oppm):

175.06 (CONH), 173.39 (COO), 163.21 (C-4),

154.89 (C-2 C=O), 145.87 (C-6), 95.59 (C-5), 88.70 (C-1 '), 87.75 (C-4'), 62.49 (C-5'),
38.31 (C-2'), 37.00 (CH2CONH), 34.27, 32.00, 29.73, 29.63, 29.47, 29.43, 29.26, 29.16,
25.14, 22.77 (methylene carbons), 14.48 (CH3). HR-MS (ESI-TOF) (m/z): C36H63N30sS,
calcd, 649.9675 ; found, 650.1885 [M +Ht.
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(-)-N 4,5'-Di(12-azidododecanoyl)-2',3'-dideoxy-3'-thiacytidine (2.3). Yield (170 mg,
1
55%); H NMR (400 MHz, CDCh,

oppm): 8.90-9.12 (br s, lH, NH), 8.18 (d, J = 7.2 Hz,

IH, H-6), 7.49 (d, J = 7.2 Hz, lH, H-5), 6.36 (m, lH, H-1'), 5.43 (dd, J = 4.9, 3.0 Hz,
lH, H-4'), 4.67 (dd, J

=

12.5 and 4.9 Hz, lH, H-5"), 4.47 (dd, J

=

12.5 and 3.0 Hz, lH,

H-5'), 3.64 (dd, J = 12.6 and 5.4 Hz, lH, H-2"), 3.20-3 .34 (m, 5H, H-2', CH2N 3), 2.49 (t,
J

=

7.2 Hz, 2H, CH2CO), 2.42 (t, J

=

7.2 Hz, 2H, CH2CO), 1.55-1.79 (m, 8H, -

cH2CH2CO, CH2CH2N3), 1.20-1.45 (br m, 28H, methylene protons);
100 MHz,

o ppm):

13

C NMR (CDC1 3,

179.51 (CONH), 174.52 (COO), 163.20 (C-4), 146.10 (C-6), 96.50

(C-5), 88.60 (C-1'), 83 .84 (C-4'), 64.82 (C-5'), 63.06, 51.87 (CH2N3), 39.43 (C-2'), 37.96
(Cl-hCONH), 34.80 (CH2COO), 34.47, 29.84, 29.78, 29.63, 29.53, 29.47, 29.23, 29.20,
27.10, 25.14 (methylene carbons). HR-MS (ESI-TOF) (m/z): C32H 53N90 5S, calcd,
675.8855 ; found, 676.6085 [M +Ht.

(-)-5'-0-(t-Butyldimethylsilyl)-2',3'-dideoxy-3'-thiacytidine (2.4). Lamivudine (2.1,
1.09 mmol, 250 mg), tert-butyldimethylsilyl chloride (500 mg, 3.27 mmol), and
imidazole (230 mg, 3.27 mmol) were dissolved in dry DMF (10 mL) and the reaction
mixture was stirred for 18 h at room temperature. The solvent was concentrated at
reduced pressure and the residue was purified with silica gel column chromatography
1

using dichloromethane and methanol (0-5%) as eluents to yield 2.4 (350 mg, 95%); H
NMR (400 MHz, CDCh, 8 ppm): 8.21 (d, J = 7.6 Hz, lH, H-6), 6.32 (dd, J = 5.2 and 2.8
Hz, lH, H-1'), 6.02 (d, J

=

7.6 Hz, lH, H-5), 5.26 (t, J

=

3.0 Hz, lH, H-4'), 4.18 (dd, J

=

11.8 and 3.0 Hz, lH, H-5"), 3.96 (dd, J = 11.8 and 3.0 Hz, lH, H-5'), 3.54 (dd, J = 12.5
and 5.2 Hz, lH, H-2"), 3.19 (dd, J = 12.5 and 2.8 Hz, lH, H-2'), 0.95 (s, 9H, (CH3) 3C),
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0.15 (s, 6H, CH3Si); HR-MS (ESI-TOF) (m/z): C14H2sN303SSi, calcd, 343.1386; found,
344.3933 [M +Ht, 686.4590 [2M +Ht.

(-)-5'-0-(t-Butyldimethylsilyl)-N4(tetradecanoyl)-2' ,3' -dideoxy-3 '-thiacytidine

(2.5),

(-)-5'-0-(t-Butyldimethylsilyl)-N4(l2-azidododecanoyl)-2' ,3' -dideoxy-3 '-thiacytidine
(2.6), and (-)-5'-0-(t-Butyldimethylsilyl)-N4(l2-thioethyldodecanoyl)-2' ,3'-dideoxy3'-thiacytidine (2.7). Compound 2.4 (140 mg, 0.4 mmol) and DMAP (70 mg, 0.6 mmol)
were dissolved in dry benzene (10 mL). The corresponding acid chloride (0.48 mmol)
(prepared as described above) was added dropwise and the reaction mixture was refluxed
for 4 h at 100 °C. The reaction mixture was cooled down to room temperature and
neutralized with saturated sodium bicarbonate solution (100 mL). The benzene layer was
separated and aqueous layer was extracted with dichloromethane (3 x 100 mL). The
organic layer was separated and mixed with benzene layer and concentrated at reduced
pressure. The residue was purified with silica gel column chromatography using
dichloromethane and methanol (0-1 % ) as eluents to afford 2.5-2. 7.

2.5. Yield (110 mg, 50%); 1H NMR (400 MHz, CD 30D,

oppm): 8.12 (d, J = 7.5 Hz, lH,

H-6), 6.24 (dd, J = 5.3, 3.5 Hz, lH, H-1'), 5.81 (d, J = 7.5 Hz, lH, H-5), 5.26 (t, J = 3.3
Hz, lH, H-4'), 4.09 (dd, J = 11.7 and 3.3 Hz, lH, H-5"), 3.96 (dd, J = 11.7 and 3.3 Hz,
lH, H-5'), 3.49 (dd, J = 12.2 and 5.3 Hz, lH, H-2"), 3.11 (dd, J = 12.2 and 3.5 Hz, lH,

H-2'), 2.24 (t, J = 7.4 Hz, 2H, CH2CO), 1.56 (t, J = 7.1 Hz, 2H, CH2CH2CO), 1.20-1.35
(hr m, 20H, methylene protons), 0.91 (s, 9H, (CH3 ) 3C), 0.86 (t, J
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=

6.8 Hz, 3H, CH3),

0.11 (s, 6H, CH3Si); HR-MS (ESI-TOF) (m/z): C2sH 51 N 30 4SSi, calcd, 553.8727; found,
554.1020 [M +Ht.

1

2.6. Yield (110 mg, 50%). H NMR (400 MHz, CDCl3, 8 ppm): 8.40-8.69 (br s, 2H, NH
and H-6), 7.44 (d, J = 7.3 Hz, lH, H-5), 6.37-6.41 (m, lH, H-1'), 5.33 (t, J = 2.5 Hz, lH,
H-4'), 4.27 (dd, J = 11.9 and 2.5 Hz, lH, H-5"), 4.01 (dd, J = 11.9 and 2.5 Hz, lH, H-5'),
3.64 (dd, J

=

12.7 and 5.2 Hz, lH, H-2"), 3.27-3.30 (m, 3H, H-2', CH2N 3), 2.47 (s, 2H,

CH2CO), 1.60-1.82 (m, 4H, CH2CH2CO, CH2CH2N3), 1.28-1.45 (br m, 14H, methylene
protons), 0.99 (s, 9H, (CH3)3C), 0.18 (s, 6H, CH3Si); HR-MS (ESI-TOF) (m/z):
C26 H46N604SSi, calcd, 556.8317; found, 567.0023 [M +Ht.

1

2.7. Yield (110 mg, 50 %); H NMR (400 MHz, CDCh, 8 ppm) 9.29-9.41 (br s, lH, NH),

8.60 (d, J

=

7.5, lH, H-6), 7.46 (d, J

=

7.5, lH, H-5), 6.37 (dd, J

5.2 and 2.3 Hz, lH,

=

H-1'), 5.32 (t, J = 2.2, lH, H-4'), 4.68 (dd, J = 11.9 and 2.2 Hz, lH, H-5"), 4.00 (dd, J =
11.9 and 2.2 Hz, lH, H-5'), 3.63 (dd, J = 12.7, 5.2, lH, H-2"), 3.29 (d, J = 12.7, lH, H2'), 2.53-2.62 (m, 4H, CH2SCH2), 2.39 (t, J = 7.5, 2H, CH2COO), 1.52-1.83 (m, 4H,
CH2CH2COO and SCH2CH2), 1.21-1.50 (br m, 17H, methylene protons, CH3CH2S), 0.99
(s, 9H, (CH3)3C) , 0.18 (s, 6H, CH3Si); HR-MS (ESI-TOF) (m/z): C2sHs1N304S2Si, calcd,
585.3077; found, 585.8926 [M +Ht, 607.8040 [M +Nat.

{-)-N4(Tetradecanoyl)-2',3'-dideoxy-3'-thiacytidine
azidododecanoyl)-2' ,3' -dideoxy-3 '-thiacytidine
tbioetbyldodecanoyl)-2' ,3' -dideoxy-3' -thiacytidine
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(2.8),
(2.9),
(2.10).

and

(-)-N 4 (12-

Tetrabutylammonium

fluoride (1.5 mL, lM) was added to 2.5-2.7 (150 mg) and the reaction mixture was stirred
at room temperature for 3 h. Solvent was concentrated at reduced pressure and the
residue was purified with silica gel column chromatography using dichloromethane and
methanol (0-1 %) as eluents to afford 2.8-2.10.

1

2.8. Yield ( 55 mg, 65%); H NMR (400 MHz, DMSO-d6, 8 ppm): 10.85 (s, lH, NH),
8.38 (d, J = 7.5 Hz, lH, H-6), 7.23 (d, J = 7.5 Hz, lH, H-5), 6.21 (dd, J = 5.2 and 3.2
Hz, lH, H-1'), 5.26 (t, J

=

4.1 Hz, lH, H-4'), 3.82-3.85 (br s, 2H, H-5" and H-5'), 3.56

(dd, J = 12.3 and 5.2 Hz, lH, H-2"), 3.20 (dd, J = 12.3 and 3.2 Hz, lH, H-2'), 2.38 (t, J

=

7.3 Hz, 2H, CH2CO), 1.53 (t, J = 6.5 Hz, 2H, CH2CH2CO), 1.15-1.35 (s, 20H, methylene
protons), 0.89 (t, J = 6.7 Hz, 3H, CH3 );

13

C NMR (DMSO-d6, 100 MHz, 8 ppm): 174.80

(COO), 163.41 (C-4), 155.11 (C-2 C=O), 146.17 (C-6), 95.8 (C-5), 88.90 (C-1'), 87.94
(C-4'), 62.70 (C-5'), 38.51 (C-2'), 37.16 (CH2CONH), 32.16, 29.92, 29.88, 29.73, 29.57,
29.30, 25.28, 22.96 (methylene carbons), 14.77 (CH3 ); HR-MS (ESI-TOF) (m/z):
C22H31N304S, calcd, 439.6119; found, 440.3352 [M + Ht, 462.2543 [M + Nat,
878.1789 [2M +Ht, 900.0877 [2M +Nat.

2.9. Yield (50 mg, 60%); 1H NMR (400 MHz, CDCh, 8 ppm): 8.45-8.47 (br s, 2H, NH,
H-6), 7.49 (d, J

=

7.5 Hz, lH, H-5), 6.38 (dd, J = 5.3 and 3.4 Hz, lH, H-1'), 5.41 (t, J =

3.2 Hz, lH, H-4'), 4.21 (dd, J = 12.7 and 3.2 Hz, lH, H-5"), 4.01 (dd, J = 12.7 and 3.2
Hz, lH, H-5'), 3.68 (dd, J

=

12.5 and 5.3 Hz, lH, H-2"), 3.27-3.31 (m, 3H, H-2', CH2N 3 ),

2.48 (t, J = 6.8 Hz, 2H, CH2CO), 1.58-1.68 (m, 4H, CH2CH2CO, CH2CH2N 3), 1.25-1.45
(hr m, 14H, methylene protons);

13

C NMR (CDCh, 100 MHz, 8 ppm): 173.65 (COO),
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!62.40 (C-4), 155.04 (C-2 C=O), 145.47 (C-6), 96.28 (C-5), 88.32 (C-1'), 88.23 (C-4'),
62.99 (C-5'), 51.67 (CH2N3), 39.18 (C-2'), 38.05 (CH2CONH), 29.61, 29.54, 29.45,
29.31, 29.19, 29.02, 26.89, 25.03 (methylene carbons); HR-MS (ESI-TOF) (m/z):

c20H32N 604S, calcd, 452.5709; found, 453.2421 [M +Ht, 903.9628 [2M + H(
1

2.10. Yield (50 mg, 50%); H NMR (400 MHz, CDCh, 8 ppm): 8.58 (s, lH, NH), 8.028.07 (br s, lH, H-6), 6.26-6.30 (br s, lH, H-5), 6.13-6.17 (m, lH, H-1'), 5.35 (d, J = 2.8
Hz, lH, H-4'), 4.59-4.72 (m, lH, H-5"), 4.35-4.45 (m, lH, H-5'), 3.53-3.65 (m, lH, H2"), 3.20-3.32 (m, lH, H-2'), 2.45-2.75 (m, 4H, CH2SCH2), 2.33-2.43 (m, 2H, CH2COO),
1.53-1.70 (m, 4H, SCH2CH2, CH2CH2CO), 1.20-1.40 (br m, 17H, methylene protons,
CH3CH2S);

13

C NMR (CDCh, 100 MHz, 8 ppm): 174.08 (COO), 163.02 (C-4), 155.44

(C-2 C=O), 145.85 (C-6), 96.73 (C-5), 88.61 (C-1 '), 88.48 (C-4'), 63.14 (C-5'), 39.38 (C2'), 38.10 (CH2CONH), 34.83, 32.06, 26.31-30.10, 25.32 (methylene carbons), 15.23

(CH3); HR-MS (ESI-TOF) (m/z): C22H31N304S2, calcd, 471.6769; found, 472.1656 [M +

Ht, 941.7961

[2M +Ht.

(-)-S'-0-(t-Butyldimethylsilyl)-N4-(4,4 '-dimethoxytrityl)-2' ,3' -dideoxy-3' -thiacytidine
(2.11). Compound 2.4 (600 mg, 1.75 mrnol) was dissolved in dry pyridine (10 mL). A
solution of 4,4'-dimethoxytrityl chloride (DMTr-Cl, 1.4 mg, 4.4 mrnol) in 10 mL pyridine
was added to the reaction mixture dropwise at O °C. The reaction mixture was stirred for
30 min. The temperature was raised to room temperature and stirring was continued
overnight. The reaction mixture was neutralized with saturated sodium bicarbonate
solution (500 mL) and was extracted with dichloromethane (3 x 200 mL). The organic
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layer was separated and concentrated in vacuo. The residue was purified with silica gel
column chromatography using dichloromethane and methanol (0-1 %) as eluents to yield

2.11 (1.05 g, 90%).
1H NMR (400 MHz, CDCh, 6 ppm): 7.81 (d, J = 7.7 Hz, lH, H-6), 7.74 (dd, J = 5.7 and
3.3 Hz, lH, DMTr proton), 7.55 (dd, J

=

5.7 and 3.2 Hz, lH, DMTr proton), 7.12-7.33

(m, 7H, DMTr protons), 6.82-6.88 (m, 4H, DMTr protons), 6.33 (dd, J = 5.2 and 3.0 Hz,

lH, H-1'), 5.17-5.22 (m, lH, H-4'), 5.03 (d, J = 7.7 Hz, lH, H-5), 4.38 (dd, J = 14.3 and
7.1 Hz, lH, H-5"), 4.06 (dd, J

=

11.8 and 3.1 Hz, lH, H-5'), 3.81 (s, 6H, DMTr-OCH3),

3.52 (dd, J = 12.2 and 5.2 Hz, lH, H-2"), 3.17 (dd, J = 12.2 and 3.0 Hz, lH, H-2'), 0.80
(s, 9H, (CH3)3C), 0.06 (s, 6H, CH3Si); HR-MS (ESI-TOF) (m/z): C3sllt3N30 5SSi, calcd,
645.8835 ; found, 686.4624 (M+Kt, 1289.3671 (2M+Ht.

(-)-N4 -(4,4'-Dimethoxytrityl)-2',3'-dideoxy-3'-thiacytidine (2.12). Compound 2.11 (1

g, 1.55 mrnol) was dissolved in tetrabutylarnrnonium fluoride (4.65 ml, 1 M, 4.65 mrnol,)
and stirred for 3 h. The reaction mixture was concentrated at reduced pressure and the
residue was purified with silica gel column chromatography using dichloromethane (2%
triethylarnine) and methanol (0-1 % ) as eluents to yield 2.12 (820 mg, 90%).
I

H NMR (400 MHz, CD 30D, 6 ppm): 8.53 (d, J = 7.8 Hz, lH, H-6), 7.32-7.34 (m, 2H,

DMTr protons), 7.17-7.23 (m, 6H, DMTr protons), 7.11-7.13 (m, lH, DMTr protons),
6.75-7.78 (m, 4H, DMTr protons), 6.22 (dd, J = 5.3 and 2.5 Hz, lH, H-1'), 6.01 (d, J =
7.8 Hz, lH, H-5), 5.25 (t, J

=

3.2, lH, H-4'), 3.99 (dd, J

=

12.8 and 3.2 Hz, lH, H-5"),

3.84 (dd, J = 12.8 and 3.2 Hz, lH, H-5'), 3.69 (s, 6H, DMTr-OCH3), 3.51 (dd, J = 12.6
and 5.3 Hz, lH, H-2"), 3.27 (dd, J = 12.6 and 2.5 Hz, lH, H-2'); HR-MS (ESI-TOF)
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(rn/z): C29H 29N30sS, calcd, 531.1828; found, 531.92 [M +Ht, 632.6916 [M + TEA)t,
!061.1780 [2M + 1(

(-)-N4-(4,4'-Dimethoxytrityl)-5'-0-(tetradecanoyl)-2',3'-dideoxy-3'-thiacytidine
(2.13),

(-)-5' -0-(12-azidododecanoyl)-N4-(4,4 '-dimethoxytrityl)-2' ,3 '-dideoxy-3 '-

thiacytidine (2.14), and (-)-N4-(4,4'-dimethoxytrityl)-5'-0-(12-thioethyldodecanoyl)2',3'-dideoxy-3'-thiacytidine (2.15). Compound 2.12 (150 mg, 0.30 mmol), the
corresponding

fatty

acid

(0.60

mmol),

and

2-(lH-benzotriazole-1-yl)-1,1,3,3-

tetramethyluronium hexafluorophosphate (HBTU, 250 mg, 0.65 mmol) were dissolved in
dry DMF (10 mL). Diisopropylethylamine (DIPEA, 2 mL, 15 mmol) was added to the

reaction mixture and stirring was continued overnight at room temperature. The reaction
mixture was concentrated at reduced pressure and the residue was purified with silica gel
column chromatography using dichloromethane (2% triethylamine) as eluents to afford
2.13-2.15.

2.13. Yield (100 mg, 50%); 1H NMR (400 MHz, CD30D, 8 ppm) 8.62 (d, J = 7.8 Hz,

IH, H-6), 7.40-7.43 (m, 2H, DMTr protons), 7.26-7.30 (m, 6H, DMTr protons), 7.187.22 (m, lH, DMTr proton), 6.85 (d, J = 8.9 Hz, 4H, DMTr protons), 6.28-6.32 (m, lH,
H-1'), 6.08 (d, J = 7.8 Hz, lH, H-5), 5.34 (t, J = 3.1 Hz, lH, H-4'), 4.07 (dd, J = 12.8 and
3.1 Hz, lH, H-5"), 3.92 (dd, J = 12.9 and 3.1 Hz, lH, H-5'), 3.78 (s, 6H, DMTr-OCH3),
3.60 (dd, J = 5.3 and 12.3 Hz, lH, H-2"), 3.36 (d, J = 12.3 Hz, lH, H-2'), 2.29 (t, J = 7.3
Hz, 2H, CH2CO), 1.60 (t, J = 6.8 Hz, 2H, CH2CH2CO), 1.20-1.42 (br m, 20H, methylene
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protons), 0.91 (s, J = 6.6 Hz, 3H, CH3). HR-MS (ESI-TOF) (rn/z): C43 H 55 N3 06S, calcd,
741 .3812; found, 742.35 [M +Ht, 843.4629 [M + TEAt, 1483.7079 [2M +Ht

(-)-5'-0-(Tetradecanoyl)-2',3'-dideoxy-3'-thiacytidine
azidododecanoyl)-2' ,3 '-dideoxy-3 '-thiacytidine

(2.16),

(2.17)

and

(-)-5'-0-(12(-)-5'-0-(12-

tbioethyldodecanoyl)-2' ,3'-dideoxy-3'-thiacytidine (2.18): Acetic acid (AcOH, 80%,

10 mL) was added to compounds 2.13-2.15 (0.25 mmol). The reaction mixture was
heated at 80 °C for 30 min. The reaction mixture was concentrated at reduced pressure
and the residue was purified with silica gel column chromatography using
dichloromethane as the eluent to afford 2.16-2.18.

2.16. Yield (50 mg, 65%); 1H NMR (400 MHz, CDC1 3,

oppm): 7.72 (d, J = 7.5 Hz,

lH,

H-6), 6.30 (t, J = 4.7 Hz, lH, H-1 '), 5.97 (d, J = 7.5 Hz, lH, H-5), 5.32 (dd, J = 3.5 and
5.5 Hz, lH, H-4'), 4.51(dd,J=12.1 and 5.5 Hz, lH, H-5"), 4.35 (dd, J = 12.1 and 3.5

Hz, lH, H-5'), 3.52 (dd, J = 12.0 and 5.4 Hz, lH, H-2"), 3.09 (dd, J = 12.0 and 4.7 Hz,
lH, H-2'), 2.34 (t, J = 7 .6 Hz, 2H, CH2CO), 1.49-1. 72 (m, 2H, CH2 CH2 CO), 1.18-1.42
(hr m, 20H, methylene protons), 0.87 (s, J = 6.7 Hz, 3H, CH3 );

MHz,

oppm):

13

C NMR (CDCh, 100

173.39 (COO), 165.98 (C-4), 155.64 (C-2 C=O), 140.73 (C-6), 94.96 (C-

5), 87.79 (C-1'), 83.21 (C-4'), 64.48 (C-5'), 38.22 (C-2'), 34.24 (CH2COO), 32.10, 29.87,

29.84, 29.79, 29.65, 29.54, 29.45, 29.31, 25.03, 22.88 (methylene carbons), 14.33 (CH3);
HR-MS (ESI-TOF) (rn/z): C22H37N3 0 4 S, calcd, 439.2505; found, 440.2835 [M +Ht.
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1

2.17. Yield (50 mg, 65%); H NMR (400 MHz, CD30D, 5 ppm): 7.71 (d, J = 7.5 Hz, lH,
H-6), 6.29 (dd, J = 5.2 and 3.8 Hz, lH, H-1'), 6.01 (d, J = 7.5 Hz, lH, H-5), 5.33 (dd, J =
3.2 and 5.4 Hz, lH, H-4'), 4.51 (dd, J = 12.2 and 5.4 Hz, lH, H-5"), 4.35 (dd, J = 12.2
and 3.2 Hz, lH, H-5'), 3.52 (dd, J = 12.0 and 5.2Hz, lH, H-2"), 3.21-3.28 (m, 2H,

cH2N3), 3.08 (dd, J = 12.0 and 3.8 Hz, lH, H-2'), 2.34 (t, J = 7.5 Hz, 2H, CH2CO), 1.541.64 (m, 4H, CH2CH2CO, CH2CH2N3), 1.22-1.38 (br m, 14H, methylene protons);

13

C

NMR (CD 30D, 100 MHz, 5 ppm): 173.40 (COO), 164.96 (C-4), 154.96 (C-2 C=O),
140.98 (C-6), 95.31 (C-5), 87.64 (C-1'), 83.51 (C-4'), 64.32 (C-5'), 51.64 (CH2N3), 38.20
(C-2'), 34.19 (CH2CO), 29.88, 29.71, 29.60, 29.54, 29.39, 29.29, 29.24, 28.98, 26.86,
24.98, (methylene carbons); HR-MS (ESI-TOF) (rn/z): C20H32N604S, calcd, 452.2206;
found, 453.1729 [M +Ht.

2.18. Yield (50 mg, 65%); 1H NMR (400 MHz, CD30D, 8 ppm): 7.64 (d, J = 7.4 Hz, lH,
H-6), 6.29-6.35 (m, lH, H-1'), 5.91 (d, J = 7.4 Hz, lH, H-5), 5.30-5.34 (m, lH, H-4'),
4.49 (dd, J = 12.0 and 5.7 Hz, lH, H-5"), 4.35 (dd, J = 12.0 and 3.2 Hz, lH, H-5'), 3.50
(dd, J = 12.0 and 5.3 Hz, lH, H-2"), 3.04 (dd, J = 12.0 and 4.6 Hz, lH, H-2'), 2.44-2.63
(m, 4H, CH2SCH2), 2.34 (t, J = 7.4 Hz, 2H, CH2CO), 1.50-1.79 (m, 4H, SCH2CH2,
CH2CH2CO), 1.18-1.48 (br m, 17H, methylene protons);

13

C NMR (CD30D, 100 MHz, 5

ppm): 173.36 (COO), 166.01(C-4),155.60 (C-2 C=O), 140.49 (C-6), 95.35 (C-5), 87.73
(C-1'), 83.03 (C-4'), 64.55 (C-5'), 38.04 (C-2'), 34.20 (CH2COO), 31.82, 29.80, 29.67,
29.58, 29.41, 29.62, 29.11, 28.90, 25.00, 22.88 (methylene carbons), 14.33 (CH3); HR-

MS (ESI-TOF) (rn/z): C22 H37N 30 4S2, calcd, 471.2225; found, 472.2418 [M + Ht,
941.9318 [2M+Ht.
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S'-0-(Tetradecanoyl)-2',3'-didehydro-2',3'-dideoxythymidine
azidododecanoyl)-2' ,3' -didehydro-2' ,3 '-dideoxythymidine

(2.20),
(2.21 ),

5'-0-(125'-0-(12-

tbioethyldodecanoyl)-2' ,3' -didehydro-2' ,3 '-dideoxythymidine (2.22), and 5'-0-(12bromododecanoyl)-2' ,3'-didehydro-2' ,3'-dideoxythymidine (2.23). Stavudine (2.19,
100 mg, 0.4 mrnol) and DMAP (80 mg, 0.6 mrnol) were dissolved in dry benzene (20
mL) and freshly prepared acid chloride (0.48 mrnol) (as described above) was added to

the mixture. The reaction mixture was refluxed at 100 °C for 4 h. The reaction mixture
was cooled down to room temperature and neutralized with saturated sodium bicarbonate
solution (100 mL). The benzene layer was separated and the aqueous layer was extracted
with dichloromethane (3 x 100 mL). The organic layer was separated and mixed with the
benzene layer and concentrated at reduced pressure. The residue was purified with silica
gel column chromatography using dichloromethane and methanol (1 %) as eluents to
yield 2.20-2.23.

2.20. Yield (150 mg, 80%); 1H NMR (400 MHz, CDCh, 8 ppm): 9.29 (s, lH, NH), 7.27
(s, lH, H-6), 7.01-7.07 (br s, lH, H-1'), 6.26-6.32 (m, lH, H-2'), 5.91-5.95 (m, lH, H-3'),
5.04-5.09 (m, lH, H-4'), 4.44-4.55 (m, lH, H-5"), 4.17-4.34 (m, lH, H-5'), 2.34 (t, J =
7.4 Hz, 2H, CH2CO), 1.95 (s, 3H, 5-CH3), 1.61-1.67 (m, 2H, CH2CH2CO), 1.16-1.44 (br

m, 20H, methylene protons), 0.90 (s, 3H, CH3);

13

C NMR (CDCh, 100 MHz, 8 ppm):

173.72 (COO), 164.28 (C-4 C=O), 151.27 (C-2 C=O), 135.85 (C-6), 133.60 (C-3'),
127.72 (C-2'), 111.45 (C-5), 90.14 (C-1'), 84.69 (C-4'), 64,86 (C-5'), 34.51 (CH2COO),
32.29, 30.02, 29.83, 29.73, 29.64, 29.50, 25.19, 23.07 (methylene carbons), 14.52 (5-
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CI-b), 13.03 (CH3); HR-MS (ESI-TOF) (m/z): C24H3sN20 5, calcd, 434.5689; found,
456.9157 [M +Nat, 474.8787 [M +Kt, 869.0358 [2M +Ht, 891.0285 [2M +Na(

1

2.21. Yield (120 mg, 70%); H NMR (400 MHz, CDCh, 8 ppm): 9.37 (s, lH, NH), 7.24
(s, lH, H-6), 6.99-7.03 (br s, lH, H-1'), 6.27 (d, J

=

5.7 Hz, lH, H-2'), 5.90 (d, J = 5.7

Hz, lH, H-3'), 5.02-5.06 (m, lH, H-4'), 4.43 (dd, J = 12.4 and 3.8 Hz, lH, H-5"), 4.22
(dd, J

=

12.4 and 3.8 Hz, lH, H-5'), 3.26 (t, J = 6.9 Hz, 2H, CH2N 3), 2.32 (t, J = 7.5 Hz,

2H, CH2COO), 1.92 (s, 3H, 5-CH3), 1.50-1.70 (m, 4H, CH2CH2COO and CH2CH2N 3),
1.12-1.47 (br m, 14H, methylene protons);

13

C NMR (CDCh, 100 MHz, 8 ppm): 173.71

(COO), 164.35 (C-4 C=O), 151.31 (C-2 C=O), 135.89 (C-6), 133.61 (C-3'), 127.72 (C2'), 111.45 (C-5), 90.16 (C-1 '), 84.69 (C-4'), 64,86 (C-5'), 51.85 (CH2N 3), 34.49
(CH2COO), 29.81, 29.61, 29.48, 29.21, 26.30, 25.17 (methylene carbons), 13.03 (CH3);

HR-MS (ESI-TOF) (m/z): C22H33NsOs, calcd, 447.5279; found, 469.8802 [M + Nat,
485.8541 [M +Kt.

2.22. Yield (110 mg, 65%); 1H NMR (400 MHz, CDCh, 8 ppm) 8.37 (s, lH, NH), 7.25
(s, lH, H-6), 6.99-7.04 (br s, lH, H-1'), 6.29 (d, J = 5.8 Hz, lH, H-2'), 5.92 (d, J = 5.8
Hz, lH, H-3'), 5.04-5.08 (m, lH, H-4'), 4.45 (dd, J = 12.4 and 4.0 Hz, lH, H-5"), 4.24
(dd, J = 12.4 and 3.0 Hz, lH, H-5'), 2.45-2.61 (m, 4H, CH2SCH2), 2.34 (t, J = 7.5, 2H,
CH2COO), 1.94 (s, 3H, 5-CH3 ), 1.50-1.72 (m, 4H, CH2CH2COO and SCH2CH2), 1.181.42 (hr m, l 7H, methylene protons);

13

C NMR (CDCh, 100 MHz, 8 ppm): 173.69

(COO), 163.69 (C-4 C=O), 150.86 (C-2 C=O), 135.88 (C-6), 133.75 (C-3'), 127.64 (C2'), 111.40 (C-5), 90.19 (C-1 '), 84.74 (C-4'), 64.87 (C-5'), 34.52 (CH2COO), 32.07, 30.11,
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30 .04, 29.90, 29.82, 29.74, 29.65, 29.58, 29.52, 29.46, 29.35, 26.32, 25.21 (methylene
carbons), 15.24 (5-CH3), 13.04 (CH3); HR-MS (ESI-TOF) (m/z): C24H 38N20 5S, calcd,
466.6339; found, 489.4530 [M +Nat, 505.4377 [M +Kt 955.8658 [2M +Nat.

1

2.23. Yield (150 mg, 80%); H NMR (400 MHz, CDCh, 8 ppm): 8.10 (s, lH, NH), 7.24
(s, lH, H-6), 7.00 (d, J = 1.7 Hz, lH, H-1'), 6.28 (dd, J = 5.9 and 1.7 Hz, lH, H-2'), 5.90
(d, J = 5.9 Hz, lH, H-3'), 5.03-5.08 (m, lH, H-4'), 4.43 (dd, J = 12.4 and 4.0 Hz, lH, H-

5'), 4.23 (dd, J = 12.4 and 2.9 Hz, lH, H-5'), 3.54 and 3.42 (t, J = 6.8 and 6.4 Hz, 2H,

CH2 Br isotopes), 2.33 (t, J = 7.50, 2H, CH2COO), 1.93 (s, 3H, 5-CH3), 1.73-1.88 (m, 2H,
CH2CH2Br), 1.55-1.70 (m, 4H, CH2CH2COO), 1.36-1.48 (m, 2H, CH2CH2CH2Br), 1.201.35 (br m, 12H, methylene protons);

13

C NMR (CDCh, 100 MHz, 8 ppm): 173.70

(COO), 164.30 (C-4 C=O), 151.28 (C-2 C=O), 135.87 (C-6), 133.61 (C-3'), 127.74 (C2'), 111.45 (C-5), 90.16 (C-1'), 84.70 (C-4'), 64,88 (C-5'), 45.62 (CH2Br), 34.51
(CH 2 COO), 33.20, 29.82, 29.76, 29.62, 29.48, 29.45, 29.13, 28.54, 27.25, 25.18

(methylene carbons), 13.03 (5-CH3); HR-MS (ESI-TOF) (m/z): C22 H33 BrN20 5, calcd,
485.4118; found 507.2254 [M + Natand 509.1860 [M + Nat (Brome isotopes).

(-)-5'-0-(t-Butyldimethylsilyl)-5-fluoro-2' ,3' -dideoxy-3' -thiacytidine

(2.25).

Emtricitabine (2.24, 500 mg, 2.18 mrnol), tert-butyldimethylsilyl chloride (1 g, 6.54
mmol), and imidazole (440 mg, 6.54 mrnol) were dissolved in dry DMF (10 mL) and the
reaction mixture was stirred for 18 h at room temperature. The solvent was concentrated
at reduced pressure and the residue was purified with silica gel column chromatography
using dichloromethane and methanol (0-5%) as eluents to yield 2.25(700 mg, 90%).
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1H NMR (400 MHz, CDCh, 8 ppm): 8.50-9.20 (br s, 2H, NH2), 8.17 (d, J = 6.4 Hz, lH,
H-6), 6.25 (dd, J = 5.2 and 2.4 Hz, lH, H-1'), 5.17-5.21 (t, J = 2.4 Hz, lH, H-4'), 4.15
(dd, J = 11.8 and 2.4 Hz, lH, H-5"), 3.90 (dd, J = 11.8 and 2.4 Hz, lH, H-5'), 3.47 (dd, J
== 12.4 and 5.2 Hz, lH, H-2"), 3.14 (dd, J = 12.4 and 2.4 Hz, lH, H-2'), 0.90 (s, 9H,

(CH3 ) 3C), 0.10 (s, 6H, CH3Si);

13

C NMR (CDCh, 100 MHz, 8 ppm): 158.24 (J = 14.5

Hz, C-4), 153.73 (C-2C=O), 136.32 (J = 240.7 Hz, C-5), 126.04 (J

=

32.7 Hz, C-6),

88.22 (C-1'), 87.30 (C-4'), 63.66 (C-5'), 39.11 (C-2'), 25.85, 18.56 (CH3)3C-Si), -5.47, 5.49 (CH3-Si); HR-MS (ESI-TOF) (rn!z): C14H2sFN30 3SSi, calcd, 361.1292; found ,
362.4160 [M +Ht, 723.8098 [2M + H(

(-)-5' -O-(t-Butyldimethylsilyl)-N4 -(4,4 '-dimethoxytrityl)--5-fluoro-2' ,3' -dideoxy-3' thiacytidine (2.26). Compound 2.25 (600 mg, 1.75 mmol) was dissolved in dry pyridine
(10 rnL). A solution of DMTr-Cl (700 mg, 1.2 equiv) in 10 mL pyridine was added to
the reaction mixture dropwise at 0 °C. The reaction mixture was stirred for 30 min. The
temperature was raised to room temperature and stirring was continued overnight. The
reaction mixture was neutralized with saturated sodium bicarbonate solution (100 mL)
and was extracted with dichloromethane (3 x 100 mL). The organic layer was separated
and concentrated at reduced pressure. The residue was purified with silica gel column
chromatography using dichloromethane and methanol (0-1 %) as eluents to yield 2.26 (1.0

g, 86%).
I

H NMR (400 MHz, CDCh, 8 ppm): 8.73-9.40 (br s, lH, NH), 8.49 (d, J = 6.0, lH, H-6),

7.27 (d, J = 3.6 Hz, SH, DMTr protons), 7.17 (d, J = 8.7 Hz, 4H, DMTr protons), 6.83

(d, J = 8.7 Hz, 4H, DMTr protons), 6.26-6.29 (br s, lH, H-1 '), 5.23-5.25 (br s, lH, H-4'),
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4.25 (dd, J = I0.2 and 1.8 Hz, IH, H-5"), 3.94 (d, J = I0.2 Hz, IH, H-5'), 3.80 (s, 6H,
DMTr-OCH3), 3.53 (dd, J = I2.2, 4.6, IH, H-2"), 3.24 (d, J = I2.2, lH, H-2'), 0.94 (s,

9H, (CH3) 3C), 0.15 (s, 6H, CH3Si);

13

C NMR (CDCh, IOO MHz, 8 ppm): 158.63 (C-4),

t55.85 (C-2 C=O), I5I.47, I47.33 (DMTr-C), 139.46 (C-5), I29.I4, I27.86, I27.77
(DMTr-C), I 27 .09 (C-6), I I 3 .17 (DMTr-C), 89 .14 (C-I '), 87 .26 (C-4'), 81.44 (DMTr-CNH), 63 .22 (C-5'), 55.26 (DMTr-OCH3), 39.59 (C-2'), 25.86 (CH3-C), I8.66 ((CH3)3C-

Si), -5.46, -5.50 (CH3-Si); HR-MS (ESI-TOF) (m/z): C3sH43FN30sSSi, calcd, 663.2598;
found, 663.9596 [M +Ht, 765.0250 [M + TEAt.

(-)-N 4 -(4,4 '-Dimethoxytrityl)--5-fluoro-2' ,3 '-dideoxy-3' -thiacytidine

(2.2 7).

Compound 2.26 (1 g, 1.55 mmol) was dissolved in IM solution of tetrabutylammonium
fluoride (4.5 ml, IM, 3 equiv) and stirred for 3 h. The reaction mixture was concentrated
at reduced pressure and the residue was purified with silica gel column chromatography
using dichloromethane (2% triethylamine) and methanol (2 %) as eluents to yield 2.27
(750 mg, 90%).
1

H NMR (400 MHz, CDCh, 8 ppm): 7.83-7.96 (m, IH, H-6), 7.I0-7.35 (m, 9H, DMTr

protons), 6.80 (s, 4H, DMTr protons), 6.42-6.46 (br s, IH, OH), 6.15-6.19 (br s, lH, H1'), 5.14-5.I8 (br s, lH, H-4'), 4.06-4.20 (m, lH, H-5"), 3.93 (d, J = 12.5, lH, H-5'), 3.78

(s, 6H, DMTr-OCH3 ), 3.34-3.50 (m, lH, H-2"), 2.98-3.15 (m, lH, H-2'); HR-MS (ESITOF) (m/z): C29H29 FN30 5 S, calcd, 549.1734; found, 550.5078 [M + Ht, 651.6923
[M+TEAt, 1122.0138 [2M +Nat.
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(-)-N 4-(4,4'-Dimethoxytrityl)-5'-0-(tetradecanoyl)-5-fluoro-2',3'-dideoxy-3'thiacytidine (2.28), (-)-5'-0-(12-azidododecanoyl)-N4-(4,4 '-dimethoxytrityl)-5-fluoro-

2. ,3'-dideoxy-3'-thiacytidine

(2.29),

and

(-)-( 4,4 '-dimethoxytrityl)-5'-0-(12-

thioethyldodecanoyl)- 5-fluoro-2' ,3 '-dideoxy-3 '-thiacytidine (2.30). Compound 2.27

(250 mg, 0.45 mmol), the corresponding fatty acid (0.90 mmol) and HBTU (350 mg, 0.90
mmol) were dissolved in dry DMF (10 mL). DIPEA (2mL, 15 mrnol) was added to the
reaction mixture and stirring was continued overnight at room temperature. The reaction
mixture was concentrated at reduced pressure and the residue was purified by reversed
phase HPLC using C 1s column and water/acetonitile as solvents as described above to
afford 2.28-2.30.

2.28. HR-MS (ESI-TOF) (rn/z): C43 H 54 FN3 06S, calcd, 759.3717; found, 760.3287 [M +

Ht, 861.4357 [M+TEAt, 1520.6604 [2M + H(
2.29. Yield (250 mg, 71 %); 1H NMR (400 MHz, CDCh, 8 ppm): 8.20-9.00 (br s, lH, 4NH), 8.07 (d, J = 6.1 Hz, lH, H-6), 7.22-7.33 (m, SH, DMTr protons), 7.17 (d, J = 8.8

Hz, 4H, DMTr protons), 6.83 (d, J = 8.8 Hz, 4H, DMTr protons), 6.27-6.31 (br s, lH, H1'), 5.34-5 .39 (m, J = 3.1 Hz, lH, H-4'), 4.65 (dd, J = 12.6 and 3.9 Hz, lH, H-5"), 4.45
(dd, J = 12.6 and 2.6 Hz, lH, H-5'), 3.71 (s, 6H, DMTr-OCH3), 3.57 (dd, J = 5.1 and

12.6 Hz, lH, H-2"), 3.20-3.31 (m, 3H, CH2N3, H-2'), 2.40 (t, J = 7.3 Hz, 2H, CH2CO),
l.55-1. 75 (m, 4H, CH2CH2N3 , CH2CH2CO), 1.23-1.41 (br m, 14H, methylene protons);
13

C NMR (CDCh, 100 MHz, 8 ppm): 173 .12 (COO), 158.62 (C-4), 156.47 (C-2 C=O),

152.13, 147.33 (DMTr-C), 139.46 (C-5), 129.14, 127.86, 127.77 (DMTr-C), 127.09 (C-
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6), 113.16 (DMTr-C), 87.25 (C-1'), 85.13 (C-4'), 81.44 (DMTr-C-NH), 62.91 (C-5'),
55.27 (DMTr-OCH3), 51.49 (CH2N3), 39.16 (C-2'), 33.96, 29.44, 29.38, 29.21, 29.14,
29.07, 28.84,

26.71,

24.82

(methylene

Carbons);

HR-MS

(ESI-TOF)

(m/z):

c41 H49FN6 0 6 S, calcd, 772.3418; found, 770.8986 [M +Ht.
1

2.30. Yield (240 mg, 70%); H NMR (400 MHz, CDCh,

oppm): 8.50-9.40 (br s,

lH, 4-

NH), 8.09 (d, J = 5.8 Hz, lH, H-6), 7.23-7.34 (m, SH, DMTr protons), 7.17 (d, J = 8.8

Hz, 4H, DMTr protons), 6.83 (d, J = 8.8 Hz, 4H, DMTr protons), 6.27-6.31 (br s, lH, HI'), 5.34-5 .38 (br s, lH, H-4'), 4.66 (dd, J = 12.7 and 3.8 Hz, lH, H-5"), 4.45 (dd, J =
12.7 and 2.1 Hz, lH, H-5'), 3.79 (s, 6H, DMTr-OCH3), 3.58 (dd, J = 12.1 and 4.6 Hz,
IH, H-2"), 3.23 (d, J = 12.1, lH, H-2'), 2.49-2.58 (m, 4H, CH2SCH2), 2.41 (t, J = 7.4 Hz,
2H, CH2CO), 1.52-1.72 (m, 4H, SCH2CH2, CH2CH2CO), 1.23-1.43 (br m, 17H,
methylene protons);

13

C NMR (CDCh, 100 MHz,

oppm):

173.09 (COO), 158.63 (C-4),

156.23 (C2 C=O), 151.71, 147.33 (DMTr-C), 139.46 (C-5), 129.14, 127.85, 127.77
(DMTr-C), 127.08 (C-6), 113.17 (DMTr-C), 87.24 (C-1'), 85.26 (C-4'), 81.44 (DMTr-CNH), 62.84 (C-5'), 55.26 (DMTr-OCH3), 39.23 (C-2'), 33.98, 31.69, 29.65, 29.51, 29.41,

29.26, 29.22, 29.18, 28.96, 25.96, 24.82 (methylene carbons), 14.84 (CH3); HR-MS (ESITOF) (m/z): C43H 54 FN30 6 S2, calcd, 791.3438; found, 790.0172 [M +Ht.

(-)-5'-0-(Tetradecanoyl)-5-fluoro-2' ,3 '-dideoxy-3 '-thiacytidine (2.31 ), (-)-5'-0-(12azidododecanoyl)-5-fluoro-2' ,3 '-dideoxy-3 '-thiacytidine (2.32), and (-)-5-fluoro-5'-0(12-thioethyldodecanoyl)-2' ,3'-dideoxy-3 '-thiacytidine (2.33). AcOH (80%, 10 mL)

was added to compounds 2.28-2.30 (0.3 mmol). The reaction mixture was heated at 80
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oc for 30 min. The reaction mixture was concentrated at reduced pressure and the residue
was purified by reversed phase HPLC using C1s column and water/acetonitile as solvents
as described above to yield 2.31-2.33.

1

2.31. Yield (120 mg, 87%); H NMR (400 MHz, CDCh, 8 ppm): 8.03 (d, J = 6.2 Hz, lH,
H-6), 6.25-6.29 (m, lH, H-1'), 5.33-5.37 (m, lH, H-4'), 4.63 (dd, J = 12.6 and 4.1 Hz,
lH, H-5"), 4.43 (dd, J = 12.6 and 2.2 Hz, lH, H-5'), 3.56 (dd, J = 12.6 and 5.2 Hz, lH,
H-2"), 3.23 (d, J = 12.6 Hz, lH, H-2'), 2.29-2.43 (m, , 2H, CH2CO), 1.55-1.73 (m, 2H,
CH2CH2CO), 1.15-1.49 (br m, 20H, methylene protons), 0.89 (s, J = 6.2 Hz, 3H, CH3 );
13 C

NMR (CDC13, 100 MHz, 8 ppm): 173.15 (COO), 157.20 (J = 16.4 Hz, C-4), 152.07

(C-2 C=O), 135.94 (J = 240.1 Hz, C-5), 126.29 (J = 32.4 Hz, C-6), 87.26 (C-1'), 85.02
(C-4'), 63.00 (C-5'), 39.00 (C-2'), 34.22 (CH2CO), 31.93, 29.65, 29.61, 29.46, 29.36,
29.28, 29.24, 29.11, 24.83, 22.70 (methylene carbons), 14.13 (CH3); HR-MS (ESI-TOF)
(m/z): C22H36FN30 4S, calcd, 457.2411; found, 458.0814 [M +Ht, 915.1334 [2M +Ht.

2.32. Yield ( 125 mg, 88%); 1H NMR (400 MHz, CDCh, 8 ppm) 8.90-9.70 (bs, 2H, 4NH2), 8.05 (d, J = 5.9 Hz, lH, H-6), 6.25-6.29 (m, lH, H-1'), 5.33-5.37 (m, lH, H-4'),
4.62 (dd, J = 12.6 and 4.0 Hz, lH, H-5"), 4.43 (dd, J = 12.6 and 1.8 Hz, lH, H-5'), 3.56
(dd, J = 12.6 and 5.2 Hz, lH, H-2"), 3.24 (t, J = 6.7 Hz, 3H, H-2', CH2-N 3), 2.30-2.43
(m, 2H, CH2CO), 1.53-1.69 (m, 4H, CH2CH2CO, CH2CH2N3), 1.20-1.40 (br m, 14H,

methylene protons);

13

C NMR (CDCh, 100 MHz, 8 ppm): 173.13 (COO), 156.96 (J =

16.0 Hz, C-4), 151.89 (C-2 C=O), 135.95 (J = 237.1 Hz, C-5), 126.45 (J = 32.7 Hz, C6), 87.25 (C-1'), 85.05 (C-4'), 63.00 (C-5'), 51.47 (CH2N 3), 38.90 (C-2'), 34.21 (CH2CO),
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29

.42, 29.36, 29.23, 29.18, 29.11, 29.08, 29.04, 28.82, 26.69, 24.79, 24.76 (methylene

carbons); HR-MS (ESI-TOF) (m/z): C20H31FN604S, Calcd, 470.2112; found, 471.0575

[M +Ht, 941.0986 [2M + Ht.

1
2.33. Yield ( 110 mg, 80%); H NMR (400 MHz, CDCl3) 8 8.07 (d, J = 6.1 Hz, lH, H-6),
6.26-6.30 (m, lH, H-1 '), 5.37 (t, J = 2.4 Hz, lH, H-4'), 4.65 (dd, J = 12.6 and 4.1 Hz, lH,
H-5"), 4.45 (dd, J = 12.6 and 2.4 Hz, lH, H-5'), 3.58 (dd, J = 12.7 and 5.3 Hz, lH, H-2"),
3.23 (dd, J = 12.7 and 2.1 Hz, lH, H-2'), 2.49-2.58 (m, 4H, CH2SCH2), 2.30-2.45 (m,
2H, CH2COO), 1.53-1.69 (m, 4H, SCH2CH2, CH2CH2CO), 1.24-1.42 (br m, 17H,
methylene protons).

13

C NMR (CDCh, 100 MHz, 8 ppm): 173.08 (COO), 156.00 (J =

17.2 Hz, C-4), 150.87 (C-2 C=O), 135.67 (J= 239.3 Hz, C-5), 126.79 (J= 32.5 Hz, C-6),
87.20 (C-1 '), 85.46 (C-4'), 62.75 (C-5'), 39.21 (C-2'), 33.96 (ClhCOO), 31.68, 29.65,
29.50, 29.40, 29.32, 29.24, 29.15, 29.07, 28.96, 28.88, 25.92, 24.80, 24.73 (methylene
carbons), 14.83 (G.h); HR-MS (ESI-TOF) (m/z): C22H36FN304S2, calcd, 489.2131;
found, 489.9879 [M +Ht, 978.9209 [2M +Ht.

(-)-5'-0-(12(N-Fmoc-aminododecanoyl)-N 4-(4,4'-dimethoxytrityl)-2',3'-dideoxy-3'thiacytidine

(2.34)

and

(-)-5 '-0-(3(N-Fmoc-aminopropanoyl)-N4-(4,4 '-

dimethoxytrityl)-2' ,3'-dideoxy-3'-thiacytidine (2.35). Compound 2.12 (320 mg, 0.60
mmol), the corresponding Fmoc-amino acid (1.2 mmoL), and HBTU (500 mg, 1.3 mmol)
were dissolved in a mixture of dry DMF (10 mL) and DIPEA (2 mL, 15 mmol). The
reaction mixture was stirred overnight at room temperature. The reaction mixture was
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concentrated and dried under reduced pressure to afford crude 5'-0-Fmoc-amino acid
derivatives ofN4-DMTr-2',3'-dideoxy-3'-thiacytidine, 2.34 and 2.35.

2.34. HR-MS (ESI-TOF) (m/z): C41H44N40sS, calcd, 824.288; found, 825.2218 [M +

Ht, 1650.0664 [M +Ht.
2.35. HR-MS (ESI-TOF) (m/z): Cs6H62N40sS, calcd, 950.4288; found, 951.8527 [M +

H(
(-)-5 '-0-(3-Aminopropanoyl)-N 4-(4,4 '-dimethoxytrityl)-2' ,3 '-dideoxy-3 '-thiacytidine
(2.36) and (-)-5 '-0-(12-aminododecanoyl)-N 4-(4,4 '-dimethoxytrityl)-2' ,3 '-dideoxy-3 'thiacytidine (2.37). The crude products were dissolved in THF (10 mL). To the reaction

mixture was added piperidine (6 µL, 0.06 mmol) and 1-octanethiol (10 mmol solution in

THF, 0.6 mL, 6 mrnol). The reaction mixture was allowed to stir for 1 h at room
temperature. The reaction solution was concentrated at reduced pressure. The residue was
purified with reversed phase HPLC using C 18 column and water/acetonitrile as solvents

as described above to yield 2.36 and 2.37.

2.36. Overall yield (200 mg, 55%); HR-MS (ESI-TOF) (m/z): C32H34N406S, calcd,

602.2199; found, 603.1806 [M +Ht, 1205.0313 [2M +Ht.

2.37.0verall yield

=

210 mg, 52%); HR-MS (ESI-TOF) (m/z): C41Hs2N406S, calcd,

728.3608; found, 729.2265 [M +Ht, 1458.1201 [2M +Ht.
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General procedure for the Synthesis of 5'-0-(5(6)-Carboxyfluorescein) Derivatives
of 3TC (2.38 and 2.39). A mixture of 5(6)-carboxyfluroscein (430 mg, 1.15 mmol), the
corresponding N4-DMTr-5'-0-arninoacyl derivative of larnivudine (2.36 or 2.37, 0.29
mmoL), and HBTU (440 mg, 1.15 mmol) were dissolved in a mixture of dry DMF (10

mL) and DIPEA (2 mL, 15 mmol) and stirred overnight at room temperature. The
reaction mixture was concentrated and dried under vacuum. ACOH (80%, 10 mL) was
added to the reaction mixture and was heated at 80 °C for 30 min. The final compounds
were purified with reversed phase HPLC using C1s column and using water/acetonitile as
solvents as described above.

(-)-5'-0-(3-(N (5(6)-Carboxyfluorescein )aminopropanoyl)-2' ,3 '-dideoxy-3 'thiacytidine (2.38). Yield (40 mg, 20%); 1H NMR (400 MHz, CD 3CN + D 20 ,
8.41 (s, 0.5H, FAM-Ar-H, 5 or 6 isomer), 8.11 and 8.12 (two d, J

=

o ppm)

8.0 Hz, lH, H-6),

8.00-8.05 (m, lH, FAM-Ar-H, 5 or 6 isomer), 7.93 (d, J = 8.0 Hz, 0.5H, FAM-Ar-H, 5 or

6 isomer), 7.53 (s, 0.5H, FAM-Ar-H, 5 or 6 isomer), 7.29 (d, J = 8.0 Hz, 0.5H, FAM-ArH, 5 or 6 isomer), 6.78-6.90 (m, 4H, FAM-Ar-H), 6.71 (dd, J = 2.4 and 8.9 Hz, 2H,
FAM-Ar-H, 5 or 6 isomer), 6.10 and , 6.17 (two d, J = 8.0, 2H, H-1 ', H-5), 5.36-5.42 and

5.25-5.31 (two m, J = 2.9 Hz, lH, H-4'), 4.55 (dd, J = 12.6 and 4.4 Hz, lH, H-5"), 4.32
(dd, J == 12.6 and 2.9 Hz, lH, H-5'), 3.45-3 .69 (m, 3H, H-2" and CH2NH), 3.13-3.21 (m,

IH, H-2'), 2.72 and 2.61 (two t, J = 6.5 Hz, 2H, CH2CO);

MHz,

o ppm):

13

C NMR (CD3CN + D20, 100

172.49, 172.32 (COO), 168.80 (CONH), 167.24, 167.11 (COO-FAM),

160.71 (Ar-C-FAM), 159.78, 159.72 (C-4), 154.66 (C-2 C=O), 147.62, 147.55 (Ar-C-
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FAM), 144.50, 144.39 (C-6), 136.44, 133.91, 130.70, 129.60, 128.39, 115.06, 111.93,
l02.87 (FAM-C), 94.32, 94.26 (C-5), 87.38, 87.21 (C-1 '), 85.17, 84.98 (C-4'), 63.93,
63.81 (C-5'), 49.09 (CThNH2), 37.98, 37.87 (C-2'), 36.15, 36.06 (CH2COO); HR-MS
(ESI-TOF) (m/z): C32H26N4010S, calcd, 658.137; found, 330.2546 [M + 2H]

2

+,

659.2739

[M +Ht, 1317.2294 [2M +Ht.

(-)-5 '-0-(12-(N (5(6)-Carboxyfluorescein )aminododecanoyl)-2' ,3' -dideoxy-3 '1
thiacytidine (2.39). Yield (30 mg, 16%);. H NMR (400 MHz, CD3CN + D 20, 8 ppm)
8.28-8.35 (m, 0.5H, FAM-Ar-H, 5 or 6 isomer), 8.11 and 8.12 (two d, J = 8.0 Hz, lH, H6), 7.96-8.04 (m, l.5H, FAM-Ar-H), 7.52 (s, 0.5H, FAM-Ar-H, 5 or 6 isomer), 7.25 (d, J
=

8.0 Hz, 0.5H, FAM-Ar-H, 5 or 6 isomer), 6.68-6.74 (m, 2H, FAM-Ar-H), 6.59-6.67

(m, 2H, FAM-Ar-H), 6.56 (dd, J = 2.3 and 8.8 Hz, 2H, FAM-Ar-H), 6.13-6.22 (m, lH,

H-1'), 6.08 and 6.09 (two d, J = 8.0, 2H, H-5), 5.33-5.40 (m, lH, H-4'), 4.50 (dd, J =
12.5 and 4.8 Hz, lH, H-5"), 4.38 (dd, J

=

12.5 and 3.1 Hz, lH, H-5'), 3.54 (dd, J = 5.5

and 12.6 Hz, lH, H-2"), 3.34 (m, 3H, H-2' and CH2NH), 2.25-2.34 (m, 2H, CH2COO),
1.40-1.60 (m, 4H, CH2CH2CO, CH2 CH2NH), 1.11-1.25 (br m, 16H, methylene protons);
13

C NMR (CD 3CN+D 20, 100 MHz, 8 ppm): 174.02 (COO), 170.02 (CONH), 167.21

(COO-FAM), 160.84 (C-4), 153 .67 (C-2 C=O), 148.19, 145.23 (Ar-C-FAM), 142.19 (C6), 137.63 , 135.24, 130.52, 130.39, 130.10, 128.11, 126.38, 125.50, 124.85, 123.85,
113.80, 110.95, 103.48 (FAM-C), 94.73 (C-5), 88.12 (C-1 '), 85.72 (C-4'), 64.39 (C-5'),
49.69 (CH2NH2), 38.55 (C-2'), 34.54 (CH2COO), 30.17, 30.13, 30.07, 30.01, 29.94,
29.87,

29.80,

29.71,

29.59

(methylene
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carbons),

27.58

(CH2CH2NH2),

25.54

(CHzCH2COO); HR-MS (ESI-TOF) (m/z): C418,i4N4010S, calcd, 784.2778; found,
393.0862 [M + 2H]

2

+,

784.9019 [Mt, 1569.4510 [2M +Ht.

2.3.3. Anti-IDV Assays

Anti-HIV activities of the compounds were evaluated according to the previously
reported procedure (Krebs et al., 1999). In summary, HeLa (Human cervical carcinoma:
ATCC CCL-2.1) cell line was used to measure inactivation of both cell-free virus
preparations and virus-infected cell preparations. Cells were plated in culture plates 24 h
prior to each experiment.

Cell-free viral preparations of HIV-1

strains IIIB

(lymphocytotropic strain) and BaL (monocytotropic strain) were used for cell-free assay.
For cell-associated assay, SulTl cells were infected with IIIB virus 5 days prior to the
experiment. Cell-free virus and virus-infected cells were mixed with different compounds
and diluted to make different concentrations. The mixture was further diluted with the

buffer and added to the HeLa cells. The cells were incubated at 37 °C for 48 h, stained for
~-galctosidease

expression and compared with

~-galctosidease

expression from the

~-gal-

positive cells in absence of any microbicidal compound to get IC 50 values.

2.3.4. Cellular Uptake Study

All of the stock solutions for compounds FAM, 2.38, and 2.39 were prepared in
DMSO. The human T lymphoblastoid cells CCRF-CEM (ATCC No. CCL-119) were
grown on 25 cm2 cell culture flasks with RMPI-1640 medium containing 10% fetal
bovine serum. Upon reaching about 70% confluency, the cells were treated as described
below and incubated for 1 h or longer at 3 7 °C.
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2.3.4.1. Cellular Uptake of FAM, 2.38 and 2.39 at Different Time Points

When the cells reached about 70% confluency, FAM, 2.38, or 2.39 (1 mL, 20

µM) in RMPI-1640 medium were added to 1 rnL of cells to make the final concentration
as 10 µM. The cells were incubated for 0.5, 1, 2, 4, and 8 hat 37 °C. Then the flow
cytometry assays were performed as described below.

2.3.4.2. Cellular Uptake of 2.39 at Different Concentrations

When the cells reached about 70% confluency, 1 rnL of graded concentrations (0,
1O, 20, 40, 80, and 200 µM in RMPI-1640) of 2.39 was added to 1 rnL of cells to make
the final concentration as 0, 5, 10, 20, 40, and 100 µM. The cells were incubated for 1 h
at 37 °C. Then the flow cytometry assays were performed as described in General
Information.

2.3.4.3. Cellular Uptake of 2.38 and 2.39 with Trypsin Treatment.

The assays were performed as previously described in section 2.3.4.1 at 1 h time
point with the exception that the cells used were incubated with 0.25% trypsin/0.53 mM
EDTA for 5 min before washing with PBS (pH 7.4).

2.3.4.4. Flow Cytometry

The cells were washed twice with PBS (pH 7.4) at 2000 rpm for 5 min. Then the
cells were analyzed by flow cytometry (F ACS Cali bur: Becton Dickinson) using FITC
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channel and CellQuest software. The data presented are based on the mean fluorescence
signal for 10000 cells collected. All the assays were done in triplicate.

2.3.5. Cell Viability Assay

When the cells reached about 70% confluency, the cells were incubated with a
solution of CCRF-CEM cell alone or 10 µM FAM, 2.38, or 2.39 for 24 hat 37 °C. Then
20 µL of the cells from each flask were treated with µl of trypan blue (0.1 %) for 1 min.
The cells were then transferred to a Cellometer® counting slide and analyzed using
Cellometer Auto T.4 (Nexcelom Bioscience). All the assays were performed in triplicate.

2.3.6. Real Time Fluorescence Microscopy in Live CCRF-CEM Cell Line

The cellular uptake studies and intracellular localization of CCRE-CEM cell
alone, or incubated with 2.38 and 2.39 were imaged using a ZEISS Axioplan 2 light
microscope equipped with transmitted light microscopy with a differential-interference
contrast method and an Achroplan 40X objective. The human T lymphoblastoid cells
CCRF-CEM (ATCC No. CCL-119) were grown on 60 mm Petri Dishes with RPMI-1640
medium containing 10% fetal bovine serum. Upon reaching about 70% confluency, the
cells were incubated with a solution of 10 µM of 2.38 and 2.39 for 1 hat 37 °C. They
were then observed under the fluorescent microscope under bright field and FITC
channels (480/520 nm).
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2.4. Results and discussion
2.4.1. Chemistry
2.4.1.l. Fatty Acyl Ester Derivatives of 3TC, d4T, and FTC

A number of fatty acyl esters of 3TC, d4T and FTC were synthesized (Figure 2.1)
to improve the cellular uptake, anti-HIV activity, and resistant profile of the parent
nucleosides.

Four

fatty

acids,

myristic

acid,

12-azidododecanoic

acid,

12-

thioethyldodecanoic acid, and 12-bromododecanoic acid, were used for the conjugation
with nucleoside analogs.

R 20H ___....

+

R1 =C13H2r
N3-C11H22CH3CHrS-C11H2r
Br-C11H2r

~~
IN~O

NH 2

0

YNH
N~O
~-fOH HO\-d

F~N
1

~-fOH
s

N~O

s

3TC (2.1)

FTC (2.24)

d4T (2.19)

R 20H = Nucleoside (3TC, FTC, d41)
Figure 2.1. General structures of fatty acyl ester derivatives of nucleosides.

Scheme 2.1 depicts the synthesis of the fatty acyl ester derivatives of 3TC. 5'Hydroxyl and/or 4-amino positions were substituted with the fatty acids to synthesize
three classes of compounds: two 5' ,N4-disubstituted (2.2 and 2.3), three N4-substituted
(2.8-2.10), and three 5'-0-ester (2.16-2.18) of 3TC. 5',N4-Disubstituted derivatives (2.2

and 2.3) were synthesized by reacting 3TC with the appropriate fatty acyl chloride in
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presence of DMAP as a base. N4-substituted derivatives (2.8-2.10) were synthesized by
selectively protecting 5'-hydroxyl group with tert-butyldimethylsilyl chloride in the
presence of imidazole as a base to afford 2.4, 5'-TBDMS protected 3TC was further
reacted with the fatty acyl chloride followed by deprotection of TBDMS to afford N4substituted derivatives (2.8-2.10). 5'-0-Fatty acyl derivatives of 3TC (2.16-2.18) were
synthesized by first protecting 4-amino group of 2.4 with DMTr protecting group to
afford 2.11. The TBDMS group was then removed from 5'-0-position by treatment of
2.11 with TBAF to yield N 4-DMTr derivative of 3TC (2.12). Compound 2.12 was then

reacted with the fatty acids in the presence of HBTU and DIPEA followed by DMTr
deprotection to afford 5'-0-(fatty acyl) ester derivatives of 3TC (2.16-2.18).

Four 5'-0-(fatty acyl) ester derivatives of d4T (2.19-2.22) were synthesized by
reaction of d4T with the appropriate fatty acyl chloride (myristoyl chlroide, 12azidododecanoyl chloride, 12-thiaethyldodecanoyl chloride, and 12-bromododecanoyl
chloride) in the presence of DMAP as a base (Scheme 2.2).

Furthermore, three 5'-0-fatty acyl ester derivatives of FTC (2.31-2.33) were
synthesized (Scheme 2.3) using a similar approach described above for the synthesis of
5'-0-(fatty acyl) ester derivatives of 3TC (2.16-2.18).

All compounds were synthesized at 100 mg scale and were tested for the anti-HIV
and cytotoxicity assays. Compounds 2.8, 2.16, and 2.17 were further synthesized in larger
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scale (5 g) for further biological evaluations. These three compounds were first purified

by using silica gel column chromatography (>90% purity) and then HPLC (>99% purity).

2.1

R-COCI, DMAP

l

TBDMS-Cl,
Imidazole, DMF

R-COCI, DMAP

DMTr

~N
N~O
1

I ; (OH~R_C~O~O~H=--
~?

Acetic acid .,

HBTU,NMM
2.12

Scheme 2.1. Synthesis of fatty acyl ester derivatives of 3TC.
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R-COCI, DMAP, Benzene

2.19

2.20 R = C 13 H27

=N3-C 11 H2r
2.22 R = Et-S-C 11 H2 r
2.23 R = Br-C 11 H2 r
2.21 R

Scheme 2.2. Synthesis of 5'-0-(fatty acyl) ester derivatives of Stavudine (d4T).

2.24 IBDMS-Cl
2.25

RCOOH, HBTU,
DIPEA ,DMF
TBAF

.,

2.27

2.28 R = C 13H27
2.29R=NrC 11 H 2r
2.30R=CH3 CH2S-C11H2r

Acetic acid

Scheme 2.1. Synthesis of fatty acyl ester derivatives of FTC.
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2,4.1.2. 5(6)-Carboxyfluorescein Derivatives of 3TC
3TC

was

attached

to

5(6)-carboxyfluorescein using

P-alanine

and

12-

aminododecanoic acid as linkers. First, 3TC-DMTr (2.12) was reacted with the
corresponding Fmoc-amino acid in the presence of HBTU and DIPEA. Second, N-Fmoc
deprotection to free amino group was achieved in the presence of piperidine. Finally,
FAM was attached to free amino group in the presence of HBTU and DIPEA, followed

by DMTr deprtotection to afford 5(6)-carboxyfluorescein derivatives of 3TC, 2.36 and

2.37 (Scheme 2.4). These compounds were used for cellular uptake studies to determine
cellular uptake profile of fatty acyl ester derivatives of 3 TC. 3 TC attached to FAM
through p-alanine (2.36) was used as a control 3TC analog. 3TC attached to FAM
through 12-aminododecanoyl(2.37) was used as an analog of 5'-0-(12-azidododecanoyl)2',3'-dideoxy-3'-thiacytidine (2.17) and other fatty acid ester analogs of 3TC .
.DMTr

_..DMTr

~N

::tN

lN~O

10
-S ( OH
C-::-i

lN~O

Fmoc-NH-(CH2)n-OH, HBTU, DIPEA, DMF

I

{_;)

--j 1(' ~NHFmoc
0

Cs

a

2.12
2.34; n = 2
2.35; n = 11

j

Piporidioo (20%)

1. 5(6)-FAM , HBTU,

2. Acetic Acid

2.38; n = 2
2.39; n = 11

0

Scheme 2.4. Synthesis of 5'-carboxyfluorescein derivatives of 3TC (2.38 and 2.39)
through different linkers.
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2.4.2. Biological Activities
Although 3TC, FTC, and d4T are less potent than FLT against cell-free virus
assays, but they exhibited a higher anti-HIV activity against cell-associated virus. Table
2.2 illustrates the anti-HIV-1 activities of the fatty acyl ester derivatives of3TC, d4T, and
FTC in comparison with 3TC, FTC, and d4T against cell-free and cell-associated virus.

The data provide structure-anti-HIV activity relationships for different fatty acyl
ester derivatives of 3TC by comparing N4-substituted, 5'-0-substituted, and 5'-0,N 4disubstituted compounds. In general, when the N4 and/or 5'-0 positions were substituted
with a fatty acid, minimal cytotoxicity was observed (EC 50 > 200 µM).

Anti-HIV activity of the 3TC derivatives was dependent on the site of
esterification.

5'-0,N4-Disubstituted derivatives of 3TC, 2.2 and 2.3, displayed

significantly less activity against both cell-free and cell-associated HIV (EC 50

=

73-> 154

µM) when compared with other fatty acyl derivatives of 3TC and 3TC.

On the other hand, all the N 4- or 5' -0-monosubstituted derivatives of 3TC (2.8-

2.10 and 2.16-2.18) exhibited a higher potency than that of 3TC against cell-free virus.
Although the 5'-0-monosubstituted ester derivatives (2.16-2.18) were the most potent
compounds against cell-free virus (EC 50 = 0.2-2.3 µM) among all 3TC derivatives as
determined by the viral inhibition assays, they lost their effectiveness when used in the
cell-to-cell transmission assay (EC 50 > 212-228 µM).
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On the other hand, N4-myristoyl derivative of 3TC, 2.8, exhibited the anti-HIV activity
against cell-free (ECso = 0.7-10.9 µM) and cell-associated virus (EC 50 = 0.7 µM).
Compound 2.8 was the most versatile analog in the cell-associated lymphocytotropic
strain (CTC) based inhibition assay and showed 114-fold higher anti-HIV activity against
cell-associated virus when compared with 3TC (ECso = 80.3 µM) Furthermore,
compound 2.8 was also more potent than FTC (ECso = 88.6 µM) andd4T (EC 50 = 136.1
µM) in cell-to cell transmission assay (Table 2.2).

In general, three of 5'-0-(fatty acyl) ester derivatives d4T (2.21-2.23) showed higher antiHIV activities (EC 50 = 2.3-14.9 µM) against cell-free virus when compared with d4T

(ECso = 26.8-28.1 µM), but were only moderately active when compared to other
corresponding fatty acyl derivatives of 3TC and FTC. Among all fatty acyl ester
derivatives of d4T, 12-azidododecanoyl ester 2.21 was the most potent compound and
showed 4-9 fold higher anti-HIV activities against cell-free and cell-associated virus
when compared with d4T (Table 2.2).

Unlike 3TC and d4T derivatives, 5'-0-(fatty acyl) ester derivatives of FTC, 2.31-2.33,
were consistently active against both cell-free and cell-associated virus (Table 2.2). These
compounds exhibited the highest anti-HIV activity against cell-free virus (ECso

=

0.04-

0.8 µM) among all the fatty acyl ester derivatives and their parent nucleoside analogs. 5'0-Myristoyl derivative of FTC (2.31) displayed about 10-24 fold higher anti-HIV
activities than those of FTC against cell-free and cell associated virus. 5'-0-12-
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thioethyldodecanoyl derivative of FTC (2.33) displayed slightly higher anti-HIV activity
than 2.31 , but showed higher toxicity against normal cells (EC 50 = 93.6 µM).

In summary, structure-function analysis revealed that the anti-HIV activity of
fatty acyl substituted derivatives of nucleosides was clearly dependent on the nature of

the nucleoside and fatty acid analog. The rate of cellular uptake and the intracellular
hydrolysis to parent nucleoside and fatty acids determine the overall anti-HIV activities
of the conjugates.

Table 2.3 shows the anti-HIV activities (in µg/mL) of the 5'-0-fatty acyl ester
derivatives of FTC compared with the corresponding physical mixtures. The equimolar
(50:50) physical mixture of FTC with myristic acid (2.34) and 12-thioethyldodecanoic
acid (2.35) showed significantly less anti-HIV activities (EC 50

=

0.1-9.9 µM) than the

corresponding 5'-0-fatty acyl ester derivatives, 2.31 and 2.33 (EC 50

=

0.02-2.4 µM),

respectively, against cell-free and cell-associated virus. The anti-HIV activity of the
physical mixtures was only slightly higher than that of FTC. The results indicate that the
conjugation of FTC with myristic acid analog is critical in improving the anti-HIV profile
of the conjugate. The comparative studies of physical mixtures with the corresponding
ester conjugate indicated that the esterification is important for the inhibitor activity,
especially against cell-associated virus.
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Table 2.2. In vitro assays of 3TC, d4T and FTC analogs for inhibition of HIV.
CT Ce
EC(SO)

{~M)

{~M)

I 1.3

80.3

Diluent

2.1 (3TC)

DMSO

RIO

> 200

VBl(IIIB
CEC(SO)
(µM)
32.7

2.2

DMSO

RIO

> 200

> 154.0

135.2

> I54.0

2.3

DMSO

RIO

> 200

> 148.1

72.7

> I48.1

2.8

dH20

DMSO

> 200

10.9

0.7

0.7

2.9

dH20

DMSO

> 200

29.4

3.8

I4.6

2.10

DMSO

RlO

>200

5.3

0.4

> 2I2.2

2.16

DMSO

RlO

> 200

0.5

> 0.2

> 227.7

2.17

DMSO

RlO

> 200

0.9

0.7

> 221.1

2.18

DMSO

RlO

> 200

2.3

0.2

> 2I2.2

2.19 (d4T)

DMSO

RlO

>200

26.8

28.I

I36.1

2.20

DMSO

RlO

> 200

78.3

I2.4

> 230.3

2.21

DMSO

RIO

> 200

6.7

3.1

22.4

2.22

DMSO

RIO

> 200

14.4

5.8

46.5

2.23

dH20

DMSO

> 200

14.9

2.3

> 206.5

2.24 (FTC)

DMSO

RIO

> 200

1.9

0.7

88.6

2.31

DMSO

RlO

> 200

0.1

0.07

3.7

2.32

DMSO

RlO

> 200

0.8

0.2

9.1

2.33

DMSO

RlO

93.6

0.05

0.04

4.9

AZT

DMSO

RlO

> 200

10.9

14.2

>375

FLT

DMSO

RlO

> 200

0.8

0.4

>4IO

DMSO

DMSO

RlO

>200

>IOO

>IOO

>100

Compound

iolvent

{~M)

3

VBl(BaL)a
EC(SO)

CTS 3
EC(SO)b

Cytotoxicity assay; b50% Effective concentration; cviral entry inhibition assay (lymphocytotropic strain);

dViral entry inhibition assay (monocytotropic strain); ccell- to- cell transmission assay (IIIB).

In summary, the conjugation of RT inhibitor nucleoside analogs with selected
long chain fatty acids (NMT inhibitors) exerted anti-HIV synergic effect. Among 3TC
derivatives, 2.8, 2.16, and 2.17 exhibited the best anti-HIV profile. 5'-0-Myristoyl FTC
derivative (2.31) showed consistent anti-HIV activity against cell-free (IIIB and BaL)
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strains and cell-associated virus, and was the most potent compound among fatty acyl
derivatives of FTC, 3TC, and d4T .. Compounds 2.8, 2.16, and 2.17 are currently under
further biological evaluations.
Table 2.3. Comparison of anti-HIV activities of fatty acyl derivatives of FTC with
physical mixtures of FTC + fatty acids ..

Compound

Chemical Name

CTS"

VBI(IlIW

VBI(BaL)a

CTC

EC(SO)b

EC(SO)

EC(SO)

EC(SO)

(µg/ml)

(µg/ml)

(µg/ml)

(µg/ml)

2.24

FTC

> 100

0.48

0.18

21.9

2.31

5'-0-Myristoyl FTC

> 100

0.056

0.033

1.7

45.8

0.024

0.02

2.4

> 100

0.6

0.1

9.9

> 100

0.1

0.2

9.8

> 100

>100

>100

>100

5'-0-(122.33

thioethyldodecanoyl) FTC
Myristic acid +FTC

2.34

(50:50)
12-thioethyldodecanoic

2.35

DMSO

acid+ FTC (50:50)
DMSO

3

Cytotoxicity assay; b50% Effective concentration; 0 Viral entry inhibition assay (lymphocytotropic
strain); dViral entry inhibition assay (monocytotropic strain); ecell- to- cell transmission assay (IIIB).

2.4.3. Spermicidal Activity.
The spermicidal activities of several fatty acids have been previously reported
(Brown-Woodman et al., 1985; Jianzhong et al., 1987). The spermicidal activities of 3TC
(2.1), d4T (2.19), and their fatty acyl ester derivatives 2.2, 2.3, and 2.20-2.22 were
compared with N-9, a marketed spermicidal product (Figures 2.2 and 2.3). In a doseresponse study to evaluate spermicidal activity, none of these derivatives shows
significant sperm immobilizing or spermicidal activity, even at their maximum
concentrations (1 mg/mL).
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Figure 2.2. In vitro assays for spermicidal activity of 3TC (2.1), 2.2, and 2.3.
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2.4.4. Cellular Uptake Study

Studies were performed to understand cellular uptake profile of 5'-0-fatty acyl
derivatives in comparison with 3TC. 3TC attached to FAM through /)-alanine (2.38) was
used as a control 3TC analog. 3TC attached to FAM through 12-aminododecanoic acid
(2.39) was used as an analog of 5'-0-(12-azidododecanoyl)-2',3'-dideoxy-3'-thiacytidine

(2.16) and other fatty acid ester analogues of 3TC. The human T lymphoblastoid cells
(CCRF-CEM, ATCC No. CCL-119) were used for the study and were grown to the 70%
confluency in the culture media. The cells were incubated with the fluorescein-substituted
conjugates (2.38 and 2.39) in different time periods, concentrations, and in the presence
or absence of trypsin (Figures 2.4-2.6), DMSO and FAM were used as control for the
study. The cells were analyzed by flow cytometry (FACSCalibur: Becton Dickinson)
using FITC channel and CellQuest software. The data presented are based on the mean
fluorescence signal for 10000 cells collected. All the assays were carried out in triplicate.

First, cells were incubated with 10 µM of the compounds in different time periods
(0.5 h, 1 h, 2 h, 4 h and 8 h, Figure 2.4). Compound 2.39 exhibited 3-6 fold higher
cellular uptake than that of 2.38 and FAM alone. The results clearly indicate that
presence of long chain enhances the cellular uptake of 3TC, by increasing lipophilicity.
The continuous incubation of cells with compounds up to 8 h did not show significant
difference in the cellular uptake, suggesting that most of the fatty acyl ester derivative is
absorbed into cells within first 30 min and the cellular uptake was not time dependent.

110

200

Compounds (10 µM) at Different Time Point

180
160

.,...
.,...c:

140
120

~

...
=
f;::
Q

c:

.,
OI

100
80

::;
60
40
20
0

Figure 2.4. Cellular uptake studies for 5(6)-carboxyfluorescein derivatives of 3TC (2.38
and 2.39) along with FAM and DMSO as controls at different time intervals.

Cells were then incubated with different concentrations (5, 10, 20, 40 and 100
µM) of carboxyfluorescein derivatives of 3TC, 2.38 and 2.39 for 1 h (Figure 2.5). The
data suggest that the cellular uptake was concentration dependent.
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Figure 2.5. Cellular uptake studies for 5(6)-carboxyfluorescein derivative of 3TC (2.39)
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To confirm that the enhanced uptake of 5(6)-carboxyfluorescein derivative of
3TC, 2.39, is not due to the absorption on the cell membrane surface, cells were
incubated with 10 µM of DMSO, 2.38, and 2.39 for 1 h and then half of the cells were
finally treated with trypsin for 5 min to wash the adsorbed molecules (if any) from the
cell membrane. The comparison of the data between trypsin treated and untreated cells
indicates that only small amount of the fluorescence was due to the absorption on the cell
membrane surface. The cellular uptake studies after trypsin treatment showed that the
cellular uptake of 2.39 was still much higher than those of control compounds and 2.38
(Figure 2.6). Cellular uptake for the trypsin-treated cells with 2.39 was approximately 7
times higher than that of 2.38. On the other hand, trypsin-untreated cells incubated with
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2.39 showed only 4-fold higher cellular uptake than 2.38. The results suggest that the
higher cellular uptake of 2.39 is not due to artificial absorption to the cell membrane.
300.00

250.00

200.00
~

....,
.."'.
c

g

150.00

~

..
::;"'
c

100.00

50.00

DMSO

2.38

2.38 + Trypsin

2.39

2.39 + Trypsin

Figure 2.6. Cellular uptake studies for 2.38 and 2.39 with DMSO as controls with and
without treatment with trypsin.

2.4.5. Cell Viability Study
Cell viability study was performed to analyze the effect of FAM, 2.38 and 2.39 on
the live cells. CCRF-CEM cells were incubated with 10 µM of the compounds and mixed
with trypan blue (0.1 %) to color the dead cells. The percentage of viability was calculated
using Cellometer Auto T.4 (Nexcelom Bioscience). It was observed that at least 80% of
the cells were viable in presence of the compounds in 24 h incubation period (Figure 2.7).
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Figure 2.7. Cell viability assay after 3h and 24 h incubation of 2.38 and 2.39 with CCRFCEM cells. DMSO and FAM were used as positive controls.

2.4.6. Real Time Fluorescence Microscopy in Live CCRF-CEM Cells
CCRF-CEM cells were incubated with 10 µM of DMSO, FAM, 2.38 and 2.39 for
1 h and were imaged using light microscope (ZEISS Axioplan 2) equipped with
transmitted light microscopy with a differential-interference contrast method and an
Achroplan 40X objective. Cells showed no significant fluorescence when incubated with
DMSO, FAM, and 2.38 (Figure 2.8). On the other hand, cells incubated with 2.39
showed fluorescence. The results further confirm the higher cellular uptake of 2.39, a
fatty acyl derivative of 3TC, in comparison to 2.38 and FAM alone. In general, these data
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indicate that the fatty acyl derivatives of nucleosides have better cellular uptake than their
parent nucleosides.

Control-B

. F~M·B
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Figure 2.8. Real time fluorescence microscopy in live CCRF-CEM cell line. Control=

DMSO, FAM = 5(6)-carboxyfluorescein.
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z.5. Conclusions.

Several bifunctional 5'-0-substituted or N4-substituted fatty acyl derivatives of
3TC, d4T, and FTC were designed and synthesized as prodrugs and their biological
activities, such as anti-HIV activities, spermicidal properties, and cellular uptake
studies. In general, the conjugation of selected fatty acids with RT inhibitor nucleoside
analogs resulted in activity better anti-HIV profile because of improved cellular uptake
of the conjugates and intracellular hydrolysis of the conjugates yielding two parent
analogs targeting RT and NMT.

Among all the ester derivatives, 2.31, 2.32, 2.8, 2.16, and 2.17 were found to
have better anti-HIV activity profile in comparison to 3TC, d4T, FTC and other fatty
acyl derivatives. 5'-0-Myrsitoyl derivative of FTC (2.31), was found to be the most
potent anti-HIV compound among the tested compounds and displayed consistent
activity against cell-free (IIIB and BaL) stains and cell-associated virus. The physical
mixtures of FTC with myristic acid (2.34) and 12-thioethyldodecanoic acid (2.35)
showed significantly less anti-HIV activity than the corresponding 5'-0-fatty acyl
ester derivatives, 2.31 and 2.33, respectively .. The data indicate that conjugation of the
nucleoside with myristic acid analogs is important in achieving a higher anti-HIV
activity possibly by improving the cellular uptake. The significant enhancement of
cellular uptake cannot be obtained by physically mixing the nucleoside and fatty acid.

3TC derivatives, 2.8, 2.16 and 2.17, exhibited higher anti-HIV activities than
other 3TC derivatives. Furthermore, N 4-myristoyl derivative of 3TC, 2.8, showed the

117

highest anti-HIV activities against cell-associated virus when compared with all tested
fatty acyl ester derivatives of nucleosides here.

The presence of long chain fatty acid at 5'-position enhanced the lipophilicity
of 3TC and the cellular uptake as was shown by cellular uptake studies of 5'carboxyfluroscein derivatives of FLT containing short chain (2.38) and long chain
(2.39) alkyl ester groups. F ACS experiments showed that 2.39 had at least 3-5 fold

higher cellular uptake in CCRF-CEM cells than 2.38. Fluorescence microscopy of the
cells incubated with these compounds further confirmed the FACS results as cells
incubated with 2.39 showed significantly higher fluorescence when compared with
cells incubated with FAM and 2.38. These results suggest that the increased inhibition

by the fatty acyl ester derivatives of 3TC, FTC, and d4T may be due to their increased
rate of uptake and intracellular hydrolysis yielding two antiviral agents with different
targets, parent nucleoside and fatty acid analog. These data provided insights for more
rational design of additional potent and safe anti-HIV microbicides using the 3TC or
FTC as the parent nucleosides. When taken together, the results will have significant
implications for the design of more potent and innovative anti-HIV agents.
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3.1. Abstract
Three classes of mono- di-, or trinucleoside conjugated on multivalent
scaffolds (e.g., dicarboxylic acids, amino acids, and peptides) were synthesized to
generate broad-spectrum anti-HIV agents with higher barrier to drug resistance, and/or
higher cellular uptake: (i) Unsymmetrical and symmetrical dinucleoside conjugates of
succinic acid or suberic acid; (ii) Peptides containing one nucleoside and one
myristoyl group; and (iii) Dinucleoside- and trinucleoside glutamic acid derivatives
with or without myristoyl moiety. Unsymmetrical dinucleoside succinate derivatives
were synthesized by reacting nucleoside succinate derivatives with 3'-azido-2',3'dideoxythymidine (AZT), 3'-fluoro-2',3'-dideoxythymidine (FLT), or 2',3'-dideoxy-3'thiacytidine (3TC) in the presence of HBTU. Symmetrical dinucleoside suberate
derivatives were synthesized from the reaction of suberic acid with the corresponding
nucleoside in the presence of HBTU. Small peptides containing one nucleoside and
one myristoyl group attached to the amino acid side chains were synthesized by using
Fmoc-solid phase protocol. Dinucleoside- and trinucleoside glutamate derivatives
containing different nucleosides attached on carboxylic groups and myristoyl or acetyl
groups at amino group were synthesized by using multi-step solution phase methods.
The anti-HIV activities of several synthesized compounds were determined against
cell-free virus and compared with the corresponding physical mixtures. Among all the
tested compounds, a glutamate derivative containing three different nucleosides, AZT,
FLT, and 3TC, (3.37; EC 50 = 0.96 µM), was found to be the most potent conjugate,
and exhibited 35-fold higher anti-HIV activity than both AZT (ECso
3TC (EC 50

=

=

34.4 µM) and

32.7 µM). Compound 3.37 had a comparable anti-HIV activity to FLT
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(ECso

=

0.8 µM). N-Myristoylated conjugates of the glutamic acid showed 1.5-6

higher anti-HIV activities than the corresponding N-acetylated conjugates. In general,
when compared with the corresponding conjugated derivatives, the physical mixtures
demonstrated higher anti-HIV activity. In addition, the physical mixtures containing
myristic acid exhibited 2-3 fold higher anti-HIV activity than those without myristic
acid. These data suggest that the presence of myristic acid plays an important role in
improving anti-HIV activity of the conjugated compounds or the physical mixtures.

3.2 Introduction

Scaffolds are defined as skeleton, core, or template of the structure to which
multiple functional groups and moieties may be attached. The scaffolds may have
multiple positions for multivalent linkages. Some examples of scaffolds include
polycarboxylic acid derivatives, amino acids, and peptides. Herein, we compared the
anti-HIV activities of nucleosides conjugated on small peptides with those conjugated
on dicarboxylic acid derivatives (i.e., suberic acid, succinic acid) and glutamic acid.
For example, diversity in the structure and physicochemical properties of peptides
allow their applications in targeted drug delivery, enzyme inhibitors, and scaffolds.
Peptides-based prodrugs are commonly used in drug delivery. Peptides have
been used as linkers to deliver drugs at desired site where they undergo site specific
enzymatic hydrolysis to deliver the active molecules. For example, Chau et al. have
used a specific peptide sequence of matrix metalloproteinase, an enzyme
overexpressed in cancer cells, to deliver anti-cancer drugs, such as methotrexate to the
cancer cells (Chau et al., 2004, Chau et al., 2005, and Chau et al., 2006). Peptides with

123

different chain lengths have also been used as spacers to deliver active drugs after
Jysosomal hydrolysis of the peptide conjugates (Penugonda et al., 2007, Subr et al.,
I 992, Soyez et al., 1996).

Peptide esters have been previously used to improve the bioavailability of the
active drugs. Peptide prodrugs of lopinavir showed higher oral bioavailability than
Jopinavir itself (Agarwal et al., 2008). Peptide conjugates of 5-aminolaevulinic acid
showed improved pharmacological response as a result of better cellular uptake
(Bourre et al., 2008).
Furthermore, peptide derivatives are also being used to produce direct
pharmacological activity against some targeted enzymes. Ramipril, enalapril, and
captopril are peptide-based compounds that are used as angiotensin converting
enzyme inhibitors (Acharya et al., 2003). Enfuvirtide is a recently approved anti-HIV
drug that acts as the anti-HIV entry blocker, and is a peptide structure based derivative
(Lazzarin, 2005). Several HIV protease inhibitors, such as lopinavir, saquinavir, are
also peptide-based drugs (Agarwal et al., 2008, Cvetkovic et al., 2003).
Although the introduction of highly active antiretroviral therapy (HAART) in
the mid-l 990s has resulted in a decrease of the morbidity and mortality in the HIV-1
patient population that has access to treatment, therapy failure still occurs. A
combination of reverse transcriptase (RT) inhibitor nucleoside analogs is used m
HAART to reduce the viral load. Each nucleoside analog has different cellular uptake
rate and pharmacokinetics. Several of nucleoside analogs succumb to newly developed
resistant virus. For example, Lamivudine is a (-)-2',3'-dideoxy-3'-thiacytidine analog
that is used in the treatment of both HIV-1 and hepatitis disease (Skalski et al., 1993) ..
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Although Lamivudine has good activity against wild type HIV, a single point mutation
at 184 residue results in 3TC-resistant mutant virus (Ml84V/I) (Mulder et al., 2008,
Sarafianos et al., 1999, Diallo et al., 2003). Several studies have provided different
reasons for resistance development, such as cytidine deamination and the generation
of steric hindrance at 184 amino acid residues. Similar to the HIV, mutation at Met552
with Val and Ile (M552V/I) results in 3TC and FTC resistant HBV strains (Das et al.,

2001). Nucleoside analogs are also very polar and have limited cellular uptake.
Therefore it is logical to develop new and more potent multi-nucleoside conjugates,
with major advantages to HAART therapy that display broad-spectrum activity against

drug-resistant HIV, have higher cellular uptake, and can deliver several RT nucleoside
inhibitors simultaneously to the HIV-infected cells.
The objective of this research was to design multi-nucleoside conjugates
substituted on a multivalent scaffold. The conjugates may have application in delivery
of several nucleosides to the infected cells, broad-spectrum activity, and a higher
barrier to drug resistance. Herein, we report the synthesis and anti-HIV evaluation of,
three classes of nucleoside analog (AZT, FLT, or 3TC) conjugates. In the first class,
combinations of two similar or different nucleosides, (AZT, FLT, or 3TC) were
attached to the carboxylic acid groups of succinic acid and suberic acid. Second class
of compounds includes myristoyl or acetyl derivatives of di- or trinucleoside-glutamic
acid conjugates containing more than one nucleoside. In the third class of compounds,
peptide derivatives containing nucleosides and myristoyl group on the side chain were
synthesized.
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Nucleoside-scaffold conjugates were designed with the expectation that the
attachment of more than one nucleoside analog to the scaffold will generate a prodrug
capable of delivering different nucleosides to the HIV-infected cells . Myristic acid
was attached to the scaffolds to improve the lipophilicity of the conjugates and their
cellular uptake. It was expected that once the conjugate enters the cells, it will be
hydrolyzed by esterase and/or peptidases to generate parent nucleoside analogs. The
release of different nucleosides will help to increase the barrier to resistance to the
individual compounds. The combined conjugates may have also the benefits of
synergistic antiviral effects on HIV-1 and HIV-2, increased antiviral spectrum, dosing
simplicity, and favorable pharmacokinetic properties.

3.3 Materials and Methods

3.3.1 Materials
Succinic acid, succinyl chloride, suberic acid, pyridine, acetonitrile, and
diisopropylethylamine (DIPEA) were purchased from Fisher Scientific. Fmoc
protected amino acids (Fmoc-Glu-OtBu, Fmoc-Ser-OH, Fmoc-Lys(Mtt)-OH, Fmoc-PAla-OH, Fmoc-Gly-OH, and 2-(lH-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) were purchased from Novabiochem. Lamivudine,
Zidovudine, and Alovudine were purchased from Euro Asia Tran Continental
(Bombay, India). All the other reagents including solvents were purchased from Fisher
Scientific.
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The products were purified on a Phenomenex®Gemini 1O µm ODS reversedphase column (2.1

x

25 cm) with Hitachi HPLC system using a gradient system at

constant flow rate of 17 ml/min (Table 3.1).

Table 3.1. HPLC method used for the purification of the compounds.
Acetonitrile
Concentration
B (%)
0.0

Flow rate
(mL/min)

0.00

Water
Concentration
A(%)
100.0

1.0

100.0

0.0

17.0

45.0

0.0

100.0

17.0

55.0

0.0

100.0

17.0

59.0

100.0

0.0

17.0

60.0

100.0

0.0

1.0

Time
(minutes)

1.0

PS3 automated peptide synthesizer (Rainin Instrument Co., Oakland, CA) was
used to synthesize peptides. In general, all peptides were synthesized by the solidphase synthesis strategy employing N-(9-fluorenyl)methoxycarbonyl (Fmoc)-based
chemistry and Fmoc-L-amino acid building blocks. 2-(lH-Benzotriazole-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and NMM in N,Ndimethylformamide (DMF) were used as coupling and activating reagents,
respectively. Wang resin, Fmoc-amino acid Wang resins, coupling reagents, and
Fmoc-amino acid building blocks were purchased from Novabiochem.
The chemical structures of final products were characterized by nuclear
magnetic resonance spectrometry ( 1H NMR and

13

C NMR) determined on a Bruker

NMR spectrometer (400 MHz). Chemical shifts are reported in parts per millions
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(ppm). The chemical structures of final products were confirmed by a high-resolution
PE Biosystems Mariner API time-of-flight electrospray mass spectrometer.

3.3.2. Chemistry
3.3.2.1. Synthesis of Unsymmetrical and Symmetrical Dinucleoside Conjugates of
Succinic acid or Suberic acid. FLT, AZT, and 3TC were attached to succinic acid

and suberic acid to synthesize dinucleoside derivatives of succinic acid and suberic
acid respectively.

5'-0-(Succinate)-3'-fluoro-2',3'-dideoxythymidine (3.1) and 5'-0-(succinate)-3'azido-2',3'-dideoxythymidine (3.2). Succinic anhydride (290 mg, 2.90 mrnol) and

nucleoside (AZT or FLT) (l.45 mmol) were dissolved in dry pyridine (15.0 mL). The
reaction mixture was stirred at room temperature overnight. The solvent was
evaporated under reduced pressure and the crude product was purified with reversed
phase HPLC using a C 18 column and water/acetonitrile as solvents as described above
in Table 3.1.

1

3'-Fluoro-2',3'-dideoxy-5'-0-(succinate)thymidine (3.1). Yield (350 mg, 70%); H

NMR (400 MHz, CDCh, 8 ppm): 10.73 (s, lH, NH), 7.41 (s, lH, H-6), 6.06 (dd, J=
4.5 and 9.7 Hz, lH, H-1'), 5.36 (dd, J= 4.6 and 53.4 Hz, lH, H-3'), 4.99 (d, J= 12.7
Hz, lH, H-5"), 4.38-4.54 (m, lH, H-4'), 4.14 (dd, J

=

3.5 and 12.7 Hz, lH, H-5'),

2.53-2.97 (m, 4H, succinate protons), 2.40-2.51 (m, lH, H-2"), 2.01-2.23 (m, lH, H2'), 1.86 (s, 3H, 5-CH3 );

13

C NMR (CDCh, 100 MHz, 8 ppm): 178.40 (COOH),
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l73.26 (COOFLT), 167.11 (C-4 C=O), 149.52 (C-2 C=O), 138.20 (C-6), 109.96 (C5), 93.81(J=176.9 Hz, C-3'), 86.05 (C-1'), 83.88 (J= 26.9 Hz, C-4'), 63.79 (J= 10.9
Hz, C-5'), 39.22 (J = 20.1 Hz, C-2'), 29.03 (succinate CH2), 28.82 (succinate CH2),
12.70 (5-CH3); HR-MS (ESI-TOF) (m/z): C14H11FN201: calcd, 344.1020; found,
345.4061 [M +Ht, 689.5581 [2M +Ht.

5'-0-(Succinate)-3'-azido-2',3'-dideoxythymidine (3.2). Yield (350 mg, 70%); 1H

NMR (400 MHz, CD30D, 8 ppm): 11.37 (br s, lH, NH), 7.51 (s, lH, H-6), 6.14 (t, J=
6.5 Hz, lH, H-1'), 4.49 (dd, J= 5.9 and 13.4 Hz, lH, H-3'), 4.32 (dd, J= 4.5 and 12.1
Hz, lH, H-5"), 4.19 (dd, J= 3.7 and 12.1 Hz, lH, H-5'), 3.96 (dd, J= 4.5 and 9.5 Hz,
lH, H-4'), 2.27-2.52 (m, 6H, succinate protons, H-2", H-2'), 1.80 (s, 3H, 5-CH3); HRMS (ESI-TOF) (m/z): C 14H11N 50 7 : calcd, 367.1128; found, 368.1823 [M + Ht,
390.1566 [M +Nat, 735.3566 [2M + Ht, 757.3207 [2M +Nat, 789.2567 [2M +
2Nat

[5'-0-(3'-Azido-2 ',3 '-dideoxythymidinyl)] [5'-0-(3'-fluoro-2 ',3 'dideoxythymidineyl)]-1,4-succinate (3.3). Compound 3.1 (100 mg, 0.29 mmol),

AZT (100 mg, 0.37 mmoL), HBTU (440 mg, 1.15 mmol), and DIPEA (2 mL, 15
mmol) were dissolved in dry DMF (10 mL) and stirred overnight at room temperature.
The reaction mixture was concentrated and dried under vacuum. The residue was
purified with reversed phase HPLC using a C 18 column and water/acetonitrile as
solvents as described above to yield 3.3 (110 mg, 65%).
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1H NMR (400 MHz, CD3CN, 8 ppm): 7.35, 7.34 (s, 2H, AZT H-6, FLT H-6), 6.18
(dd, J= 5.7 and 53.4 Hz, lH, FLT H-1'), 6.05 (t, J= 6.3 Hz, lH, AZT H-1'), 5.21 (dd,

J= 5.1 and 9.0 Hz, lH, FLT H-3'), 4.04-4.42 (m, 6H, AZT H-3', AZT H-5', AZT H5", FLT H-5', FLT H-5", FLT H-4'), 3.97 (dd, J = 4.6 and 9.2 Hz, lH, AZT H-4'),
2.09-2.73 (m, 8H, succinate protons, AZT H-2", AZT H-2', FLT H-2", FLT H-2'),
1.80 (s, 6H, 5-CH3);

13

C NMR (CD3CN, 100 MHz, 8 ppm): 173.58, 173.56 (COOFLT,

COOAZT), 165.96, 165.92 (FLT C-4 C=O, AZT C-4 C=O), 151.74, 151.68 (FLT C-2
C=O, AZT C-2 C=O), 137.41, 136.96 (FLT C-6, AZT C-6), 111.88, 111.76 (FLT C-5,
AZT C-5), 94.80 (J = 175.1 Hz, FLT C-1'), 85.97 (FLT C-3'), 85.60 (AZT C-1'),
83.05 (J= 26.4 Hz, FLT C-4'), 83.14 (AZT C-4'), 64.68, 64.37 (AZT C-5', FLT C-5'),
61.8 (AZT C-3'), 38.05 (J = 20.6 Hz, FLT C-2'), 37.15 (AZT C-2'), 29.5 (succinate
CH2),

12.5,

12.45

(FLT 5-CH3,

AZT 5-CH3);

HR-MS

(ESI-TOF)

(m/z):

C24H2sFN 7010: calcd, 593.1882; found, 594.0366 [M +Ht.

[5'-0-(3 '-Fluoro-2 ',3'-dideoxythymidineyl)] [(-)-5'-0-(2' ,3'-dideoxy-3'thiacytidinyl) ]-1,4-succinate (3.4). The synthesis of (-)-N4-(4,4'-dimethoxytrityl)2',3'-dideoxy-3 '-thiacytidine was previously described in Chapter 2. Compound 3.1
(100 mg, 0.29 mmol), 2.12 (100 mg, 0.37 mmoL), HBTU (440 mg, 1.15 mmol), and
DIPEA (2 mL, 15 mmol) were dissolved in dry DMF (10 mL) and stirred overnight at
room temperature. The reaction mixture was concentrated, and acetic acid (80%, 10
mL) was added to the residue. The mixture was stirred at 80 °C for 30 min. The
reaction mixture was concentrated and dried under vacuum. The residue was purified
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with reversed phase HPLC using a C1s column and water/acetonitrile as solvents as
described above to yield 3.4 (80 mg, 50 %).
1H NMR (400 MHz, CD3CN, 8 ppm): 7.98 (d, J = 7.9 Hz, lH, 3TC H-6), 7.37 (s, lH,
FLT H-6), 6.16-6.23 (m, 2H, 3TC H-1', FLT H-1'), 6.12 (d, J= 7.9 Hz, lH, 3TC H-5),
5.36 (t, J= 4.2 Hz, lH, 3TC H-4'), 5.23 (dd, J= 5.2 and 53.4 Hz, lH, FLT H-3'), 4.184.46 (m, 5H, 3TC H-5', 3TC H-5", FLT H-4', FLT H-5', FLT

H~5"),

3.53 (dd, J= 5.6

and 12.2 Hz, lH, 3TC H-2'), 3.22 (dd, J= 3.0 and 12.2 Hz, lH, 3TC H-2"), 2.48-2.68
(m, 5H, succinate protons, FLT H-2"), 2.14-2.24 (m, lH, FLT-H-2'), 1.80 (s, 3H,

FLT-5-CH3 );

13

C NMR (CD3CN, 100 MHz, 8 ppm): 173.64 (COOFLT), 173.40 (-

COO 3TC), 165.98 (3TC C-4 C=O), 160.28 (FLT C-4 C=O), 151.78 (3TC C-2 C=O),
148.20 (FLT C-2 C=O), 145.05 (3TC C-6), 137.03 (FLT C-6), 111.94 (FLT C-5),
95 .01 (3TC C-5), 94.85 (J = 175.0 Hz, FLT C-3'), 87.95 (3TC C-1'), 86.03 (FLT Cl'), 85.03 (3TC C-4'), 83.10 (J= 26.5 Hz, FLT C-4'), 64.88, 64.77 (FLT C-5', 3TC C5'), 38.14 (J = 20.4 Hz, FLT C-2'), 38.09 (3TC C-2'), 29.54, 29.44 (succinate CH2 ),
12.50 (FLT 5-CH3); HR-MS (ESI-TOF) (m/z): C22H 26FN 5 09S: calcd, 555.1435;
found, 556.0964 [M +Ht.

[5'-0-(3 '-Azido-2 ',3 '-dideoxythymidinyl)] [(-)-5'-0-(2' ,3 '-dideoxy-3'thiacytidinyl) ]-1,4-succinate (3.5). Compound 3.2 (100 mg, 0.29 mmol), 2.12 (100
mg, 0.37 mrnoL), HBTU (440 mg, 1.15 mmol), and DIPEA (2 mL, 15 mmol) were
dissolved in dry DMF (1 O mL) and stirred overnight at room temperature. The
reaction mixture was concentrated and acetic acid (80%, 10 mL) was added to the
residue. The mixture was stirred at 80 °C for 30 min. The reaction mixture was
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concentrated and dried under vacuum. The residue was purified with reversed phase
HPLC using a C 1s column and water/acetonitile as solvents as described above to yield
3.5 (80 mg, 50 %).
'H NMR (400 MHz, CD3CN, 8 ppm): 7.99 (d, J = 7.9 Hz, lH, 3TC H-6), 7.35 (s, lH,
AZT H-6), 6.21 (dd, J= 3.2 and 5.5 Hz, lH, 3TC H-1'), 6.13 (d, J= 7.9 Hz, lH, 3TC
H-5), 6.06 (t, J= 6.4 Hz, lH, lH, AZT H-1',) 5.36 (t, J= 4.1 Hz, lH, 3TC H-4'), 4.43
(d, J = 4.0 Hz, lH, AZT H-3'), 4.23-4.29 (m, 4H, 3TC H-5', 3TC H-5", AZT H-5',
AZT H-5"), 3.87-4.05 (m, lH, AZT H-4'), 3.53 (dd, J= 5.5 and 12.2 Hz, lH, 3TC H2'), 3.22 (dd, J = 3.2 and 12.2 Hz, lH, 3TC H-2"), 2.64 (s, 4H, succinate protons),
2.38 (t, J = 6.4 Hz, 2H, AZT H-2' and H-2"), 1.80 (s, 3H, AZT 5-CH3 );

13

C NMR

(CD 3CN, 100 MHz, 8 ppm): 173.60 (COOAZT), 173.38 (COO 3TC), 165.92 (3TC C4 C=O), 160.34 (AZT C-4 C=O), 151.67 (3TC C-2 C=O), 148.20 (AZT C-2 C=O),
145.02 (3TC C-6), 137.42 (AZT C-6), 111.76 (AZT C-5), 95.00 (3TC C-5), 87.96 .
(3TC C-1'), 85.60 (AZT C-1'), 85.07 (3TC C-4'), 82.25 (AZT C-4'), 64.85, 64.30
(AZT C-5', 3TC C-5'), 60.85 (AZT C-3'), 38.13 (3TC C-2'), 37.20 (AZT C-2'), 29.54,
29.44 (succinate CH2), 12.48 (AZT 5-CH3); HR-MS (ESI-TOF) (rn/z): C22H26Ns09S:
calcd, 578.1543; found, 579.0164 [M +Ht.

Di[S'-0-(3'-azido-2',3'-dideoxythymidinyl)]-1,4-succinate (3.6) and di[S'-0-(3'fluoro-2',3'-dideoxythymidinyl))-1,4-succinate (3.7). FLT or AZT (0.45 mmol) and
DMAP (110 mg, 0.90 mmoL) were dissolved in dry benzene (10 mL). Succinyl
chloride (22 µL, 0.2 mmoL) was added to the reaction mixture. The reaction mixture
was stirred overnight at room temperature, concentrated at reduced pressure, and dried
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under vacuum. The residue was purified with reversed phase HPLC using a C1s
column and water/acetonitile as solvents as described above to yield 3.6 or 3.7.
1
3.6. Yield (100 mg, 80%); H NMR (400 MHz, CD30D,

o ppm): 7.40 (s, 2H, H-6),

6.09 (t, J= 6.4 Hz, 2H, H-1'), 4.40 (dd, J= 4.8 and 9.0 Hz, 2H, H-3'), 4.23-4.36 (m,
4H, H-5' and H-5",), 4.00 (dd, J = 4.8 and 9.0 Hz, 2H, H-4'), 2.70 (s, 4H, succinate
protons), 2.34-2.51 (m, 4H, H-2' and H-2"), 1.87 (s, 3H, 5-CH3 );
100 MHz,

oppm):

13

C NMR (CD30D,

173.30 (COOAZT), 165.87 (C-4 C=O), 151.70 (C-2 C=O), 137.36

(C-6), 111.78 (C-5), 86.23 (C-1'), 82.63 (C-4'), 64.46 (C-5'), 61.37 (C-3'), 37.68 (C2'), 29.56 (succinate CH2), 12.68 (5-CH3); HR-MS (ESI-TOF) (m/z): C24 H28N 100 10 :
calcd, 616.199; found, 617.1990 [M +Ht, 1233.1624 [M +Ht.

3.7. Yield (100 mg, 80%); 1H NMR (400 MHz, CD30D,

o ppm):

7.43 (s, 2H, H-6),

6.27 (dd, J= 6.5 and 8.9 Hz, 2H, H-1'), 5.24 (dd, J= 4.9 and 53.6 Hz, 2H, H-3'), 4.354.48 (m, 4H, H-4', H-5"), 4.27 (dd, J = 2.8 and 10.9 Hz, 2H, H-5'), 2.70 (s, 4H,
succinate protons), 2.50-2.641 (m, lH, H-2"), 2.18-2.44 (m, lH, H-2'), 1.89 (s, 3H, 5CH3);

13

C NMR (CD 30D, 100 MHz,

o ppm):

173.68 (COOFLT), 166.41 (C-4 C=O),

152.36 (C-2 C=O), 137.40 (C-6), 112.50 (C-5), 95.11(J=177.2 Hz, C-3'), 86.90 (Cl'), 83 .97 (J= 26.2 Hz, C-4'), 65.28 (C-5'), 38.90 (J= 21.1 Hz, C-2'), 30.02 (succinate
CH2), 13.25 (5-CH3); HR-MS (ESI-TOF) (m/z): C24H28 F2N4010: calcd, 570.1773 ;
found, 571.2164 [M + Ht, 1141.1336 [M +Ht.

Di [5 '-0-(3 '-azido-2 ',3 '-dideoxythymidinyl)]-1,8-su berate (3.8) and di [5 '-0-(3 'fluoro-2',3'-dideoxythymidinyl)]-1,8-suberate (3.9). AZT or FLT (0.58 rnrnol),
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suberic acid (50 mg, 0.29 rnrnol), HBTU (440 mg, 1.15 rnrnol), and DIPEA (2 mL, 15
nunol) were dissolved in dry DMF (10 mL). The reaction mixture was stirred
overnight at room temperature, concentrated, and dried under vacuum. The residue
was purified with reversed phase HPLC using a C1s column and water/acetonitile as
solvents as described above to yield 3.8 and 3.9.
1

3.8. Yield (60 mg, 30 %); H NMR (400 MHz, CD30D, 8 ppm): 7.33 (s, 2H, H-6),

6.07 (t, J= 6.3 Hz, 2H, H-1'), 4.11-4.34 (m, 6H, H-3', H-5', and H-5"), 4.23-4.36 (m,
4H, H-4'), 2.33 (dt, 8H, CH2COO, H-2' and H-2"), 1.80 (s, 6H, 5-CH3 ), 1.52 (t, J= 6.2
Hz, 4H, CH2 CH2COO), 1.18-1.30 (br m, 4H, suberate methylene);

13

C NMR (CD 30D,

100 MHz, 8 ppm): 174.78 (COOAZT), 165.78 (C-4 C=O), 151.66 (C-2 C=O), 137.24
(C-6), 111.65 (C-5), 85.59 (C-1'), 83.28 (C-4'), 64.04 (C-5'), 61.08 (C-3'), 37.34 (C2'), 34.44 (CH2COO), 29.03 (CH2CH2COO), 25.13 (suberate CH2), 12.52 (5-CH3);
HR-MS (ESI-TOF) (rn/z): C2sH36N1o010: calcd, 672.2616; found, 673.1400 [M +Ht.

3.9. Yield (60 mg, 30%); 1H NMR (400 MHz, CD30D, 8 ppm): 7.36 (s, 2H, H-6),
6.18 (dd, J= 5.6 and 8.9 Hz, 2H, H-1'), 5.24 (dd, J= 5.l and 53.1Hz,2H, H-3'), 4.39
(dt, J = 3.5 and 26.6 Hz, 2H, H-4'), 4.27 (dd, J= 3.5 and 12.1Hz,2H, H-5'), 4.17 (dd,
J= 3.5 and 12.1 Hz, 2H, H-5"), 2.46 (m, 2H, H-2"), 2.13-2.33 (m, 6H, CH2COO, H-

2'), 1.79 (s, 6H, 5-CH3 ), 1.44-1.55 (m, 4H, CH2CH2COO), 1.15-1.27 (m, 4H, suberate
methylene);

13

C NMR (CD 30D, 100 MHz, 8 ppm): 174.86 (COOFLT), 165.88 (C-4

C==O), 151.74 (C-2 C=O), 136.86 (C-6), 111.77 (C-5), 94.96 (J = 175.0 Hz, C-3'),
86.05 (C-1'), 83.22 (J= 26.3 Hz, C-4'), 64.30 (C-5'), 38.41, 38.20 (J= 178.3 Hz, C2'), 34.38 (CH2COO), 28.97 (CH2CH2COO), 25.06 (suberate CH2), 12.54 (5-CH3);
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HR-MS (ESI-TOF) (m/z): C2sH36F2N4010: calcd, 626.2399; found, 627.1035 [M +

Ht, 1253.4346 [M +Ht.
Di[(-)-5'-0-(2',3'-dideoxy-3'-thiacytidinyl)-1,8-suberate (3.10).

Compound 2.12

(31 O mg, 0.58 mmol), suberic acid (50 mg, 0.29 mmol) HBTU (440 mg, 1.15 mmol),
and DIPEA (2 mL, 15 mmol) were dissolved in dry DMF (10 mL). The mixture was
stirred overnight at room temperature and was concentrated at reduced pressure.
Acetic acid (80%, 10 mL) was added to the residue and the reaction mixture was
stirred at 80 °C for 30 min. The reaction mixture was concentrated and dried under
vacuum. The residue was purified with reversed phase HPLC using a C 18 column and
water/acetonitile as solvents as described above to yield 3.10 (50 mg, 30%).
1H NMR (400 MHz, CD 0D, 8 ppm): 8.02 (d, J= 7.9 Hz, 2H, H-6), 6.20 (dd, J= 5.4
3
and 3.1 Hz, 2H, H-1 '), 6.10 (d, J

=

7.9 Hz, 2H, H-5), 5.35-5.45 (m, lH, H-4'), 4.31-

4.54 (m, 4H, H-5' and H-5"), 3.54 (dd, J

=

5.4 and 12.6 Hz, 2H, H-2"), 3.20-3.27 (m,

2H, H-2'), 2.20-2.36 (m, 4H, CH2COO), 1.38-1.60 (m, 4H, CH2CH2COO), 1.12-1.32
(m, 4H, suberate methylene);

13

C NMR (CD30D, 100 MHz, 8 ppm): 174.78

(C003TC), 160.63 (C-4 C=O), 148.60 (C-2 C=O), 144.99 (C-6), 94.80 (C-5), 88.01
(C-1'), 85.45 (C-4'), 64.30 (C-5'), 38.30 (CH2COO), 34.38 (CH2CH2COO), 29.04 (C2'), 25.17 (suberate CH 2); HR-MS (ESI-TOF) (m/z): C 24 H32N60sS2: calcd, 596.1723;
found, 597.0920 [M +Ht, 1193.4381 [M +Ht.
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3.3.2.2. Synthesis of Peptide-Nucleosides Conjugates (Peptides Containing one
nucleoside and one Myristoyl Group)

Several peptide conjugates of AZT, FLT, 3TC, and myristic acid were
synthesized employing a PS3 automated peptide synthesizer and Fmoc solid-phase
peptide synthesis using Fmoc-L-amino acid building blocks. The peptide-nucleoside
conjugates were assembled on Wang resin solid support at room temperature. The
building blocks, Fmoc-Glu(nucleoside)-OH and Fmoc-Ser(myristoyl)-OH, were
synthesized from Fmoc-Glu(OH)-tBu and Fmoc-Ser-OH, respectively, as described
below:

Fmoc-Glu(3 '-fluoro-2 ',3 '-dideoxythymidine-5 '-yl)-OH (3.12) and Fmoc-Glu(3 'azido-2' ,3 '-dideoxythymidine-5 '-yl)-OH. Fmoc-Glu(OH)OtBu (5 g, 11.8 mmol),

FLT or AZT (3.5 g, 14.1 mmol), and HBTU (6.67 g, 17.6 mmol) were dissolved in
DMF (25 mL). DIPEA (5 mL, 38 mmol) was added to the solution and the reaction
mixture was stirred at room temperature overnight. The solvent was removed at
reduced pressure to yield crude Fmoc-Glu(3'-fluoro-2',3'-dideoxythymidine-5'yl)OtBu (3.11) or Fmoc-Glu(3'-azido-2',3'-dideoxythymidine-5'-yl)OtBu (3.13).
3.11. HR-MS (ESI-TOF) (m/z): C34 H38FN30 9: calcd, 651.2592; found, 652.1312 [M +

Ht; 1303.2873. [2M + Ht; 3.13. HR-MS (ESI-TOF) (m/z): calcd, C34H3sN609;

found,: 674.27 [M +Ht, 697.0440. [M +Na(

TF A (20 rnL) was added to the reaction mixture containing 3.11 or 3.12. The reaction
mixture was stirred for 1 h to remove t-butyl protecting group at C-terminal. TF A was
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removed at reduced pressure and the residue was purified with HPLC using a C1s
column and water/acetonitile as a solvents using method as described above to yield
3.12 and 3.14.

1
3.12. Overall yield (5.0 g, 70%); H NMR (400 MHz, CD30D, 8 ppm): 7.78 (d, J =
7.4 Hz, 2H, Fmoc Ar-H), 7.60-7.69 (m, 2H, Fmoc Ar-H), 7.35-7.42 (m, 3H, H-6,
Fmoc Ar-H), 7.31 (dt, J = 7.4 and 3.3 Hz, 2H, Fmoc Ar-H), 6.23 (dd, J = 6.4 and 9.3
Hz, lH, H-1'), 5.27 (dd, J= 5.9 and 53.3 Hz, lH, H-3'), 4.34-4.51 (m, SH, H-4', H-5",
Glu CH( a), and Fmoc NHCOOCH2), 4.28 (dd, J= 5.9 and 9.1 Hz, lH, H-5'), 4.22 (t, J
= 6.7 Hz, lH, Fmoc NHCOOCH2CH), 2.10-2.58 (m, 6H, Glu CH2CH2COO

(p and y

methylene), H-2", and H-2'), 1.87 (s, 3H, CH3); HR-MS (ESI-TOF) (m/z):
C30H30FN30 9: calcd, 595.1966; found, 596.2122 [M +Ht, 1191.4197 [2M +Ht.

3.14. Overall yield (5.2 g, 70%); 1H NMR (400 MHz, CD 30D, 8 ppm): 7.78 (d, J =
7.4 Hz, 2H, Fmoc Ar-H), 7.35-7.70 (m, 2H, Fmoc Ar-H), 7.44 (s, lH, H-6), 7.37 (t, J
= 7.4 Hz, 2H, Fmoc Ar-H), 7.30 (t, J = 7.4 Hz, 2H, Fmoc Ar-H), 6.10 (t, J = 6.4 Hz,
lH, H-1'), 4.15-4.45 (m, 7H, H-3', H-5', H-5", Glu-a-CH, Fmoc NHCOOCH2CH),
4.05 (dd, J = 4.8 and 9.0 Hz, lH, H-4'), 2.52 (t, J = 7.2 Hz, 2H, Glu-CH2COO

CP-

methylene), 2.32-2.48 (m, 2H, Glu-CH2CH2COO (y-methylene), 2.14-2.30 (m, lH, H2'), 1.90-2.05 (m, lH, H-2"), 1.85 (s, 3H, 5-CH3 );

13

C NMR (CD30D, 100 MHz, 8

ppm): 175.27 (COOH), 173.97 (COOAZT), 162.39 (C-4 C=O), 152.25 (C-2 C=O),
145.40, 142.73 (Fmoc Ar-C), 137.85 (C-6), 128.95, 128.33, 126.42, 121.08 (Fmoc ArC), 112.02 (C-5), 86.70 (C-1 '), 83.176 (C-4'), 68.16 (CH20CONH), 64.88 (C-5'),
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62.15 (Glu CH(a), 54.57 ((C-3'), 37.88 (C-2'), 31.47 (Glu y-CH 2), 27.99 (Glu

~-CH 2 ),

12.73 (5-CH3); HR-MS (ESI-TOF) (m/z): C30H30N609: calcd, 618.2074; found,
619.5564 [M +Ht.

Fmoc-Ser(O-Myristoyl)OH (3.15). Fmoc-Ser(OH)OH (5 g, 15.3 mmol) and DIPEA
(1

omL, 75 mmol) were dissolved in DMF (20 rnL). Myristic chloride (10 g, 23 mmol)

was added to the solution. The reaction mixture was stirred for overnight. The solvent
was removed at reduced pressure and the residue was purified using silica gel column
chromatography using dichloromethane (DCM)/methanol (0-5%) as eluents. The
compound was eluted at 5% methanol in DCM to yield 3.15 (5.3 g, 63%).
1

H NMR (400 MHz, CDCh,

oppm): 7.70 (d, J= 7.4 Hz, 2H, Fmoc Ar-H), 7.53 (d, J =

6.9 Hz, 2H, Fmoc Ar-H), 7.34 (t, J= 7.4 Hz, 2H, Fmoc Ar-H), 7.25 (t, J = 7.4 Hz, 2H,
Fmoc Ar-H), 5.50 (d, J
4.45 (dd, J

=

=

8.0 Hz, serine CH(a)), 4.65-4.71 (m, lH, serine CH" (J3)),

3.9 and 11.4 Hz, lH, serine CH' (J3)), 4.32-4.39 (m, 2H, Fmoc

NHCOOCH2), 4.17 (t, J = 6.9 Hz, lH, Fmoc NHCOOCH 2CH), 2.26 (t, J = 7.5 Hz,

2H, CH2COO), 1.54 (t, J = 6.3 Hz, 2H, CH2 CH 2 COO), 1.13-1.25 (br m, 20H,
Methylene protons), 0.80 (t, J = 6.6 Hz, 3H, CH3 ) ; HR-MS (ESI-TOF) (m/z):
C32Hi3N06: calcd, 537.309; found, 538.2673 [M +Ht, 1075.5442 [2M +Ht.

Myristoyl-Glu(3'-fluoro-2',3'-dideoxythymidine-5'-yl)-Lys(myristoyl)OH

[My-

Glu(FLT)-Lys(My)-OH, 3.16]. Fmoc-Lys(Mtt)-Wang resin (300 mg, 0.45 mmol/g)

was swelled in DMF for 30 min and Fmoc-Glu(FLT)-OH (320 mg, 0.54 mmol),
HBTU (200 mg, 0.54 mmol), and NMM (0.54 mmol) were added to the swelled resin
suspension in DMF. The mixture was shaken overnight at room temperature. The resin
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was filtered and washed two times with DMF (10 mL). Fmoc deprotection was carried
out using piperidine in DMF (20%,10 mL). The resin was washed with DMF (3 x 10
mL). To the resin was added TFA:DCM mixture (5%, 10 mL) to remove methyltrityl
protecting group (Mtt) at lysine side chain. The mixture was shaken for 1 h at room
temperature. The resin was washed with DCM (3 x 10 mL) and DMF (10 mL) and
swelled in DMF (10 mL). Myristic anhydride (100 mg, 1.08 mmol) and DIPEA (2
mL, 15 mmol) were added to the swelled resin. The mixture was shaken for 2 h at
room temperature. The resin was washed with DMF (2 x 10 mL). A mixture of
TFA/anisole/water (95:2.5:2.5, 10 mL) was added to the resin and the mixture was
shaken for 1 h. After filtration, the solution was concentrated and dried under reduced
pressure. The crude peptide conjugates were purified with reversed phase HPLC using
a C 18 column and water/acetonitile as solvents as described above and were
lyophilized to yield 3.16 (10 mg, 8.0%).
HR-MS (ESI-TOF) (rn/z): C49 Hs 4 FN50 10 : calcd, 921.6202; found, 922.9989 [M +Ht,
1845.9558 [2M +Ht.

Acetyl-Glu(3'-fluoro-2',3'-dideoxythymidine-5'-yl)-P-Ala-Lys(myristoyl)OH [AcGlu(FLT)-~Ala-Lys(My)-OH,

3.17]

and

dideoxythymidine-5'-yl)-~Ala-Lys(myristoyl) OH

Acetyl-Glu(3'-azido-2',3'(Ac-Glu(AZT)-PAla-Lys(My)-

OH, 3.18]. The peptide was assembled on Fmoc-Lys(Mtt)-Wang resin (600 mg, 0.45
rnmol/g) by Fmoc solid-phase peptide synthesis strategy on a PS3 automated peptide
synthesizer at room temperature using Fmoc protected amino acids [Fmoc-P-Ala-OH
(C + 1) and Fmoc-Glu(nucleoside)-OH (C + 2) (3.12 or 3.14, 1.08 mmol)]. HBTU
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(1.08 mmol) and NMM (1.08 mmol) in DMF were used as coupling and activating
reagents, respectively. Fmoc deprotection at each step was carried out using piperidine
in DMF (20%).

NH2-Glu(FLT)-~Ala-Lys(Mtt)-Wang

resin or

NH 2 -Glu(AZT)-~Ala

K(Mtt)-Wang resin was transferred to the reaction vessel and swelled in DMF (2 mL)
for 30 min. Acetic anhydride (2 mL) and DIPEA (2 mL, 15 mmol) were added to the
mixture. The reaction was shaken at room temperature for 30 min to cap the Nterminal with acetyl group. N-Acetylated resin was washed with DMF (2 x 1O mL).
To the resin was added TFA:DCM (5%, 10 mL). The mixture was shaken for 1 hat
room temperature. The resin was washed with DCM (3 x 10 mL) and DMF (10 mL)
and swelled in DMF (10 mL). Free amino group at lysine side chain was further
myristoylated by adding myristic anhydride (100 mg, 1.08 mmol) and DIPEA (2 mL,
15 mmol) to the swelled resin. The mixture was shaken for 2 h at room temperature.
The resin was washed with DMF (3 x 10 mL). A mixture of TF A/anisole/water
(95:2.5:2.5 v/v/v, 10 rnL) was added to the resin and the mixture was shaken for 1 h.
After filtration, the solution was concentrated and dried under reduced pressure. The
crude peptide conjugates were purified with reversed phase HPLC using a C 18 column
and water/acetonitile as solvents as described above and were lyophilized to yield 3.17
and3.18 .

3.17. Overall yield (20 mg, 8%); 1H NMR (400 MHz, CD 30D,

FLT H-6 ), 6.28 (dd, J

=

o ppm): 7.48 (s,

5.6 and 8.8 Hz, lH, FLT H-1' ), 5.29 (dd, J

=

lH,

53.5 and 4.4

Hz, lH, FLT H-3'), 4.20-4.70 (m, 6H, FLT H-4' and FLT H-5", Ser COCHNH
(CH(a), Ser CH20 (CH(~), Glu COCHNH (CH(a)), 4.07 (dd, J= 3.9 and 17.8 Hz, lH,
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FLT H-5'), 3.72-3.92 (m, 2H, Gly COCH2NH (CH(a)), 3.38-3.58 (m, 2H, P-Ala
cH2NH),

2.24-2.64 (m, 8H, FLT H-2', FLT H-2",

cH2CH2COO), 2.16 (t, J

=

P-Ala CH2COO, Glu

7.2 Hz, 3H, myristate CH2COO), 1.94-2.08 (m, 3H, Ac

cH3), 1.88 (s, 3H, FLT 5-CH3), 1.52-1.66 (m, 2H, myristate CH2CH2COO), 1.22-1.38

(br m, 20H, methylene protons), 0.90 (t, J

=

6.3 Hz, 3H, myristate CH3); HR-MS

(ESI-TOF) (m/z): C40H6sFN6011: calcd, 824.4695; found, 825.6640 [M + Ht,
1651.2282 [2M +Ht.

1
3.18. Overall yield (20 mg, 8%); H NMR (400 MHz, CD30D, 8 ppm): 7.48 (s, lH,
H-6 AZT), 6.14 (t, J= 6.6 Hz, lH, AZT H-1'), 4.20-4.70 (m, 6H, AZT H-5', AZT H5", AZT H-3', Ser COCHNH (CH(a), Ser CH20 (CH(p), Glu COCHNH) (CH(a), 4.07
(dd, J = 4.9 and 8.9 Hz, lH, AZT H-4'), 3.84-4.05 (m, 2H, Gly COCH2NH (CH( a)),
3.44 (dd, J= 6.6 and 12.5 Hz, 2H, P-Ala CH2NH), 2.10-2.66 (m, lOH, FLT H-2', FLT
H-2", P-Ala CH2COO, Glu CH2CH2COO, myristate CH2COO), 1.92-2.09 (m, 3H, Ac
CH3 ), 1.89 (s, 3H, 5-CHrAZT), 1.52-1.72 (m, 2H, myristate-CH2CH2COO), 1.24-

1.50 (br m, 20H, methylene protons), 0.90 (t, J = 6.5 Hz, 3H, myristate CH3); HR-MS
(ESI-TOF) (m/z): C40H6sN90 11 : calcd, 847.4804; found, 848.9452 [M + H(

Acetyl-Ser(myristoyl)-P-Ala-Glu{3 '-fluoro-2 ',3 '-dideoxythymidine-5 '-yl)-Gly-OH
[Ac-Ser(My)-PAla-Glu(FL T)Gly-OH,

3.19)

and

Acetyl-Ser(myristoyl)-P-Ala-

Glu(3 '-azido-2 ',3 '-dideoxythymidine-5 '-yl)-Gly-OH

[Ac-Ser(My)-PAia-

Glu(AZT)Gly-OH, 3.20). The peptide was assembled on Fmoc-Gly-Wang resin (600

mg, 0.45 mmol/g) by Fmoc solid -phase peptide synthesis strategy using Fmoc
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protected amino acids [Fmoc-Glu(nucleoside)-OH (C + 1) (3.12 or 3.14), Fmoc-,BAla-OH (C + 2) and Fmoc-Ser(Myristoyl)-OH (C + 3) (3.15), each 1.08 mmol].
HBTU (1.08 mmol) and NMM (1.08 mmol) in DMF were used as coupling and
activating reagents, respectively. Fmoc deprotection at each step was carried out using
piperidine in DMF (20%). NH2-Ser(My)-,BAla-Glu(FLT)Gly-Wang resin or NH2Ser(My)-,BA1a-Glu(AZT)-Gly-Wang resin was transferred to the reaction vessel and
swelled in DMF (2 mL) for 30 min. Acetic anhydride (2 mL) and DIPEA (2 mL, 15
mmol) were added to the mixture. The reaction was shaken at room temperature for 30
min to cap N-terminal with acetyl group. N-Acetylated resin was washed DMF (2 x 10
mL). To the resin was added the peptide was cleaved from the resin by a mixture of

TFA/anisole/water (95:2.5:2.5 v/v/v, 10 mL) and the mixture was shaken for 1 h. After
:filtration, the solution was concentrated and dried under reduced pressure. The crude
peptide conjugates were purified with reversed phase HPLC using a C 18 column and
water/acetonitile as solvents as described above and were lyophilized to yield 3.19 and
3.20.

3.19. Overall yield (20 mg, 8%); HR-MS (ESI-TOF) (m/z): C39H61FN6013: calcd,

841.4281 ; found, 842.0071 [M +Ht, 1683.8930 [2M +Ht.

3.20. Overall yield (20 mg, 8 %); HR-MS (ESI-TOF) (m/z): C39H61N9013: calcd,

863.4389; found, 864.9022 [M +Ht, 1729.8398 [2M +Ht.
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3.3.2.3. Synthesis of Dinucleoside- and Trinucleoside Glutamic Acid Derivatives
With or Without Myristoyl Moiety Glutamate-nucleoside conjugates containing
more than one nucleoside with or without myristoyl group were synthesized by using
solution phase synthesis.

Fmoc-Glu{FLT)-3TC-DMTr (3.21) Compounds 3.12 (500 mg, 0.84 mmol), 2.12
(535 mg, 1 mmol), and HBTU (650 mg 1.7 mmol) were dissolved in DMF (IO mL).
DIPEA (5 mL, 37 mmol) was added to the solution and the reaction mixture was
stirred overnight at room temperature. The solvent was removed and the residue was
dried under reduced pressure. The residue was purified with reversed phase HPLC
using a C 18 column and water/acetonitile as solvents as described above and was
lyophilized to yield 3.21 (820 mg, 75%).
1

H NMR (400 MHz, CDCh, 5 ppm): 8.99 (s, lH, FLT NH), 7.74 (d, J = 7.5 Hz, lH,

Fmoc Ar-H), 7.55 (d, J

=

7.6 Hz, IH, 3TC H-6), 7.38 (t, J

=

7.5 Hz, Fmoc Ar-H),

7.06-7.33 (m, 13H, DMTr Ar-H, Fmoc Ar-H, and FLT H-6), 6.76-6.87 (m, 4H, DMTr
Ar-H protons), 6.34 (m, lH, 3TC H-1 '), 6.14-6.22 (m, lH, FLT H-1 '), 5.64 (d, J= 7.6

Hz, lH, 3TC H-5), 5.05-5.27 (m, 2H, FLT H-3' and 3TC H-4'), 4.24-4.45 (m, 8H, 3TC
H-5', 3TC H-5", Fmoc NHCOOCH2CH, FLT H-4', FLT H-5', FLT H-5"), 4.17 (t, J =
6.7 Hz, lH, Glu HN-CH-COO CH(a)), 3.75 and 3.78 (twos, 6H, DMTr CH30), 3.46
(dd, J= 11.8 and 5.3 Hz, lH, 3TC H-2''), 2.97 (dd, J= 11.8 and 5.3 Hz, IH, 3TC H2'), 1.97-2.67 (m, 6H, FLT H-2', FLT H-2", and Glu CH2CH2COO), 1.86 (s, 3H, 5CH3);

13

C NMR. (CDCh, 100 MHz, 0 ppm): 172.00 (FLT COO), 171.25 (3TC

coo),

165.06 (3TC C-4), 163.50 (FLT C-4 C=O), 158.69 (DMTr Ar-C-OCH3), 156.00 (3TC
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DMTr Ar-C), 111.41 (FLT C-5), 95.17 (3TC C-5), 93.20 (J= 178.3 Hz, FLT C-3'),
87.64 (3TC C-1'), 86.01 (FLT C-1'), 83.16 (3TC C-4'), 82.16 (J= 26.9 Hz, FLT C-4'),
81.69 (DMTr Ph3C-NH), 70.34 (Fmoc CI--h-OCONH), 67.15 (FLT C-5'), 65.76 (3TC
C-5'), 55.28 (DMTr OCH3), 53.40 (CH(a)), 47.04 (Fmoc CH-CH2-0CONH), 38.16
(FLT C-2'), 37.36 (3TC C-2'), 29.86, (Glu y-CH2), 27.16 (Glu

~-CH2 ),

12.64 (FLT 5-

CI-h); HR-MS (ESI-TOF) (m/z): Cs9Hs1FN6013S: calcd, 1108.3688; found, 1109.4804
[M +Ht, 1131.4395[M +Nat, 1147.4739 [M +Kt, 2218.5704 [2M +Ht.

NHi-Glu(FLT)-3TC-DMTr (3.22). Compound 3.21 (800 mg, 0.72 mmol) was
dissolved in THF (10 mL). Piperidine (7.18 µI, 0.072 mmol) and 1-octanethiol (7.3
mmol, 10 mM solution in THF, 0.73 mL) were added to the reaction mixture. The
mixture was stirred for 1 h at room temperature. The solvent was removed and the
residue was dried under reduced pressure. The residue was purified with reversed
phase HPLC using a C 18 column and water/acetonitile as solvents as described above
and lyophilized to yield 3.22 (300 mg, 50%).
I

H NMR (400 MHz, CDCh, 8 ppm): 7.44 (d, J= 7.8 Hz, lH, 3TC H-6), 7.25-7.33 (m,

4H, DMTr Ar-H), 7.18-7.21 (m, 2H, DMTr Ar-Hand FLT H-6), 7.12 (d, J= 8.8 Hz,
4H, DMTr Ar-H), 6.84 (d, J= 8.8 Hz, 4H, DMTr Ar-H), 6.20 (dd, J= 5.7 and 8.6 Hz,
lH, FLT H-1 '), 6.13 (t, J

=

5.2 Hz, lH, 3TC H-1 '), 5.33 (dd, J

=

4.0 and 6.0 Hz, lH,

3TC H-4'), 5.10-5.31 (m, 2H, FLT H-3' and 3TC H-5), 4.28-4.45 (m, 4H, 3TC H-5',
3TC H-5", FLT H-5', and FLT H-5"), 4.18-4.26 (m, lH, FLT H-4'), 4.07 (t, J= 6.6
Hz, lH, HN-CH(CH2)-COO (CH(a)), 3.77 (s, 6H, DMTr-CH30), 3.41 (dd, J = 11.9
and 5.2 Hz, lH, 3TC H-2"), 3.05 (dd, J= 11.9 and 5.2 Hz, lH, 3TC H-2'), 2.10-2.66

144

(rn, 6H, FLT H-2', FLT H-2", and Glu CH2CH2COO), 1.85 (s, 3H, 5-CH3 );
(CDCh, 100 MHz,

oppm):

13

C NMR

172.56 (FLT COO), 169.13 (3TC COO), 165.55 (3TC C-

4 FLT C-4 C=O), 159.68 (DMTr Ar-C-OCH3), 159.16 (3TC C-2 C=O), 151.51 (FLT
'
C-2 C=O), 145.56 (3TC C-6), 136.96 (FLT C-6), 130.77, 130.72, 129.30, 129.09
128.86, 128.41 , 127.35, 114.33, 113.70 (DMTr Ar-C), 111.90 (FLT C-5), 96.74 (3TC
C-5), 94.11(J = 177.9 Hz, FLT C-3'), 88.58 (3TC C-1'), 86.72 (FLT C-1'), 82.92 (J =
26.6 Hz, FLT C-4' ), 82.78 (3TC C-4'), 71.72 (DMTr Ph3C-NH), 67.15 (FLT C-5'),
64.53 (3TC C-5'), 55.66 (DMTr OCH3), 52.36 (CH(a)), 37.85 (J = 21.1 Hz, FLT C2'), 37.27 (3TC C-2'), 29.70, (Glu y-CH2), 25.80 (Glu

~-CH 2 ),

12.73 (FLT 5-CH3);

HR-MS (ESI-TOF) (m/z) : C44H41FN6011S: calcd, 886.3008; found, 887.4078 [M +

Ht, 1817.4315 [2M +Ht.

C13 H27 -CONH-Glu(FLT)-3TC (3.24). Compound 3.22 (100 mg, 0.12 mmol) and

myristic anhydride (100 mg, 0.24 mmol) were dissolved in DMF (10 mL). DIPEA (5
mL, 37 mmol) was added to the solution. The mixture was stirred for 2 h at room
temperature. The solvent was removed under reduced pressure to yield C13H21-CONHGlu(FLT)-3TC-DMTr (3.23) .
3.23. HR-MS (ESI-TOF) (m/z): C 58 H 73 FN 60 12 S: calcd, 1096.4991; found, 1097.2874
[M +Ht, 2193 .8167 [2M +Ht.

Compound 3.23 was dissolved in acetic acid (80% in water, 10 mL) and was heated at
80 °C for 30 min to remove DMTr protection. Acetic acid was removed under reduced
pressure and the residue was purified with reversed phase HPLC using a C1s column
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and water/acetonitrile as solvents as described above and was lyophilized to yield 3.24
(40 mg, 45%).
3.24. 1H NMR (400 MHz, CDCh, 8 ppm): 8.13 (d, J= 7.8 Hz, lH, 3TC H-6 ), 7.45 (s,

lH, FLT H-6), 6.28 (dd, J= 3.6 and 5.4 Hz, lH, FLT H-1'), 6.22 (dd, J= 5.7 and 8.8
Hz, lH, 3TC H-1'), 6.17 (d, J = 7.8 Hz, lH, 3TC H-5 ), 5.43 (dd, J= 3.2 and 4.9 Hz,
lH, 3TC H-4' ), 5.25 (dd, J = 5.2 and 53 .7 Hz, lH, FLT H-3'), 4.59 (dd, J = 4.9 and
12.4 Hz, lH, 3TC H-5" ), 4.31-4.55 (m, 4H, 3TC H-5', FLT H-5', FLT H-5", FLT H4'-), 4.27 (dd, J= 3.0 and 10.8 Hz, lH, Glu HN-CH-COO CH(a)), 3.54-3.65 (m, 2H,
3TC H-2' and H-2"), 2.11-2.65 (m, 8H, FLT H-2', FLT H-2", myristate CH2COO, and
Glu CH2CH2COO), 1.86 (s, 3H, 5-CH3), 1.58 (t, J = 6.8 Hz, 2H, CH2CH2COOH),
1.20-1.35 (br m, 20H, methylene protons), 0.85 (t, J = 6.6 Hz, 3H, CH3 );

13

C NMR

(CD30D, 100 MHz, 8 ppm): 175.92, 172.97 (FLT COO, 3TC COO), 172.13 (CONH),
165.61 (3TC C-4 ), 160.80 (FLT C-4 C=O), 151.57 (3TC C-2 C=O), 147.96 (FLT C-2
C=O), 145.21 (3TC C-6 ), 136.97 (FLT C-6 ), 111.34 (FLT C-5 ), 97.92 (3TC C-5),
93.27 (J= 179.4 Hz, FLT C-3' ), 87.99 (3TC C-1'), 86.32 (FLT C-1' ), 82.19 (J= 26.6
Hz, FLT C-4' ), 81.68 (3TC C-4' ), 64.96 (FLT C-5'), 64.14 (3TC C-5'), 54.23
(CH(a)), 37.59 (J= ·20.8 Hz, FLT C-2'), 36.96 (3TC C-2'), 36.40 (CH2COO), 31.93,
26.34, 30.34, 30.21, 30.09, 29.91, 29.76, 29.69, 26.80, 23.16 (methylene carbons, Glu
y-CH2, Glu ~-CH 2 ), 13.88 (myristate CH3), 12.10 (FLT 5-CH3); HR-MS (ESI-TOF)
(mlz): C31HssFN6010S: calcd, 794.3684; found, 795.1608 [M +Ht, 1590.3674 [2M +

Ht,
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CHrCONH-Glu(FLT)-3TC (3.26). Compound 3.22 (100 mg, 0.12 mmol) and acetic
anhydride (2 mL, 20 mmol) were dissolved in DMF (10 mL). DIPEA (5 mL, 37
mmol) was added to the solution. The reaction mixture was stirred for 2 h at room
temperature. The solvent was removed under reduced pressure to yield CH3 -CONHGlu(FLT)-3TC-DMTr (3.25).
3.25. HR-MS (ESI-TOF) (m/z): C46lit9FN6012S: calcd, 928.3113; found, 929.1423 [M

+Ht
Compound 3.25 was dissolved in acetic acid (80% in water, 10 mL) and was heated at
80 °C for 30 min to remove DMTr protection. Acetic acid was removed under reduced
pressure and the residue was purified with reversed phase HPLC using a C 18 column
and water/acetonitile as solvents as described above and was lyophilized to yield 3.26
(30 mg, 40%).
3.26. 1H NMR (400 MHz, CD 30D, 8 ppm): 8.13 (d, J= 7.8 Hz, lH, 3TC H-6), 7.46
(s, lH, FLT H-6), 6.28 (dd, J= 3.7 and 5.4 Hz, lH, FLT H-1'), 6.23 (dd, J= 5.7 and
8.8 Hz, lH, 3TC H-1'), 6.16 (d, J= 7.8 Hz, lH, 3TC H-5), 5.44 (dd, J= 3.1and4.9
Hz, lH, 3TC H-4'), 5.25 (dd, J = 5.2 and 53.7 Hz, lH, FLT H-3'), 4.60 (dd, J = 4.9
and 12.4 Hz, lH, 3TC H-5"), 4.32-4.55 (m, 4H, 3TC H-5', FLT H-5', FLT H-5", and
FLT H-4'), 4.26 (dd, J = 3.3 and 11.4 Hz, lH, Glu HN-CH-COO CH( a)), 3.71 (dd, J

= 5.7 and 12.6 Hz, lH, 3TC H-2"), 3.58 (dd,

J = 5.7 and 12.6 Hz, lH, 3TC H-2'),

2.11-2.63 (m, 6H, FLT H-2', FLT H-2", and Glu CH2CH2COO), 1.96 (s, 3H, acetyl
CH3), 1.86 (s, 3H, 5-CH3);

13

C NMR (CD 30D, 100 MHz, 8 ppm): 173.71, 173.65

(FLT COO, 3TC COO), 172.86 (CONH), 161.46 (3TC C-4), 161.21 (3TC C-2 C=O),
152.33 (FLT C-2 C=O), 146.00 (3TC C-6 ), 137.69 (FLT C-6), 112.06 (FLT C-5),
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95.23 (J = 176.4 Hz, FLT C-3' ), 95.14 (3TC C-5), 88.73 (3TC C-1' ), 87.13 (FLT C-1'
), 85.55 (3TC C-4' ), 84.03 (J= 26.0 Hz, FLT C-4'), 65.69 (FLT C-5' ), 64.99 (3TC C5' ), 53.03 (CH(a)), 38.64 (FLT C-2' ), 38.42 (3TC C-2'), 31.04 (Glu y-CH 2), 27.55
(Glu

~-CH2 ),

22.48 (acetyl CH3), 12.78 (FLT 5-CH3); HR-MS (ESI-TOF) (m/z):

c25 H31 FN6010S: calcd, 626.1806; found, 627.6073 [M +Ht, 1254.9359 [2M +Ht.
Fmoc-Glu(FLT)-AZT (3.27). Compound 3.12 (500 mg, 0.84 mmol), AZT (269 mg, 1
mmol), and HBTU (650 mg 1.7 mmol) were dissolved in DMF (10 mL). DIPEA (5

mL, 37 mmol) was added to the solution and the reaction mixture was stirred over
night. The solvent was removed and the residue was dried under reduced pressure. The
residue was purified with reversed phase HPLC using a C 18 column and
water/acetonitile as solvents as described above and was lyophilized to yield 3.27 (620
mg, 85%).
1H NMR (400 MHz, CDC1 ,
3

oppm): 9.24 (s,

lH, FLT NH), 9.09 (s, lH, AZT NH),

7.75 (d, J= 7.2 Hz, lH, Fmoc Ar-H), 7.57 (d, J= 3.6 Hz, lH, Fmoc Ar-H), 7.38 (t, J=
7.2 Hz, Fmoc Ar-H), 7.29 (t, J= 7.2 Hz, 2H, Fmoc Ar-H), 7.15 (s, lH, FLT H-6), 7.07
(s, lH, AZT H-6), 6.14 (t, J= 8.1 Hz, lH, FLT H-1' ), 5.80 (t, J= 6.9 Hz, lH, AZT H1'), 5.17 (dd, J= 2.0 and 55.6 Hz, lH, FLT H-3'), 4.23-4.60 (m, 6H, AZT H-5', AZT
H-5", AZT H-3', FLT H-4', FLT H-5', and FLT H-5"), 4.19 (t, J= 6.7 Hz, lH, Glu

HN-CH-COO CH(a)), 3.95-4.05 (m, lH, AZT H-4' ), 2.16-2.69 (m, 8H, AZT H-2',
AZT H-2", FLT H-2', FLT H-2", and Glu CH2CH2COO), 1.88 (br s, 6H, FLT 5-CH3
and AZT 5-CH3 );

13

C NMR (CDC1 3, 100 MHz,

o ppm):

172.3, 171.4 (FLT COO,

AZT COO), 163.85, 163.72 (FLT C-4 C=O, AZT C-4 C=O), 156.23 (Fmoc OCONH),
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150.10, 149.98 (AZT C-2 C=O and FLT C-2 C=O), 143.74, 143.55, 141.3l(Fmoc ArC), 137.23, 135.88 (AZT C-6, FLT C-6), 127.88, 127.10, 125.05, 125.00, 120.08,
(Fmoc Ar-C), 111.37, 111.28 (AZT C-5, FLT C-5), 93.23 (J = 177.8 Hz, FLT C-3' ),
87.82 (FLT C-1' ), 86.53 (AZT C-1' ), 82.21(J=26.3 Hz, FLT C-4' ), 81.72 (AZT C4' ), 68.00 (Fmoc CH2-0CONH), 63.82 (FLT C-5'), 60.29 (AZT C-5'), 53.48, 53.31
(AZT C-3', CH(a)), 47.04 (Fmoc CH-CH2-0CONH), 37.58 ( J= 20.1 Hz, FLT C-2'),
36.94 (AZT C-2'), 29.72 (Glu y-CH2), 25.60 (Glu

~-CH2),

12.57, 12.43 (AZT 5-CH3 ,

FLT 5-CH3); HR-MS (ESI-TOF) (m/z): C40H41FNs012: calcd, 844.2828; found,
845.0241 [M + H(

NH2-Glu(FLT)-AZT (3.28). Compound 3.27 (610 mg, 0.72 mmol) was dissolved in
THF (IO mL). Piperidine (7.18 µl, 0.072 mmol) and 1-octanethiol (7.3 mmol, 10 mM
solution in THF, 0.73 mL) were added to the reaction mixture. The mixture was stirred
at room temperature for 1 h. The solvent was removed and the residue was dried under
reduced pressure. The residue purified with reversed phase HPLC using a C 18 column
and water/acetonitile as solvents as described above and lyophilized to yield 3.28 (225
mg, 50%).
1
H NMR (400 MHz, CD 3 0D,

oppm): 7.44 (s,

lH, FLT H-6), 7.38 (s, lH, AZT H-6 ),

6.22 (dd, J= 8.1 Hz, lH, FLT H-1'), 6.02 (t, J= 6.9 Hz, lH, AZT H-1' ), 5.23 (dd, J=
2.0 and 55.6 Hz, lH, FLT H-3'), 4.20-4.55 (m, 6H, AZT H-5', AZT H-5", AZT H-3',
FLT H-4', FLT H-5', and FLT H-5"), 4.15 (t, J = 6.7 Hz, lH, Glu HN-CH-COO
CH(a)), 3.98-4.04 (m, lH, AZT H-4' ), 2.16-2.69 (m, 8H, AZT H-2', AZT H-2", FLT
H-2', FLT H-2", CH2CH2COO), 1.87 (br s, 6H, FLT 5-CH3, AZT 5-CH3);
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13

C NMR

(CD 30D, 100 MHz, 8 ppm): 173.29, 170.17 (FLT COO, AZT COO), 166.40, 163.72
(FLT C-4 C=O, AZT C-4 C=O), 152.33 , 152.19 (AZT C-2 C=O, FLT C-2 C=O),
139.13, 137.89 (AZT C-6, FLT C-6), 114.03, 112.08 (AZT C-5, FLT C-5), 95.07 (J=
176.7 Hz, FLT C-3'), 88.12 (FLT C-1'), 87.34 (AZT C-1'), 83.86 (J= 27.3 Hz, FLT C4'), 82.72 (AZT C-4'), 66.90 (FLT C-5'), 61.99 (AZT C-5'), 53.23, 52.28 (AZT C-3',
CB(a)), 38.26 (J = 21.2 Hz, FLT C-2'), 37.10 (AZT C-2'), 30.14 (Glu y-CH 2 ), 26.63
(Glu

~-CH2 ),

12.73, 12.53 (AZT 5-CH3, FLT 5-CH3); HR-MS (ESI-TOF) (m/z):

c25 H31 FN 8010: calcd, 622.2147; found, 622.9532 [M +Ht, 1244.9406 [2M + H(
C13 H27 -CONH-Glu(FLT)-AZT (3.29). Compound 3.28 (75 mg, 0.12 mmol) and
myristic anhydride (100 mg, 0.24 mmol) were dissolved in DMF (10 rnL). DIPEA (5
mL, 37 mmol) was added to the solution. The mixture was stirred for 2 h at room
temperature. The solvent was removed under reduced pressure and the residue was
purified with reversed phase HPLC using a C 18 column and water/acetonitile as
solvents as described above and was lyophilized to yield 3.29 (40 mg, 40%).
1
H NMR (400 MHz, CD 30D, 8 ppm): 7.45, 7.44 (two s, 2H, AZT H-6, FLT H-6),
6.23 (dd, J= 8.9 and 5.6 Hz, lH, FLT H-1'), 6.09 (t, J= 6.7 Hz, lH, AZT H-1'), 5.24
(dd, J = 5.0 and 53.6 Hz, lH, FLT H-3'), 4.32-4.48 (m, 6H, AZT H-5', AZT H-5",
AZT H-3', FLT H-4', FLT H-5', and FLT H-5"), 4.22 (dd, J=3.8 and 11.4 Hz, lH, Glu

HN-CH-COO CH(a)), 4.06 (dd, J = 4.8 and 8.6 Hz, lH, AZT H-4'), 2.15-2.60 (m,
lOH, AZT H-2', AZT H-2", FLT H-2', FLT H-2", myristate CH2COO, Glu

CH2CH2COO) , 1.87 (s, 6H, FLT 5-CH3 , AZT 5-CH3), 1.58 (t, J = 6.6 Hz, 2H,
CH2CH2COO), 1.23-1.33 (br m, 20H, methylene protons), 0.87 (t, J= 6.7 Hz, 3H, 5-
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cH3);

13 C

NMR (CDCl3, 100 MHz, 8 ppm): 173.78, 172.37, 171.56 (FLT COO, AZT

COO, CONH), 164.01 (FLT C-4 C=O and AZT C-4 C=O), 150.27 (AZT C-2 C=O,
FLT C-2 C=O), 137.14, 135.77 (AZT C-6, FLT C-6), 111.37 (AZT C-5, FLT C-5),
93.27 (J= 179.4 Hz, FLT C-3'), 87.56 (FLT C-1'), 86.32 (AZT C-1'), 82.19 (J= 26.6
Hz, FLT C-4'), 81.68 (AZT C-4'), 63.83 (FLT C-5'), 60.33 (AZT C-5'), 51.48, 51.35
(AZT C-3', CH(a)), 37.59 (J = 20.8 Hz, FLT C-2'), 36.96 (AZT C-2'), 36.39
(CH2COO), 34.14, (Glu y-CH2), 31.93 (Glu ~-CH2), 30.04, 29.90, 29.83, 29.66, 29.60,

29.51 , 29.46, 29.36, 29.31, 29.16, 27.27 25.59, 24.97, 22.70 (methylene carbons),
14.15 (My-CH3) 12.73, 12.53 (5-CH3-AZT, 5-CH3-FLT); HR-MS (ESI-TOF) (m/z):

C39H57 FNs011: calcd, 832.4131; found, 832.8583 [M +Ht, 1665.8057 [2M + H(

CH3-CONH-Glu(FLT)-AZT (3.30). Compound 3.28 (75 mg, 0.12 mmol) was
dissolved in DMF (10 mL). DIPEA (5 mL, 37 mmol) and acetic anhydride (2 mL, 20
mmol) were added to the solution. The reaction mixture was stirred for 2 h at room
temperature. The solvent was removed under reduced pressure and the residue was
purified with reversed phase HPLC using a C 18 column and water/acetonitile as
solvents as described above and was lyophilized to yield 3.30 (30 mg, 35%).
1

H NMR (400 MHz, CD 3CN, 8 ppm): 7.45, 7.43 (two s, 2H, AZT H-6, FLT H-6),

6.23 (dd, J= 8.8 and 5.6 Hz, lH, FLT H-1'), 6.09 (t, J= 6.6 Hz, lH, AZT H-1'), 5.24
(dd, J = 5.0 and 53.6 Hz, lH, FLT H-3'), 4.33-4.47 (m, 6H, AZT H-5', AZT H-5",
AZT H-3', FLT H-4', FLT H-5', FLT H-5"), 4.22 (dd, J =3.2 and 11.0 Hz, lH, Glu
HN-CH-COO CH(a)), 4.07 (dd, J= 4.6 and 8.8 Hz, lH, AZT H-4'), 2.11-2.61 (m, 8H,

AZT H-2', AZT H-2", FLT H-2', FLT H-2", and Glu CH2CH2COO), 1.96 (s, 3H,
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acetyl CH3), 1.87 (s, 6H, FLT 5-CH3, AZT 5-CH3); 13 C NMR (CD 30D, 100 MHz, 8
ppm): 172.17, 172.10, 171.40 (FLT COO, AZT COO, CONH), 164.93 , 164.82 (FLT
C-4 C=O, AZT C-4 C=O), 150.93, 150.73 (AZT C-2 C=O, FLT C-2 C=O), 136.57,
136.07 (AZT C-6, FLT C-6), 110.55 (AZT C-5, FLT C-5), 93.69 (J = 176.6 Hz, FLT
C-3'), 85.80 (FLT C-1'), 85.51 (AZT C-1'), 82.42 (J = 26.0 Hz, FLT C-4'), 81.55
(AZT C-4'), 64.31 (FLT C-5'), 60.94 (AZT C-5'), 51.75 (AZT C-3', CH(a)), 36.96 (J
= 20.6 Hz, FLT C-2'), 36.14 (AZT C-2'), 29.39 (Glu y-CH2), 26.04 (Glu P-CH2), 20.88
(acetyl CH3), 12.73, 12.53 (AZT 5-CH3, FLT 5-CH3); HR-MS (ESI-TOF) (m/z):
C37H55 FN6010S: calcd, 794.3684; found, 795 .1608 [M +Ht, 1590.3674 [2M +Ht.

Fmoc-Glu(AZT)-3TC-DMTr (3.31). Compound 3.14 (520 mg, 0.84 mmol), 2.12

(535 mg, 1 mmol), and HBTU (650 mg 1.7 mmol) were dissolved DMF (10 mL).
DIPEA (5 mL, 37 mmol) was added to the solution and to the reaction mixture was
stirred overnight at room temperature. The solvent was removed and the residue was
dried reduced pressure. The residue purified with reversed phase HPLC using a C 18
column and water/acetonitile as solvents as described above and was lyophilized to
yield 3.31 (840 mg, 87%).
HR-MS (ESI-TOF) (m/z): C 59 H 57 FN 60 13 S: calcd, C 59H 57N9013S; found, 1131.3797
[M +Ht, 1132.3485 [M +Ht, 2265.1887 [2M +Ht.

NH2-Glu(AZT)-3TC-DMTr (3.32). Compound 3.31 (815 mg, 0.72 mmol) was

dissolved in THF (1 O rnL). Piperidine (7.18 µl , 0.072 mmol) and 1 and 1-octanethiol
(7.3 mmol, 10 mM solution in THF, 0.73 rnL) were added to the reaction mixture. The
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mixture was stirred for 1 hat room temperature. The solvent was removed at reduced
pressure and the residue was purified with HPLC using a C 18 column and
water/acetonitile as a solvent as described above to yield 3.32 (325 mg, 50%).
1H

NMR (400 MHz, CDCh, cS ppm): 8.04 (d, J= 7.8 Hz, lH, 3TC H-6 ), 7.02-7.47

(m, lOH, DMTr Ar-Hand AZT H-6 ), 6.82 (d, J = 8.8 Hz, 4H, DMTr Ar-H), 6.186.35 (m, lH, 3TC H-1 '), 6.15 (d, J = 7.8 Hz, lH, 3TC H-5), 6.07 (t, J = 6.5 Hz, lH,

AZT H-1 '), 5.30-5.55 (m, lH, 3TC H-4'), 4.66 (dd, J = 6.4 and 12.1 Hz, lH, 3TC H5'), 4.57 (dd, J= 3.2 and 12.1 Hz, lH, 3TC H-5"), 4.26-4.46 (m, 3H, AZT H-3', AZT
H-5', and AZT H-5"), 4.21 (t, J = 6.6 Hz, lH, Glu HN-CH-COO CH(a)), 3.93-4.07
(m, lH, AZT H-4'), 3.75 (s, 6H, DMTr CH30), 3.63-3.70 (m, lH, 3TC H-2"), 3. 75
(dd, J= 12.3 and 5.5 Hz, lH, 3TC H-2'), 2.67 (t, J= 7.0 Hz, 2H, CH2 COO), 2.07-2.56
(m, 4H, AZT H-2', AZT H-2", Glu CHCH2CH2COO), 1.85 (s, 3H, AZT 5-CH3 );

13

C

NMR (CDCh, 100 MHz, cS ppm): 173.20 (AZT COO), 169.95 (3TC COO), 166.25
(3TC C-4, AZT C-4 C=O), 161.54 (DMTr Ar-C-OCH3), 160.03 (3TC, C-2 C=O),
148.70 (AZT C-2 C=O), 145.48 (3TC C-6), 138.34 (AZT C-6), 137.37, 131.25,
129.32, 128.7, 127.69, 114.00 (DMTr Ar-C), 111.86 (AZT C-5), 95.32 (3TC C-5),
88.88 (AZT C-1'), 87.15 (3TC C-1'), 84.02 (AZT C-4'), 82.93 (3TC C-4'), 67.30 (AZT
C-5'), 65.16 (3TC C-5'), 62.06 (DMTr OCH3), 55.69 (AZT C-3'), 53.03 (CH(a)),
37.48 (AZT C-2'), 37.38 (3TC C-2'), 30.15 (Glu y-CH 2), 26.53 (Glu P-CH2), 12.54
(AZT 5-CH3); HR-MS (ESI-TOF) (m/z): C44 H47N 9 0 11 S; calcd, 909.3116; found,
910.4154 [M +Ht, 1821.5154 [2M +Ht.

153

c13H 2,-CONH-Glu(AZT)-3TC

(3.34). Compound 3.32 (100 mg, 0.12 mmol) and

myristic anhydride (100 mg, 0.24 mmol) were dissolved in DMF (10 mL). DIPEA (5
mL, 37 mmol) was added to the solution. The mixture was stirred for 2 h at room
temperature. The solvent was removed under reduced pressure to yield C 13 H2rCONHGlu(AZT)-3TC-DMTr (3.33).
3.33. HR-MS (ESI-TOF) (m/z): CssH13N9012S: calcd, 1119.5099; found, 1120.3183

[M+Ht.
Acetic acid (80% in water, 10 mL) was added to compound 3.33. The mixture was
heated at 80 °C for 30 min to remove DMTr protection. Acetic acid was removed
under reduced pressure and the residue was purified with reversed phase HPLC using
a C 18 column and water/acetonitile as solvents as described above to yield 3.34 (35
mg, 50%).
3.34. 1H NMR (400 MHz, CDCh, 8 ppm): 7.91 (d, J= 7.8 Hz, lH, 3TC H-6), 7.17 (s,
lH, AZT H-6), 6.20 (dd, J = 3.7 and 5.2 Hz, lH, 3TC H-1 '), 6.14 (d, J = 7.8 Hz, lH,
3TC H-5), 5.94 (t, J= 6.5 Hz, lH, AZT H-1'), 5.31 (dd, J= 4.3 and 3.6 Hz, lH, 3TC
H-4'), 4.32-4.58 (m, 4H, 3TC H-5', 3TC H-5", AZT H-3'), 4.21-4.29 (m, 3H, AZT H5', AZT H-5", Glu HN-CH-COO (CH(a)), 3.94 (dd, J = 3.7 and 5.1 Hz, lH, AZT H4'), 3.47 (dd, J= 5.2 and 12.6 Hz, lH, 3TC H-2"), 3.13 (dd, J= 3.7 and 12.6 Hz, lH,
3TC H-2'), 2.07-2.51 (m, 8H, AZT H-2', AZT H-2", myristate CH2COO, and Glu

CH2CH2COO) , 1.81 (s, 3H, AZT 5-CH3 ), 1.40-1.58 (m, 2H, CH2CH2COOH), 1.041.27 (br m, 20H, methylene protons), 0.78 (t, J = 7.0 Hz, 3H, CH3);

13

C NMR

(CD30D, 100 MHz, 8 ppm): 175.92, 172.79 (AZT COO, 3TC COO), 171.70 (CONH),
164.82 (3TC C-4), 160.74 (AZT C-4 C=O), 150.67 (3TC C-2 C=O), 148.15 (AZT C-2
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c==O), 143.44 (3TC C-6), 136.83 (AZT C-6), 111.32 (AZT C-5), 94.90 (3TC C-5),
87.07 (AZT C-1 '), 86.45 (3TC C-1 '), 84.35 (AZT C-4'), 81.86 (3TC C-4'), 64.38 (AZT
C-5'), 63.75 (3TC C-5'), 60.80 (AZT C-3'), 51.54 (CH(a)), 38.22 (AZT C-2'), 37.05
(CH 2COO), 36.24 (3TC C-2'), 32.11, 30.11, 29.99, 29.83, 29.55, 29.47, 29.40, 25.80

(methylene carbons), 26.77 (Glu y-CH2), 22.85 (Glu

~-CH2),

14.19 (myristate CH3),

12.40 (AZT 5-CH3); HR-MS (ESI-TOF) (m/z): C31HssN9010S: calcd, 817.3793;
found, 818.2535 [M +Ht, 1636.0917 (2M +Ht.

CH 3-CONH-Glu(AZT)-3TC (3.36). To compound 3.32 (110 mg, 0.12 mmol) in

DMF (10 mL) was DIPEA (5 mL, 37 mmol) and acetic anhydride (2 mL, 20 mmol).
The reaction mixture was stirred for 2 h at room temperature. The solvent was
removed under reduced pressure to yield CH 3-CONH-Glu(AZT)-3TC-DMTr (3.35).
3.35. HR-MS (ESI-TOF) (m/z): C46H49N9012S: calcd, 951.3221; found, 952.2062 [M

+Ht, 1903.9995 [2M + H(

Acetic acid (80% in water, 10 mL) was added to compound 3.35. The reaction mixture
was heated at 80 °C to remove DMTr protection. Acetic acid was removed under
reduced pressure and the residue was purified with reversed phase HPLC using a C1s
column and water/acetonitile as a solvents as described above to yield 3.36 (35 mg,
55%).

1
3.36. H NMR (400 MHz, CD 30D,

oppm): 8.02 (d, J = 7.9 Hz,

lH, 3TC H-6), 7.33

(s, lH, FLT H-6), 6.20-6.30 (m, lH, 3TC H-1'), 6.03-6.16 (m, 2H, AZT H-1' and 3TC
H-5), 5.42 (t, J = 3.7 Hz, lH, 3TC H-4'), 4.43-4.62 (m, 3H, 3TC H-5", 3TC H-5', and
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AZT H-3'), 4.25-4.35 (m, 3H, AZT H-5', AZT H-5", Glu HN-CH-COO (CH(a)), 4.02
(dd, J= 4.5 and 9.1 Hz, lH, AZT H-4'), 3.57 (dd, J= 5.5 and 12.4 Hz, lH, 3TC H-2"),
3.24 (dd, J = 3.4 and 12.4 Hz, lH, 3TC H-2'), 2.11-2.53 (m, 6H, AZT H-2', AZT H2", Glu CH2CH2COO), 1.96 (s, 3H, acetyl CH3), 1.87 (s, 3H, 5-CH3);

13

C NMR

(CD30D, 100 MHz, 8 ppm): 173.22, 172.50 (AZT COO, 3TC COO), 172.24 (CONH),
165.41 (3TC C-4), 161.32 (AZT C-4 C=O), 151.49 (3TC C-2 C=O), 148.53 (AZT C-2
C=O), 144.96 (3TC C-6), 137.32 (AZT C-6), 111.56 (AZT C-5), 95.03 (3TC C-5),
87.92 (AZT C-1'), 86.03 (3TC C-1'), 84.92 (AZT C-4'), 82.40 (3TC C-4'), 65.19 (AZT
C-5'), 64.42 (3TC C-5'), 61.36 (AZT C-3'), 52.36 (CH(a)), 38.29 (AZT C-2'), 37.36
(3TC C-2'), 30.65 (Glu y-CH2), 27.06 (Glu

~-CH2),

22.60 (acetyl CH3), 12.60 (FLT 5-

CH3); HR-MS (ESI-TOF) (m/z): C2sH31N9010S : calcd, 649.1915; found, 650.2228 [M

+Ht, 1299.0050 [2M +Ht.

FLT-Succ-NH-Glu(AZT)-3TC (3.37). Compound 3.32 (110 mg, 0.12 mmol),
DIPEA (5 mL, 37 mmol), and FLT-Succinate (100 mg, 0.30 mmol) were dissolved in
DMF (10 mL). The reaction mixture was stirred for 2 h at room temperature. The
solvent was removed under reduced pressure. Acetic acid (80% in water, 10 mL) was
added to the residue. The reaction mixture was heated at 80 °C to remove DMTr
protection. Acetic acid was removed under reduced pressure and the residue was
purified with HPLC using a C 18 column and water/acetonitile as a solvent as described
above to yield 3.37 (55 mg, 50 %).
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1H NMR (400 MHz, CD3CN, 8 ppm): 8 10.7 (s, lH, NH), 9.59 (s, 2H, NH), 7.97 (d, J
::: 7.6 Hz, lH, 3TC H-6), 7.77 (s, lH, NH), 7.36 (s, lH, FLT H-6), 7.29 (s, lH, AZT
H-6), 6.96 (d, lH, NH) , 6.17-6.26 (m, 2H, 3TC H-1' and FLT H-1'), 6.14 (d, J = 7.6
Hz, lH, 3TC H-5), 6.06 (t, J= 6.3 Hz, lH, AZT H-1'), 5.40 (t, J= 3.6 Hz, lH, 3TC H4'), 5.24 (dd, J = 4.8 and 53.7 Hz, lH, FLT H-3'), 4.16-4.59 (m, 9H, 3TC H-5', 3TC
H-5", FLT H-5', FLT H-5", FLT H-4', AZT H-5', AZT H-5", AZT H-3', Glu HN-CHCOO (CH( a)), 4.00 (dd, J

=

6.6 Hz, lH, AZT H-4'), 3.56 (dd, J = 11.9 and 5.2 Hz,

lH, 3TC H-2"), 3.24 (dd, J = 11.9 and 5.2 Hz, lH, 3TC H-2'), 2.05-2.66 (m, 12H,
Succinate OOCCH2CH2CON, FLT H-2', FLT H-2", AZT H-2', AZT H-2", and Glu

CH2CH2COO), 1.83 (s, 6H, FLT 5-CH3 and AZT 5-CH3);

13

C NMR (CD 3CN, 100

MHz, 8 ppm): 174.50, 173.95, 172.95 (3TC COO, FLT COO, AZT COO), 166.38
(3TC C-4), 161.62 (AZT C-4 C=O and FLT C-4 C=O), 152.38, 152.27, 148.86 (AZT
C-2, FLT C-2, 3TC C-2 C=O), 145.83, 138.25, 137.50 (FLT C-6, AZT C-6, 3TC C-6),
112.22, 112.04 (FLT C-5, AZT C-5), 95.43 (J= 176.5 Hz, FLT C-3'), 96.42 (3TC C5), 88.78 (3TC C-1'), 86.85 (FLT C-1'), 86.81 (AZT C-1'), 86.81 (3TC C-4'), 84.11 (J
== 26.0 Hz, FLT C-4'), 83.16 (AZT C-4'), 65.93, 65.05, 64.99 (3TC C-5', FLT C-5',

AZT C-5'), 62.20 (AZT C-3'), 52.64 (CH(a)), 38.79 (3TC C-2'), 38.48 (J= 19.0 Hz,
FLT C-2'), 37.76 (AZT C-2'), 31.86, 31.06, (succinate two-CH 2), 30.24 (Glu y-CH2),
27.71 (Glu P-CH2), 12.89, 12.75 (AZT 5-CH3 and FLT 5-CH3); HR-MS (ESI-TOF)
(m/z): C37H44FN 11 0 15 S: calcd, 933 .2723; found, 934.2864 [M +Ht, 1867.6791 [2M

+Ht,
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3.4. Results and discussion
3.4.1. Chemistry
3.4.1.l. Unsymmetrical and Symmetrical 5',5'-Dinucleoside Conjugates of
Succinic Acid or Suberic Acid

Several 1,4-dinucleoside succinate and 1,8-dinucleoside suberate ester
derivatives were synthesized (Schemes 3.1-3.3).

Unsymmetrical dinucleoside succinate derivatives were synthesized in twostep synthesis. First, nucleoside succinates, FLT succinate (3.1) and AZT succinate
(3.2), were synthesized by the reaction of FLT or AZT with succinic anhydride in

presence of pyridine as the base (Scheme 3.1 ). FLT succinate was then reacted with
AZT in the presence of HBTU and DIPEA as a base and 3TC-DMTr (2.12) in the
presence of HBTU and DIPEA, followed by acetic acid to give FLT-AZT 1,4succinate (3.3) and FLT-3TC 1,4-succinate (3.4), respectively. Similarly, AZTsuccinate was reacted with 3TC-DMTr (2.12) followed by DMTr removal to give
AZT-3TC 1,4-succinate (3.5).

Symmetrical dinucleoside 1,4-succinate derivatives of AZT (3.6) and FLT
(3. 7) were synthesized by reaction of nucleosides with succinyl chloride in the

presence of DMAP as the base (Scheme 3.2). Symmetrical dinucleoside 1,8-suberate
were synthesized by reaction of two equivalents of nucleosides, FLT, AZT, or DMTr3TC, with one equivalent of suberic acid in presence of HBTU and DIPEA. Acetic
acid cleavage was used to deprotect the DMTr group in 3TC conjugate (Scheme 3.3).
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Succinic anhydride, Pyridine

FLT R= F
AZT R=N3
AZT, HBTU, DIPEA

I. 3TC-DMTr, HBTU , DIPEA
2. Acetic Acid

3.4 R =F
3.5 R =N 3

3.3 R = F

Scheme 3.1. Synthesis of unsymmetrical 5',5'-dinucleoside 1,4-succinate derivatives

of FLT, AZT, and 3TC.

!-oH

DMAP, Benzene

~OH
0

R

3.6 R
3.7 R

= N3
=F

Scheme 3.2. Synthesis of symmetrical 5',5'-dinucleoside 1,4-succinate derivatives of

FLT and AZT.
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1. HBTU , DIPEA, DMF
2. Acetic acid

3.10 R = C6 H 12

Scheme 3.3. Synthesis of symmetrical 5',5'-dinucleoside 1,8-suberate derivatives of

FLT, AZT, and 3TC.

3.4.1.2. Synthesis of Peptide-Nucleoside Conjugates (Peptides Containing One
Nucleoside and One Myristoyl Group).

Peptide-nucleoside derivatives (3.16-3.20) containing one nucleoside and one
myristoyl moiety attached in the peptide side chains were synthesized in three steps:
(i) Fmoc-building block synthesis; (ii) Peptide assembly on the resin using automated
peptide synthesizer; and (iii) Deprotection followed by acylation of the free amino
groups. Step-by-step synthetic procedures are shown in the schemes 3.6-3.8.
Fmoc-Glu(nucleoside)-OH were synthesized by reaction of Fmoc-Glu(OH)tBu with the corresponding nucleoside (AZT or FLT) in the presence of HBTU and

DIPEA, followed by the deprotection of tBu group with TFA (Scheme 3.4).
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Fmoc-Glu(OH)OtBu, HBTU
DIPEA, DMF

R
R =NJ AZT
R = F FLT

TFA:Water (95:5)

3.11 R = F
3.13 R =NJ

.. .
R
3.12 R = F
3.14 R =NJ

Scheme 3.4. Synthesis of Fmoc-Glu(FLT)-OH (3.12) and Fmoc-Glu(AZT)-OH (3.14).

Fmoc-Ser(OMys)OH (3.15), a fatty acid building block, was synthesized by
the reaction of Fmoc-Ser(OH)-OH with myristoyl chloride in the presence of DIPEA
(Scheme 3.5).

0
H
II
Fmoc-N-C(H-c-oH
Myristoyl Chloride, DIPEA, DMF

CH2
I
Oyc1JH21

0
3.15

Scheme 3.5. Synthesis of Fmoc-Ser(OMys)OH (3.15).
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Dipeptide My-Glu(FLT)-Lys(My)-OH (3.16) was synthesized by assembling
Fmoc protected building block, Fmoc-Glu(FLT)-OH, on Fmoc-Lys(Mtt)-Wang resin
by using Fmoc solid phase peptide synthesis strategy at room temperature Lysine side
chain protecting group Mtt was removed by adding 5% TF A to the resin NH 2Glu(FLT)-Lys(Mtt)-Wang resin. The free amino groups were myristoylated by using
myristic anhydride and the peptide was cleaved from the resin by using 95% TF A
cocktail to yield 3.16 (Scheme-3.6).

For the synthesis of peptide-nucleoside conjugates 3.17 and 3.18, the peptide
was assembled on Fmoc-Lys(Mtt)-Wang resin by Fmoc solid-phase peptide synthesis
strategy on a PS3 automated peptide synthesizer at room temperature using Fmoc
protected amino acids [Fmoc-f3-Ala-OH and Fmoc-Glu(nucleoside)-OH (3.12 or
3.14)], followed by acetylation. After acidic removal of lysine Mtt group, the N-

terminal was myrisotylated using myristic anhydride in the presence of DIPEA as the
base to afford 3.17 and 3.18 (Scheme 3.7).
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1. Piperidine (20%)
2. Fmoc-Glu(FLT)-OH, HBTU, NMM
3. Piperidine (20%)
4. TFA, DCM (95:5)

F

I. Myristic anhydride, DIPEA, DMF
2. TFA, H 2 0, Anisole, (95:2.5:2.5)

F
3.16

Scheme 3.6. Solid phase synthesis of My-Glu(FLT)-Lys(My)-OH (3.16).

i. Piperidine 20%
ii. HBTU + Fmoc-BA!a-OH, NMM
iii. HBTU + Fmoc-Glu(OFLT)-OH or
Fmoc-Glu(OAZT)-OH, NMM
iv. DIPEA +Acetic anhydride
v. TFA (5%) in DCM
vi. DIPEA + Myristic anhydride
vii. TFA (95%)

Scheme 3. 7. Solid phase synthesis of peptide-nucleoside conjugates 3.17 and 3.18.
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Solid-phase reaction of building blocks, [Fmoc-Glu(nucleoside)-OH (3.12 or
3.14), Fmoc-~-Ala-OH, and Fmoc-Ser(Myristoyl)-OH (3.15) on Fmoc-Gly-Wang

resin, followed by cleavage afforded 3.19 and 3.20 (Scheme 3.8).
i. piperidine (20%) .
ii. HBTU + Fmoc-Glu(OFLT)-OH
or Fmoc-Glu(OAZT)-OH
iii. HBTU + Fmoc-IlAla-OH
iv. HBTU + Fmoc-Ser(OMy}-OH
v. DIPEA+ Acetic anhydride
vi. TF A: Water:Anisole

H/

0
C H
~H
"y" 13 27
HO~
N y ; ;N O
II
N
NH

--------

o

H

C(H2

~

_JH2

01

o'l
X=F3.19
X= N3 3.20

px

Jl

o

l N~O
o I

A0

/NH

Scheme 3.8. Synthesis of Peptide-nucleoside conjugates 3.19 and 3.20.

3.4.1.3. Synthesis of Dinucleoside- and Trinucleoside Glutamic Acid Derivatives
with or without Myristoyl Moiety

The synthesis of glutamate esters containing two to three nucleosides, with or
without myristic acid, was accomplished by solution phase synthesis. The conjugates
were synthesized by reaction of an appropriate building block, such as FmocGlu(FLT)-OH (3.12) or Fmoc-Glu(AZT)-OH (3.14) as at free a-carboxylic acid with
other nucleosides, such as 3TC-DMTr or AZT, in the presence of HBTU and DIPEA
afforded 3.21, 3.27 or 3.31. In the next step, Fmoc deprotection was accomplished in
the presence of piperidine and octanethiol to afford 3.22, 3.28, or 3.32. Octanethiol
was used in excess as a scavenger since the conjugates were not stable to piperidine or
other bases like DMAP. The use of piperidine in proportions more than 0.1 equivalent
or the increase in the cleavage reaction time resulted in the loss of nucleoside from
side chain of glutamate at &-carboxylic acid. After the removal of Fmoc protection
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from amino group, N-terminal was reacted with myristic anhydride or acetic anhydride
in the presence of DIPEA. Deprotection of DMTr group was accomplished with acetic
acid reaction. This strategy provided the synthesis of the glutamate ester containing
two different nucleosides with or without myristic acid (3.24, 3.26, 3.29, 3.30, 3.34,
and 3.36). Myristoyl and acetyl capping at N-terminal was carried out to provide
peptides with high and low lypophilicity, respectively (Schemes 3.9 and 3.10).

Finally, a glutamate conjugate containing three different nucleosides attached
was synthesized (Scheme 3.10). In this molecule, the first, second, and third
nucleosides were attached to C-terminal, to the side chain, amino group, respectively.
A glutamate conjugate containing two different nucleosides, 3TC and AZT, at a and 8carboxylic acids (NH 2 -Glu(AZT)-3TC-DMTr) (3.32) was first reacted with FLTsuccinate in the presence of DIPEA followed by acetic acid cleavage to afford a
glutamate conjugate containing three nucleosides (3.37).
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Scheme 3.9. Synthesis of Glutamic acid esters of nucleosides (AZT and FLT)
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3.12, R 1 = F
3.14, R1 = N3
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Scheme 3.10. Synthesis of Glutamic acid esters ofnucleosides (AZT, FLT and 3TC).
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3.4.2 Biological evaluation
All the compounds were tested for their anti-HIV activity and cytotoxicity profile.
Tables 3.2-3.4 illustrate the anti-HIV-I activities of the selected compounds and the
corresponding physical mixtures against cell-free virus (IIIB) strain. The compounds
are currently under evaluation against other strains of virus.

Table 3.2. Anti HIV Activity of peptide-nucleoside conjugates
Chemical Name
Compound

CTSa

Cell-free HIV-1

(µg/mL)
a

(IIIB)b
(µg/mL)

(µM)

A.ZT

3'-azido-2',3'-dideoxythymidine (AZT)

> 100

9.2

34.4

FLT

3'-fluoro-2' ,3 '-deoxythymidine (FLT)

>100

0.2

0.8

3.19

FLT(Glutamyl)-myrsitoyllysine

>100

8.7

10.4

3.16

FLT(myristoylglutamyl)-mysritoyllysine

>100

24.7

26.8

3.17

Myristoylserine-FLT(glutamyl)glycine

>100

9.3

11.1

3.18

Myristoylserine-AZT(glutamyl)glycine

>100

54.5

63.1

aCytotoxicity assay; cViral entry inhibition assay (lymphocytotropic strain); Data represent EC 50 (50%
effective concentration). Single-round infection assay where compounds, virus and cells were incubated
for 2 hours. Cells were then washed and cultured for additional 48h. Infection was measured by HIVLTR driven Galactosidase expression.

As shown in Table 3.2, all the peptide-nucleoside conjugates (3.16-3.19) displayed
poor anti-HIV activity (EC 50 > 10 µM when compared to FLT (EC 50 = 0.8 µM).
Myristoylated peptide-AZT conjugate 3.18 was almost two fold less active than AZT.
Peptide conjugates were nearly 13-79 folds less active than FLT. The results indicate
that the peptides may not be an appropriate scaffold for the attachment of nucleosides
and attachment of myristic acid did not improve the ant-HIV profile of the
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nucleosides. This may be due to the low cellular uptake of compounds containing
peptide backbone.

The anti-HIV activities for glutamate esters of two different nucleosides were
evaluated against monocytotropic stain of virus and compared with the physical
mixture of the corresponding nucleosides with or without myristic acid (Table 3.3).
The data showed improved anti-HIV activity for molecules containing myristic acid
when compared to the molecules without the fatty acid. Glutamate ester of FLT and
3TC with myristic acid (3.24) exhibited 8.5-fold higher activity than the corresponding
conjugate without myristic acid (3.26). Furthermore, compound 3.24 was the most
active conjugate among glutamic ester of two nucleosides. However, the anti-HIV
activity for all the compounds was less than that of FLT.

Surprisingly, the physical mixtures of nucleosides and glutamic acid with
myristic acid showed higher potency than the corresponding conjugates. This result
indicates that attachment of nucleosides to the amino acid backbone is deleterious,
possibly because of poor cellular uptake.

In general, the presence of the myristic acid in the conjugates or physical

mixtures improved the anti-HIV activity. The possible reason for the better activity
could be the improved lypophilicity, which ultimately results in higher cellular uptake
of the active compounds and higher solubility of the physical mixtures in the presence

169

of myristic acid in tested solutions. More investigations are required to confirm these
hypotheses.

Table 3.3. Dinucleoside-Glutamic Acid Derivatives with or without Myristoyl
Moiety

Chemical Name
Compound

CT Sa

Cell-free IDV-1

(IIIB)b

{µg/mL)3
(µg/mL)

µM

AZT

3'-azido-2',3'-dideoxythymidine (AZT)

>100

9.2

34.4

FLT

3'-fluoro-2',3'-deoxythymidine (FLT)

>100

0.2

0.8

>100

7.5

32.7

2',3'-dideoxy-3'-thiacytidine
3TC

(lamivudine, 3TC)

3.26

FLT(acetylglutamyl)-3TC

>100

10.7

17.1

3.24

FLT(mysristoylglutamyl)-3TC

>100

1.6

2.0

3.38

FLT+ 3TC + Glutamic acid

>100

0.6

>100

0.3

FLT+ 3TC + Glutamic acid+
3.39

Myristic acid

3.30

FLT(acetylglutamyl)-AZT

>100

9.0

13 .5

3.29

FLT(mysristoylglutamyl)-AZT

>100

2.0

2.4

3.40

FLT +AZT+ Glutamic acid

>100

1.0

>100

0.3

FLT + AZT + Glutamic acid+
3.41

Myristic acid

3.36

AZT(acetylglutamyl)-3TC

>100

7.8

12.0

3.34

AZT(mysristoylglutamyl)-3TC

>100

4.9

6.0

3.42

AZT+ 3TC + Glutamic acid

>100

1.7

>100

1.9

3.43

AZT+ 3TC + Glutamic Acid+
Myristic Acid

a

Cytotoxicity assay; 0 Viral entry inhibition assay (lymphocytotropic strain); Data represent ECso (50%
effective concentration). Single-round infection assay where compounds, virus and cells were incubated
for 2 hours. Cells were then washed and cultured for additional 48h. Infection was measured by HIVLTR driven Galactosidase expression.
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Table 3.4 displays the anti-HIV activity of a glutamate derivative with three
different nucleosides (3.37). Compound 3.37 showed 35-fold higher anti-HIV activity
that AZT and 3TC,, but had a comparable activity to FLT against IIIB strain of virus

ECso = 0.8 µM. Compound 3.37 was > 10 folds better active than the corresponding
molecule with two nucleosides (3.26) indicating that the addition of three nucleosides
to the glutamate improves the anti-HIV activity. Compound 3.37 exhibited 4-17 times
better anti-HIV activity when compared with disubstituted succinate derivatives of
AZT and FLT (3.6 and 3. 7).

The activity of 3.37 was also compared to the corresponding physical mixtures
either with or without myristic acid (Table 3.4). The data showed higher anti-HIV
activity for the physical mixture 3.45 than 3.37. Physical mixture containing FLT,
AZT, 3TC, and glutamic acid (3.45) showed comparable activity to 3.37. Replacing
FLT with FLT-succinate in the physical mixture (3.46) resulted in decrease in antiHIV activity by 2 fold, possibly because of slow hydrolysis of FLT-succinate to FLT.
This data is consistent with our earlier results suggesting that glutamate and peptides
are not appropriate scaffolds for improving anti-HIV profile.

Addition of myristic acid in equivalent ratio to the physical mixture (3.46)
improved the activity by three fold in comparison with 3.37 and the physical mixture
3.45. These data were consistent with those obtained for the physical mixtures of two
nucleosides and myristic acid described above.
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Table 3.4. Anti HIV Activity of glutamic acid ester of three different Nucleosides in
comparison with succinate derivatives of nucleosides
Chemical Name
Compound

CT Sa

Cell-free IDV-1
(IIIB)

µg/mL.

µg/mL

µM

AZT

3'-azido-2',3'-dideoxythymidine (AZT)

>100

9.2

34.4

FLT

3'-fluoro-2' ,3 '-deoxythymidine (FLT)

>100

0.2

0.8

3TC

2',3'-dideoxy-3'-thiacytidine (3TC)

>100

7.5

32.7

3.6

AZT-succinate-AZT

>100

8.6

13.9

3.7

FLT-succinate-FLT

>100

2.1

3.7

3.37

FLT-Succinate-AZT(glutamyl)-3TC

>100

0.9

0.96

>100

1.8

>100

0.8

>100

0.3

FLT-Succinate +AZT+ 3TC + Glutamic
3.44
3.45

acid
FLT+ AZT+ 3TC + Glutamic acid
FLT+ AZT+ 3TC + Glutamic acid+

3.46

Myristic acid

aCytotoxicity assay; cviral entry inhibition assay (lymphocytotropic strain); Data represent EC 50 (50%
effective concentration). Single-round infection assay where compounds, virus and cells were incubated
for 2 hours. Cells were then washed and cultured for additional 48h. Infection was measured by HIVLTR driven Galactosidase expression.

3.5. Conclusions
Three classes of mono- di-, or trinucleoside conjugated on multivalent
scaffolds (e.g., polycarboxylic acids, amino acids, and peptides) were synthesized with
the expectation to improve the cellular uptake profile of the nucleosides, to exert
synergistic effect by delivering different ant-HIV nucleosides at the same time to the
infected cells, and to generate broad-spectrum anti-HIV agents with higher barrier to
drug resistance.
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Peptides or glutamate conjugated with myristic acid and nucleosides exhibited
higher anti-HIV activities when compared with those substituted only with
nucleosides. Increasing the number of anti-HIV nucleosides to 2 or 3 on the peptide
chain enhanced the anti-HIV potency. Physical mixtures of nucleosides with amino
acids and fatty acids used in the conjugation also showed significantly higher potency.
The presence of one myristic acid in the conjugates or physical mixtures improved the
anti-HIV activity, but addition of two myristic acids to the conjugates was not
beneficial.

Glutamate-nucleoside derivatives showed higher anti-HIV activity than
dinucleoside succinate derivatives. The glutamate conjugate with three different
nucleosides (3.37) was found to be the most potent compound in three classes of
compounds evaluated here. Compound 3.37 had higher anti-HIV activity than AZT
and 3TC, and showed comparable activity to FLT (EC 50 = 0.8 µM). Although
glutamate conjugates containing two nucleosides exhibited higher activity than AZT
and 3TC, but they were less active than FLT. Presence of myristic acid in the glutamic
acid conjugates and their corresponding physical mixtures improved the anti-HIV
activity.

The advantages of these compounds will be more clearly defined with further
evaluation against multiple drug resistant strains. Selected compounds are currently
under further biological evaluations for their broad-spectrum anti-HIV properties.
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4.1. Abstract

Reported solution-phase methods for the synthesis of 3'-fluoro-3'-deoxythymidine
(FLT) are cumbersome, require purification of intermediates, and include several
protecting/deprotecting steps. To circumvent these problems, a solid-phase strategy
was designed for the synthesis of FLT. Thyrnidine was immobilized on trityl resin via
the 5'-hydroxyl group. The subsequent mesylation of the free 3'-hydroxyl group in the
presence

of

methanesulfonyl

chloride

afforded

the

polymer-bound

3'-0-

mesylthymidine. Nucleophilic substitution of the mesyl moiety by hydroxyl group in
the presence of sodium hydroxide produced the polymer-bound threothymidine.
Fluorination with diethylarninosulfur trifluoride followed by acidic cleavage of the
polymer-bound FLT in the presence of trifluoroacetic acid afforded FLT.

4.2. Introduction

3'-Fluoro-3'-deoxythymidine (FLT, alovudine) is a nucleoside analogue
structurally related to 3'-azido-3'-deoxythymidine (AZT), a commercially available
anti-human immunodeficiency virus type 1 (HIV-1) drug. FLT has a substitution of
fluorine for the hydroxyl group at the 3' position of the ribose ring of thymidine, and
has been reported to be one of the most active inhibitors of HIV in vitro. FLT is up to
10-fold more potent than AZT in vitro (Pan et al., 1992, Kong et al. , 1992) and is at
least 10 times more active than AZT in monkeys infected with suruan
immunodeficiency virus (Lundgren et al., 1991). Further investigations of this
compound (Matthes et al., 1987, Cheng et al., 1987) showed that FLT-5'-triphosphate
(FLT-TP) is a potent and selective inhibitor ofHIV-1 reverse transcriptase.
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isolates with mutations resulting in multidrug resistance against all

currently available reverse transcriptase inhibitors including AZT had no evidence of
cross resistance to FLT (Kim et al., 1994). American Cyanamid Co discontinued the
development of FLT in 1994 because of the observed hematological toxicity (Hoshi et
al., 1994). However, Medivir continued to test FLT for the treatment of patients with
multidrug-resistant HIV infection. The phase Ila clinical trials of FLT was
successfully completed in July 2002. All patients underwent treatment without any
serious side effects (Calvez et al., 2002, Rusconi, 2003). FLT is currently undergoing
further clinical tests.

Recently 3'-[ 18 F]fluoro-3'-deoxythymidine ([ 18 F]FLT) has been proposed as a
new marker for imaging tumor proliferation by positron emission tomography (PET)
(Seitz et al., 2002, Wagner et al., 2003). The introduction of 18 F at the ribose rather
than labelling the nucleotide with

18

F enhanced the metabolic stability of the marker

(Shields et al., 1998). [18 F]FLT was predominantly taken up by proliferating cells.
Further phosphorylation of [18 F]FLT by thymidine kinase 1 (TK-1) resulted in
intracellular trapping of the metabolite, [18F]FLT-monophosphate (Shields et al., 1998,
Wodarski et al., 2000).

The synthesis of FLT in solution phase has been carried out by using several
protecting and deprotecting steps (Herdewijn et al., 1987, Sahlberg et al., 1992, Hager
et al., 1992, Kumar et al., 2004, Yun et al., 2003). These reactions are cumbersome
and the intermediates need to be purified in each step. Furthermore, the overall yield is
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not satisfactory. Because of revival of research interest for using FLT as anti-HIV
agent or as a marker in tumor imaging by PET, there is a need for an alternative facile
and effective synthesis of this compound. We designed a solid-phase strategy for the
synthesis of FLT using unprotected thymidine to circumvent some of the problems
associated with the solution-phase methods.

4.3. Materials and Methods
4.3.1. Materials

All the chemicals and solvents were purchased from fisher scientific. Trityl
resin was purchased from Novabiochem. All reactions were carried out in Bio-Rad
polypropylene columns by shaking and mixing using a Glass-Col small tube rotator in
dry conditions at room temperature unless otherwise stated. Trityl chloride resin (1.6

mmol/g) was purchased from Novabiochem. Other chemicals and reagents were
purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI). The chemical
structure of FLT was confirmed by nuclear magnetic resonance spectrometry ( 1H
NMR,

13

C NMR) on a NMR spectrometer (400 MHz) and a high-resolution PE

Biosystems Mariner API time-of-flight mass spectrometer.

4.3.2. Synthesis
Polymer-bound thymidine (4.3). The reaction vessel containing trityl chloride resin
(4.2, 1.6 mmol/g, 0.36 rnmol, 225 mg), thymidine (4.1, 350 mg, 1.44 mmol) and

anhydrous pyridine (10 rnL) was shaken at room temperature for 48 h. The resin was
collected by filtration and washed with DMF (2 x 25 rnL), DCM (2 x 25 mL), and
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anhydrous MeOH (2

x

25 mL), respectively, and dried under vacuum to give 4.3 (272

mg, 91 % yield). IR (cm- 1): 3382 (0-H), 3056 (N-H), 3019 (N-H), I683 (C=O amide),
I654 (C=O amide).

Polymer-bound 3'-0-mesylthymidine (4.4). Methanesulfonyl chloride (I66 µL, 2.14
mmol) was added to swelled resin 3 (272 mg) in dry pyridine (10 rnL). The reaction
mixture was shaken for 48 h at room temperature. The resin was collected by filtration
and washed with DMF (2 x 25 rnL), DCM (2 x 25 rnL), and anhydrous MeOH (2 x 25
mL), respectively. The resin was dried under vacuum to afford 4.4 (290 mg, 98%

yield). IR (cm- 1): 3056 (N-H), 30I9 (N-H), I687 (C=O amide), I654 (C=O amide),
1356 (S02), I I 73 (S02).

The completion of reaction was confirmed by cleaving a small amount of resin
4.4 with 2% TF A in DCM. The spectral properties were identical with those of 3'-0-

mesylthyrnidine. HR-MS (ESI-TOF) (m/z): CuH 16N2 0 7 S calcd, 320.3 I 89; found,
321.2275 [M +Ht, 343.2270 [M +Nat.

Polymer-bound threothymidine (4.5). Sodium hydroxide solution (0.5 mL, IN) was
added to the swelled resin 4.4 (290 mg) in DMF (20 rnL). The mixture was shaken for
24 h. Additional amount of NaOH solution (1 rnL, IN) was added, and the reaction
mixture was refluxed for 24 h. The resin was collected by filtration and washed with
water (2 x 25 rnL), DMF (2 x 25 rnL), DCM (2 x 25 rnL), and anhydrous MeOH (2 x

I8I

25 mL), respectively, and dried under vacuum to yield 4.5 (262 mg, 98%). IR (cm-

1
):

3407 (0-H), 3056 (N-H), 3019 (N-H), 1686 (C=O amide).

Polymer-bound 3' -fluoro-3' -deoxythymidine (4.6). Completely dried resin 4.5 (262

mg) was swelled in dry benzene (10 mL) and THF (1 mL) and cooled to 0 °C. DAST
(135 µL, 1.02 mmol) was added to the reaction vessel. The reaction mixture was
shaken for 72 h at room temperature. The resin was collected by filtration and washed
with water (2 x 25 mL), DMF (2 x 25 mL), DCM (2 x 25 mL), and anhydrous MeOH
(2 x 25 mL), and dried under vacuum to afford 4.6 (248 mg, 95%). IR (cm- 1): 3056
(N-H), 3017 (N-H), 1683 (C=O amide), 1659 (C=O amide).

3'-Fluoro-3'-deoxythymidine (4.7). Resin 4.6 (248 mg) was suspended in DCM

containing 3% TF A (I 0 mL) and was shaken at room temperature for 1 h. The resin
was collected by filtration. The filtrate was concentrated under reduced pressure and
purified by silica-gel column chromatography using DCM and methanol as eluents
(98:2, v/v) to afford FLT (39 mg, 55%). 1H NMR,

13

C NMR, and high resolution time-

of-flight electrospray mass spectrometry confirmed the structure of the compound.
Melting point (177-178 °C) (reported mp 176-177 °C) (Herdewijn et al., 1987) and the
NMR data corresponded to those reported in the literature (Herdewijn et al., 1987,
Sahlberg et al., 1992, Hager et al., 1992, Kumar et al., 2004, Yun et al., 2003). High
resolution ESI-MS for FLT (4.7) (C 10H 13 FN2 0 4) cacld, 244.2196; found, 267.2051 [M

+Nat.
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4.4. Results and Discussion

Recent phase Ila clinical trials of FLT for the treatment of patients with
multidrug-resistant human immunodeficiency virus infection showed promising
results without any serious side effects. Furthermore, [ 18F] FLT has been proposed as a
new marker for imaging tumor proliferation by PET. Thus, there is an increased
research interest in studying the biological properties of FLT. We designed a solidphase method for the synthesis of FLT.

Scheme 4.1 displays the solid-phase synthesis of FLT. 5'-Hydroxyl group of
thymidine (4.1) was immobilized on trityl chloride resin (4.2) in the presence of
pyridine to yield polymer-bound thymidine (4.3, 91%). Resin 4.3 was subjected to
reaction with methanesulfonyl chloride in the presence of pyridine to afford polymerbound 3'-0-mesylthymidine (4.4, 98%). The reaction of 4.4 with sodium hydroxide in
DMF for 48 h gave polymer-bound threothymidine (4.5, 98%). Diethylaminosulfur
trifluoride (DAST) was added to the suspension of resin 4.5 in anhydrous benzene and
THF to produce polymer-bound FLT (4.6, 95%). The reaction was continued for 72 h.
Washing and acidic cleave of trityl' resin with TFAIDCM (3%) afforded FLT (4.7,
55%) (overall yield 45%) (Scheme 1).

Scheme 4.2 shows the solution-phase synthesis of FLT according to the
modified reported procedure (Yun et al., 2003). Thymidine was converted to 5'-0(4,4' -dimethoxytrityl)thymidine 4.8 (90%) in the presence of 4,4' -dimethoxytrityl
chloride and dry pyridine. Subsequent mesylation of -3'-hydroxyl group in 4.8 with
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methanesulfonyl

chloride

in the presence of pyridine

afforded

5' -0-(4,4' -

dimethoxytrityl)-3'-0-mesylthymidine 4.9 (94%). Basic hydrolysis of 4.9 with
ethanolic sodium hydroxide afforded 5' -0-(4,4' -dimethoxytrityl)threothymidine 4.10,
which was fluorinated with DAST and sequential acidic deprotection to afford FLT
(4.7, 23%) (overall yield 19%).
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Scheme 4.1. Solid-phase synthesis of FLT. Reagents: (i) pyridine, 48 h; (ii) MsCl, pyridine, 48 h; (iii)
NaOH (IN), DMF, H20, 24 h; (iv) NaOH (IN), reflux, 24 h; (v) DAST, benzene, THF, 72 h; (vi)
TFAJDCM (3%), 1 h.
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The novelty of the method lies in its simplicity. Thymidine is mixed with trityl
chloride and is thereby "captured" as an immobilized compound through the 5' hydroxyl group. Washing the support allows for the recovery of an excess of
thymidine and removal of unreacted reagents, and guarantees that no unreacted
starting materials remain. This makes the method very economical and cost-effective.
Trityl chloride resin has a hindered structure, thereby allowing for the regioselective
reaction. The most reactive hydroxyl group (5' -hydroxyl group) of thymidine reacts
selectively with hindered resin when an excess amount ofthymidine (4 eq) is used.
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Scheme 4.2. Solution-phase synthesis of FLT. Reagents: (i) pyridine, 4,4'-dimethoxytrityl chloride
(DMTrCI), 3 h; (ii) MsCI, pyridine, 3 h; (iii) NaOH (1 N), EtOH, 12 h (RT), 3 h (reflux); (iv) DAST,
benzene, THF, 2 h; (vi) CH3COOH (80%), 15 min, reflux.

This solid-phase strategy allowed the synthesis of FLT in a short time when
compared to the solution-phase approaches. The synthesis was accomplished without
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the need for purification of intermediates. The intermediates and the final compound
remained trapped on the resin, which facilitated the separation of any unreacted
reagent by washing and filtration. The solid-phase method allowed facile isolation and
recovery of the final product.

Reported solution-phase approaches to the synthesis of FLT include a variety
of protecting groups (Herdewijn et al., 1987, Sahlberg et al., 1992, Hager et al., 1992,
Kumar et al., 2004). For example, in a parallel modified solution-phase method, (Yun
et al., 2003) 5'-hydroxyl group of thymidine was protected by 4,4'-dimethoxytrityl
group to afford 4.8. Subsequent mesylation, basic hydrolysis, fluorination, and acidic
cleavage reactions afforded FLT (4. 7). All the intermediates were purified by silica gel
column chromatography in a time consuming process.

FLT was synthesized in a higher overall yield (45% overall yield) by the solidphase method when compared to that for the solution-phase method[1 8J carried out in
parallel (19% overall yield). The successful application of the solid-phase strategy for
the synthesis of FLT provides insight for the synthesis of other 3'-substituted
nucleosides using a similar methodology.
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5.1. Abstract

Fatty

acyl-glycol

phosphate

triester

conjugates

of

3'-fluoro-2',3'-

dideoxythymidine (FLT) were prepared in three steps from the reaction of
diisopropylphoramidous dichloride with fatty acyl-substituted glycols, followed by a
coupling reaction with FLT and oxidation with tert-butyl hydroperoxide (t-BuOOH).
Additionally, a number of fatty alcohols were reacted with diisopropylphoramidous
dichloride to produce the phosphitylating intermediates, which underwent coupling
reactions with 3'-azido-2',3'-dideoxythymidine (AZT) and FLT followed by oxidation
with t-BuOOH to yield fatty alcohol phosphate triester derivatives of AZT and FLT.

5.2. Introduction

2',3'-Dideoxynucleoside analogs are used clinically against the human
immunodeficiency virus (HIV). There are numerous reasons to utilize nucleotide
prodrug strategy in order to make anti-HIV nucleosides more effective against the
virus. Bypassing the first rate-limiting phosphorylation step (Van et al., 1990),
increasing the lipophilicity, and enhancing the cellular uptake and half-life in blood
are some of them (Parang et al., 2000).

On entering the cell, the majority of anti-HIV nucleoside analogs, such as 3'fluoro-2 ',3 '-dideoxythymidine (FLT, alovudine) and 3'-azido-2 ',3 '-dideoxythyrnidine
(AZT, zidovudine), are phosphorylated to monophosphates, diphosphates, and
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triphosphates forms by host cellular kinases to show antiviral activity. Negativelycharged nucleoside monophosphates cannot be directly used because of their high
polarity and poor cellular uptake. Furthermore, they are readily dephosphorylated on
cell surfaces and in extracellular fluids by non-specific phosphohydrolases. In order to
bypass the first rate-limiting phosphorylation step in the metabolic conversion of
nucleoside analogs, numerous prodrugs of 5'-monophosphate types, such as neutral
species of phosphotriester derivatives of nucleosides have been proposed (Parang et
al., 2000, Meier et al., 2004, Rose et al., 2005, Thumann et al., 2996, Meier et al.,

2002, Meier et al., 2006, Farquhar et al., 1994, Jochum et al., 2005) with the hope that
these

prodrugs

would

release

the

corresponding nucleoside-monophosphates

intracellularly. The phosphotriesters must have acceptable stability prior to cellular
uptake and selective intracellular biotransformation of the active species. Furthermore,
extensive efforts have been carried out to synthesize lipophilic prodrugs of anti-HIV
nucleosides by esterification strategy (Parang et al., 2000, Parang et al., 1998, Parang
et al., 1998, Parang et al., 1998). Both strategies have not yet provided an anti-HIV
prodrug agent with a clear-cut therapeutic advantage for clinical use. The major
challenge of developing nucleotide prodrugs has been in the selection of a suitable
phosphate-masking group. By judicious choice of the alcohols used in triester
formation, it may be possible to improve cellular uptake and to direct intracellular
hydrolysis to nucleoside monophosphates. Thus, further research to identify prodrugs
containing both phosphotriester and lipophilic groups with distinct advantages,
relative to parent anti-HIV nucleosides is warranted.
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Herein, we report the synthesis of uncharged fatty acyl and fatty alcohol
phosphotriester derivatives of AZT and FLT (Figure 5 .1 ). The lipophilic moieties,
fatty acyls or fatty alcohols, were incorporated into the structure with the aim of

improving interaction with membrane bilayers and cellular uptake of anti-HIV
nucleoside phosphotriester derivatives and to release nucleoside monophosphates
intracellularly, bypassing the first phosphorylation step (Figure 5.2).

Figure 5.1. Fatty acyl and fatty alcohol phosphotriester derivatives of AZT and FLT.
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5.3. Materials and Methods
5.3.1. Materials

Alovudine (FLT) was synthesized according to the previously reported method
(Herdewijn et al., 1987). Zidovudine (AZT) was purchased from Euro Asia Tran
Continental (Bombay, India). 12-Bromododecanoic acid and 5-ethyl-lH-tetrazole
were purchased from Sigma Aldrich. All the other chemicals including myristoyl
chloride, glycol, tert-butyl hydroperoxide, diisopropylphosphoramidous dichloride,
sodium hydride, sodium iodide, ethanethiol, dimethylamino pyridine (DMAP), 12crown-4-ether, N,N-dimethylformamide (DMF), benzene and tetrahydrofuran (THF)
were purchased from Fisher scientific. The products were purified on a
Phenomenex®Jupiter 10 µm ODS reversed-phase column (2.1

x

25 cm) with Hitachi

HPLC L-715 0 system with diode array detector. The chemical structures of final
desalted products were characterized by nuclear magnetic resonance spectrometry ( 1H
31

NMR,

De

NMR,

P NMR) determined on a Bruker DPX NMR spectrometer (400

MHz).

De

NMR spectra are fully decoupled. Chemical shifts are reported in parts per

millions (ppm). The chemical structures of final products were confirmed by a highresolution PE Biosystems Mariner API 2000 time-of-flight electrospray mass
spectrometer.
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5.3.2. Chemistry
2-Hydroxyethyl tetradecanoate (5.1) and 2-hydroxyethyl 12-bromododecanoate
(5.2). A mixture of ethylene glycol (1 mL, 18 rnmol) and fatty acyl chloride (4 rnmol)
were refluxed for 3 h in the presence of DMAP (600 mg, 5 rnmol) as a base in dry
benzene (10 mL) and DMF (10 mL). The reaction mixture was cooled down to room
temperature and neutralized with sodium bicarbonate solution (5%). The organic layer
was separated and the aqueous layer was extracted with DCM (3 x 100 mL). The
organic layers were mixed together, dried with anhydrous sodium sulfate, and
evaporated under vacuum. Crude products were purified by using silica gel column
chromatography and hexane and dichloromethane (50:50) as eluting solvents to afford

5.1 and 5.2 in 70% yield.

2-Hydroxyethyl tetradecanoate (5.1). 1H NMR (400 MHz, CDCh, 8 ppm): 8 4.16 (t,

J= 4.8 Hz, 2H, COOCH2 ), 3.76 (t, J= 4.8 Hz, 2H, CH20H), 2.78-2.89 (br s, lH, OH),
2.30 (t, J= 7.6 Hz, 2H, CH2 COO), 1.59-1.70 (m, 2H, CH2CH 2 COO), 1.20-1.41 (br m,
20H, methylene envelope), 0.84 (t, J= 6.8 Hz, 3H, CH3);

13

C NMR (CDCh, 100 MHz,

8 ppm): 174.72 (COO), 66.20 (COOCH2), 61.35 (CH20H), 34.54 (CH2COO), 32.23,
30.06, 30.03, 29.94, 29.84, 29.74, 29.66, 29.52, 25.27, 23.06 (methylene carbons),
14.48 (CH3); HR-MS (ESI-TOF) (mJz): C 16H3203: calcd. 272.2351; found 273.6315

[M+Ht.

2-Hydroxyethyl 12-bromododecanoate (5.2). 1H NMR (400 MHz, CDC1 3, 8 ppm): 8
4.16 (t, J= 4.7 Hz, 2H, COOCH2), 3.78 (t, J= 4.7 Hz, 2H, CH20H), 3.37 (t, J= 6.9
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Hz, 2H, CH2Br), 2.40-2.52 (br s, lH, OH), 2.31 (t, J= 7.7 Hz, 2H, CH2COO), 1.781.87 (m, 2H, BrCH2CH2), 1.53-1.65 (m, 2H, CH2CH2CO), 1.35-1.45 (m, 2H,
BrCH2CH2CH2.), 1.20-1.35 (please give a range) (br m, 12H, methylene envelope);

nc

NMR (CDCh, 100 MHz,

o ppm):

174.36 (COO), 65.96 (COOCH2), 61.20

(CH20H), 34.25 (CH2COO, CH2Br), 32.90, 29.52, 29.47, 29.31, 29.19, 28.82, 28.23,
24.97 (methylene carbons); HR-MS (ESI-TOF) (m/z): C 14 H27 Br03: calcd. 322.1144;
found 323.5677 [M +Ht.

2-Hydroxyethyl 12-iodododecanoate (5.3). Compound 5.2 (1.7 g, 5.3 mmol) was

mixed with sodium iodide (1.6 g, 10.7 mmol) in dry acetone (100 mL) and the
reaction mixture was stirred for 18 h at room temperature. After filtration, water (250
rnL) was added to the filtrate and extracted with dichloromethane (3 x 100 mL). The

organic layers were mixed together, dried with anhydrous sodium sulfate,
concentrated under vacuum, and dried overnight to give 5.2 (95% yield).
1H NMR (400 MHz, CDCh,

o ppm): o 4.20-4.27 (m, 2H, COOCH2), 3.80-3.86 (m,

2H, CH20H), 3.17 (t, J= 7.0 Hz, 2H, CH2I), 2.33 (t, J= 7.5 Hz, 2H, CH2COO), 2.152.30 (br s, lH, OH), 1.74-1.84 (m, 2H, ICH2CH2), 1.58-1.69 (m, 2H, CH2CH 2CO),
1.35-1.42 (m, 2H, ICH2CH2CH2), 1.22-1.35 (br m, 12H, methylene protons);

NMR (CDCh, 100 MHz,

oppm):

13

C

174.17 (COO), 65.82 (COOCH2), 61.17 (CH20H),

34.10 (CH2COO), 33.46, 30.41, 29.36, 29.29, 29.14, 29.03, 28.43, 24.82 (methylene
carbons), 7.31 (CH2I); HR-MS (ESI-TOF) (m/z): C14H21I03: calcd. 370.l 005; found
393.0269 [M +Nat.
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2-Hydroxyethyl 12-azidododecanoate (5.4). Compound 5.3 (1.8 g, 4.9 mmol) was

mixed with sodium azide (1g,15.4 mmol) and 12-crown-4 ether (2.6 mL, 15.9 mmol)
in DMF (100 mL). The reaction mixture was stirred overnight at room temperature.
The solvent was evaporated using reduced pressure and the crude product was purified
using silica gel column chromatography and hexane and dichloromethane (50:50) as
eluting solvents to afford 5.4 (55% yield).
1H NMR (400 MHz, CDCh,

oppm): o4.18 (t, J= 4.7 Hz, 2H, COOCH2), 3.79 (t, J=

4.7 Hz, 2H, CH20H), 3.23 (t, J = 7.0 Hz, 2H, CH2N 3 ), 2.23 (t, J = 7.7 Hz, 2H,
CH2COO), 1.50-1.64 (m, 4H, NJCH2CH2, CH2CH2CO), 1.15-1.45 (br m, 14H,
methylene envelope);

13

C NMR (CDCh, 100 MHz,

o ppm):

174.17 (COO), 65.77

(COOCI-h), 61.05 (CfhOH), 51.34 (CH2N3), 34.05 (CH2COO), 29.31, 29.26, 29.11,
28.98, 28.70, 26.57, 24.77 (methylene carbons); HR-MS (ESI-TOF) (m/z):
C14H21N303: calcd. 285.2052; found 308.1454 [M +Nat.

2-Hydroxyethyl

13-thiapentadecanoate

(5.5).

2-Hydroxyethyl-12-

bromododecanoate (5.2) (2.0 g, 6.2 mmol) was added to a mixture containing sodium
hydride (200 mg, 8.3 mmol) and ethanethiol (470 mg, 7.6 mmol) in dry THF (50 mL).
The mixture was stirred at room temperature for 1 h and then refluxed for 16 h. The
reaction mixture was cooled down to the room temperature and water (200 mL) was
added to it. The solution was extracted with dichloromethane (3 x 100 mL). The
organic layer was separated, dried with anhydrous sodium sulfate, and evaporated
under vacuum.

The crude product was purified using silica gel column
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chromatography and hexane and dichloromethane (50:50) as eluting solvents to afford

5.5 (60% yield).
'H NMR (400 MHz, CDCh, 8 ppm): 8 4.16 (t, J= 4.7 Hz, 2H, COOCH2), 3.78 (t, J=
4.7 Hz, 2H, CH20H), 2.56-2.64 (br s, lH, OH), 2.40-2.56 (m, 4H, CH2SCH2), 2.31 (t,

J= 7.7 Hz, 2H, CH2COO), 1.50-1.65 (m, 4H, SCH2CH2, and CH2CH2CO), 1.14-1.40
(br m, 17H, methylene envelope, CH3CH2S);

13

C NMR (CDCh, 100 MHz, 8 ppm):

174.66 (COO), 66.24 (COOCH2), 61.42 (CH20H), 34.54 (CH2COO), 31.90, 29.99,
29.66, 29.78, 29.61, 29.49, 29.31, 26.42, 25.26 (methylene carbons), 15.19 (CH3);
HR-MS (ESI-TOF) (m/z): C16H3203S: calcd. 304.2072; found 327.2986 [M +Nat,
343.2708 [M +Kt.

Synthesis

of

fatty

acyl-glycol

ester

conjugates

5.14-5.17.

Diisopropylphosphoramidous dichloride (0.5 equivalent, 300 mg, 1.5 mmol) and
DMAP (1 equiv., 360 mg, 3 mmol) were dissolved in THF (100 mL) and cooled down
to -80 °C. Solution of 5.1-5.5 (800 mg, 3 mmol) in THF (20 mL) was added dropwise
to the reaction mixture with constant stirring during 1 h period. The reaction mixture
was continued to stir for 3 h to yield intermediates 5.6-5.9. DMAP hydrochloride was
filtered out and FLT (0.5 equiv, 350 mg, 1.5 mmol) and 5-ethyl-lH-tetrazole (585 mg,
4.5 rnmol) were added to the reaction mixture and stirred overnight to produce 5.105.13. t-BuOOH in decane (5-6 M) (450 µL, 4.5 mmol) was added to the reaction

mixture and stirring was continued for 4 h. To the reaction mixture was added water
(100 rnL) and the solution extracted with dichloromethane (3 x 50 mL). The organic
layer was dried with anhydrous sodium sulfate and evaporated under vacuum. The
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crude products were purified using reverse-phase HPLC and acetonitrile (100%) as the
eluting solvent to afford 5.14-5.17 in 7-17% overall yield (70-180 mg).

3 '-Fluoro-2 ',3 '-dideoxythymidine-5 '-[(bis(2-tetradecanoylglycolyl] phosphate
(5.14). 1H NMR (400 MHz, CDCh,

o ppm): o 8.27 (s,

lH, N-H), 7.41 (s, lH, H-6),

6.42 (dd, J= 9.2 and 5.4 Hz, lH, H-1'), 5.30 (dd, J= 53.2 and 4.9 Hz, lH, H-3'), 4.40
(dd, J = 26.6 and 2.5 Hz, lH, H-4'), 4.25-4.34 (br m, lOH, H-5' and H-5",
COOCH2CH20), 2.53-2.67 (m, lH, H-2'), 2.30-2.38 (m, 4H, CH2CO), 2.09-2.28 (m,

lH, H-2"), 1.95 (s, 3H, 5-CH3), 1.56-1.66 (m, 4H, CH2CH2 CO), 1.21-1.35 (br m, 40H,
methylene envelope), 0.89 (t, J = 6.80 Hz, 3H, CH3);

13

C NMR (CDCh, 100 MHz,

o

ppm): 173.38 (COO), 163.08 (C-4 C=O), 152.99 (C-2 C=O), 135.01 (C-6), 112.20 (C5), 93.35 (J = 178.6 Hz, C-3'), 84.93 (C-1 '), 82.71 (J = 27.1 Hz, C-4'), 66.84 (CH20P), 66.07 (COOCH2), 62.44 (C-5'), 37.93 (J = 20.7 Hz, C-2'), 33.99 (CH2COO),
31.91, 29.65, 29.61, 29.47, 29.35, 29.28, 29.13, 24.80, 22.69 (methylene carbons),
14.12 (CH3), 12.41 (5-CH3 );
standard, 162 MHz,

31

P NMR (CDCb, HJP04 85% in water as external

o ppm): 4.79; HR-MS (ESI-TOF) (m/z): C42H14FN20 11 P: calcd.

832.5014; found 855.4673 [M +Nat.

3'-Fluoro-2',3'-dideoxythymidine-5'-[(bis(2-(12bromododecanoyl)glycolyl)]phosphate (5.15). 1H NMR (400 MHz, CDCh,

o 8.30 (s,
(dd, J

oppm):

lH, N-H), 7.41 (s, lH, H-6), 6.42 (dd, J = 9.2 and 5.4 Hz, lH, H-1 '), 5.25

= 53.4 and 5.1 Hz, lH, H-3'), 4.40 (dd, J = 26.6 and 2.5 Hz, lH, H-4'), 4.25-

4.33 (br m, IOH, H-5', H-5", and COOCH2CH20), 3.54 (t, J = 6.8 Hz, 2H, BrCH2),
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3.42 (t, J= 6.8 Hz, 2H, BreH2), 2.55-2.67 (m, lH, H-2'), 2.29-2.38 (m, 4H, eH2eO),
2.09-2.28 (m, lH, H-2"), 1.95 (s, 3H, 5-eH3), 1.73-1.89 (m, 4H, CH2eH2Br), 1.571.67 (m, 4H, eH2eH2CO), 1.36-1.47 (m, 4H, eH2eH2CH2eO), 1.20-1.35 (br m, 24H,
methylene envelope); De NMR (eDeh, 100 MHz, 8 ppm): 173.81(COO),163.79 (e4 C=O), 150.61 (e-2 C=O), 135.44 (e-6), 112.20 (e-5), 93.79 (J = 178.0 Hz, e-3'),
85.33 (e-1'), 83.07 (J= 26.8 and 7.6 Hz, e-4'), 67.30 (J= 10.9 and 6.0 Hz, CH2-0P),
66.54 (eOOCH2), 62.90 (J= 6.8 Hz, e-5'), 45.63 (CH2Br), 38.32 (J= 21.2 Hz, e-2'),
34.45 (CH2eOO), 33.21, 30.10, 29.86, 29.79, 29.66, 29.50, 29.27, 29.15, 28.55, 27.26,
27.19 (methylene carbons), 12.85 (5-CH3 );
external

standard,

162

MHz,

8

31

P NMR (eDel3, H 3P0 4 85% in water as

ppm):

4.78;

HR-MS

(ESI-TOF)

(m/z):

C3 sH64Br2FN20IIP: calcd. 932.2599; found 955.4436 [M + Nat, 976.3518, [M +
2Na(

3'-Fluoro-2',3'-dideoxythymidine-5'-[(bis(2-(12azidododecanoyl)glycolyl)]phosphate (5.16). 1H NMR (400 MHz, eDeh, 8 ppm): 8

9.37 (s, lH, N-H), 7.39 (s, lH, H-6), 6.41 (dd, J= 9.2 and 5.4 Hz, lH, H-1'), 5.23 (dd,
J= 53.4 and 5.1 Hz, lH, H-3'), 4.38 (dd, J= 26.5 and 2.5 Hz, lH, H-4'), 4.22-4.29 (br

m, IOH, H-5', H-5", and eooeH2CH20), 3.23 (t, J= 7.0 Hz, 4H, N3eH2), 2.53-2.70
(m, lH, H-2'), 2.29-2.35 (m, 4H, eH2eO), 2.10-2.30 (m, lH, H-2"), 1.92 (s, 3H, 5CH3), 1.52-1.68 (m, 8H, N 3CH 2eH2 ), 1.20-1.45 (br m, 28H, methylene envelope); De

NMR (eDeh, 100 MHz, 8 ppm): 173.80 (COO), 164.06 (e-4 C=O), 150.80 (e-2
C=O), 135.41(C-6),112.20 (e-5), 93.80 (J= 178.4 Hz, e-3'), 85 .31 (e-1'), 83.55 (J

= 26.8 and 7.9 Hz, C-4'), 67.27 (J = 5.7 and 10.9 Hz, CHi-OP), 66.52 (COOCH2),
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62.91(J=5.0 Hz, C-5'), 51.85 (ClfiN3), 38.31(J=20.9 Hz, C-2'), 34.36 (Cl-I2COO),

29.78, 29.72, 29.64, 29.62, 29.51, 29.21, 27.01, 25.18 (methylene carbons), 12.83 (5CH3); 31 P NMR (CDCh, H3P04 85% in water as external standard, 162 MHz, 8 ppm):
2.81; HR-MS (ESI-TOF) (m/z): C3sH64FNs011P: _calcd. 858.4416; found 859.3552 [M

+Ht, 881.3245 [M +Nat, 897.2941 [M +Kt.

3'-Fluoro-2',3'-dideoxythymidine-5'-[(bis(2-(12thioethyldodecanoyl)glycolyl)]phosphate (5.17). 1H NMR (400 MHz, CDCh,

o

ppm): 8 8.65 (s, lH, N-H), 7.41 (s, lH, H-6), 6.42 (dd, J= 9.2 and 5.4 Hz, lH, H-1'),
5.25 (dd, J = 53.4 and 5.1 Hz, lH, H-3'), 4.40 (dd, J = 26.5 and 2.5 Hz, lH, H-4'),
4.25-4.35 (br m, lOH, H-5', H-5", and COOCH2CH20), 2.59-2.75 (m, lH, H-2'), 2.492.59 (m, 8H, CH2SCH2), 2.29-2.38 (m, 4H, CH2CO), 2.09-2.29 (m, lH, H-2"), 1.95 (s,
3H, 5-CH3), 1.53-1.72 (m, 8H, CH2CH2S, CH2CH2CO), 1.20-1.39 (br m, 34H,
methylene envelope, CH3CH2S);

13

C NMR (CDCh, 100 MHz,

oppm): 173.80 (COO),

163.72 (C-4 C=O), 150.55 (C-2 C=O), 135.45 (C-6), 112.19 (C-5), 93.77 (J = 178.6

Hz, C-3'), 85.35 (C-1'), 83.07 (J= 26.8 and 7.8 Hz, C-4'), 67.28 (J= 11.1 and 5.6 Hz,
CH2-0P), 66.58 (COOCI-12), 62.90 (J= 5.1 Hz, C-5'), 38.34 (J= 21.1 Hz, C-2'), 34.40
(CH2COO), 32.33, 32.06, 30.13, 30.05, 29.91, 29.84, 29.78, 29.65, 29.53, 29.36,
26.31, 26.31, 25.20 (methylene carbons), 15.23 (Cl-13), 12.84 (5-Cl-13); 31 P NMR
(CDCh, H3P0 4 85% in water as external standard, 162 MHz, 8 ppm): 2.82; HR-MS
(ESI-TOF) (m/z): C42H 74FN20 11 PS 2: calcd. 896.4456; found 897.3566 [M +Ht.
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Synthesis of fatty alcohol phosphotriester derivatives of AZT and FLT (5.235.25). Diisopropylphosphoramidous dichloride (0.5 equiv., 300 mg, 1.5 mrnol) and
DMAP (1 equiv., 360 mg, 3 mmol) were dissolved in THF (100 mL). The reaction
mixture was cooled down to -80 °C. Solution of alcohols (800 mg, 3 mmol) in THF
(20 mL) was added dropwise with constant stirring during 1 h period. The reaction
mixture was continued to stir for 3 h to afford 5.18-5.19. DMAP hydrochloride was
filtered out and FLT or AZT (1.5 mmol) and 5-ethyl-lH-tetrazole (585 mg, 4.5 mmol)
was added to the reaction mixture and stirred overnight to yield 5.20-5.22. t-BuOOH
in decane (5-6 M) (450 µL, 4.5 mrnol) was added to the reaction mixture and stirring
was continued for 4 h. To the reaction mixture was added water (100 rnL) and the
solution was extracted with dichloromethane (3 x 50 mL). The organic layer was dried
with anhydrous sodium sulfate and evaporated under vacuum. The crude products
were purified using reverse-phase HPLC and acetonitrile (100%) as the eluting solvent
to afford 5.23-5.25 in 6-20% overall yield (45-180 mg).

3 '-Fluoro-2 ',3 '-dideoxythymidine-5 '-bis(decanoyl)-phosphate (5.23).

1

H NMR

(400 MHz, CDCh, 5 ppm): 5 9.71 (s, lH, N-H), 7.44 (s, lH, H-6), 6.44 (dd, J = 9.2
and 5.4 Hz, lH, H-1'), 5.27 (dd, J= 53.2 and 4.9 Hz, lH, H-3'), 4.37 (dd, J= 26.9 and
2.4 Hz, lH, H-4'), 4.18-4.30 (m, 2H, H-5' and H-5"), 4.00-4.09 (m, 4H, CH20P), 2.512.65 (m, lH, H-2'), 1.95-2.19 (m, lH, H-2"), 1.92 (s, 3H, 5-CH3), 1.62-1.72 (m, 4H,
CH2CH2 0P), 1.17-1.38 (br m, 32H, methylene envelope), 0.85 (t, J

CH3 );

13

=

6.7 Hz, 3H,

C NMR (CDCh, 100 MHz, 5 ppm): 164.32 (C-4 C=O), 150.98 (C-2 C=O),

135.32 (C-6), 112.20 (C-5), 94.09 (J= 178.0 Hz, C-3'), 85.06 (C-1'), 83.26 (J= 27.0
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and 6.9 Hz, C-4'), 68.80 (CfhOP), 66.89 (J= 11.3 and 4.8 Hz, C-5'), 38.54 (J= 20.7
Hz, C-2'), 32.25, 30.70, 30.10, 29.87, 29.66, 29.49, 25.79, 23.05 (methylene carbons),
14.49 (CH3), 12.86 (5-CH3); 31 P NMR (CDCh, HJP0 4 85% in water as external
standard, 162 MHz, 8 ppm): 5.09. HR-MS (ESI-TOF) (nifz): C30Hs4FN201P: calcd.
604.3653 ; found 605.0470 [M +Ht, 642.9381 [M +Kt.

3 '-Fluoro-2 ',3 '-dideoxythymidine-5'-bis(l1-bromoundecanoyl)phosphate

1H NMR (400 MHz, CDCh,

o ppm): 8 8.95 (s,

(5.24):

lH, N-H), 7.45 (s, lH, H-6), 6.42 (dd,

J= 9.2 and 5.4 Hz, lH, H-1'), 5.25 (dd, J= 53.4 and 5.1 Hz, lH, H-3'), 4.35 (dd, J=

26.6 and 2.5 Hz, lH, H-4'), 4.18-4.28 (m, 2H, H-5' and H-5"), 4.00-4.10 (m, 4H,
CH20P), 3.35 (t, J= 6.8 Hz, 4H, BrCH2 ), 2.52-2.65 (m, lH, H-2'), 2.01-2.19 (m, lH,

H-2"), 1.92 (s, 3H, 5-CH3), 1.80-1.89 (m, 4H, BrCH2CH2), 1.63-1.71 (m, 4H,
CH2CH20P), 1.33-1.44 (m, 4H, CH2CH2CH20P), 1.21-1.33 (br m, 24H, methylene
envelope);

13

C NMR (CDCh, 100 MHz, 8 ppm): 163.89 (C-4 C=O), 150.69 (C-2

C=O), 135.38 (C-6), 112.16 (C-5), 94.97 (J= 178.0 Hz, C-3'), 85.08 (C-1'), 83.56 (J=
27.0 Hz, C-4'), 68.79 (CH20P), 63.85 (C-5'), 53.43 (CH2Br), 38.56 (J = 20.0 Hz, C2'), 34.51, 33.18, 30.73, 30.66, 30.09, 29.95, 29.83, 29.80, 29.77, 29.48, 29.12, 28.53,
26.15, 25.80 (methylene carbons), 12.87 (5-CH3); 31 P NMR (CDC13, H3P0 4 85% in
water as external standard, 162 MHz,

o ppm):

5.03. HR-MS (ESI-TOF) (m/z):

C32Hs6Br2FN20 7P: calcd. 788.2176; found 789.9278 [M +Ht.

3'-Azido-2',3'-dideoxythymidine-5'-bis(decanoyl) phosphate (5.25): 1H NMR (400

MHz, CDCh, 8 ppm): 8 9.92 (s, lH, N-H), 7.39 (s, lH, H-6), 6.20 (t, J= 6.6 Hz, lH,
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H-1 ), 4.26-4.33 (m, lH, H-3), 4.15-4.28 (m, 2H, H-5' and H-5"), 3.95-4.05 (m, 5H,

cH20P, H-4'), 2.34-2.42 (m, lH, H-2'), 2.22-2.29 (m, lH, H-2"), 1.87 (s, 3H, 5-CH3),
1.55-1.68 (m, 4H, CH2CH20P), 1.10-1.33 (br m, 40H, methylene envelope), 0.80 (t, J
== 6.7 Hz, 3H, CH3);

13

C NMR (CDCb, 100 MHz, 8 ppm): 163.82 (C-4 C=O), 150.31

(C-2 C=O), 134.96 (C-6), 111.31 (C-5), 84.45 (C-1 '), 82.14 (C-4'), 66.84 (CH 20P),
59.98 (C-5'), 52.71 (C-3'), 37.33 (C-2'), 31.65, 30.11, 30.05, 29.47, 29.30, 29.15,
29.06, 28.90, 25.20, 22.45 (methylene carbons), 13.90 (CH3), 12.28 (5-CH3). 31 P
NMR (CDCb, H3P0 4 85% in water as external standard, 162 MHz, 8 ppm): 5.08; HRMS (ESI-TOF) (m/z): C30Hs4Ns01P: calcd. 627.3761; found 628.3108 [M +Ht.

5.3.3. Anti-HIV assays
Anti-HIV activities of the compounds were evaluated according to the
previously reported procedure (Krebs et al., 1999). In summary, HeLa (Human
cervical carcinoma: ATCC CCL-2.1) cell line was used to measure inactivation of
both cell-free virus preparations and virus-infected cell preparations. Cells were plated
in culture plates 24 hrs prior to each experiment. Cell-free viral preparations of HIV-1
strains IIIB (lymphocytotropic strain) and BaL (monocytotropic strain) were used for
cell-free assay. For cell-associated assay, SulTl cells were infected with IIIB virus 5
days prior to the experiment. Cell-free virus and virus-infected cells were mixed with
different compounds and diluted to make different concentrations. The mixture was
further diluted with the buffer and added to the HeLa cells. The cells were incubated at
37°C for 48 h, stained for P-galctosidease expression and compared with P-
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galctosidease expression from the

~-gal-positive

cells in absence of any microbicidal

compound to get ICso values.

5.4. Results and Discussion

In the first class of compounds, two identical fatty acids were linked through a

glycol linker to a phosphate group, which was attached to 5'-0-position of FLT to
afford bis(fatty acyl-glycol)phosphate triester derivatives. The selection of fatty acids
was based on the previously reported moderate anti-HN activities of 12bromododecanoic acid, 12-azidododecanoic acid, and 12-thioethydodecanoic acid
(Parang et al., 1997). In the second class of compounds, fatty alcohols and
nucleosides, FLT and AZT, were directly attached to phosphotriester group.

The synthetic procedures used for the synthesis of phosphotriester derivatives
of nucleosides were based on P(III) chemistry using phosphoramidite approach and
consisted of three steps: (i) the derivatization of diisopropylphosphoramidous
dichloride with fatty-acyl-glycols or fatty alcohols to afford phosphoramidites, (ii) the
reaction of resulting phophoramidates with FLT or AZT in the presence of ethyl-lHtetrazole, and (iii) oxidation of P(III) to P(V).

For the synthesis of compounds in the first class, fatty acid-glycol ester
conjugates 5.1-5.5 (Scheme 5.1) were prepared. 2-Hydroxyethyl tetradecanoate (5.1)
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and 2-hydroxyethyl 12-bromododecanoate (5.2) were synthesized (70% yield) from
the treatment of the corresponding fatty acyl chloride (4 mmol) and ethylene glycol
(18 mmol) in the presence of dimethylaminopyridine (DMAP) (5 mmol) in benzene
and DMF (Scheme 5.1).

Ryo~

+

OH

0
5.1 R
5.2 R

Nal, acetone ..

= CH3(CH2)1r
= Br(CH 2)w

1-(CH2)11yO~OH
0

5.2

j

j

c,H,SH' Na H, TH F

5.5

5.3
NaN,. 12-crown-4 ether, DM F

5.4

Scheme 5.1. Synthesis of fatty acid-glycol ester conjugates 5.1-5.5.

2-Hydroxyethyl 12-bromododecanoate (5.2) was used for the synthesis of 2hydroxyethyl 12-azidododecanoate (5.4) and 2-hydroxyethyl 13-thiapenatadecanoate
(5.5). Bromosubstituted ester conjugate 5.2 (5.3 mmol) was treated first with sodium

iodide (10.7 mmol) in acetone to yield the corresponding iodosubstituted glycol ester
5.3 (95%). Compound 5.3 (4.9 mmol) was reacted with sodium azide (15.4 mmol) in

the presence of 12-crown-4 ether (15.9 mmol) in DMF to yield 5.4 in 55% yield.
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similarly, nucleopbilic reaction of ethanethiol (7.6 mmol) with 5.2 (6.2 mmol) in the
presence of sodium hydride (8.3 mmol) afforded 12-tbioethyl substituted analog 5.5 in
60% yield (Scheme 5.1).

Scheme 5.2 outlines the synthesis of bis(fatty acyl-glycol)phosphotriester
derivatives of FLT (5.14-5.17 using P(III) chemistry. In general, fatty acyl-glycol ester
conjugates 5.1-5.5 (3 mmol) were treated in THF with diisopropylphosphoramidous
dichloride (1.5 mmol) in the presence of DMAP (3 mmol) at -80 °C to afford
intermediate bis(fatty acyl-glycol) diisopropyl phosphoramidite conjugates (5.6-5.9).
Low temperature proved to be important for the success of this coupling reaction as
shown by the failure of the reaction of 5.1 with diisopropylphosphoramidous
dichloride in the presence of pyridine at room temperature. The intermediates 5.6-5.9
should be used immediately in the next reaction without purification because of the
activity of the phosphorous in trivalent form in these compounds. Subsequent
conversion of phosphoramidite intermediates to phosphotriesters was accomplished by
treatment with FLT (1.5 mmol) in presence of 5-ethyl-lH-tetrazole (4.5 mmol)
followed by in situ oxidation with tert-butyl hydroperoxide (t-BuOOH, 4.5 mmol) to
obtain bis(fatty acyl-glycol)phosphotriester derivatives of FLT (5.14-5.17). The
chemical structures of 5.14-5.17 were determined by 1H NMR,
and high-resolution ESI mass spectrometry (Table 5.1).
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13

C NMR,

31

p NMR,

Table 5.1. The physicochemical characteristics and anti-HIV activities of compounds
5.14-5.17 and 5.23-5.25.
Compd.
No.

31pNMR.

5.14

4.79

5.15

4.78

955.4436

5.16

HR-MS (ESI-TOF)

.t\rlti-HIVbICso
(uM)

855.4673 [M +Na]

>100

6.3

tMM+2Na].
+ NaJ\_976.3518,

63

7.7

2.81

859.3552 [M +Ht, 881.3245
[M +Nat, 897.2941 [M +Kt

76

6.5

5.17

2.82

897.3566 [M +Ht

87

12.5

5.23

5.09

605.0470 tM + ~r· 642.9381
M+KT

>100

14.1

5.24

5.03

789.9278 [M +Ht

33

7.0

5.25

5.08

628.3108 [M +Ht

>100

19.8

(8, ppmt

Overall
Yield(%)

"The spectra were measured on a 400 MHz spectrometer using CDCh as the solvent (H3P0 4 85% in
water as external standard);

bIC50 : 50% inhibitory concentration.
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Rl(O~OH

DMAP, THF
-80 °C

+

0
5.1
5.2
5.4
5.5

R = CH3(CH2)1 r
R = Br(CH2)11R =N3-(CH2)11R =C2Hs-S-(CHv11-

FLT

t-BuOOH

_

5-ethyl-1 H-tetrazole

5.10
5.11
5.12
5.13

5.14
5.15
5.16
5.17

R = CH3(CHv1r
R = Br(CHv11R = N3-(CHi) 11 R = C2Hs-S-(CH2)11-

R = CH3(CH2)1r
R = Br(CHvw
R = N3 -(CHi} 11 R = C2H5-S-(CH2)11-

Scheme 5.2. Synthesis of fatty acyl-glycol ester conjugates 5.14-5.17.

For the synthesis of fatty alcohol phosphotriester derivatives of the
nucleosides, AZT was first attached to bis(diisopropyl-amino)chlorophosphine in the
presence of pyridine. However, the intermediate was not stable during purification by
silica gel column chromatography. Alternatively, the synthesis of fatty alcohol
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phosphotriester derivatives of AZT and FLT (5.20-5.22) was accomplished by the
reaction

of

dialkoxy

substituted

phosphitylating

reagents,

diisopropylamino

dialkoxyphosphine, with AZT and FLT in the presence of 5-ethyl-lH-tetrazole in THF
(Scheme 5.3). First dialkoxy substituted phosphitylating reagents were synthesized
using diisopropylphosphoramidous dichloride and different fatty alcohols (i.e.,
decanol and 11-bromoundecanol). Solution of alcohols (3 mmol) in THF (20 mL) was
added to a mixture of diisopropylphosphoramidous dichloride (1.5 mmol) and DMAP
(3 mmol) in THF (100 mL) at -80 °C to afford 5.18 and 5.19. FLT or AZT (1.5 mrnol)
and 5-ethyl-lH-tetrazole (4.5 mmol) were added to the reaction mixture to yield 5.205.22. Oxidation of phosphite triesters 5.20-5.22 to phosphate triesters was
accomplished with t-BuOOH (4.5 mmol) to afford 5.23-5.25. The chemical structures
of 5.23-5.25 were determined by 1H NMR,

13

ESI mass spectrometry (Table 5.1 ).
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C NMR,

31

P NMR, and high-resolution

DMAP, THF

-80 °C

5.18 R1 = CH3
5.19 R1 Br-CH2

=

0

'{NH

+

HO'd

NAO
5-ethyl-1 H-tetrazole

R2

t-BuOOH ..

=
=

=
=

5.23 R 1 CH3
R2 F
5.24 R1 = Br-CH2 R2 = F
R2 N3
5.25 R 1 CH3

Scheme 5.3. Synthesis of fatty alcohol phosphotriester derivatives of AZT and FLT
(5.23-5.25).

Using a single-round infection assay (Krebs et al., 1999) with HIV-1 IIIB and
transformed HeLa cells expressing HIV receptors (CD4) and coreceptors (CXCR4 and
CCR5), the newly synthesized triester derivatives showed only modest antiviral
activity, significantly lower than that of their parent nucleosides, AZT and FLT (IC 50=
10 and 0.8 µM, respectively).
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In summary, the results presented herein show that the synthesis of different

classes of lipophilic phosphate triesters of FLT and AZT can be successfully
accomplished by using P(III) chemistry. The extension of this methodology should
prove to be useful for the development of lipophilic phosphotriester prodrugs of other
nucleosides. The premature hydrolysis of the phosphate-masking group bond in the
extracellular medium, however, may have yielded a negatively-charged diester with
low cellular uptake and reduced antiviral potency. The phosphotriesters must have
acceptable stability in cell culture prior to cellular uptake and selective intracellular
transformation of the active species. We were not able to determine the stability of
compounds because of their extremely low water solubility. The extracellular
hydrolysis of phosphotriester derivatives of nucleosides has been previously reported.
For example, McGuigan et al. (1990 and 1994) reported that some of dialkyl and
diaryl phosphotriester derivatives of AZT were inactive because of the rapid in vitro
hydrolysis to release the nucleotide extracellularly. The utility of phosphotriester
derivatives of nucleosides will be enhanced by a clearer understanding of the
mechanisms pertaining to their bioconversion, uptake, and cellular incorporation.

212

5.5. References
Farquhar, D., Khan, S., Srivastva, D. N., Saunders, P. P. Synthesis and Antitumor
Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate
(FdUMP): A Strategy To Introduce Nucleotides into Cells. J Med Chem., 1994, 37,
3902- 3909.
Herdewijn, P., Balzarini, J., De Clercq E., Pauwels, R., Baba, M., Broder, S.,
Vanderhaeghe, H. 3'-Substituted 2',3'-dideoxynucleoide analogues as potential antiHIV (HTLV-IWLAV) agents. J Med Chem., 1987, 30, 1270-1278.
Jochum, A. , Schlienger, N., Egron, D., Peyrottes, S., Perigaud, C. Biolabile constructs
for pronucleotide design. J Organometallic Chem., 2005, 690, 2614-2625.
Krebs F. C., Miller, S. R., Malamud, D., Howett, M. K.; Wigdahl, B. Inactivation of
human immunodeficiency virus type 1 by nonoxynol-9, C21G, or an alkyl sulfate,
sodium dodecyl sulfate. Antiviral Res. , 1999, 43, 157-173.
McGuigan, C., Nicholls, S. R., O'Connor, T. J., Kinchington, D. Synthesis and antiHIV activity of some novel substituted dialkyl phosphate derivatives of AZT and
ddCyd. Antiviral Chem. Chemother., 1990, 1, 25-33.
McGuigan, C., Pathirana, R. N., Davis, M. P. H., Balzarini, J., De Clercq, E. Diary!
phosphate derivatives act as pro-drugs of AZT with reduced cytotoxicity compared to
the parent nucleoside. Bioorg. Med Chem. Lett., 1994, 4, 427-430.
Meier, C. CycloSal-Pronucleotides - Design of Chemical Trojan Horses Mini-Rev.
Med Chem., 2002, 2, 219-234.
Meier, C., Ruppel, M. F., Vukadinovic, D., Balzarini, J. "Lock-in"-cycloSalPronucleotides - A New Generation of Chemical Trojan Horses? Mini-rev. Med
Chem., 2004, 4,383-394.
Meier, C., Balzarini, J. Application of the cycloSal-prodrug approach for improving
the biological potential ofphosphorylated biomolecules. Antiviral Res., 2006, 71, 282292.
Parang, K., Wiebe, L. I., Knaus, E. E., Huang, J. S., Tyrrell, D. L. In Vitro AntiHepatitis B Virus Activities of 5'-0-Myristoyl Analogue Derivatives of 3 '-Fluoro2',3'-dideoxythymidine (FLT) and 3'-Azido-2',3'-dideoxythymidine (AZT). J
Pharm. Pharmaceut. Sci., 1998, 1, 107-113.
Parang, K. , Wiebe, L. I., Knaus, E. E. Novel Approaches for Designing 5'-0-Ester
Prodrugs of 3'-Azido-2'3'-dideoxythymidine (AZT). Current Med Chem., 2000, 7,
995- 1039.

213

parang, K., Knaus, E. E., Wiebe, L. I. Synthesis, in vitro anti-human
immunodeficiency virus structure-activity relationships and biological stability of 5'0-myristoyl analogue derivatives of 3'-azido-2'3'-dideoxythymidine (AZT) as
potential prodrugs. Antiviral. Chem. Chemother., 1998, 9, 311-323.
Parang, K., Knaus, E. E., Wiebe, L. I. Synthesis, In Vitro Anti-HIV Activity, and
Biological Stability of 5'-0-Myristoyl Analogue Derivatives of 3'-Fluoro-2',3'Dideoxythymidine (FLT) as Potential Bifunctional Prodrugs of FLT. Nucleosides &
Nucleotides, 1998, 17, 987-1008.
Parang, K., Wiebe, L. I., Knaus, E. E., Huang, J. S., Tyrrell, D. L., Csizmadia, F. In
vitro antiviral activities of myristic acid analogs against human immunodeficiency and
hepatitis B viruses. Antiviral Res., 1997, 34, 75-90.
Rose, J. D., Parker, W. B., Secrist III, J. A. bis(tBuSATE) Phosphotriester Prodrugs of
8-Azaguanosine and 6-Methylpurine Riboside; bis(POM) Phosphotriester Prodrugs of
2'-Deoxy-4'-Thioadenosine and Its Corresponding 9a. Anomer. Nucleoside Nucleotides
Nucleic Acids, 2005, 24, 809-813.
Thumann-Schweitzer, C., Gosselin, G., Perigaud, C., Benzaria, S., Girardet, J. L.,
Lefebvre, I., Imbach, J. L., Kim, A., Aubertin, A. M. Anti-human immunodeficiency
virus type 1 activities of dideoxynucleoside phosphotriester derivatives in primary
monocytes/macrophages. Res Viral., 1996, 147,155-163.
Van Roey, J. P., Taylor, E. W., Chu, C. K., Shinazi, R. F. Correlation of molecular
conformation and activity of reverse transcriptase inhibitors. Ann. N Y Acad Sci.,
1990, 616, 29-40.

214

Chapter 6

Synthesis, Analysis, in Vitro Characterization and in Vivo Disposition of a
Lamivudine-Dextran Conjugate for Selective Antiviral Delivery to the Liver

Krishna C. Chimalakonda, 8 Hitesh K. Agarwal,b Anil Kumar,b Keykavous
Parang, b and Reza Mehvar8

0

Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University
Health Sciences Center, 1300 Coulter, Amarillo, Texas 79106, bDepartment of
Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI,
USA, 02881.

Published in Bioconjugate Chem. (2007) _IB, 2097-2108.

215

6.1. Abstract

A liver-selective prodrug (3TCSD) of the antiviral drug lamivudine (3TC) was
developed and characterized. 3TC was coupled to dextran

(~25

kDa) using a succinate

linker and the in vitro and in vivo behavior of the conjugate were studied using newlydeveloped size-exclusion and reversed-phase analytical methods. Synthesized 3TCSD
had a purity of> 99% with a degree of substitution of 6.5 mg 3TC per 100 mg of the
conjugate. Furthermore, the developed assays were precise and accurate in the
concentration ranges of 0.125-20, 0.36-18, and 1-50 µg/mL for 3TC, 3TC succinate
(3TCS), and 3TCSD, respectively. In vitro, the conjugate slowly released 3TC in the
presence of rat liver lysosomes, whereas it was stable in the corresponding buffer. In
vivo in rats, conjugation of 3TC to dextran resulted in forty- and seven-fold decreases
in the clearance and volume of distribution of the drug, respectively. However, the
accumulation of the conjugated 3TC in the liver was fifty-fold higher than that of the
parent drug. The high accumulation of the conjugate in the liver was associated with a
gradual and sustained release of 3TC in the liver. These studies indicate the feasibility
of the synthesis of 3TC-succinate-dextran and its potential use for the selective
delivery of 3TC to the liver.

6.2. Introduction

Lamivudine

(~-L-2',3'-dideoxy-3'-thiacytidine,

3TC) is

a deoxycytidine

nucleoside analog that inhibits hepatitis B virus (HBV) replication and is used in the
treatment of chronic hepatitis B infection (Jarvis et al., 1999). In addition to the
efficacy of antiviral drugs against HBV, treatment of HBV infection is significantly
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dependent on the pharmacokinetics of these drugs, in particular their distribution and
accumulation in the liver. To be effective, 3TC needs to enter liver cells and be
phosphorylated to its active form 3TC 5'-triphosphate intracellularly before
incorporation into DNA of HBV by DNA polymerase (Shaw et al., 1999, Younger et
al., 2004). Therefore, strategies that direct the drug to its site of action (liver) may

increase the effectiveness of the drug and decrease its potential side effects · in other
non-target organs. Indeed, several studies (Bijsterbosch et al., 1996, Rensen et al.,
1996, Fiume et al., 1997, DeVrueh et al. , 2000, Tu et al., 2004, Erion et al., 2005,
Reddy et al., 2005) have attempted to target antiviral drugs to the liver for the
treatment of HBV infection.

Dextrans

are

glucose

polymers,

which

are

under

investigation

as

macromolecular carriers for delivery of drugs and other therapeutic agents, such as
proteins, after the systemic administration of the dextran-drug conjugates (Larsen et
al., 1989, Takakura et al, 1995, Mehvar, 2000, Mehvar, 2003). Additionally,
conjugates of dextrans with non-steroidal (Harboe, et al., 1989, Larsen et al., 1989) and
steroidal (McLeod et al. , 1993, McLeod et al., 1994) anti-inflammatory drugs have
been studied for local delivery of these drugs to the colon. In a series of studies
(Mehvar, 1997, Mehvar et al., 1995, Mehvar et al., 1994), we previously showed that
the plasma kinetics and tissue distribution of dextran carriers are dependent on the Mw
of the polymer. Therefore, dextrans of different Mw's may be useful for the delivery of
drugs to different tissues after the systemic administration of the conjugate.

For

example, dextrans with Mw' s of 20 kDa to 70 kDa showed a high degree of selectivity
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for the liver when liver:plasma area under the concentration-time curve (AUC) ratio
was considered (Mehvar et al., 1994). The liver selectivity of these dextrans was
attributed to their sizes, which restrict their passage through most vascular bed pores,
while allowing unrestricted passage through the substantially larger pore sizes of the
liver sinusoids (Mehvar et al., 1994, Mehvar et al., 1987).

In addition to the molecular weight, both the electric charge (Nakane et al.,

1987, Nishida et al., 1990) and chemical modification (V ansteenkiste et al. , 1991 ,
Nishikawa et al., 1993) of dextrans may affect their organ and cellular distribution.
For example, it has been reported that positively charged dextrans are taken up by the
liver more rapidly and extensively than neutral or negatively charged dextrans
(Nakane et al., 1987, Nishida et al., 1990). Additionally, whereas unmodified dextrans
distribute to both parenchymal and non-parenchymal cells of the liver (Nishikawa et
al, 1992), galactosylation or mannosylation of dextrans results in selective delivery of
the macromolecule to the parenchymal and non-parenchymal cells, respectively
(Vansteenkiste et al., 1991, Nishikawa et al., 1993). Because electrical or chemical
modifications of dextrans may alter their safety profiles (Yarnaoka et al. , 1995), we
have recently used unmodified neutral dextrans for delivery of methylprednisolone to
the liver for local immunosuppression (Mehvar et al., 2000, Zhang et al., 2001 ,
Chimalakonda et al., 2006, Chimalakonda et al., 2003). These studies showed that
after systemic administration, the conjugate selectively accumulates in the liver, where
it gradually releases the active drug, resulting in more intense and sustained
pharrnacologic effects. Collectively, the above studies suggest that both unmodified
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and glycosylated dextrans may be suitable for systemic delivery of therapeutic agents
to the liver.

The aim of the present study was to synthesize and characterize a conjugate of
3TC with dextran -25 kDa, intended for selective delivery of the anti-HBV drug to the
liver. The conjugation of 3TC to dextran was achieved through a succinate linker,
resulting in a macromolecular prodrug, potentially releasing 3TC and 3TC succinate
(3TCS). Therefore, analytical methods were also developed for quantitation of the
intact prodrug and simultaneous quantitation of its potential release products (3TC and
3TCS) in biological samples. In addition to in vitro characterization, the plasma
pharrnacokinetics and tissue disposition of the prodrug and parent drug were also
studied in rats, a species which has recently been used as a model for human HBV
infection (Wu et al., 2003 , Takahashi et al., 1995, Wu et al., 2001). To the best of our
knowledge, this is the first report of designing a macromolecular prodrug of anti-HBV
drug larnivudine for targeted delivery to the liver.

6.3. Material and Methods

6.3.1. Materials
Dextran with an average M..11 of -25 kDa (actual .Uv=23,500 Dalton) was
purchased from Dextran Products (Scarborough, Ontario, Canada). Lamivudine (3TC)
was purchased from Kemprotec (Middlesbrough, U.K.). Stavudine and kits for liver
lysosomal isolation and acid phosphatase were purchased from Sigma Chemical (St.
Louis, MO). For Chromatography, HPLC grade acetonitrile (Mallinckrodt Chromar
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HPLC) was obtained from VWR Scientific (Minneapolis, MN). All other reagents
were analytical grade and obtained through commercial sources.

6.3.2. Animals
Adult, male Sprague-Dawley rats were used in this study for in vitro blood and
liver lysosome and in vivo disposition studies as outlined in the subsequent sections.
All the procedures involving animals in this study were consistent with the "Principles
of Laboratory Animal Care" (NIH publication Vol. 25, No. 28, revised 1996) and
approved by the Texas Tech University Health Sciences Center Institutional Animal
Care and Use Committee.

6.3.3. Synthesis of 3TC-Succinate-Dextran (3TCSD) Conjugate
The complete procedure for the synthesis of 3TCSD conjugate is depicted in
Schemes 6.1 and 6.2 and described in detail below. The chemical structures of final
desalted products were characterized by nuclear magnetic resonance spectrometry
31

eH

NMR,

13

C NMR,

MHz).

13

C NMR spectra are fully decoupled. Chemical shifts are reported in parts per

P NMR) determined on a Bruker DPX NMR spectrometer (400

millions (ppm). The chemical structures of final products were confirmed by a highresolution PE Biosystems Mariner API 2000 time-of-flight electrospray mass
spectrometer.

(-)-4-N-(4,4'-Dimethoxytrityl)-5'-0-(succinate)-2',3'-dideoxy-3'-thiacytidine (6.1).
4-Dimethylaminopyridine (DMAP, 100 mg, 0.82 mmol) and succinic anhydride (290
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mg, 2.90 mmol) were added to a solution of (-)-N4 -(4,4'-dimethoxytrityl)-2',3'dideoxy-3'-thiacytidine (2.12, 770 mg, 1.45 mmol) in dry pyridine (15.0 mL).
Compound 2.12 was synthesized as described above in Chapter 2. The reaction
mixture was stirred at room temperature overnight. After completion of the reaction,
the solvent was evaporated under

red~ced

pressure and the crude compound was

purified by column chromatography over silica gel using dichloromethane/methanol
containing 1% triethylamine as the eluents to yield 6.1 (0.82 g, 90%). 1H NMR (400
MHz, DMSO-d6, 8 ppm): 8.56 (br s, lH, NH), 7.60-7.70 (d, J

=

7.8 Hz, lH, H-6),

7.14-7.24 (m, 9H, aromatic hydrogens, DMTr), 6.72-6.84 (m, 4H, aromatic hydrogens,
DMTr), 6.30-6.38 (m, lH, H-1'), 6.10 (d, J= 7.8 Hz, lH, H-5), 5.25-5.35 (m, lH, H4'), 4.22-4.34 (m, 2H, H-5' and H-5"), 3.71 (s, 6H, DMTr-OCH3), 3.58-3.63 (m, 2H,
H-2' and H-2"), 3.00-3.10 (m, 4H, CH2CH2); HR-MS (ESI-TOF) (mlz): C33H33N30sS
calcd, 631.1988; found 632.1715 [M +Ht, 654.1472 [M +Nat.

(-)-5'-0-(Succinate)-2' ,3'-dideoxy-3'-thiacytidine (3TCS, 6.2). Acetic acid (AcOH,

10 mL, 80%) was added to compound 6.1 (100 mg, 0.16 mmol). The reaction mixture
was heated at 80 °C for 30 min. The solvent was removed under reduced pressure and
the crude compound was purified by HPLC (acetonitrile/water gradient) to yield 6.2
(47 mg, 90%). 1H NMR (400 MHz, DMSO-d6, 8 ppm): 12.29 (s, lH, COOR), 9.509.80 (br s, 2H, NH 2), 7.60-7.70 (m, lH, H-6), 6.20-6.32 (m, lH, H-1'), 5.81-5.93 (m,
lH, H-5), 5.30-5.36 (m, lH, H-4'), 4.30-4.40 (m, 2H, H-5' and H-5"), 3.71-3.80 (m,
2H, H-2'), 3.00-3.200 (m, 5H, H-2" and CH2CH2); HR-MS (ESI-TOF) (mlz):
C12H1sN306S calcd, 329.0682; found 330.3316 [M +Ht, 658.3471 [2Mt.
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(-)-Dextran-5'-0-(succinate)-2' ,3 '-dideoxy-3 '-thiacytidine (3TC-succinate-dextran
conjugate, 3TCSD, 6.3). DMAP (70.0 mg, 0.57 mmol), N,N-diisopropylethylamine

(DIPEA, 100 µL, 0.61 mmol), and N,N'-diisopropylcarbodiimide (DIC) (50 µL, 0.32
mmol) were added to a solution of compound 6.1 (275.0 mg, 0.44 mmol) and dextran
20 kDa (130 mg) in dry dimethylsulfoxide (DMSO, 3.0 mL) under nitrogen
atmosphere. The reaction mixture was stirred at 40 °C for 48 h. After the completion
of reaction, the reaction mixture was cooled to room temperature and cold diethyl
ether: ethanol (45 mL, 50:50 v/v) was added. The mixture was washed twice with cold
ethanol:diethyl ether (50:50, v/v) and finally with cold ethanol:acetonitrile (70:30, v/v)
and centrifuged. The precipitate was dried under vacuum to give (-)-dextran-4-N-(4,4'dimethoxytrityl)-5'-0-(succinate)-2',3'-dideoxy-3'-thiacytidin

[4-N-(4'-

dimethoxytrityl)-larnivudine-succinate-dextran conjugate, 6.3].

Acetic acid (AcOH, 10 mL, 80%) was added to compound 6.3. The reaction
mixture was stirred at room temperature for 3 hand then heated at 80 °C for 30 min.
The solvent was removed under reduced pressure and the residue was washed three
times with cold diethyl ether:ethanol (45 mL, 50:50 v/v) and centrifuged to give 3TCsuccinate-dextran conjugate (3TCSD, 6.4). 1H NMR (400 MHz, D20, ()ppm): 7.888.04 (br s, lH, H-6), 6.25-6.35 (m, lH, H-1'), 6.05-6.15 (br s, lH, H-5), 5.41-5.50 (m,
lH, H-4'), 4.85-5.05 (m, anomeric hydrogen of dextran, H-1), 4.28-4.58 (m, 2H, H-5'
and H-5"), 3.40-4.10 (m, H-2' and H-2" of 3TC, H-2, H-3, H-4, H-5, and H6 of
dextran), 3.30-3.38 (m, 4H, CH2CH2 of succinate).
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6.3.4. Further Characterization of 3TC-Succinate-Dextran Conjugate (3TCSD,

6.4)
The purity of the powder was determined using both the size exclusion (SEC)
and reversed-phase (RPC) chromatographic methods. The degree of substitution of
3TC in 3TCSD was determined by hydrolysis of the conjugate under basic conditions.
To 1 mg of the conjugate were added 1 mL of 0.1 N NaOH and 0.6 mL of methanol.
After leaving at room temperature for 5 min, 30 min, and 24 h, 100 µL of the sample
was micropipetted into a microcentrifuge tube containing 100 µL of 0.1 M HCl. An
aliquot (50 µL) was then injected into HPLC. The concentration of the released 3TC
was determined using a reversed-phase method based on 3TC standard solutions as
described below.

6.3.4.1. High Performance Liquid Chromatography
Size-exclusion (SEC) and reversed-phase (RPC) chromatographic methods
were developed and validated for quantitation of the conjugate 3TCSD and its
potential hydrolysis products (3TC and 3TCS), respectively, in buffers or biological
samples.

6.3.4.1.1. Size-Exclusion Liquid Chromatography (SEC)
Lamivudine-succinate-dextran conjugate (3TCSD) was analyzed in nonbiological and biological (plasma and tissue) samples at ambient temperature using a
30 cm x 7.8 mm analytical, gel chromatography column (PolySep-GFC 3000;
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Phenomenex, Torrance, CA). The mobile phase consisted of water:acetonitrile:acetic
acid (75:25:0.2, v/v/v) and was pumped at a flow rate of 1.0 mL/min.

6.3.4.1.2. Reversed-Phase Liquid Chromatography (RPC)

A reversed-phase chromatographic method was developed to quantitate the
concentrations of 3TC and 3TCS in aqueous and biological samples. The separation of
3TC, 3TCS, and internal standard (stavudine, IS) was achieved on a 250 mm x 4.6 mm
Cl8 column (Microsorb-MV, Varian, Lake Forest, CA) preceded by a 5-cm guard
column. The mobile phase consisted of KH 2P04 (50 mM) :methanol:triethylamine
(90:10:0.1, v/v, pH 7.0), which was pumped at a flow rate of 1 mL/min.

6.3.4.2. HPLC System

The HPLC instrument consisted of a 510 pump (Waters; Milford, MA), a 717
plus auto sampler (Waters; Milford, MA), and a 486 UV detector (Waters) set at a
wavelength of 276 nm. The chromatographic data was managed using Empower
version 2 software. Calibration curves were constructed by plotting the peak areas of
3TCSD or peak area ratios of 3TC or 3TCS over IS against the concentration in the
sample using a weight of 1/concentration.

6.3.4.3. Sample Preparation

For the

size exclusion chromatography, to

100 µL

of plasma in

microcentrifuge tubes were added 20 µL of methanol and 20 µL of 20% (w/v)
trichloroacetic acid. After vortex mixing for 5 s, the samples were centrifuged in a
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microcentrifuge at 16,000 rpm for 5 min. A 100 µL aliquot of the supernatant was
mixed with 50 µL of 0.5 M phosphate buffer (pH 6.0), and a 75-µL aliquot was
injected into the HPLC.

To determine the concentrations of 3TCSD in the tissues by the SEC method,
tissues were homogenized in 3 volumes of water using a homogenizer at a rate of
10,000 rpm. To 100 µL of the whole homogenate in siliconized microcentrifuge tubes
were added 50 µL of 0.5 M phosphate buffer (pH 7.0) and 50 µL of cold methanol.
Samples were then briefly vortex-mixed and 40 µL of trichloroacetic acid (40%) was
added to precipitate proteins. After vortex-mixing for 5 s, the samples were
centrifuged in a microcentrifuge at 10,000 rpm for 3 min. A 100 µL aliquot of the
supernatant was mixed with 50 µL of 1 M sodium acetate, and a 75-µL aliquot was
injected into the HPLC.

The preparation of plasma samples for reversed-phase chromatography was
similar to that for the SEC method with one exception; for the reversed-phase system,
50 µL of 50 µg/mL stavudine was added as internal standard to the plasma sample
before protein precipitation.

Similarly, the tissue samples for reversed-phase

chromatography were prepared as described above for the SEC method, but without
the addition of 0.5 M phosphate buffer.
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6.3.4.4. Validation of Assays

The inter-run precision (%CV) and accuracy (%error) of the assays were
detennined from the analysis of quality control samples (n = 5) based on reported
guidelines (Shah et al., 1992). The concentrations of quality control samples were 1.0,
10, or 50 µg/mL for 3TCSD (SEC method), 0.125, 5.0, and 20 µg/mL for 3TC (RPC
method), and 0.36, 5.4, and 18 µg/mL for 3TCS (RPC method). Calibration curves for
SEC of 3TCSD contained 0, 1, 2, 5, 10, 15, 25, or 50 µg/mL of the prodrug (3TC
equivalent). For RPC, calibration curves consisted of 0.0, 0.125, 0.25, 0.5, 1.0, 2.0,
5.0, 10, or 20 µg/mL of 3TC and 0.0, 0.36; 0.72, 1.80, 3.6, 5.4, 9.0, or 18 µg/mL of
3TCS as 3TC equivalents.

To determine the recovery of 3TCSD, 3TC, and 3TCS from plasma after
protein precipitation, plasma samples (n = 5) containing 5 or 100 µg/mL 3TCSD, 5 or
50 µg/mL 3TC, or 1.8 or 18 µg/mL 3TCS were subjected to the above assays and the
peak areas were determined. The peak areas of these samples were then compared
with those containing an equal concentration of each analyte in distilled water,
injected directly into the HPLC. Similarly, the recoveries of 3TCSD and 3TC from the
liver samples (n = 5) containing 5 µg/mL 3TCSD or 0.5 µg/mL of 3TC were
determined.

226

6.3.5. In Vitro Release Characterization.
6.3.5.1. Release Characteristics in Buffers.

The prodrug (3TCSD), at a concentration equivalent to 100 µg/mL 3TC, was
dissolved in 10 rnM KH2P04 (pH 4.4) or phosphate buffer (pH 7.4). The solutions
were then incubated at 37 °C (n = 3). Samples (100 µL) were taken at 0, 3, 6, 12, and
24 hand subjected to the above HPLC methods for the quantitation of intact 3TCSD
(SEC method) and released 3TC or 3TCS (RPC method).

6.3.5.2. Release Characteristics in Rat Blood

Blood was obtained from rats by cardiac puncture. Approximately 4 ID of
heparin was added to each rnL of blood to prevent coagulation. Immediately after the
collection of blood, 3TCSD conjugate (in 10 rnM isotonic phosphate buffer at pH 7.4)
was added to produce a blood concentration of 100 µg/rnL (3TC equivalent) (n = 3).
The solution was then incubated at 37 °C. Blood samples (1 rnL) were collected at 0,
3, 6, and 12 h in heparinized microcentrifuge tubes. After centrifugation of the blood,
the plasma samples (100 µL) were subjected to the assays described above for the
determination of 3TC, 3TCS, and/or intact 3TCSD.

6.3.5.3. Release Characteristics in Rat Liver Lysosomes

Crude lysosomal fractions were prepared from the liver of untreated rats
according to the procedure described in the lysosome isolation kit (Sigma). Briefly,
the rat livers were perfused with ice-cold PBS before removal of the livers. The livers
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were then homogenized in 4 volumes of the extraction buffer, followed by differential
centrifugation for isolating the lysosomal fraction. The protein concentrations in
Iysosomal preparations were determined by Bio-Rad protein assay (Bio-Rad,
Herecules, CA, USA). The activity of acid phosphatase, a lysosomal marker, in the
preparation was tested using a commercial kit (Sigma). The specific enzyme activity
in the lysosomal fraction was >9-fold that in the liver homogenate.

For lysosomal hydrolysis studies, 3TCSD (100 µg/mL, 3TC equivalent) was
incubated at 37 °C in 50 mM acetate buffer (pH 4.0) in the presence of 5 mM reduced
glutathione and 5 mg/rnL lysosomal protein (n = 3). Samples (100 µL) were then
taken at 0, 3, 6, 9, 12, and 24 hand treated as described above before reversed-phase
and size-exclusion HPLC analysis.

6.3.6. In Vivo Disposition

A total of 42 adult male Sprague-Dawley rats were divided equally into two
groups of 21 rats each, treated with 3TCSD or 3TC. The mean± S.D. of the body
weights of rats were 241 ± 8 and 240 ± 6 g for the 3TCSD- and 3TC-injected groups,
respectively. The animals had free access to drinking water and rat chow before and
during the course of experiments.

Single iv bolus doses (5 mg/kg; 3TC equivalent) of 3TCSD or the parent drug
3TC were injected into the penile vein of the animals under isoflurane anesthesia.
Different groups of rats (n = 3/group/time point) were euthanized at 0 (before drug
administration), 5, 15, 60, 120, or 180 min following drug administration, and tissues
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(liver, spleen, kidneys, heart, lungs, and brain?) and blood (cardiac puncture) were
collected. Additionally, total urine output was collected from zero to 180 min or to 24
h for the 3TC- or D3TCS-injected group (n

=

3/group).

Immediately after excision, the tissues were rinsed in ice-cold saline solution
to remove excess blood. Afterwards, the tissues were blotted dry and kept frozen until
analysis. After centrifugation of the blood in a pre-chilled and heparin-coated
rnicrocentrifuge tube, the plasma was collected. To prevent in vitro hydrolysis of
3TCSD during storage, plasma (500 µL) was mixed with a 10% acetic acid solution
(100 µL). Plasma, tissue, and urine samples were kept frozen at - 80 °C until analysis.

6.3.7. Pharmacokinetic Analysis

Non-compartmental analysis was performed by usmg WinNonlin"'5.0.1
computer program (Pharsight Co.; Mount View, California). Terminal elimination rate
constant (/1.z) was estimated from the log-linear portion of the plasma or tissue
concentration-time courses. Area under the plasma or tissue concentration-time curve
(AUC) was estimated from the average plasma or tissue concentrations at different
time points using linear trapezoidal rule with extrapolation to infinity only for the
plasma profiles. For tissues, AUCs were not extrapolated beyond the quantifiable
samples because of uncertainty about the terminal half lives. Other estimated
pharmacokinetic parameters included: apparent total body clearance (CL), renal
clearance (CLR), volume of distribution at steady-state (V55), terminal volume of
distribution (V z), fraction of the drug excreted unchanged in urine (fe), mean residence
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time (MRT), and maxrmum observed drug concentration (Cmax). The maxunum
concentrations of 3TCSD or 3TC in plasma (Co) after the injection of the conjugate or
parent drug were estimated by the program. The concentrations of drugs in the tissues
were corrected (Mehvar et al., 1994) for the residual blood using the blood volume
fraction of different tissues.

6.3.8. Statistical Analysis

Because of destructive sampling procedure used for the collection of blood and
tissues from different animals at each time point, the composite kinetic parameter
AUC could not be obtained for individual rats (Mehvar et al., 1994). Therefore the
variance of AUC was estimated by a reported (Bailer et al., 1988, Yuan et al., 1993)
procedure based on the standard error of mean and number of samples at each time
point. The pairwise comparison of AUCs was then carried out at an a level of 0.05
and a Bonferroni-adjusted a of 0.05 or 0.0167 for pairwise comparison of two (1
comparison) or three (3 comparison) means, respectively. The critical values of Z
(Zcrit) for the two-sided test using the Bonferroni-adjusted a of 0.05 and 0.0167 were

1.96 and 2.39, respectively, and the observed Z (Zobs) was calculated as reported
before (Bailer et al., 1988, Yuan et al., 1993). A Zobs value > Zcrit was used as an
indication of a significant difference between the AUCs.
The differences between groups in their kinetic parameters that could be
estimated for individual rats (e.g., Cmax and CLR) were determined using a two-tailed
unpaired t test at a significance level (a) of 0.05. When possible, data are presented as
mean ± S.D.

230

6.4. Results and Discussion

Targeted delivery of anti-HBV drugs to the liver, for the treatment of viral
hepatic diseases, has attracted the attention of scientists for several years. In one of the
first publications on this subject, Balboni et al. showed that conjugation of cytosine
arabinoside and 5-fluorodeoxyuridine to albumin resulted in accumulation of these
antiviral drugs in the mouse liver cells, increasing the effectiveness of the drugs in
comparison with the free drugs (Balboni et al, 1976). Further works by Fiume and
colleagues (Fiume et al., 1997) modified this strategy by the use of lactosaminated
albumin as the carrier, selectively targeting the asialoglycoprotein receptors on the
hepatocytes with the galactose moiety of lactose. Additionally, conjugates of antiviral
drugs with galactosylated poly-L-lysine, instead of albumin, have been .synthesized
and tested by the same group (Fiume et al., 1986, Fiume et al., 1997). Others have
used arabinogalactan

(Enriquez et al.,

1995) or glycosylated lipoproteins

(Bijsterbosch et al., 1996, DeVrueh et al., 2000), as liver-accumulating carriers, or
prodrugs that release the active drug based on metabolism by hepatic cytochrome
P450 (Erion et al., 2005, Reddy et al., 2005) for targeted delivery of antiviral drugs to
the liver. These studies support the general concept that targeted delivery of antiviral
drugs to the liver potentially increases the efficacy of these drugs in the treatment of
viral liver infections while, at the same time, decreasing their toxic effects in other
tissues. However, the choice of carrier and targeting moieties need optimization to
reduce carrier-related side effects, such as increased alkaline phosphatase levels seen
with lactosylated human serum albumin (Fiume et al., 1997), or to improve drawbacks

231

associated with variability in density and affinity seen with the asialoglycoprotein
receptors (Rensen et al., 1996).

6.4.1. Synthesis and Characterization of 3TCSD
In addition to our study, we are aware of only one other study that used dextran
as a macromolecular prodrug of antiviral agents (Tu et al., 2004). In that study,
acyclovir was conjugated to dextran with a Mw of 40 kDa. However, to synthesize the
conjugate, dextran was first oxidized to dextran aldehyde before direct reaction of the
aldehyde groups of dextran with the amine group of acyclovir to produce a Schiff s
base, without any spacer between acyclovir and dextran. Modification of dextrans,
including their oxidation, may alter the degradation and safety profiles of native
dextrans, which have been used clinically for almost six decades as plasma volume
expanders (Thoren, 1981 ). Therefore, we designed this strategy for conjugation of
3TC to dextran to minimize changing the structure of native dextran molecule.
Consequently, 3TC was coupled to dextran through a succinate linker, thus avoiding a
need for oxidation of dextran as previously reported (Tu et al., 2004).

In the present study, we used dextran with a Mw of -25 kDa as an alternative to

the currently studied carriers for the selective delivery of 3TC to the liver in HBV
treatment. The synthesis of the conjugate was challenging because of the presence of
free N4-amino group in the structure of 3TC, which had to be protected before the
reaction of 3TC with succinic anhydride for the synthesis of 3TCS. Lamivudine (3TC)
was conjugated to dextran using a succinate linker in two major steps by synthesis of
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5'-0-succinate ester of the drug (Scheme 6.1), followed by the reaction of the ester
conjugate with dextran (Scheme 6.2).

In this study, Larnivudine was initially reacted with TBDMS-Cl in the

presence of imidazole to yield 5' -0-TBDMS-larnivudine (2.4). The protection of N4amino group of 5'-0-protected larnivudine was carried out in the presence ofDMTr-Cl
and pyridine to give N4-DMTr-5'-0-TBDMS-larnivudine (2.11). The deprotection of
5' -0-TBDMS in the presence of tetrabutylarnrnoniurn fluoride (TBAF) afforded N4 DMTr derivative of larnivudine (2.12). This strategy was described in detail in
Chapter 2.

Compound 2.12 was used in the reaction with succinic anhydride to generate
N4-DMTr-5'-0-succinate ester conjugate of larnivudine (6.1) (Scheme 6.1).
Compound 6.1 was reacted with dextran in the presence of DIC and DMAP to afford
N4-(DMTr)larnivudine-succinate-dextran conjugate (6.3) that was deprotected in the
presence of acetic acid to afford larnivudine-succinate-dextran conjugate (3TCSD, 6.4)
with a reasonable degree of 3TC substitution (6.5%, w/w) (Scheme 6.2).
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Scheme 6.1. Synthesis of 4-N-(4,4'-Dimethoxytrityl)-5'-0-(succinate)-2',3'-dideoxy3'-thiacytidine (6.4).

The purity of the conjugate was > 99% as determined by the reversed phase
analysis of a 100-µg/mL solution of the conjugate (n = 3), which contained only 0.296
± 0.041 µg/mL of 3TC without any measurable peak of 3TCS. The degree of

substitution of the final product, which was obtained by the base hydrolysis of 3TCSD
to 3TC followed by reversed-phase quantitation of the released 3TC, was 6.5 mg
larnivudine in 100 mg of 3TCSD powder. The complete hydrolysis of 3TCSD was
confirmed by a complete disappearance of the 3TCSD peak in the SEC method.
Additionally, the area of the unhydrolyzed 3TCSD peak in the SEC method was the
same as the area of the released 3TC peak in the reversed-phase method after
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appropriate volume correction, indicating that the degree of substitution may be
determined directly from the area of 3TCSD peak without hydrolysis.

Dextran 25 kDa, DIC,
DMAP, DMSO, DIPEA

6 .1

6.3

80% Acetic acid

6.4

Scheme 6.2. Synthesis of 3TCS-Dextran (3TCSD, 6.4).

6.4.2. Size-Exclusion Chromatographic Method

Larnivudine-succinate-dextran (3TCSD) has two ester bonds in its structure
(Scheme 6.2), whose hydrolysis potentially releases 3TC or 3TCS. Therefore, to
completely determine the fate of the conjugate and its potential release products in
both in vitro and in vivo experiments, analytical methods capable of measurement of
all three moieties are needed. To quantitate 3TCSD in both aqueous and biological
samples, a SEC assay was developed. The method is capable of separating the
conjugate peak from the endogenous peaks (Figure 6.1) and accurately and precisely
quantitating the conjugate (Table 6.2).

235

Chromatograms of plasma samples taken from a rat before (blank) and 180

min after the administration of a single 5-mg/kg dose (3TC equivalent) of 3TCSD are
demonstrated in Figure 6.1. Dextran-lamivudine succinate eluted at -5.3 min and was
well separated from the endogenous peaks in plasma, which eluted after the conjugate
peak (Figure 6.1 ). Additionally, the relationship between the peak area of 3TCSD and
the detector response was linear (/ 2: 0.998) over the studied range 1 to 50 µg/mL .

The results of the assay validation in plasma are presented in Table 6.1.
Excellent accuracy of the assay is demonstrated by error values of < 1% for all the
concentrations (even at the lowest concentration of 1 µg/mL). The assay is also
deemed precise because the C.V. values are < 13% for the inter-run data (Table 6.1).
Based on the data presented in Table 1, the limit of quantitation of the assay is at least
equal to 1 µg/mL.
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Figure 6.1. Chromatograms of plasma samples taken from a rat before (A) and 180
min after (B) the administration of a single 5 mg/kg dose (3TC equivalent) of 3TCSD,
subjected to the size-exclusion chromatographic method. The 180 min sample
contained 9.70 µg/mL 3TCSD.
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Table 6.1. Inter-Run Accuracy and Precision for Quantitation of 3TCSD using the
SEC Assay (n = 5)
Added Cone.
(µg/mL)

Calculated Cone.
(µg/mL)

1

CV
(%)

Error
(%)

0.992

12.8

-0.84

10

10.1

2.34

0.70

50

49.6

1.60

-0.80

The recovery of 3TCSD from plasma was 88.0 ± 4.2% and 94.1 ± 4.6% at
concentrations of 5 and 50 µg/mL, respectively. The recovery of 3TCSD from liver
was 94.2 ± 9.5% at a concentration of 5 µg/mL.

6.4.3. Reversed-Phase Chromatographic Method.
Several HPLC assays are currently available for determination of 3 TC m
plasma and/or tissues (Zhou et al., 1997, Kenney et al., 2000, Zheng et al., 2001,
Alnouti et al., 2004, Bezy et al., 2005, Kano et al., 2005). These assays use either
solid-phase extraction (Kenney et al., 2000, Zheng et al., 2001, Bezy et al., 2005) or
protein precipitation (Zhou et al., 1997, Alnouti et al., 2004, Kano et al., 2005) for
sample preparation. Additionally, all of them use reversed-phase chromatography with
C1s (Zhou et al., 1997, Kenney et al., 2000, Bezy et al., 2005), Cs (Kano et al., 2005),
or phenyl ( Zheng et al., 2001, Alnouti et al., 2004) columns for separation of 3TC
from the endogenous peaks. To quantitate both 3TC and 3TCS simultaneously in our
samples, we had to modify these assays. We found that a protein precipitation method
with a combination of methanol and trichloroacetic acid resulted in the highest
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recovery (2'.:. 86%) for both 3TC and 3TCS from biological samples. Additionally, our
chromatographic conditions resulted in complete separation of 3TC, 3TCS, and IS
from the endogenous peaks (Figure 6.2) and accurate and precise quantitation of 3TC
and 3TCS (Table 6.2).

Figure 6.2 depicts the chromatograms of plasma samples at zero (blank) and 15
min after the administration of a single 5-mg/kg dose of 3TC to rats and at 3 h after
the in vitro incubation of 3TCSD in blood. Lamivudine, internal standard (stavudine),
and 3TCS eluted at

~11,

17, and 26 min, respectively and were well separated from

the endogenous peaks in plasma (Figure 6.2). Additionally, the relationship between
the peak area ratios of 3TC and 3TCS and the sample concentrations was linear

(r2 2'.:.

0.998) over the studied concentration range of 0.125 to 20 µg/mL for 3TC and 0.36 to
18 µg/mL (3TC equivalent) for 3TCS.

Validation results for the reversed-phase assay of 3TC and 3TCS in plasma are
presented in Table 6.2. Excellent accuracy of the assay is demonstrated by error values
of< 11 % for all the concentrations. The assay is also deemed precise because the C.V.
values are< 9% for all the concentrations except for the lowest concentration of 3TC,
which showed an acceptable C.V. of 16.8% (Table 6.2). Based on the data presented
in Table 6.2, the limit of quantitation of the assay is 0.125 and 0.36 µg/mL for 3TC
and 3TCS, respectively.
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Figure 6.2. Chromatograms of plasma samples taken from a rat before (A) and 15 min
after (B) the administration of a single 5 mg/kg dose of 3TC to rats and at 3 h after in
vitro incubation of 3TCSD with rat blood (C), subjected to the reversed-phase
chromatographic method. Sample B contained 1.84 µg/rnL 3TC, and sample C
contained 3.97 and 5.12 µg/rnL 3TC and 3TCS, respectively.
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Table 6.2. Inter-Run Accuracy and Precision for Quantitation of 3TC and 3TCS in
Plasma using the Reversed-Phase Assay (n = 5)
Analyte

Added Cone. (µg/mL)

Calculated Cone. (µg/mL)

CV(%)

Error(%)

3TC

0.125

0.138

16.8

10.9

3TC

5.0

4.75

3.15

-5.04

3TC

20

20.8

5.83

4.00

3TCS

0.36

0.378

8.33

5.14

3TCS

5.4

5.18

4.18

-3.73

3TCS

18

18.8

3.93

4.32

For 3TC, the degrees of recovery from plasma were 101 ± 1.8% and 104 ±
1.8% at concentrations of 5 and 50 µg/mL, respectively. For 3TCS, the values were
89.7 ± 8.5% and 85.7 ± 2.6% at concentrations of 1.8 and 18 µg/mL, respectively.
The recovery of 3TC from the liver samples at a concentration of 0.5 µg/mL was 95.7
± 5.25%.

6.4.4. Release Characteristics in Buffers
The SEC and reversed-phase HPLC assays described above were used to
investigate the stability of 3TCSD and formation of 3TC and 3TCS at 37 °C in buffers
at pH 4.4 (Figure 6.3) and blood at pH 7.4 (Figure 6.4). The conjugate was very stable
at pH 4.4 as demonstrated by both SEC (Figure 6.3, top) and reversed-phase (Figure
6.3, bottom) assays. The concentrations of 3TCSD did not significantly change over
24 h of incubation at 37 °C at pH 4.4 (Figure 6.3, top). Additionally, reversed-phase
analysis showed minor concentrations(< 1% of the initial concentration of 3TCSD) of
3TC and 3TCS released over the incubation time of 24 h (Figure 6.3, bottom). On the
other hand, measurable hydrolysis of 3TCSD occurred at pH 7.4 (Figure 6.4). In the
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SEC method, the concentrations of 3TCSD declined - 16% during 24 h of incubation
at pH 7.4 and 37 °C, with an apparent first-order half life of 108 h (Figure 6.4, top).
The decline in the concentration of 3TCSD (Figure 6.4, top) was associated with an
almost identical increase in the concentrations of free 3TC and 3TCS in the sample
analyzed by the reversed-phase method (Figure 6.4, bottom).

6.4.5. Release Characteristics in Rat Blood

Figure 6.5 shows the decline in the 3TCSD concentration (top) and associated
increases in the concentrations of 3TC and 3TCS (bottom), after incubation of the
conjugate in rat blood at 37 °C. The total 3TC (3TC plus 3TC succinate) released
during 12 h of incubation in blood was 8.45 ± 0.04% (Figure 6.5, bottom) in
agreement with an equivalent decline (7.75 ± 0.80%) in the concentration of the
prodrug in the SEC assay (Figure 6.5, top). The first-order half life of the decline in
the 3TCSD concentration in plasma was 110 h.

A comparison of 24-h degradation data at pH 7.4 (Figure 6.4) with 12-h
degradation data in blood (Figure 6.5) suggests that the degradation of 3TCSD in
blood is only due to a slow chemical hydrolysis of the conjugate. This is because the
degradation half lives of 3TCSD in buffer at pH 7.4 and in blood are almost identical
(108 and 110 h, respectively), indicating lack of enzymatic hydrolysis of the conjugate
in blood. This data is consistent with our previous report on a dextran conjugate of
methylprednisolone succinate, which similarly showed little, if any, enzymatic
hydrolysis in blood (Mehvar et al., 2000). Nevertheless, the relatively long half life of
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3TCSD in blood in vitro (110 h) indicates that the conjugate is stable in blood long

enough for the uptake by the liver.
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Figure 6.3. Average concentration-time courses of the intact 3TCSD (top) and
released 3TC, 3TCS, and total 3TC (3TC plus 3TCS) (bottom) after incubation of the
conjugate at pH 4.4 (37 °C). Error bars represent SD values (n = 3). Error bars for
3TCSD are too small to be observable.
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6.4.6. Release Characteristics in Rat Liver Lysosomes
Previous works (Larsen et al., 1989, Zhang et al., 2001) on other ester
conjugates of dextrans have proposed that the intact conjugates are resistant to the
effects of esterases because of steric hindrance of dextrans. However, after exposure
of the conjugate to dextranases, which depolymerize dextrans, esterases can hydrolyze
the ester bonds in the conjugate. It has been reported (Larsen, 1989) that dextranases
are present in lysosomes, predominantly in the liver. Additionally, dextrans enter cells
via endocytosis, which results in their accumulation in the lysosomal compartments
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(Lake et al., 1985, Stock et al., 1989). Therefore, lysosomal exposure of dextran
conjugates to dextranases may facilitate their further enzymatic hydrolysis. In vitro
data showed significant amounts of 3TC released at pH 4 only in the presence of rat
liver lysosomes (Figure 6.6). It was found that the presence of lysosomes in the
medium induced a slow release of 3TC (7.36 ± 0.30 µg/rnL after 24 h) without any
detectable 3TCS. In contrast, the release of 3TC or 3TCS in the same medium in the
absence of lysosomes was negligible (Figure 6.6). These results confirms our
hypothesis of 3TC release in lysosomes

6.4.7. In Vivo Disposition

Plasma concentration-time courses of 3TCSD and 3TC after the injection of
single 5-mg/kg (3TC equivalent) doses of the prodrug or the parent drug are depicted
in Figure 6.7. After the injection of unconjugated 3TC, the drug was eliminated
relatively rapidly and could not be detected at the last sampling time of 3 h (Figure
6.7). In contrast, the concentrations of 3TCSD were several folds higher than those of
3TC and remained high even at the last sampling time after the injection of the
conjugate. The plasma concentrations of both 3TC and 3TCSD declined multiexponentially (Figure 6.7). Additionally, no quantifiable concentrations of 3TC or
3TCS were detected in plasma of 3TCSD-injected rats.
The plasma pharmacokinetic parameters of 3TC and 3TCSD after the injection
of the parent drug or the prodrug are listed in Table 6.3. Conjugation of 3TC to
dextran resulted in an almost forty-fold decrease in the total CL of the drug and a
similar degree of increase in its plasma AUC. The decrease in total CL was associated
with an eighty-fold decrease in the CLR of the drug when conjugated to dextran.
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Consequently, the fraction of the drug excreted unchanged into urine decreased from
65% for the parent drug to 31 % for the conjugate (Table 6.3). Additionally, dextran
conjugation decreased the extent of distribution of the drug as reflected in Vss and Vz
values (Table 6.3), although to a lesser degree than that seen with the CL values (7-12
fold versus 40-80 fold, respectively). The declines in both the clearance and volume of
distribution upon conjugation resulted in longer terminal half life and MRT values for
the conjugate, compared with the parent drug (Table 6.3).
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Figure 6.7. Plasma concentration-time courses of the conjugated (3TCSD) and
unconjugated (3TC) larnivudine after iv administration of single 5-mg/k:g doses (3TC
equivalent) of 3TC or 3TCSD to rats. Standard deviation values are shown as error
bars (n = 3 rats for each point).
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The literature information about the pharmacokinetics of 3TC in rats is limited.
We are aware of only one study reporting the plasma concentration-time course and
AUC of the drug after a 230 mg/kg iv dose (Reddy et al., 2005). However, no other
pharmacokinetic parameters were reported in that study. We estimated a CL value of
27. l mL/min/kg from the AUC and dose values reported in that study. This value is
very close to our value of 32.6 mL/min/kg after a much smaller dose of 5 mg/kg
(Table 3), suggesting linear pharmacokinetics of 3TC in the dosage range of 5-230
mg/kg.

Table 6.3. Plasma Pharmacokinetic Parameters (Mean ± S.D.) of Unconjugated
(3TC) and Dextran-Conjugated (3TCSD) Lamivudine after a Single iv Dose (5
mg/kg, 3TC Equivalent) of 3TC or 3TCSD
3TC-Injected Rats

3TCSD-Injected Rats 0

3TC

3TCSD

Parameter

4.94 ± 0.93t
AUC, µg min/mL

153

± 7t

52.5

± 6.5

5930 ± 153

CL, mL/min per kg

32.6b

0.844b

CLR, mL/min per kg

21.3 ± 2.1 t

fe, %

65.3 ± 6.5t
1786b
930b

0.263 ± 0.089
31.2 ± 10.6
152b
135b

0.0183b
37.9b

o.00554b
125b

Vz, mL/kg
Vss. mL/kg
'\

flvz,

. -I

min

t112(Az), min
MRT, min
28.5b
160b
0
No quantifiable concentrations of3TC or 3TCS were detected in
flasma after 3TCSD injection.
Standard deviations could not be determined because of destructive sampling
method.
t Significantly different (P<0.05) from the corresponding value for the 3TCSDinjected rats.
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The hepatic concentration-time courses (top) and AUC values (bottom) of the
conjugate and regenerated 3TC after the administration of the conjugate and those of
3TC after the injection of the parent drug itself are depicted in Figure 6.8. After the
injection of 3TC, the hepatic concentrations of the drug were measurable only in the
first two samples; no detectable 3TC levels were found in the liver beyond 15 min
following the administration of the parent drug (Figure 6.8, top). However, relatively
high concentrations of 3TCSD were detected until the last sampling point.

This

resulted in > fifty-fold higher (P<0.0001) AUCs for the conjugated 3TC, compared
with the parent drug (Figure 6.8, bottom). Additionally, the conjugated 3TC slowly
released 3TC in the liver (Figure 6.8, top) with an AUC that was approximately 2.5fold larger (P<0.0001) than that of the parent drug during the sampling time (Figure
6.8, bottom). No measurable concentrations of 3TCS were found in the liver.

Conjugation of 3TC to dextran substantially decreased both the CL and volume
of distribution of 3TC (Table 6.3), while at the same time increasing the accumulation
of the drug in the liver (Figure 8). A similar disposition pattern was also observed for a
dextran prodrug of methylprednisolone with a succinate linker (Zhang et al., 2001).
The simultaneous decrease in volume of distribution and increase in liver
accumulation upon dextran conjugation is due to the relatively large pore sizes of the
liver sinusoids in comparison with those in the vascular beds of most other organs,
allowing unrestricted access of the conjugate to the space of Disse and internalization
of the conjugate (Mehvar et al., 1994).
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Because of limited number of liver samples with quantifiable 3TC
concentrations after 3TC injection and slow apparent declines in the liver
concentrations of the conjugate and regenerated 3TC after conjugate injection (Figure
6.8, top), terminal half lives were not estimated for the liver. Consequently, liver AUC
values depicted in Figure 6.8 (bottom panel) are related to the sampling period without
extrapolation to infinity. However, the significant differences between the liver AUCs
after 3TC and 3TCSD injections would be expected to be even larger if extrapolated
AUCs were used. This is because the apparent decline in the 3TCSD or regenerated
3TC concentrations was substantially slower than that in the liver concentrations of
the parent drug (Figure 6.8, top).

The slow decline in the 3TCSD concentrations in the liver (Figure 6.8, top) is
in agreement with previous ex vivo studies using isolated perfused rat livers (Mehvar
1997) showing that, once in the liver, the rate of exocytosis of dextrans from the liver
cells is negligible. Therefore, the main reason for the decline in the liver
concentrations of the conjugate is its elimination by the liver, which is relatively slow
based on the in vitro studies in lysosomes (Figure 6.6). Nevertheless, in contrast to
undetectable concentrations of 3TC in the liver beyond 15 min after the parent drug
injection, high concentrations of the conjugate in the liver were associated with a
gradual and sustained generation of the parent drug in this tissue (Figure 6.8).
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Figure 6.8. Liver concentration-time courses (top) and AUC values (bottom) of
parent (3TC) and/or conjugated (3TCSD) lamivudine after iv administration of single
5 mg/kg doses (3TC equivalent) of 3TC or 3TCSD to rats. Standard deviation values
are shown as error bars (n = 3 rats for each time point). Asterisks indicate significant
differences from the other two groups.
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The kidney concentration-time courses (top) and AUC values (bottom) of the
conjugate and regenerated 3TC after the administration of the conjugate and those of
3TC after the injection of the parent drug itself are depicted in Figure 6.9 and Table 4.
In addition to the liver (Figure 6.8), kidney was the only other organ where high

concentrations of the conjugated and regenerated 3TC were found (Figure 6.9). In
contrast to the liver (Figure 6.8), however, relatively high and persistent
concentrations of 3TC were found in the kidney even after the injection of the parent
drug (Figure 6.9). Therefore, conjugation of 3TC with dextran did not increase the
availability of free 3TC in the kidneys, as the AUCs of regenerated and parent 3TC
were not significantly different (Figure 6.9). The substantial accumulation of the
conjugate in the kidneys is consistent with the Mw dependency of the renal excretion
of the carrier dextrans in rats (22). Whereas a significant portion of the dose of
dextrans with Mw's of 4 kDa and 20 kDa was excreted into urine, renal excretion of
dextrans with Mw' s of 70 kDa and 150 kDa was negligible. Interestingly, kidneys have
been suggested as an extrahepatic site for virus replication in different models of HBV
infection (Di Bisceglie et al., 1990, Ogston et al., 1989). Therefore, accumulation of
the conjugate and release of 3TC in this organ, in addition to that in the liver, may be
of potential therapeutic benefit in chronic HBV infection.
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In contrast to the liver (Figure 6.8) and kidneys (Figure 6.9), the concentrations
of the conjugate and/or regenerated 3TC were very low or undetectable in the lungs,
spleen, and heart (brain) after 3TCSD injection (data not shown). Additionally, no
released 3TC could be detected in these tissues. The concentrations of 3TC after 3TC
injection in organs other than kidney were also low or below the limit of detection in
most of the samples.

Although our conjugate released both 3TC and 3TCS in vitro in buffers
(Figures 6.3 and 6.4) and rat blood (Figure 6.5), only 3TC was observed in biological
samples after in vivo administration of the conjugate (Figures 6.8 and 6.9). This
suggests rapid conversion of any released 3TCS to 3TC in vivo. Our previous work on
a methylprednisolone-succinate-dextran conjugate (Zhang et al., 2001) also showed
similar results, in that no measurable concentrations of methylprednisolone succinate
were found in biological samples after the administration of the conjugate to rats. The
rapid conversion of 3TCS to 3TC in vivo is advantageous because 3TCS is not
expected to have any biological effects by itself. This is due to the fact that to be
effective, 3TC should undergo stepwise phosphorylation at the 5'-position to
monophosphate, diphosphate, and triphosphate form before 5'-triphosphate 3TC is
incorporated into the viral DNA (Johnson et al., 1999). Therefore, 3TCS, which has a
succinate moiety at the 5 '-position (Schemes 6.1, and 6.2), cannot be converted to the
active 5' -triphosphate 3TC without first being converted to 3TC.
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The tissue exposure to 3TC after the administrations of the equivalent doses of
the conjugate and the parent drug is the most relevant parameter in terms of targeting
index. The ratios of 3TC AUCs after the conjugate and parent drug administration
were 2.41 for the liver, 0.721 for the kidneys, and zero for the remaining studied
tissues. These data clearly show that the conjugation of 3TC to dextran only increased
the targeting of the drug to the liver. On the other hand, conjugation decreased
accumulation of 3TC in all the other tissues except the kidneys, where conjugation did
not have any significant effect. The significantly higher accumulation of 3TC in the
liver is in conformity with the hypothesis of the study, i.e., conjugation of 3TC with
dextran allows preferential accumulation of the drug in the liver.

6.5. Conclusions

In conclusion, a method is presented for the synthesis of a conjugate of native

dextran with the antiviral drug 3TC using a succinate linker. Additionally, validated
size-exclusion and reversed phase assays are developed for the determination of
purity, in vitro release characteristics, and in vivo disposition of 3TCSD. Using these
methods, the parent conjugate and its degradation products, 3TC and 3TCS, may be
quantitated in non-biological and biological samples. In vitro studies indicate an
evidence of lysosomal degradation and relative stability of the conjugate in buffers
and blood. Additionally, in vivo studies after the administration of the conjugate or the
parent drug to rats suggest that the conjugation increases the delivery of the drug to the
liver, resulting in higher exposure of the liver to the regenerated antiviral drug.
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7.1. Abstract

Sulfonate and sulfate polyanionic microbicides, such as sodium cellulose
sulfate (CS, 7.1), are inhibitors of HIV entry and sperm-function. CS was first reacted
with 2-bromoacetic acid to yield CS-acetate (CSA, 7.2), which was further reacted
with AZT, FLT, and 3TC to give AZT-CSA (7.3, 1.78% loading), FLT-CSA (7.4,
1.43% loading), and 3TC-CSA (7.5, 1.07% loading), respectively. Furthermore, CS
was conjugated to nucleoside analogs (AZT, FLT, and 3TC) through succinate linker
to produce bifunctional nucleoside-CS conjugates. For the synthesis of the conjugates
containing succinate linker, CS was reacted with AZT-succinate and FLT-succinate to
give AZT-succinate-CS (7.6, 18.48% loading) and FLT-succinate-CS (7.7, 7.87%
loading), respectively. These conjugates were designed to improve the anti-HIV
profile of parent compounds. It was expected that extracellular hydrolysis of
conjugates will release nucleosides and CS providing broad-spectrum activity, a
higher barrier to drug resistance, microbicidal, and contraceptive activity. The antiHIV activities of the conjugates were evaluated and were compared with the
corresponding physical mixtures of nucleoside analogs and anionic polymers and with
different classes of polyanionic polymers, such as dextran acetate, cellulose phosphate,
and cellulose acetate. Cellulose acetate, cellulose phosphate, and dextran acetate were
found to have no anti-HIV activities, suggesting the importance of the presence of
sulfate on the cellulose for generating anti-HIV activities. The conjugates containing
CS-acetate were found to be more potent than CS and other derivatives. AZT-CSA
(7.3) and FLT-CSA conjugates (7.4) exhibited higher anti-HIV activities than CS (7.1)

and AZT-succinate-CS and FLT-succinate-CS-conjugates (7.6 and 7.7). The presence
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of both sulfate and the acetate groups on cellulose were critical for generating
maximum anti-HIV activity, possibly by increasing the negative charge density that is
essential for blocking HIV entry. However, the compounds were less potent than the
corresponding physical mixtures of nucleoside analogs with CSA (7.2), due to
incomplete hydrolysis.

7.2. Introduction

Sulfonate and sulfate polyanionic microbicides inhibit the HIV entry into the
cell (Chan and Kim, 1998; Gao et al., 1999; Ketas et al., 2003; Vlieghe et al., 2002)
and sperm-function (Anderson et al., 2000). Sodium cellulose sulfate (Ushercell, CS)
is a polyanionic non-cytotoxic microbicide and its 6% gel has been studied as vaginal
contraceptive and a broad spectrum antimicrobial agent (Mauck et al., 2001, Malonza
et al., 2005).

Polyanionic sulfates are the polymers such as dextran, cellulose, styrene etc
with sulfate groups in their structure (Bugatti et al., 2007, Moulard et al., 2000, Gao et
al., 1999, Vlieghe et al., 2002). The negatively-charged sulfate group interacts with
positively-charged viral protein (Shattock et al., 2002). Viral envelop protein gp120 is
know to have positively charged residues in its V3 loop. Viral entry in the host cell
depends on the interaction with the negatively-charged surface of the coreceptors
CXCR4 and CCR5 (Kajumo et al., 2000). Polyanionic sulfates exhibit their inhibitory
activity by blocking the interaction between negatively-charged coreceptors and
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positively charged V3 loop of viral gp120 protein (D'Cruz et al., 2004, Baba et al.,
1998, Turpin, 2002).

Different strains of HIV are known to have different V3 loops and therefore
show different interactions with the host cell. X4-strains of HIV possess a higher
positive charge density on their V3 loop than R5 strains of virus (Shattock ~t al., 2002,
Meylan et al., 1994). This property of X4 makes them susceptible to polyanionic
inhibitors. On the other hand, several polyanionic derivatives like dextran sulfate and
heparin show insignificant activity against R5 strain of virus (Scordi-Bello et al., 2005,
D'Cruz et al., 2004).

Similar to other polyanionic derivatives, sodium cellulose sulfate (CS, 7.1),
interacts with the positively-charged viral envelope proteins, and prevents the virus
from interaction with coreceptors. Various studies show that CS possesses significant
anti-HIV activity against both the strains of virus, but it is more active against X4
strain (IC 5o = 0.65 µg/rnl) than R5 strain (IC 5o = 18.67 µg/ml) of virus (Scordi-Bello et
al., 2005, Neurath et al., 2002). The ability of CS to inhibit both strains of virus
efficiently suggests that some additional mechanism may be involved for viral
inhibition (Scordi-Bello et al., 2005, Neruth et al., 2002).
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Other than the anti-microbial activity, CS also shows contraceptive activity
because of its ability to reversibly inhibit hyaluronidase (IC 50 = 1.7 mg/ml), which is
an important enzyme for the interaction of spermatozoa with the egg (Anderson et al.,
2002). CS also inhibits sperm penetration of cervical mucus membrane (Anderson et
al., 2002).

CS showed promising results in the preclinical studies, phase I and phase II
clinical trials sponsored by CONRAD. In preclinical studies, CS prevented conception
in rabbits when applied vaginally before insemination, and was also found to inhibit
HIV, Neisseria gonorrhoeae, and Chlamydia trachomatis (Crucitti et al., 2007,
Anderson et al., 2002). Results from phase I clinical trials showed that CS was very
safe and non-irritating to penile and vaginal application (Mauck et al., 2001, Mauck et
al., 2001). CS vaginal gel (6%) was well tolerated as vaginal microbicide in both
healthy and HIV-infected women and produced similar results in comparison to K-Y
jelly, a commercially available product for contraceptive (El-Sadr et al., 2006,
Malonza et al., 2005, Schwartz et al., 2006).

Despite the initial success, CS failed the phase III clinical trial study in January
2007 (Wakabi, 2007). It was found that after women stopped using CS gel, they were
more prone to the HIV infection than those who were using placebo. Therefore, the
study of 6% CS gel as anti-HIV and contraceptive agent was terminated as it was
suspected to increase a woman's susceptibility to HIV infection (Conrad.org).
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Herein, we report the synthesis and biological evaluation of bifunctional
cellulose sulfate conjugates with nucleoside reverse transcriptase (RT) inhibitors, 3'azido-2',3'-dideoxythymidine (Zidovudine, AZT), 3'-fluoro-2',3'-dideoxythymidine
(Alovudine, FLT,), and 2',3'-dideoxy-3'-thiacytidine (Lamivudine, 3TC). Two
different linkers (acetate and succinate) were used to conjugate the nucleoside analogs
with CS with different loading values. It was expected that the conjugates would be
cleaved by hydrolytic activity of cellular esterase enzymes, resulting in two separate
components as CS (HIV entry blocker) and nucleoside analogs (RTis). CS inhibits
viral entry inside the cell and is active against X4 strain and cell-associated virus. On
the other hand, nucleoside analogs are equally active against RS and X4 strains and
inhibit the function of RT enzyme and HIV replication. In general, the conjugates
were expected to provide synergistic and broad-spectrum anti-HIV activity against
susceptible and multidrug-resistant strains of virus. Conjugates were also expected to
exert contraceptive activity from the released CS.

7.3. Materials and Methods

7.3.1. Materials.
All reagents including CS and cellulose phosphate, ether, dialysis membrane
(3000 MW cut off) and solvents were purchased from Fisher Scientific. Size exclusion
chromatography was carried out on a Hitachi analytical HPLC system on a analytical
gel chromatography column (PolySep-GFC 3000, 300 mm x 7.8 mm; Phenomenex,
Torrance, CA) to determine the loading of the nucleoside-linker-CS conjugates The
mobile phase was comprised of potassium phosphate mono basic buffer (0.1 M, pH =
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7.4):acetonitrile (75:25, v/v) and was pumped at a flow rate of 1.0 mL/min. Cellulose
sulfate derivatives were extracted by solvent precipitation method and precipitates
were centrifuged by using Legend™ RT Refrigerated Tabletop Centrifuge.

7.3.2. Chemistry
Cellulose Sulfate Acetate (CSA, 7.2), Cellulose Acetate (CA, 7.14) and Dextran
Acetate (DA, 7.15) The polymers, cellulose sulfate, cellulose, and dextran were
converted to 2-acetyl substituted derivatives according to the previously reported
procedure (Thomas et al., 1995). The polymer (1 g) and 2-bromoacetic acid (6 g, 43.5
rnmol) were dissolved in water (25 mL). Sodium hydroxide (40%, 7.5 ml) was added
to the reaction mixture and the mixture was stirred for 18 h at room temperature. The
reaction mixture was concentrated at reduced pressure and dialyzed using a membrane
(3000 M.Wt. cut off). The solution was further concentrated and dried under reduced
pressure to afford 2-acetyl substituted polymers 7.2, 7.14, and 7.15.

AZT-Cellulose Sulfate Acetate (AZT-CSA, 7.3) and FLT-Cellulose Sulfate
Acetate (FLT-CSA, 7.4). Compound 7.2 (100 mg), nucleoside (AZT or FLT) (0.25
rnmol), and dimethylaminopyridine (DMAP, 30 mg, 0.25 rnmol) were dissolved in
dimethyl sulfoxide (DMSO) (3 mL). Diisopropylcarbodiimide (DIC, 30 µL, 0.2
rnmol) was added to the solution. The reaction mixture was stirred at 40 °C for 24 h.
The reaction mixture was cooled to room temperature. Cold diethyl ether:methanol
(45 mL, 50:50 v/v) was added to the reaction mixture, and then the layer was washed
twice first with cold methanol:diethyl ether ((50 mL, 50:50, v/v) and ether (50 mL),
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cold methanol:diethyl ether ((50 mL, 50:50, v/v) and ether (50 mL), respectively. The
mixture was centrifuged and the precipitate was dried under vacuum to afford 7.3
(loading percentage= 1.78% ± 0.00) or 7.4 (loading percentage= 1.43% ± 0.06).

3TC-Cellulose Sulfate Acetate (3TC-CSA, 7.5). 3TC-cellulose sulfate acetate was
synthesized using (-)-N4-(4,4'-dimethoxytrityl)-2',3'-dideoxy-3'-thiacytidine (2.12) and
CSA as starting materials. The synthesis of 2.12 was described above in Chapter 2.
CSA (100 mg), 2.12 (130 mg, 0.25 mmol), and DMAP (30 mg, 0.25 mmol) were
dissolved in DMSO (3 mL). DIC (30 µL, 0.2 mmol) was added to the solution. The
reaction mixture was stirred at 40 °C for 24 h. Acetic acid (80%, 10 ml) was added to
the reaction mixture and the mixture heated at 80 °C for 30 min. Acetic acid was
evaporated under reduced pressure. To the residue was added cold diethyl
ether:methanol (45 mL, 50:50 v/v). The mixture was washed twice with cold
methanol:diethyl ether (50 mL, 50:50, v/v) and ether (50 mL), respectively, and
centrifuged. The precipitate was dried under vacuum to give 7.5 (loading percentage
1.07% ± 0.00).

AZT-Succinate-Cellulose Sulfate (AZT-Succinate-CS, 7 .6). AZT-succinate (3.2)
was synthesized as described in Chapter 3 from the reaction of AZT with succinic
anhydride. Compound 3.2 (200 mg, 0.55 mmol), triphenylphosphine (TPP, 300 mg,
1.15 mmol), and sodium cellulose sulfate (7.1, 100 mg) were dissolved in DMSO (3
mL). DIAD (100 µI, 0.5 mmol) was added to the reaction mixture. The mixture was
stirred at 40 °C for 24 h. Cold diethyl ether: methanol (45 mL, 50:50 v/v) was added to
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the reaction mixture. The mixture was washed twice with cold methanol:diethyl ether
(50 ml, 50:50, v/v) and ether (50 mL), respectively, and was centrifuged. The
precipitate was dried under vacuum to give AZT-succinate-cellulose sulfate (7.6,
loading percentage= 18.48% ± 0.23).

FLT-Succinate-Cellulose Sulfate (7.7). FLT-succinate (3.1) was synthesized as
described in Chapter 3 from the reaction of FLT with succinic anhydride. Compound

3.1 (200 mg, 0.58 mmol), DMAP (60 mg, 0.25 mmol) and sodium cellulose sulfate
(7.1, 100 mg) were dissolved in DMSO (3 mL). DIC (50 µl, 0.32 mmol) was added to

the reaction mixture. The mixture was stirred at 40 °C for 24 h. Cold diethyl
ether:methanol (45 mL, 50:50 v/v) was added to the reaction mixture. The mixture
was washed twice with cold methanol:diethyl ether (50 mL, 50:50, v/v) and ether (50
mL), respectively, and was centrifuged. The precipitate was dried under vacuum to

give FLT-succinate-cellulose sulfate (7.7, loading percentage= 7.87% ± 0.11).

7.3.3. Purity and Loading Percentage Determination of Conjugates of Nucleoside
Analogs with Cellulose Sulfate and Cellulose Sulfate Acetate. The percentage of
purity and degree of substitution of the nucleoside analogs were determined using size
exclusion chromatography (SEC). Initially, a method was developed and validated for
parent nucleosides analogs, AZT, FLT and 3TC, dissolved in potassium phosphate
monobasic (KH 2P04) buffer (pH= 7.4) on a 30 cm x 7.8 mm gel chromatography
column (PolySep-GFC 3000). Calibration curves of different concentrations (3, 6, 9,
12 and 15 µg/ml) versus area under the curve (AUC) were plotted for each analog.
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Similarly, the conjugates were passed through the column. The loading percentage
was calculated from the calibration curve. The mobile phase consisted of
buffer:acetonitrile (75:25, v/v) and was pumped at a flow rate of 1.0 mL/min.

7.3.4. Anti-IDV Assays. Anti-HIV activities of the compounds were evaluated

according to the previously reported procedure (Krebs et al., 1999). In summary, HeLa
(Human cervical carcinoma: ATCC CCL-2.1) cell line was used to measure
inactivation of both cell-free virus preparations and virus-infected cell preparations.
Cells were plated in culture plates 24 hrs prior to each experiment. Cell-free viral
preparations of HIV-I strains IIIB (lymphocytotropic strain) and BaL (monocytotropic
strain) were used for cell-free assay. For cell-associated assay, SulTl cells were
infected with IIIB virus 5 days prior to the experiment. Cell-free virus and virusinfected cells were mixed with different compounds and diluted to make different
concentrations. The mixture was further diluted with the buffer and added to the HeLa
cells. The cells were incubated at 37°C for 48 hrs, stained for ~-galctosidease
expression and compared with

~-galctosidease

expression from the

~-gal-positive

cells

in absence of any microbicidal compound to get IC 50 values.

7.4. Results and discussion
7.4.1. Chemistry

The synthesis of cellulose sulfate acetate conjugates with AZT, FLT, and
3TC was accomplished using building block synthesis strategy. For the synthesis
of nucleoside-CSA conjugates, cellulose sulfate (7.1) was reacted first with 2-
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bromoacetic acid in presence of sodium hydroxide to afford cellulose sulfate
acetate (CSA, 7.2). CSA was then reacted with AZT, FLT, or N 4-DMTr-3TC to
yield cellulose sulfate acetate conjugates of AZT (7.3, AZT-CSA, 1.78% loading),
FLT (7.4, FLT-CSA, 1.43% loading), or N4-DMTr-3TC-CSA (7.5'), respectively.
Deprotection of DMTr group in 7.5' afforded 3TC-CSA (7.5, 1.07% loading)
(Scheme 7.1 ).

For the synthesis of sodium cellulose sulfate conjugates linked to AZT or FLT
through a succinate linker, AZT and FLT were first reacted with succinic anhydride to
synthesize AZT succinate and FLT succinate, which were then reacted with cellulose
sulfate to afford cellulose sulfate succinate conjugates of AZT (7.6, 18.48% loading)
and FLT (7.7, 7.87% loading) (Scheme 7.2). The Purity and percentage of loading of
the nucleosides in the conjugates were determined using the SEC method as described
above.
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Br~

NaOH, Water

OH

AZT, FLT, or N 4-DMTr-3TC
DIC, DMP A, DMSO

OH
7.3 ROH=AZT
7.4 ROH=FLT
7.5' ROH=N4-DMTr-3TC
tACOH (800/o)

7.5 ROH=3TC

Scheme 7.1. Synthesis of cellulose sulfate acetate conjugates of AZT, FLT and 3TC.
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Succinic Anhydride
Pyridine
X = N 3 AZT
X = F FLT
TPP, DIAD , DMSO for
AZT derivative or ·
DIC, DIPEA, DMAP, DMSO
for FLT derivative

ylNH

o~

3

S0 Na
__L/0,

~~

--~-o~3~a~c{
OH

~OH
N•O,S,~;
0.
0

'O
HO

OH O

O

O/

OH

00

lNAo

O

X

7.6 (Loading 18.48%)
7.7 (Loading 7.87%)

Scheme 7.2. Synthesis of AZT-succinate-CS (7.6) and FLT-succinate-CS (7.7)
conjugates.

7.4.2. Biological Activities
7.4.2.1. Anti-HIV Activities Against Cell-Free and Cell-Associated Strains
Table 7 .1 shows the antiviral activities of the cellulose sulfate-nucleoside
conjugates with different loading percentages compared to those of CS, AZT, and
FLT. CS exhibited approximately I 0-fold higher activity against X4 virus (IIIB strain,
ECso

=

5.9 µg/ml)) than R5 virus (BaL strain, ECso
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=

62.5 µg/ml) (Table 7.1). The

data is consistent with the reported data (Shattock et al., 2002, Meylan et al., 1994)
that X4 strains possess higher number of positive charges on their V3 loop of gp120
protein surface compared to those of R5 strains. Higher number of positive charges on
V3 loop of X4 strains makes them more susceptible to interaction with anionic
polymer CS. On the other hand, conjugation of CS with nucleosides in all conjugates
made R5 strains susceptible more susceptible sometimes even more than X4 strains.

Nucleoside-CSA conjugates (AZT-CSA, 7.3, 1.78%; FLT-CSA, 7.4, 1.43%)
demonstrated higher anti-HIV activities than that of CS (7.1). Unlike AZT and FLT
(EC 5o > 100 µg/rnL), the conjugates 7.3 and 7.4 were consistently active against cellassociated HIV (CTC assay) (EC 5o

=

5.6-5.8 µg/rnL). The improved anti-HIV

activities of 7.3 and 7.4 compared to CS is possibly due to the release of two anti-HIV
agents with different mechanisms of action and the presence of additional negativelycharged acetate in the structure. Similarly, cellulose sulfate-acetate (7.2) exhibited
significantly higher potency than CS (7.1) against cell-free virus.

The higher anti-HIV activity of 7.3 (EC 50

= 8.1 µg/rnL) and 7.4 (EC 5o = 1.5

µg/rnL) against R5 strains compared to that of CS (EC 50

=

62.5 µg/ml) demonstrates

the synergistic effect of CS conjugation with AZT or FLT. AZT and FLT are active
against both R5 (BaL) and X4 (IIIB) strains of virus, but CS is more active against X4
(IIIB) and cell-associated virus.
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CSA (7.2) was tested for anti-HIV activity as a control, and surprisingly it
showed slightly higher activity than 7.3 against cell-free virus and was almost equally
active against X4 and RS strains. The better activity of 7.2 and its conjugates, 7.3 and
7.4, can also be attributed to the presence of free negatively-charged carboxylate

group of the acetate groups substituted on CS that enhance the negative charge density
along with sulfate. The presence of additional negative charges on the polymer may
have improved the HIV entry blocking properties of CS by interacting with positive
charges of the viral protein. Although the substitution of acetate group on cellulose
sulfate increased the anti-HIV activity of CS, but cellulose acetate (7.14) was
completely inactive (Table 7.2), suggesting that the presence of sulfate of cellulose is
critical in maintaining the anti-HIV activity of the polymer.

3TC-CSA conjugate (7.5, 1.07% loading) showed significantly different antiHIV profile compared with AZT-CSA and FLT-CSA conjugates. Conjugate 7.5
showed almost 37-fold less anti-HIV activity against X4 strain, and was not active
against cell-associated virus. The poor anti-HIV activity of 3TC conjugate could be
due to the interaction of free 4-arnino group of 3TC with the negatively charged
groups on CSA that reduces the available free negative charge of the conjugate for
binding to V3 loops of the virus.

To determine the contribution of sulfate group in generating anti-HIV activity
of CS, cellulose phosphate and dextran acetate were studied as controls. These
compounds were found to be totally inactive in viral inhibition assay
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(Ta~le

7.2),

suggesting that negatively charged acetate and phosphate alone are not sufficient for
efficient interactions with V3 loops of the virus.
The

anti-HIV

activities

of nucleoside-succinate-CS

conjugates, AZT-

succinate-CS (7.6, 18.48%) and FLT-succinate-CS (7.7, 7.87%) were also evaluated.
Both conjugates demonstrated at least 6-fold higher anti-HIV activity against X4
strains than CS suggesting the contribution of nucleoside analog in anti-HIV activity
(Table 7.1). However, 7.6 and 7.7 exhibited less anti-HIV activity against the cell
associated virus (EC 50 = 75-88 µg/mL) than that of CS (EC 50 = 2.5 µg/mL). The
conjugates also showed less anti-HIV activity against cell-free virus when compared
with AZT and FLT.
Table 7.1. Anti-HIV activities of nucleoside-cellulose sulfate conjugates.
Compound

Chemical Name

CTs•

VBI(IllB)c

VBI(BaL)a

CTC"

EC(SO)b

EC(SO)

EC(SO)

EC(SO)

(µg/ml)

(µg/ml)

(µg/ml)

(µg/ml)

Code

7.1

Sodium Cellulose Sulfate
(Mo!. wt. 2,000,900 Da)

>100

5.9

62.5

2.5

7.2

Cellulose Sulfate Acetate (CSA)

>100

1.3

1.8

6.6

7.3

AZT-Cellulose Sulfate Acetate
(AZT-CSA, 1.78% loading)

> 100

2.5

8.1

5.6

7.4

FLT-Cellulose Sulfate Acetate
(FLT-CSA, 1.43% loading)

>100

2.3

1.5

5.8

7.5

3TC-Cellulose Sulfate Acetate
(3TC-CSA, 1.07% loading)

> 100

92.4

75 .l

> JOO

7.6

AZT-Succinate-Cellulose Sulfate
(AZT-Sue-CS, 17.2% loading)

> 100

2.2

9.9

74.8

7.7

FLT-Succinate-Cellulose Sulfate
(FLT-Sue-CS, 7.87% loading)

>100

6.2

6.1

87.6

AZT

Zidovudine

>100

2.4

4.2

> 100

FLT

Alovudine

> 100

<0.1

<0.1

> 100

3TC

Lamivudine

100

7.5

2.6

18.4

0

aCytotoxicity assay; b50% Effective concentration; Viral entry inhibition assay (lymphocytotropic
strain); dViral entry inhibition assay (monocytotropic strain); °Cell- to- cell transmission assay (UIB).
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Although 7.6 and 7.7 had 10 and 6 times higher loading values than the
corresponding conjugates substituted with acetate (7.3 and 7.4), respectively, the
cellulose sulfate succinate conjugates were generally less active than cellulose sulfate
acetate conjugates (Table 7.1). The less anti-HIV activity of conjugates containing
succinate linker, despite of their higher nucleoside loading, compared to those
containing acetate linker could be due to incomplete hydrolysis of 7.6 and 7.7 to
parent nucleosides or the hydrolysis of the conjugate to generate inactive nucleosidesuccinate derivatives instead of free nucleosides. Furthermore, upon hydrolysis of
conjugates containing acetate linker, the acetate group will remain intact on the CS
that contributes to overall negative charge of the anionic polymer.

Table 7.2 shows the anti-HIV activities (in µg/mL) of the nucleoside-CS
conjugates compared with the corresponding physical mixtures. The physical mixture
of AZT ( 1. 78%) + CSA (7 .8) showed slightly better anti-HIV activity against cell free
virus than the corresponding AZT-CSA conjugate (7.3). In comparison to 7.3, the antiHIV activity of 7.8 was almost 1.5- and 3.5-fold higher against lymphocytotropic and
monocytotropic strains of cell-free virus, respectively, but was 1.5-fold less active
against cell associated virus.

When CSA was replaced with CS in the physical mixture with AZT in 7.11
(17.2%), the anti-HIV activity was reduced significantly (2-9 fold) against cell-free
virus when compared with the corresponding CSA conjugate 7.8 containing even a
lower loading of AZT (l.78%), suggesting the major contribution of CSA in overall
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activity. The physical mixture of AZT with CS (7.11, 17.2%) that was in a similar
ratio to the AZT-succinate-CS conjugate (7.6), showed 2-7-fold less anti-HIV activity
against cell-free virus when compared with AZT-CSA conjugate 7.3 (1.78%) and
AZT-succinate-CS conjugate 7.6 (17.2%).

Similar results were found in the case of FLT-CSA conjugate (7.9) and 3TCCSA (7.5) when compared with the corresponding physical mixtures, 7.4 and 7.10,
respectively. Physical mixture of CSA and FLT (7.9, 1.43%) exhibited approximately
3-5 fold higher anti-HIV activity against VBI (cell-free virus) when compared with the
corresponding FLT-CSA conjugate (7.4, 1.43%). In the case of 7.10, the free amino
group was not able to reduce the anionic interactions of sulfate group as described
above in the conjugate 7.5.

However, the overall anti-HIV activity of 7.9 was reduced by 8-22 times
against cell-free virus when CSA in 7.9 (l.43%) was replaced with CS in 7.12
(1.43%), suggesting the importance of CSA in overall anti-HIV activity.

The anti-HIV activity in 7.12 was increased by 10-20 fold against cell-free
virus when the FLT content was increased from 1.43% to 7.85% in 7.13. The data
indicates that higher concentration of FLT in the physical mixture improves activity.

The physical mixture of FLT with CS (7.13%) still exhibited 6-fold lower antiHIV activity against cell-associated virus when compared with FLT-CSA conjugate
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(7.9, 1.43%). These data confirm that CSA is a more appropriate polymer for
conjugation with nucleosides or making physical mixtures since all CSA derivatives
exhibited better anti-HIV profile when compared with CS derivatives.

The physical mixture of AZT + cellulose acetate (7.17, 1.78%) showed
significantly less activity against cell-free virus when compared with AZT-CSA
conjugate (7.3, 1.78%) and AZT + CSA (7.8, 1.78%) and was inactive against cellassociated virus. Similarly, the physical mixture of FLT + cellulose acetate (7.18,
1.43%) showed 9-21 fold less activity against cell-free virus when compared with FLT

+ CSA (7.9, 1.43%) and was inactive against cell-associated virus. The result was not
surprising since cellulose acetate is inactive polymer and the percentage of AZT or
FLT were low in the physical mixture.

In general, the conjugation of nucleosides with CS provided better anti-HIV
profile against both X4 and RS strains of virus. The substitution of acetate group on
CS improved the anti-HIV activity, possibly by creating new negative charges after
hydrolysis or the presence of free acetate groups on the polymer. Succinate spacer was
less optimal than the acetate group for linking of the nucleoside with CS.
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Table 7.2. Anti-HIV activities of cellulose acetate, dextran acetate, cellulose
phosphate, and physical mixtures of nucleosides with CS, CSA, and cellulose.

Compound
Code

Chemical Name

CTS"
EC(SO)b
(µg/ml)

VBI(IIIB)c
EC(SO)
(µg/ml)

VBl(BaL)d
EC(SO)
(µg/ml)

CTc•
EC(SO)
(µg/ml)

7.8

AZT (1.78 %) + CSA

> JOO

1.7

2.5

8.0

7.9

FLT (1.43 %) + CSA

> 100

0.72

0.31

4.72

7.10

3TC (1.07%) + CSA

> 100

0.65

1.73

5.79

7.11

AZT (17.2%) + CS

> 100

16.2

15.3

7.6

7.12

FLT (1.43 %) + CS

> 100

6.2

7.1

7.4

7.13

FLT (7.85 %) + CS

> 100

0.7

0.3

26.4

7.14

Cellulose Acetate

> 100

> 100

> 100

> 100

7.15

Dextran Acetate

> 100

> 100

> 100

> 100

7.16

Cellulose Phosphate

> 100

72.1

> 100

> 100

7.17

AZT (1.78%) +Cellulose
Acetate

>100

75.5

8.5

> 100

7.18

FLT (1.43%) + Cellulose
Acetate

> 100

6.8

6.5

> 100

7.19

3TC (1.07%) + Cellulose
Acetate

> 100

73 .9

22.4

> 100

•cTS: Cytotoxicity assay; rEC(50) = 50% effective concentration; 8VBl(IIIB): Viral entry inhibition
assay (lymphocytotropic strain); hVBI(BaL): Viral entry inhibition assay (monocytotropic strain); iCTC:
cell- to- cell transmission assay (IIIB).

7.4.2.2. Anti-HIV activities against Multi-Drug Resistant (MDR) Isolates
AZT-CSA (7.3) and FLT-CSA (7.4) conjugates were evaluated for their antiHIV activities against MDR virus and the data were compared with the controls CS
and dextran sulfate (Table 7.3). Both CS and dextran sulfate were active against MDR
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virus (ICso

=

1.61-3.12 µg/mL), but showed less activity against R5 strain of virus

(ICso > 15 µg/mL). the result was expected since R5 virus has less positively charged
V3 loops in gp 120 protein required for interactions with anionic polymers.

On the other hand, AZT-CSA (7.3) showed almost similar anti-HIV activity
against both R5 and MDR strains than CS. AZT-CSA (7.3) was more effective than
CS, against the R5 HIV-1 lab-adapted strain BaL. The higher activity against R5 strain
is a result of AZT attachment. Furthermore, AZT is not active against MDR strain and
hence its conjugate with CS in AZT-CSA (7.3), is 2-fold less active than CS against
MDR strain. Similarly FLT-CSA (7.4) showed significantly higher activity against R5
strain versus CS (7.1) due to the presence of FLT in the conjugate. The anti-HIV
activity of 7.4 against MDR is 5-fold higher than R5 strains, since released FLT has
anti-HIV activity against AZT-MDR resistant.

Table 7.3. Anti-HIV activities of AZT-CSA and FLT-CSA conjugates against R5 and
rnultidrug resistant HIV-I clinical isolates.
Compound

Chemical Name

7.3

AZT-Cellulose Sulfate Acetate

7.4

FLT-Cellulose Sulfate Acetate

7.1

Cellulose sulfate

Dextran Sulfate

Dextran sulfate

Type of Virus

I Cso (µg/mL)

R5
MDR
R5
MDR
R5
MDR
RS
MDR

3.52
4.22
2.67
0.50
>20.0
1.61
15.7
3.12

Assay endpoint= p24 level (ELISA)
IC 50 = The minimum drug concentration that inhibits HIV-induced cytopathic effect by 50%,
calculated by using a regression analysis program for semilog curve fitting
HIV-1 clinical isolates: R5 = 92TH014; MDR = Multidrug resistant virus 7324-1
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7.4.2.3. Contraceptive activity
AZT-CSA conjugate (7.3) was selected for in vivo testing in rats for
contraceptive activity. Application of CS and 7.3 in female rats prevented the
pregnancy to 100% (Table 7.4). CS is known to have contraceptive properties and this
result indicated that contraceptive property of the CS is retained after the AZT
conjugation to the polymer.

Table 7.4. Contraceptive efficacy of AZT-CSA conjugate.
Concentration

No. of Pregnant

Pregnancy rate

(mg/ml)

females/total

(%)

TALP

Control

414

100

7.1

1

015

0

7.3

1

015

0

Group

Female rabbits were inseminated with pooled rabbit semen containing 1 mg/mL of test compound
or medium control (TALP)

7.5. Conclusions
HIV entry blocker cellulose sulfate was conjugated with RT inhibitor
nucleosides, AZT, FLT, and 3TC, through different linkers to synthesi.ze CSnucleoside conjugates as bifunctional anti-HIV agents targeting different events in
HIV life cycle. The conjugates were evaluated for their anti-HIV activity against cellfree, cell-associated and MDR virus.

The conjugation of AZT or FLT with CS provided higher anti-HIV activity
against RS strain of virus verses CS in all conjugates, suggesting the contribution of
released nucleosides in generating broad-spectrum activities.
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CS conjugates of AZT and FLT with acetate linker (AZT-CSA and FLT-CSA)
and the physical mixture of AZT or FLT with CSA exhibited higher anti-HIV activity
in cell-free virus when compared to their corresponding conjugates with succinate
linker (AZT-succinate-CS and FLT-succinate-CS), the physical mixtures of CS+ AZT
or FLT, and CS, possibly due to the creation of additional negative charges provided
from carboxylic acid of acetate group on the polymer. Similarly, cellulose sulfateacetate exhibited significantly higher potency than CS against cell-free virus. Higher
negative charge density may have contributed in stronger interactions of CS with
positive charges present in V3 Loops of gp120 and thereby blocking HIV entry.

Furthermore, AZT-CSA and FLT-CSA conjugates were more effective than
CS against both X4 and RS HIV-1 viruses. The above-described conjugates present
the advantage of not displaying weaker activity against HIV RS strains. Although in
weight the AZT-CSA and AZT were similarly potent against cell-free virus, in moles
(based on CS - 2 x 106 Daltons), the conjugate was 5 orders of magnitude more potent
(from µM to subnanomolar). Furthermore, unlike AZT, the conjugate was consistently
active against cell-associated HIV.

This study presents an alternative approach for designing more optimal antiHIV agents that may have broad-spectrum anti-HIV activities against cell-free, cellassociated and MDR virus by targeting both HIV entry and reverse transcription in
HIV life cycle.
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